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Abstract 
The aim of this study was to elucidate the underlying molecular genetic mechanisms of 
radiation-induced breast carcinogenesis. Younger women are more at risk of developing 
breast cancer than older women following radiation exposure. Circulating oestrogen 
levels are highest during adolescence and early adulthood and oestrogen has a known 
transforming effect on breast epithelial cells. One hypothesis suggests that radiation and 
oestrogen synergise to drive breast cell transformation. There are currently no known 
genetic markers of radiogenic breast cancer. In order to investigate genetic alterations 
associated with radiogenic breast cancer in vitro models of radiation-induced breast 
epithelial cell transformation was developed. 
The immortalised, non-transformed breast epithelial cell line MCF-10A was exposed to 
fractionated doses of X-rays in the presence or absence of additional oestrogen. 
Radiation-treated cells displayed several phenotypic changes some of which provided 
evidence of cell transformation, including loss of contact inhibition and change to 
mesenchyme cell morphology. Genomic analysis of radiation treated cells using high-
density polymorphism arrays identified a gene deletion of the POU2F1 transcription 
factor and amplification of the c-MYC proto-oncogene. POU2F1 has a role in cellular 
stress response and mediates DNA damage response through interactions with BRCA1. 
Amplification of c-MYC has previously been identified in breast cancers of survivors of 
the atomic bombs during World War II. Genetic alteration in POU2F1 and c-MYC may 
therefore be linked to radiation-induced breast cell transformation. Changes in gene 
copy-number were confirmed by fluorescent in situ hybridisation (FISH) and alterations 
in protein expression by western analysis.    
Gene copy number and expression of POU2F1 and c-MYC was investigated in a cohort 
of radiogenic and sporadic breast cancer tissue samples by FISH analysis and 
immunohistochemistry. Expression of c-MYC was higher in radiation-induced breast 
cancers compared to sporadic breast cancers (p = 0.002), as was the mean number of 
copies of c-MYC (p = 0.030). Loss of expression of POU2F1 was identified in one of 18 
radiation-induced breast cancers but was not observed in sporadic breast disease (0/33).  
In summary, a cell model of radiation-induced breast cell transformation identified 
POU2F1 deletion and c-MYC amplification as putative markers of transformation, 
which were subsequently identified in primary tissue samples, suggesting a role for 
these alterations in the development of radiogenic breast cancer. 
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Chapter 1: Introduction 
1.1 Cancer 
1.1.1 Cell transformation 
The malignant transformation of normal cells results from genomic mutations. The 
accumulation of these mutations affects protein activity and causes the acquisition of 
altered phenotypes. Altered phenotypes include the ability to: evade apoptosis, sustain 
proliferative signalling, be insensitive to anti-growth signals, invade and metastasise, 
have limitless replicative potential, induce angiogenesis, modify cellular metabolism 
and avoid immunological destruction (Hanahan and Weinberg, 2011). During 
transformation cells acquire characteristics which facilitate the acquisition of these 
phenotypes, such as genetic instability, which increases the occurrence of mutations  
and thereby increases the acquisition of oncogenic mutations; and immune system-
induced inflammation, which exposes cells to proteins and enzymes that promote cell 
growth and survival and to mutagenic chemicals that induce mutations (Hanahan and 
Weinberg, 2011).    
Genes that encode proteins where altered function predisposes towards cancer can be 
divided into two groups, oncogenes and tumour suppressor genes. Oncogenes are genes 
which promote cell transformation. Proto-oncogenes are normal genes which become 
oncogenes due to activating mutations or increased expression. For example, point 
mutations in the RAS family of genes can cause inappropriate or constitutive activation 
of the encoded RAS proteins which promote tumourigenesis (Pylayeva-Gupta et al., 
2011). Amplification or dysregulation of c-MYC results in protein over-expression and 
has been detected in many cancers (Meyer and Penn, 2008), and a chromosome 
translocation which creates the constitutively activated fusion protein BCR-ABL in 
chronic myeloid leukaemia promotes tumourgenesis (Goldman, 2010). Mutations that 
convert proto-oncogenes to oncogenes are often dominant. 
Tumour suppressor genes often encode proteins involved in response to cellular stress 
or DNA damage and that regulate correct progression through the cell cycle. Loss of the 
gene product through inactivating mutations or gene deletions can lead to unregulated 
cell growth and accumulation of DNA mutations. Inactivating mutations in tumour 
suppressor genes are often recessive, as described in Knudson’s “two hit hypothesis” 
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(Knudson, 1971). Notable tumour suppressor genes include P53, RB and APC (Sherr 
and McCormick, 2002; Lane and Levine, 2010; Minde et al., 2011).  
Genetic alterations which inactivate DNA repair mechanisms are also important in 
progression to cancer. An inability to repair DNA damage leads to genomic instability 
and accumulation of transforming mutations. Mutations to genes involved in base 
excision repair (BER), mismatch repair (MMR) and homologous recombination (HR) 
have all been implicated in cancer development (Mitchell et al., 2002; Shinmura et al., 
2004; Allan and Travis, 2005; Helleday, 2010).  
1.1.2 Causes of cell transformation 
Cancer can be caused by agents which are directly mutagenic and also by mechanisms 
that increase the chance of accumulating mutations. Some cancers are hereditary and 
develop because the affected individual has an increased susceptibility due to the 
inheritance of an inactive tumour suppressor gene allele. For example, the risk of 
developing breast cancer by the age of 70 in individuals with hereditary mutations of 
BRCA1 or BRCA2 has been reported to be 65% and 45%, respectively (Antoniou et al., 
2003).  
Chemicals and other exposures that cause somatic DNA mutations are called mutagens, 
and many of these are carcinogenic. Smoking is highly correlated with increased risk of 
lung cancer because tobacco contains several chemical carcinogens (Pfeifer et al., 2002). 
For example, enzymatic metabolism of benzo(a)pyrene, which is found in tobacco 
smoke, produces benzo(a)pyrene diol epoxide which can bind covalently to DNA, 
disrupt DNA replication and introduce mutations.  
Ionising radiation is also a mutagenic carcinogen. Ionising radiation causes DNA 
damage of which the most toxic is double stranded DNA breaks. Most DNA damage is 
repaired or if not, the damage can result in cell death or mutation. Cell survival and 
incorrect repair of the DNA damage can lead to chromosome aberrations such as 
deletions, duplications and translocations (Cornforth, 2006; Natarajan and Palitti, 2008). 
The effect of ionising radiation will be discussed in more detail in Sections 1.3 and 1.4. 
Some carcinogens are not mutagenic via the direct induction of DNA damage. For 
example, some hormones stimulate cell proliferation which increases DNA replication 
and the likelihood of errors in replication and reduces the chance of effective DNA 
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repair. One of the best known examples of this phenomenon is that increased oestrogen 
levels increase breast cancer risk  (Yager and Davidson, 2006). 
Infectious agents such as viruses can also cause cancer. A viral genome can be inserted 
into a host genome which may alter expression of genes which may have a transforming 
effect. A well-known example is human papillomavirus which is causative in almost all 
cases of cervical cancer. The human papillomavirus genome contains the E6 and E7 
genes which are known to act as oncogenes and can integrate into the host genome 
(Ganguly and Parihar, 2009). 
1.2 Breast cancer 
1.2.1 Normal breast structure 
The breast is made up of a number of lobes and milk ducts. The lobes contain lobules 
which comprise clusters of alveolar sacs that contain lacocytes that synthesise milk. The 
lobules are connected to small ducts which join to larger ducts and converge to one 
main duct per lobe called a lactiferous duct which transports the milk to the nipple 
(Ramsay et al., 2005). Breast epithelial cells, which are surrounded by connective and 
adipose tissue, are responsive to hormones, including oestrogen. Breast development is 
stimulated at the onset of puberty and develops further during pregnancy and lactation. 
1.2.2 Breast cancer overview 
Breast cancer is the most common cancer in women in the UK and accounted for 31% 
of all cancer cases in 2008 (Office for National Statistics, Edition: MB1 39). The life-
time risk of developing breast cancer for a woman is 1 in 8. The risk of developing 
breast cancer increases with age and in 2008 81% of cases occurred in women over 50 
years old (Office for National Statistics, Edition: MB1 39). Breast adenocarcinoma 
develops from breast epithelial cells. Non-invasive breast adenocarcinoma includes 
ducal carcinoma in situ and lobular carcinoma in situ. Eighty five per cent of invasive 
adenocarcinomas are described as ductal and 15% are lobular.  
1.2.3 Breast carcinogenesis 
The majority of breast cancers develop in patients without a family history of breast 
cancer (sporadically), but approximately 10% have a hereditary contribution (Deng, 
2006). Approximately 25% of hereditary breast cancer cases are due to germ-line 
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mutations in the BRCA1 or BRCA2 genes (Weischer et al., 2007; Desrichard et al., 
2011). BRCA1 is involved in transcriptional regulation and cell cycle checkpoint 
regulation following DNA damage and both BRCA1 and BRCA2 are directly involved 
in homologous recombination repair of DNA double strand breaks (Yoshida and Miki, 
2004; Cousineau et al., 2005; Deng, 2006; Rosen et al., 2006). Loss of function of 
BRCA1 or BRCA2 results in increased genetic instability and the accumulation of 
genetic mutations which can lead to breast cancer. Low penetrance germ-line mutations 
in genes such as CHEK2, PALB2 and BPIR1 also increase breast cancer susceptibility 
and cooperate with other hereditary factors to cause breast cell transformation (Seal et 
al., 2006; Rahman et al., 2007; Weischer et al., 2007; Desrichard et al., 2011). 
Numerous studies have demonstrated that high concentrations of circulating oestrogens 
increase breast cancer risk. Increased breast cancer risk was identified in post-
menopausal women with high circulating concentrations of oestrogen and androgens, 
which can be converted to oestrogen by aromatase. Women who are obese are also at 
increased risk of developing breast cancer, possibly because of the production of 
oestrogen by aromatases in the adipose tissue of the breast (Key et al., 2002; Key et al., 
2003; Onland-Moret et al., 2003; Walker et al., 2011). Early menarche and late 
menopause are also associated with increased breast cancer risk and a recent meta-
analysis concluded that increased circulating levels of oestrogen in pre-menopausal 
women increased breast cancer risk (Key et al., 2003; Walker et al., 2011).  
The association between exposure to exogenous oestrogen, such as oestrogens in the 
contraceptive pill, and breast cancer risk has also been studied. A comprehensive 
analysis by The Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC) 
of over 150,000 individuals in 1996 identified that the relative risk (R.R) of developing 
breast cancer was significantly elevated for current oral contraceptive users compared to 
individuals who had never taken the pill (R.R = 1.24). The risk decreased with the 
increased number of years since ceasing to take the contraceptive pill, and no excess 
risk was observed in individuals who had stopped taking the contraceptive pill more 
than 10 years previously. Modest increases in breast cancer risk have also been 
observed in more recent studies (Kumle et al., 2002; Kahlenborn et al., 2006), and 
Dumeaux et al. (2003) observed an association between risk and cumulative exogenous 
oestrogen dose received by taking the contraceptive pill. However, there have also been 
numerous studies which have observed no increase in breast cancer risk with oral 
contraceptive usage (Marchbanks et al., 2002; Vessey and Painter, 2006; Hannaford et 
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al., 2007), and therefore the association between exogenous exposure to oestrogen in 
the form of oral contraceptives and breast cancer risk is not conclusive.  
As well as oestrogen, exposure to other circulating hormones is putatively carcinogenic. 
For example, insulin and insulin-like growth factor-1 (IGF-I) increases proliferation of 
normal and transformed breast epithelial cells, promotes mammary tumour growth in 
animal models and has been associated with increased breast cancer risk (Chappell et al., 
2001; Gunter et al., 2009). Higher circulating insulin concentrations in obese women 
may contribute to the overall increased breast cancer risk in these individuals (Gunter et 
al., 2009). 
1.2.4 Breast cancer classification and treatment 
Breast cancers are classified in a number of ways. Classification can help predict 
disease prognosis and patient management. The TNM classification system describes 
the clinical stage by tumour size (T), whether it has spread to the lymph nodes (N) and 
whether the tumour has metastasised (M). The Bloom and Richardson Grade classifies a 
tumour by histology (Bloom and Richardson, 1957), which includes criteria such as the 
proportion of ductal structures, the mitotic index and the nuclear morphology. High 
grade is associated with poor prognosis.  
Treatment of breast cancer depends on many factors that include the clinical stage and 
histological classification of the tumour. Surgery is still the primary treatment option for 
most breast cancers, and can be a lumpectomy in which the tumour is resected or 
mastectomy in which the entire breast is resected. Axillary lymph nodes are also 
removed in many cases to determine if the disease has spread beyond the breast or to 
remove dissociated disease. Patients are also often treated with adjuvant chemotherapy 
or radiotherapy. Chemotherapy is often a combination of agents and the choice of 
chemotherapy depends on the status of the cancer and the age and health of the patient.  
Drugs are available to treat breast cancer depending on the molecular classification of 
the tumour. One of the most important classifications with regard to treatment choice is 
the receptor status of the cells. Three important receptors that can be expressed by 
breast cancer cells are the oestrogen receptor (ER), the progesterone receptor (PR) and 
HER2. 
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Cells which express the oestrogen receptor may be oestrogen-dependant and may 
benefit from treatment with anti-oestrogens such as tamoxifen. Tamoxifen is a 
competitive antagonist that competes with oestrogen for binding to the oestrogen 
receptor and thereby inhibits oestrogen activation (Jordan, 2006). Progesterone receptor 
expression is induced by oestrogen and therefore positive PR expression status can be 
used to identify patients who will benefit from anti-oestrogen therapy (Mohsin et al., 
2004).  HER2 is a membrane bound tyrosine kinase which is a member of the ERBB 
family of tyrosine kinase receptors. HER2 is an oncogene which causes cell 
proliferation, angiogenesis and cell invasion when over-expressed relative to normal 
breast epithelial cells (Menard et al., 2003; Menard et al., 2004). HER2 over-expression 
occurs in 25-30% of breast cancers and is treated with Trastuzumab (Herceptin); a 
monoclonal antibody which inhibits HER2 (Spector and Blackwell, 2009).  Cancers 
which do not have any of these receptors are referred to as triple-negative breast cancers 
and have a poor prognosis due in part to limited options for receptor- targeted therapy 
(Dent et al., 2007).  
Treatment can also depend on somatic genetic mutations. For example, poly ADP 
ribose polymerase (PARP) inhibitors have been developed for the treatment of cancers 
with somatic BRCA1 or BRCA2 mutations.  PARP inhibitors lead to the accumulation of 
DNA strand breaks by inhibition of base excision repair. In BRCA1 and BRCA2 wild 
type cells these breaks are repaired by homologous recombination. Cancer cells with 
acquired BRCA1 or BRCA2 mutations have defective homologous recombination and 
therefore cannot repair the strand breaks which results in cell death (Weil and Chen, 
2011).   
Breast cancers have also been classified into subtypes based on their DNA expression 
profiles. Detailed molecular and genetic classification of tumour sub-types could lead to 
a more detailed analysis of prognosis and treatment options (Jonsson et al., 2010). Five 
molecular subtypes of breast cancer were defined and shown to correlate with overall 
survival (Perou et al., 2000; Sorlie et al., 2003; Geyer et al., 2009). These molecular 
subgroups include: luminal A breast cancers, which have an expression profile similar 
to normal luminal epithelial cells of the breast, are ER-positive, express high levels of 
oestrogen responsive genes and are of low grade; luminal B breast cancers, which share 
similar characteristics to luminal A breast cancers but are more proliferative, are of 
higher grade and have a poorer prognosis; basal-like breast cancers, which are always 
ER-negative, are very often triple-negative for hormone receptor expression, express 
7 
 
genes characteristic of basal epithelial cells, are of high grade, are highly proliferative 
and often share characteristics with tumours that arise due to BRCA1 germ-line 
mutations; normal-like breast cancers, which have high expression of genes associated 
with basal epithelial cells and adipose cells, low expression of genes associated with 
luminal epithelial cells and often clusters with normal breast cells during expression 
profiling; and HER2 enriched breast cancers, which are usually ER-negative, over-
express HER2 and genes associated with the HER2 pathway, often have HER2 gene 
amplification and are an aggressive breast cancer subtype. 
1.3 Ionising radiation 
Ionising radiation is biologically harmful and is a carcinogen. The mechanisms by 
which ionising radiation causes biological damage and the effect this damage can have 
on cellular macromolecules will be discussed in section 1.4; however the basic physics 
of ionising radiation, sources of its exposure to the population and epidemiological 
evidence of its carcinogenic effect will first be discussed. 
1.3.1 Forms of ionising radiation 
Ionising radiation has the required energy to remove electrons from an atom or 
molecule thereby producing a positively charged ion. Ionising radiation can be in the 
form of particles, such as: α particles (helium nuclei), β particles (electrons and 
positrons), protons, neutrons and other heavy ions; or high energy photons, such as 
gamma rays and x-rays.  
Different types of ionising radiation react differently when they come into contact with 
a medium (Fig. 1.1). Charged particles such as α particles and heavy ions ionise 
molecules along the path that they are travelling. As they ionise atoms they lose energy 
and the linear distance that the particle travels before all energy is lost is defined as the 
range of the particle. The range of α particles and heavy ions is relatively short.  
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α, β and neutron (n) particles each move through a medium differently to cause ionisation of atoms or 
molecules. The figure shows interactions between atoms and different ionising particles as they move 
through a medium. (N.B figure is not to scale). α particles ionise atoms along its particle track. β particles 
can release breaking radiation in the form of X-rays as they decelerate when approaching a nucleus and 
can also eject orbiting electrons from a nucleus, that can go on to ionise other atoms in the medium. 
Neutrons are uncharged particles which can collide with protons creating an ionising charged particle.  
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Figure 1.1 Mechanisms of particle ionising radiation. 
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Gamma rays and x-rays (photons) do not ionise along a linear path of trajectory and the 
range of gamma and X-ray radiation is relatively long. There are 3 ways in which high 
energy photons ionise when passing through matter (Fig. 1.2): the photoelectric effect, 
compton scattering and pair production (Simpkin, 1999; Hubbell, 2006). 
 
 
 
 
 
 
 
  
 
 
 
High energy photons (e.g. gamma and X-rays) ionise atoms via 3 main mechanisms: (a) the photoelectric 
effect, whereby a photon collides with a tightly bound electron in an atom (an inner shell electron), passes 
all of its energy to the electron and therefore ceases to exist. The electron escapes its nucleus and ionises 
molecules around it, acting as a charged particle (a photoelectron). (b) compton scattering, whereby a 
photon collides with a weakly bound electron in an atom (an outer shell electron). The electron is ejected 
from the nucleus with the energy transferred to it from the photon and can ionise molecules around it. The 
photon is deflected from the collision and continues its path through the medium in a different trajectory 
with reduced energy. (c) pair production, whereby a photon collides with the nucleus of an atom giving 
up all of its energy producing an electron and a positron. The electron and positron then act as ionising 
charged particles within the medium.  
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Figure 1.2 Photon ionisation. 
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Radiation can be defined by the type of particle that constitutes the ionising radiation 
but also by the type of energy transferred during the radiation. High-linear-energy-
transfer (LET) radiation (e.g. α particles, heavy ions and neutrons) releases a high 
amount of energy along the trajectory (particle track) of the ionising particle resulting in 
dense regions of ionised atoms (Fig. 1.3a). Low-LET radiation (e.g. gamma rays and x-
rays) releases energy along the particle track more sparsely and therefore ionisation of 
atoms occurs more evenly throughout a medium (Fig. 1.3b). The dose of radiation 
relates to the total amount of energy deposited within a medium.   
 
 
 
 
 
 
 
 
 
 
 
(a) High-LET radiation induces a high frequency of ionising radiation events along the particle track 
resulting in dense regions of ionisation within a medium. (b) Low-LET radiation releases energy more 
sparsely along the particle track. As a consequence, low-LET radiation travels farther than high-LET 
radiation and ionisation occurs more homogenously through the medium. 
 
 
 
 
 
 
 
Low LET 
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High LET 
radiation 
Linear particle track 
Ionising event 
 
a b 
Figure 1.3 High and low-linear-energy transfer (LET). 
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1.3.2 Sources of ionising radiation 
Sources of ionising radiation exposure to the general population can broadly be put into 
two categories: natural and artificial. In the U.K 84% of the annual ionising radiation 
exposure to the population is from natural sources and 16% from artificial sources 
(www.ukradon.org) (Fig. 1.4).  
 
Figure 1.4 Sources of human exposure to ionising radiation in the U.K. 
Average annual radiation dose exposed to the UK population. Figure obtained from www.ukradon.org.  
Natural sources of ionising radiation exposure include cosmic rays and the external and 
internal exposure to naturally occurring molecules undergoing radioactive decay 
(UNSCEAR 2008). Radioactive decay is the spontaneous, random process by which the 
nucleus of an unstable atom (the radionuclide) loses energy in order to convert to a 
more stable form. The energy that is lost during this process is ionising radiation.  
Cosmic radiation originates from outer space and consists mainly of protons, α particles, 
heavy ions and electrons. Collisions between these particles and atoms in the 
atmosphere produce smaller charged particles (secondary radiation) which in turn can 
interact with atomic nuclei in the atmosphere to produce unstable radionuclides. Cosmic 
radiation exposure is greater at higher altitudes and at geographical locations closer to 
the magnetic poles (UNSCEAR 2008; UNSCEAR 2002). 
External exposure to ionising radiation originates from gamma ray emission of 
radionuclides in the soil and in building materials. Internal exposure comes from 
inhalation and ingestion of radionuclides (UNSCEAR 2008; UNSCEAR 2002). 
Inhalation of radon gas is a major source of internal exposure to ionising radiation. 
Radon-222 and radon-220 are gaseous radioactive decay products of the thorium 
radionuclide and uranium radionuclide series respectively, which are present in soil and 
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rocks. When radon-222 and radon-220 particles are inhaled they attach to the bronchial 
walls of the lungs and emit predominantly α particles (UNSCEAR 2008; UNSCEAR 
2002). When radon gas is emitted indoors, usually through the floor from the rocks and 
soil beneath, the build-up of radon gas can cause a significant increase in internal 
ionising radiation exposure. Radon gas levels are not uniform and depend on the 
concentration of uranium radionuclides in rocks and soil and the abundance of porous 
soil and rock deposits in a given area. Maps of radon gas levels in homes in England 
and Wales illustrate the difference between different geographical areas (Fig. 1.5).  
Therapeutic and diagnostic medical radiation and environmental pollution due to 
nuclear weapons testing, nuclear power plants and fallout from nuclear accidents are 
examples of artificial sources of radiation exposure (UNSCEAR 2008; UNSCEAR 
2002).  
X-rays are generated and used for diagnostic purposes in medicine. X-rays penetrate 
soft tissues and bone to different degrees so can produce images of internal structures 
on photographic film. (UNSCEAR 2008; UNSCEAR 2002). Ionising radiation is also 
used to treat cancer. Beams of X-rays, gamma rays or electrons are used to target 
specific tissues to give lethal doses of irradiation to malignant cells. (UNSCEAR 2008; 
UNSCEAR 2002). 
Artificial nuclear reactions used for power generation and in nuclear bombs are also a 
source of artificial radiation exposure; however the relative effect of these exposures on 
the general public is small (UNSCEAR 2008; UNSCEAR 2002). There have however 
been accidents at nuclear power plants, notably Chernobyl in 1986 and more recently 
Fukishima in Japan, which released relatively large amounts of radionuclides into the 
local environment and beyond.  
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The map shows the percentage of homes in England and Wales which contain above 200 becquerels per 
cubic metre (Bq m
-3
) of radon gas according to the Health Protection Agency (www.hpa.org.uk). The 
HPA recommends action to remove radon gas from homes with a concentration above 200 Bq m
-3
. Map 
obtained from www.ukradon.org. 
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Figure 1.5 Radon gas levels in homes in England and Wales 
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1.3.3 Ionising radiation and carcinogenesis  
Evidence for the carcinogenic effect of ionising radiation in humans largely comes from 
epidemiological study of atomic bomb survivors who lived in Hiroshima and Nagasaki 
during the Second World War (1945), populations exposed to medical radiation, and 
populations exposed to occupational radiation.  
Individuals living in Nagasaki and Hiroshima at the time of the atomic bombs were 
exposed to a range of ionising radiation doses. Detailed estimates of individual radiation 
dose were generated based on the distance from the hypocentre of the bombs and the 
amount of shielding each person had (Pierce and Preston, 1993). An increased incidence 
of leukaemia compared to the general population was identified in survivors as early as 
1952 and an elevated risk of leukaemia has since been verified in a life time study of 
approximately 120,000 bomb survivors (Preston et al., 1994). An increased risk for 
many solid cancers compared to un-irradiated populations has also been identified; 
including cancers of the oesophagus, stomach, colon, liver, lung, female breast, bladder, 
brain, central nervous system, thyroid and skin (non-melanoma) (Preston et al., 2007). 
A linear relationship between dose and risk was observed for most cancer types. The 
excess relative risk (ERR – the risk in the exposed group compared to an un-irradiated 
population) for each cancer reduced as age at the time of exposure increased.  
Diagnostic and therapeutic doses of radiation are low but are often given repeatedly, 
which means that some patients receive a large cumulative dose. Diagnostic and 
therapeutic radiation has been associated with increased cancer risk in many tissue types. 
For example, there is an established linear dose relationship for lung and breast cancer 
risk following radiotherapy for Hodgkin lymphoma (Gilbert et al., 2003; van Leeuwen 
et al., 2003). An increased risk of thyroid cancer was identified in children, but not 
adults, exposed to medical radiation (Schonfeld et al., 2011). The relationship between 
thyroid cancer risk and age has also been observed in atomic bomb survivor studies and 
children affected by the fallout from Chernobyl (Cardis and Hatch, 2011). There is also 
an established risk of developing acute myeloid leukaemia (AML) following medical 
radiation exposure, however only at low doses (Boice et al., 1987). At high therapeutic 
doses there is evidence that cell kill abrogates AML risk (Allan and Travis, 2005).  
Evidence also indicates that occupational exposure to ionising radiation can increase 
cancer risk. For example, the risks of radon gas inhalation were first identified in 
uranium miners who had a significantly increased risk of lung cancer compared to the 
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general population. The association between radon gas exposure and lung cancer risk 
was extrapolated to the general population and was found to also affect individuals who 
live in houses with high radon concentrations (Al-Zoughool and Krewski, 2009). A 
dose dependant increased risk of leukaemia in Chernobyl ‘clean up’ workers has also 
been identified (Cardis and Hatch, 2011).  
Evidence for the carcinogenic effect of ionising radiation has also been demonstrated 
using in vitro transformation assays. Classically the CH310T1/2 cell transformation 
assay has been used to establish the transformative effect of a number of carcinogenic 
agents, including exposure to ionising radiation (Combes et al., 1999). The CH310T1/2 
cell line is a non-transformed, immortalised, contact inhibited mouse fibroblast cell line. 
When CH310T1/2 cells are transformed they form cell foci and the number and 
morphology of the foci formed in response to a carcinogen allows a semi quantitative 
measure of cell transforming capability. Different forms of ionising radiation have been 
shown to transform CH310T1/2 cells and it has been established that the extent of cell 
transformation is dose dependant (Hieber et al., 1990; Mill et al., 1998). Immortalised 
human cell lines have also been used to establish the carcinogenic effect of ionising 
radiation such as the human fibroblast cell line MSU1.0 (Reinhold et al., 1996), which 
also forms foci when transformed, and a human cell hybrid cell line (HeLa x skin 
fibroblast) in which transformed cells express a specific cell surface marker and can 
therefore be identified (Mendonca and Redpath, 1989). 
Exposure to ionising radiation is therefore an established carcinogen and a risk factor in 
developing cancer in many different tissues of the body. The present study will focus on 
radiation-induced breast cancer. A more detailed review of epidemiological, in vitro and 
in vivo studies of radiogenic breast cancer will be discussed in Sections 1.5, 1.6 and 1.7. 
1.4 Ionising radiation induced DNA damage 
The interactions of ionising radiation within a cell are random and can affect any 
cellular component; however somatic damage to DNA is believed to be the key 
mechanism of cell carcinogenesis (Chadwick and Leenhouts, 2011). The following 
section will concentrate on the mechanisms of radiation-induced DNA damage, how 
damage is repaired by the cell and how damage can potentially result in mutation. 
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1.4.1 Mechanisms of DNA damage and repair 
Ionising radiation can cause both direct and indirect damage to DNA. Direct ionisation 
of atoms in the sugar phosphate backbone and nucleosides of DNA can cause DNA 
strand breaks and abasic sites. The production of free radicals in the nucleus, mainly due 
to radiolysis which produces reactive oxygen species (ROS) such as hydroxyl radicals 
(*OH) from water, can cause indirect DNA damage (Fig. 1.6) (Ward, 1985; Goodhead, 
1994). For example, hydroxyl radicals can cause strand breaks in the DNA sugar 
phosphate backbone by hydrogen extraction at the sugar moiety and ROS can cause 
oxidative damage to bases (Balasubramanian et al., 1998; Cooke et al., 2003).  
 
 
 
 
 
 
 
 
 
 
Ionisation causes water molecules to split by a process called radiolysis. Radiolysis causes a cascade of 
chemical reactions which produces free radicals (signified by an *) which are highly reactive and can 
damage DNA. 
Interactions between nucleotides, free radical species and ROS can create many 
different base products (Cooke et al., 2003; Ziech et al., 2011). The most common base 
change due to oxidative damage, and the most studied, is 8-oxo-Guanine (8-oxo-G; also 
called 8-hydroxyguanine) (Fig. 1.7). Guanine normally base pairs with cytosine, 
however 8-oxo-G preferentially pairs with adenine during replication. If un-repaired, 
base mis-pairing can result in a G:C to T:A substitution in the genome following DNA 
replication (Cooke et al., 2003) (Fig. 1.8). 
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Figure 1.6 Radiolysis of water. 
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Figure 1.7 DNA base products following interaction with free radical species and reactive oxygen. 
Free radicals and reactive oxygen species can interact with numerous atoms in DNA, resulting in the 
formation of damaged DNA bases, including 8-oxo-Guanine (highlighted by the red box) 
Figure from Cooke et al (2003).  
 
 
 
 
 
 
Oxidative damage of guanine generates 8-oxo-Guanine (G
OH
), which can induce mis-pairing with adenine 
(A) instead of cytosine (C) following replication. If unrepaired, at the next round of replication, the mis-
paired adenine is paired with thymine, ultimately resulting in a G:C→T:A substitution at the site of the 
original 8-oxo-Guanine lesion (highlighted by the red box).   
 
 
 
Figure 1.8 Base substitutions due to base mis-pairing with 8-oxo-Guanine mediated by DNA 
polymerase during DNA replication. 
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Single strand breaks, abasic sites and oxidised bases are repaired by different stages of 
the BER pathway (Fig. 1.9). Briefly, repair begins with the detection and excision of the 
damaged base by DNA glycosylases (e.g. OGG1, NTHL1) which generates an AP site 
(apurinic/apyrimidinic site). AP endonucleases (e.g. APEX1/2) cleave the DNA strand 
backbone at the AP site creating a single base gap (repair begins at this stage for 
radiation-induced abasic sites and single strand breaks). DNA polymerases (e.g. polβ) 
use the complimentary DNA strand to add the correct base to the AP site, and finally 
DNA ligases (e.g. LIGI, LIGIII and cofactor XRCC1) repair the DNA strand break 
(Fromme and Verdine, 2004; Zharkov, 2008).  
 
 
 
Horizontal lines represent the DNA strand backbone and vertical lines represent base pairing between the 
DNA strands. The red box represents a damaged base. DNA bases damage can be repaired by the BER 
pathway. The damaged base is removed by glycosylase enzymes and the DNA strand at the newly abasic 
site is cleaved by endonucleases. Polymerases replace the damaged base and ligases repair the broken 
DNA strand. DNA damage which directly causes abasic sites or single strand breaks are repaired by BER 
starting with AP endonuclease activity.  
 
 
Figure 1.9 Base excision repair pathway. 
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Base excision repair of multiple localised DNA lesions can sometimes cause both 
strands of DNA to be cleaved which generates a double strand break (Fig. 1.10) 
(Blaisdell et al., 2001). Both high-LET and low-LET radiation can create clustered 
DNA damage, either due to the high energy deposition along the particle track (high-
LET) or radiolysis of water adjacent to DNA (low-LET) (Blaisdell et al., 2001; Terato 
and Ide, 2004; Hada and Georgakilas, 2008). It has been demonstrated that clustered 
DNA damage can lead to complex chromosomal alterations (Singleton et al., 2002). It 
is also believed that complex clustered DNA damage is more difficult to repair as repair 
enzymes cannot access the DNA lesions (Asaithamby et al., 2011). It therefore appears 
that clustered DNA damage is a key biological consequence of ionising radiation.  
 
 
 
Horizontal lines represent the DNA strand backbone and vertical lines represent base pairing between the 
DNA strands. The red box represents a damaged base. Clustering of DNA damage, such as base damage 
and single strand break on opposing DNA strands, can generate a DNA double strand break due to strand 
cleavage at the damaged base during DNA repair. Direct induction of single strand breaks in close 
proximity on opposing DNA strands can also lead directly to DNA double strand breaks due to instability 
of the double helix. 
  
 
 
 
 
Figure 1.10 Clustered DNA damage causing DNA double strand breaks. 
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Double strand breaks which are not generated by BER of clustered DNA damage are 
caused by localised single strand break events on opposite DNA strands. DNA double 
strand breaks are repaired either by non-homologous end joining (NHEJ) or 
homologous recombination (HR) (Fig. 1.11 and Fig. 1.12). ATM detects the presence of 
a double strand break and begins a cascade of reactions which stop the cell cycle and 
leads either to cell death or DNA repair (Shiloh, 2003). NHEJ directly binds broken 
ends of the DNA while HR uses the DNA sequence of a sister chromatid or 
complementary chromosome as a template for repair (Li and Heyer, 2008; Mahaney et 
al., 2009; Nagasawa et al., 2010). NHEJ is active throughout the whole of the cell cycle 
whereas HR is predominantly active in the late S and G2 phases when sister chromatids 
are present (Natarajan and Palitti, 2008; Nagasawa et al., 2010), although NHEJ is still 
the dominant repair mechanism. 
Many of the proteins required for NHEJ have been identified, although the exact role 
for some of these is still unclear (Fig1.11). Briefly, NHEJ comprises 3 main stages: i) 
Detection of the double strand breaks and tethering together of the DNA ends (e.g. by 
KU70/80 heterodimer and DNA-PKcs); ii) DNA end processing to remove damaged or 
non-ligatable ends (e.g. by Artemis, DNA polymerase μ and λ, PNK, ARLF and WRN); 
and iii) ligation of the DNA ends (e.g. by DNA Ligase IV-XRCC4 complex, XLF). 
Some of the proteins involved in NHEJ may only be necessary for specific types of 
double strand break damage, for example; different types of DNA ends that need 
processing before ligation. The essential kinase activity of DNA-PKcs is also unclear 
although it is believed that autophosphorylation of the protein is required for 
disassembly of the protein complex (Mahaney et al., 2009). 
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Figure 1.11 Non-homologous end joining (NHEJ). 
Horizontal lines represent the DNA strand backbone and vertical lines represent base pairing between the 
DNA strands. The 5’ and 3’ orientation of the DNA strands is also shown. Double strand breaks (a) 
induced by ionising radiation can be repaired by NHEJ. The KU heterodimer (comprising KU70 and 
KU80) binds the ends of the double strand break (b) and then translocates along the strand (c) allowing 
space for recruitment of DNA-PKcs to bind to the extreme ends of the break. Two DNA-PKcs molecules 
interact to bring the termini in close proximity (d). Other factors are then recruited to the NHEJ process, 
including enzymes which remove damaged DNA strand ends, DNA ligases which join the DNA strands 
and DNA polymerases (e). It is currently unclear what order these factors are recruited to the double 
strand break, or whether DNA-PKcs dissociates from the double strand break before these factors are 
recruited. How the factors are released from the process is also unclear.   
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Like NHEJ, many of the proteins required for HR have been identified, but for some, 
their specific roles and interactions have not been fully elucidated (Fig. 1.12). Briefly, 
double strand breaks are identified and processed by the MRN complex (MRE11-
RAD50- NBS complex) which produces single stranded 3’ overhangs. The single 
stranded DNA is coated with replication protein A (RPA) before BRCA2/RAD52-
mediated replacement by RAD51 filaments (complexes involving RAD51 homologues 
are also implicated in this process) (Thacker, 2005). RAD51 can search for sequence 
homology and invade complimentary double stranded DNA, thereby displacing a single 
strand which is used as a template to repair the double strand break (RAD54 and 
BRCA1 may also be involved in this process). Strand invasion can be resolved in 
different ways thereby generating alternative DNA products (Filippo et al., 2008; Li and 
Heyer, 2008). 
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Figure 1.12 Homologous recombination repair of double strand breaks. 
Each line represents a single DNA strand. A double DNA strand break occurs (a), the ends of which are 
processed by 5’-3’ exonuclease enzymes to produce single strand 3’ overhangs (b).  The single stranded 
DNA is coated with RPA protein (c) which is then replaced by RAD51 filaments mediated by BRCA1 
and RAD52 (d). RAD51 filaments allow the single stranded DNA to invade a homologous DNA strand 
forming a D-loop (d). Double strand breaks can then be repaired by either synthesis-dependant strand 
annealing (SDSA) (e), or double strand break repair (DSBR) (f). In SDSA (e), synthesis of the invading 
strand uses the homologous chromosome as a template followed by dissociation of the D-loop and 
synthesis of the complimentary single DNA strand using the newly synthesised DNA as a template. 
Newly synthesised DNA strands are indicated by the green arrows. In DSBR (f) the D-loop structure from 
the homologous chromosome is used as a template for the non-invading single DNA strand, thereby 
forming 2 Holiday junctions. Depending on the resolution of the Holiday junctions by exonucleases 
different crossover products can be formed. The alternative Holiday junction break points are indicated by 
the large black arrows. 
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1.4.2 Consequences of ionising radiation-induced DNA damage 
As described in section 1.4.1, ionising radiation can cause an array of DNA damage. 
Incorrect or absent repair of this damage can have biological consequences ranging 
from single gene mutations to cell death. Radiation-induced DNA double strand breaks 
can cause chromosomal alterations that can affect large regions of DNA. The relevance 
of small scale mutations such as point mutations induced by oxidative damage cannot 
be ignored however, as the genes affected by these mutations could affect numerous 
molecular processes, such as DNA repair. The present study will assess copy number 
alterations induced by ionising radiation in relation to breast cancer. Therefore the 
following section will describe the mechanisms of copy number alterations induced by 
radiation-induced DNA double strand breaks.  
Chromosomal Aberrations 
The classic hypothesis of chromosome aberrations generated by radiation-induced 
double strand breaks is the ‘breakage and reunion’ model (Sax, 1940; Bender et al., 
1974). The model suggests that double strand breaks are generated at single or multiple 
sites on multiple chromosomes and low fidelity repair of these breaks (most likely by 
NHEJ) in different configurations generates multiple chromosome aberrations (Figure 
1.13) (Cornforth, 2006; Nagasawa et al., 2010), including: terminal and interstitial 
deletions, duplications, inversions, translocations, inter-chromosomal exchange, 
dicentric and acentric fragment formation and ring chromosome formation. 
Experimentally verified complex chromosomal rearrangements which require 3 or more 
breakpoints along 2 or more chromosomes can also be generated under the ‘breakage 
and reunion’ model (Savage and Simpson, 1994; Cornforth, 2006). 
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Figure 1.13 Chromosome aberration induction by DNA double strand breaks. 
Each line represents a chromosome. Different coloured chromosomes are non-homologous. The 
alphabetical labels on the chromosome figures represent different regions of the chromosome arm. 
Inverted regions are represented by inverted letters. Double strand breaks within the same chromosome 
can lead to a number of different chromosome alterations, such as: terminal deletion generated by one 
double strand break event (a), interstitial deletion (b) and inversion of chromosomal regions generated by 
two simultaneous double strand break events (c), and ring chromosome formation generated by two 
simultaneous double strand break events either side of a centromere (d). Double strand breaks in two 
different chromosomes can lead to chromosomal exchanges, such as: reciprocal translocations (e) and 
dicentric (chromosomes with two centromeres) and acentric (chromosomes with no centromere) 
chromosome formation (f). Multiple double strand breaks on different chromosome arms can also lead to 
inter-chromosomal exchanges (g). Double strand break and chromosomal exchange on homologous 
chromosomes can cause simultaneous duplication and deletion of DNA (h).  
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A novel mechanism of gene amplification has also been suggested which could be 
initiated by radiation-induced double strand breaks (Fig. 1.14). Breakage-fusion-bridge 
cycles describe a mechanism whereby a double strand break occurs on a chromosome 
during G0/G1 phase of the cell cycle, causing loss of its telomere. The chromosome is 
then replicated generating two sister chromatids without telomeric ends. The sister 
chromatids subsequently fuse creating a dicentric chromosome. During mitotic cell 
division the centromeres are pulled apart and a double strand break occurs close to the 
original break site generating a chromosome with an inverted repeat. Multiple rounds of 
the cycle may then occur causing amplification of the genomic region until a telomere is 
acquired (Hastings et al., 2009). 
 
Figure 1.14 Breakage fusion bridge cycle mechanism. 
Each line represents a chromosome. The alphabetical labels on the chromosome figures represent 
different regions of the chromosome arm. Inverted regions are represented by inverted letters. A double 
strand DNA break on a chromosome arm results in loss of a telomere (a-b). Replication of the 
chromosome occurs followed by fusion of the two telomere free chromosome ends creating a dicentric 
chromosome (c-d). Mitotic segregation pulls the two centromeres apart during anaphase causing a further 
double strand break close to the original one (e) thereby generating a chromosome with an inverted repeat 
(f). This chromosome replicates and forms a bridge therefore repeating the cycle (g-h). The cycle can 
continue until a telomere is acquired; therefore creating a chromosome with numerous inverted repeats 
(h).  
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Recombination alterations 
Models have been suggested in which errors in HR repair could also lead to 
chromosome/gene duplication and deletion. As stated in section 1.4.1, HR repair is not 
actively observed until S and G2 phases of the cell cycle, therefore genetic aberrations 
caused by HR repair are not likely to occur until later in the cell cycle (Natarajan and 
Palitti, 2008; Nagasawa et al., 2010).   
Non-allelic homologous recombination (NAHR) describes a mechanism by which 
double strand breaks instigate homologous recombination in homologous chromosomes 
or sister chromatids at homologous sequences but at non-allelic sites (Fig. 1.15) 
(Hastings et al., 2009). For example, repeat DNA sequences are present in 
chromosomes which can cause misalignment during homologous recombination and 
subsequent loss or gain of DNA on a chromosome arm.  
Homologous recombination repair between homologous chromosomes may also lead to 
copy-neutral loss of heterozygosity (LOH) (also called uniparental disomy), which can 
be initiated by strand breakage in a heterozygous region of the genome. Homologous 
recombination repairs the break using the homologous chromosome as a template 
thereby converting the heterozygous area into a homozygous one, but without a 
reduction in copy number (Fig. 1.16). This can be biologically relevant if the area used 
as a template contains a mutated gene which is normally masked by a wild type version. 
LOH of this gene therefore unmasks the mutated phenotype (Bishop and Schiestl, 2001; 
O'Keefe et al., 2010). 
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Figure 1.15 Non-allelic homologous recombination leading to interstitial deletion and duplication. 
Each line represents double stranded DNA. The red and black DNA stands are from homologous 
chromosomes. The alphabetical labels on the DNA strand represent specific regions of the homologous 
chromosomes. The red and black boxes represent homologous repeat sequences on the DNA strands. 
Non-allelic homologous recombination (NAHR) occurs when a double strand break initiates HR repair 
between two homologous chromosomes at incorrect homologous positions i.e. misaligned repeat 
sequences. In the above situation the recombination event results in a duplication of region “b” on one 
chromosome and deletion of region “b” on its homologous chromosome. 
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Figure 1.16 Genomic deletion leading to copy-neutral loss of heterozygosity (LOH). 
Each line represents a sister chromatid on homologous chromosomes. The position of a heterozygous 
allele (A and B) is shown on each chromatid arm. A double strand break on a sister chromatid arm 
containing allele A (a) results in a terminal deletion and therefore deletion of one copy of allele A (b). 
The sister chromatid is repaired using the homologous chromosome as a template, therefore allele A is 
replaced by allele B on the sister chromatid arm (c). Depending on chromosome segregation during 
mitosis a daughter cell could be heterozygous for the allele (d) or have acquired two copies of allele B 
therefore becoming homozygous for the allele (LOH) without loss of genetic material (copy-neutral) (e).  
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Chromatid alterations 
Chromosomal aberrations are predominantly identified in cells which have been 
exposed to ionising radiation in G0/G1 phase of the cell cycle (Nagasawa et al., 2010). 
During the S and G2 phases chromosomes are undergoing replication or have already 
been replicated thereby producing genetically identical sister chromatids. Ionising 
radiation can cause damage to sister chromatids thereby producing chromatid alterations 
such as chromatid deletions or exchanges between different sister chromatids. It has 
been demonstrated that cells exposed to ionising radiation in the S and G2 phases of the 
cell cycle predominantly display chromatid alterations (Nagasawa et al., 2010).  
Chromatid breaks are specific lesions defined as inversions or inter-chromatid and 
terminal deletions of single chromatid arms (Bryant, 2004). It has been demonstrated 
that single double strand breaks can cause chromatid breaks. For example, chromatid 
breaks are generated in cells with only one I-SCEI restriction enzyme site and the 
proportion of breaks increases linearly with radiation dose (Bryant, 1998; Rogers-Bald 
et al., 2000). Inter-chromatid deletions and inter-chromatid inversions are megabases 
(Mb) longer than gaps generated by double strand breaks. The fact that large inter-
chromatid deletions and inter-chromatid inversions (which would normally require at 
least two double strand break events) can be generated by a single double strand break 
suggests that double strand breaks may indirectly cause chromatid breaks (Bryant, 
2004). 
A model has been proposed which involves disruption of topoisomerase IIα mediated 
deconcatenation (untangling) of sister chromatids (Terry et al., 2008). Briefly, a double 
strand break within a looped domain of chromatin on a sister chromatid causes a 
disruption of the looped structure. This disruption leads to error prone excision and re-
joining of the chromatid ends during topoisomerase IIα mediated deconcatenation (Fig. 
1.17). The consequence can be loss of the looped domain or inversions caused by mis-
joining. It has been postulated that ROS generated by ionising radiation or oxidative 
damaged bases in the DNA can directly induce error-prone topoisomerase IIα 
deconcatenation (Li et al., 1999; Sutherland et al., 2000; Terry et al., 2008). Consistent 
with a role for topoisomerase IIα, lower expression reduces the frequency of chromatid 
breaks (Terry et al., 2008). It has therefore been suggested that differences in expression 
of topoisomerase IIα could affect the radio-sensitivity of cells in S and G2 phase of the 
cell cycle.  
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Figure 1.17 Chromatid breaks mediated via error-prone deconcatenation. 
Each line represents a sister chromatid within a chromatid pair. The alphabetical labels on the red 
chromatid represent different regions of the chromatid. Paired sister chromatid loops can become 
entwined (a) and need to be untangled by topoisomeraseII mediated deconcatenation (b) which cleaves 
and re-joins chromatid strands at the crossover point of the chromatin loop.  Correct re-joining of the 
chromatid ends at the crossover point results in unaltered DNA sequence (c). Incorrect re-joining of ends 
at the crossover point due to an earlier double strand break (d) in the chromatin loop which disrupts 
topoisomeraseII-mediated deconcatenation can cause excision of the loop structure resulting in DNA 
sequence deletion (e) or inversion of the DNA sequence (f). 
Figure derived from Bryant (2004). 
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Some of the mechanisms by which ionising radiation causes genetic mutations that 
contribute to cell transformation have been described. Point mutations, loss and gain of 
gene copy number, chromosome rearrangements and copy neutral LOH can affect the 
activity of both tumour suppressor genes and oncogenes which could in turn lead to 
cancer. It should be noted however that other hypotheses question the importance of 
direct induction of DNA damage to ionising radiation-induced carcinogenesis, and 
suggest that secondary indirect effects of radiation exposure are also important (Section 
1.4.3).   
1.4.3 Indirect mutagenic effects of ionising radiation 
In vitro studies of numerous cell types identified two indirect effects of ionising 
radiation exposure: radiation-induced genetic instability (RIGI) and radiation-induced 
bystander effect.  
The progeny of irradiated cells can display delayed effects, including cell death and 
genetic instability (increased rate of chromosomal aberrations) generations after the 
initial radiation exposure (Morgan, 2003; Wright, 2010). This phenomenon is seen at 
very low doses and there is no increase in effect with dose (Morgan, 2003; Wright, 
2010). Alterations to gene expression and epigenetic regulation such as methylation and 
histone modification have been postulated as being involved in RIGI (Aypar et al., 
2011). Mitochondrial disruption which leads to increased concentrations of ROS has 
also been implicated, based on an observed association between free radical levels and 
RIGI (Morgan, 2003; Kim et al., 2006; Wright, 2010; Aypar et al., 2011). A recent 
study has also suggested that ionising radiation exposure to either the nucleus or 
cytoplasm of a cell can induce RIGI (Hu et al., 2012).  
The radiation-induced bystander effect describes responses observed in cells which 
were not directly exposed to ionising radiation but which share the same local 
environment as exposed cells (Morgan, 2003; Wright, 2010). Again, the effect is seen at 
very low doses and there is no increase in effect with dose. The responses include gene 
mutations and chromosomal instability but also non-detrimental effects such as cell 
differentiation, growth inhibition, cell proliferation and the development of radiation-
resistance (Wright, 2010). The bystander effect is a result of receiving signals from 
irradiated cells via soluble factors in the growth medium or via gap junction 
communication (Hei et al., 2008). It should be noted that not all cell types produce 
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radiation-induce bystander effects and the nature of the bystander effect also varies 
(Wright, 2010).  
The non-target radiation-induced effects have predominantly been observed in vitro and 
the consequences of these effects in vivo are unknown. At very low radiation doses, 
which are unlikely to directly cause harmful genetic damage, the non-target effects may 
be biologically relevant; however at higher radiation doses it is speculated that non-
target detrimental effects will be overshadowed by direct DNA damage (Hei et al., 2008; 
Wright, 2010).  
1.5 Ionising radiation exposure and breast cancer risk 
Ionising radiation acting as a carcinogen has been introduced in section 1.3 and some 
putative mechanisms of radiation-induced cell transformation have also been detailed. 
The present study will focus on the molecular mechanisms of radiation-induced breast 
cell transformation (radiogenic breast cancer). Knowledge regarding radiation exposure 
and breast cancer risk has largely developed from the study of breast cancer 
development following radiotherapy for Hodgkin lymphoma. The following sections 
will therefore discuss the characteristics of radiogenic breast cancer in Hodgkin 
lymphoma survivors and provide further epidemiological examples of radiation-induced 
breast carcinogenesis. 
1.5.1 Breast cancer and Hodgkin lymphoma 
Hodgkin lymphoma is one of the most common cancers in young adults. A combination 
of targeted radiotherapy and chemotherapy has made the prognosis of the disease very 
favourable with cure rates currently exceeding 85% in the United Kingdom (Howlander 
et al 2011). However, many studies have shown that young women treated successfully 
with chest radiotherapy for Hodgkin lymphoma have an increased risk of developing 
breast cancer (Hancock et al., 1993; Tinger et al., 1997; Travis et al., 2003; van 
Leeuwen et al., 2003; Basu et al., 2008; El-Din et al., 2008; De Bruin et al., 2009; Elkin 
et al., 2011). Incidence rates vary between studies. For example, estimates of breast 
cancer incidence following radiotherapy of women under 30 years of age range between 
4-34% after 20-25 years follow up (Travis et al., 2005). The variance in estimates 
between studies is in part due to alternative methods of risk calculation used by 
different investigators, and also the inclusion or absence of additional parameters used 
to calculate the risk (e.g. age, sex, race, type of therapy and magnitude of radiation 
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dose). It is generally accepted however that radiation exposure increases breast cancer 
risk in women treated for Hodgkin lymphoma, and that risk is inversely associated with 
age.  
Historically, radiotherapy for Hodgkin lymphoma was administered to the mantle area 
in approximately 2 Gγ fractionated doses to a mean cumulative dose of 40 Gγ (Fig. 1.18) 
(Hancock et al., 1993; El-Din et al., 2008; De Bruin et al., 2009). Breast cancer risk in 
women treated for Hodgkin lymphoma using this method is dose dependant and the risk 
increases linearly with increased cumulative dose (Travis et al., 2003; van Leeuwen et 
al., 2003). It should be noted that current methods of radiotherapy aim to limit the area 
of the breast exposed to radiation and a recent study showed that more targeted methods 
that avoid direct exposure of the breast tissue can reduce breast cancer risk (De Bruin et 
al., 2009).  
 
Figure 1.18 Mantle radiotherapy exposure zones. 
Areas which are directly exposed to ionising radiation during mantle radiotherapy are shown by the white 
areas. N, Supraclavicular/neck; A, Axillary; M, Mediastinal. Figure reproduced from De Bruin et al 2009.  
Many studies have demonstrated that the risk of radiogenic breast cancer is inversely 
associated with age at exposure (Hancock et al., 1993; Tinger et al., 1997; Travis et al., 
2003; van Leeuwen et al., 2003; Basu et al., 2008; El-Din et al., 2008; De Bruin et al., 
2009), and some of these studies suggest that there is no increase in risk with exposure 
over the age of 30 years (Hancock et al., 1993; Travis et al., 2003; Wahner-Roedler et 
al., 2003).  The relationship between age of radiotherapy and breast cancer risk may be 
related to the higher concentration of circulating oestrogen in younger women compared 
to older women. This hypothesis derives from the observation that ablation of ovarian 
function by radiation exposure to the ovaries or concomitant treatment with alkylating 
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agents during radiotherapy abrogates the increased risk of breast cancer in Hodgkin 
lymphoma patients (Travis et al., 2003; van Leeuwen et al., 2003). Consistent with a 
role for oestrogen in driving radiogenic breast cancer, risk decreases as the duration 
between radiotherapy and menopause decreases (van Leeuwen et al., 2003). Data 
therefore suggests that exposure to ionising radiation and oestrogen has a synergistic 
relationship in driving breast epithelial cell transformation. The putative mechanisms of 
how oestrogen contributes to radiogenic breast cancer are discussed in section 1.6. 
The average latency between radiotherapy for Hodgkin lymphoma and breast cancer 
diagnosis is between 15 and 20 years, depending on the study (Hancock et al., 1993; 
Tinger et al., 1997; Travis et al., 2003; van Leeuwen et al., 2003; Basu et al., 2008; El-
Din et al., 2008; De Bruin et al., 2009). The risk of breast cancer increases from 
approximately 15 years post-exposure and there is no evidence that risk decreases 
thereafter. (Travis et al., 2003; van Leeuwen et al., 2003).  For example, a Hodgkin 
lymphoma survivor treated at age 25 years with 40 Gγ of irradiation without alkylating 
agents has an estimated risk of developing breast cancer by 35, 45 and 55 of 1.4%, 11.1% 
and 29% respectively. A woman in the general population has a risk of developing 
breast cancer by 30, 40, 50 and 60 of 0.4%, 0.5%, 2% and 4.3% (Travis et al., 2005).  
The long latency between radiation exposure and breast cancer development may be due 
to an initiating mutation inducing a “mutator phenotype” that increases genetic 
instability in breast cells, therefore causing a gradual accumulation of transforming 
mutations (Fig. 1.19) (Bielas and Loeb, 2005). Circulating oestrogen may also play a 
role in the accumulation of mutations initiated by ionising radiation (discussed in 
section 1.6).  
 
Figure 1.19 Ionising radiation induced genetic instability 
 
 
Exposure to ionising radiation causes a mutation which increases genetic instability within a cell 
(initiating mutation). The increase in genetic instability allows the accumulation of mutations over 
time, ultimately resulting in cell transformation and the development of cancer. 
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1.5.2 Epidemiological evidence of radiogenic breast cancer 
Studies of populations other than Hodgkin lymphoma survivors have also demonstrated 
the relationship between radiation exposure and breast cancer risk. For example, breast 
cancer risk was higher in American female radiological workers who worked before 
1940 compared to after 1970, presumably due to the advances in shielding technology 
after 1940. The risk increased with the number of years worked before 1940 and was 
higher in women who began working before the age of 17 (Doody et al., 2006). A study 
of female Icelandic airplane cabin crew (who are exposed to higher doses of cosmic 
radiation) identified a reduced mean age of breast cancer compared to the general 
population. The risk of developing breast cancer also increased with longer duration of 
employment (Rafnsson et al., 2001).  
Analysis of women who received numerous chest fluoroscopies during pneumothorax 
therapy identified an 86% increased risk of developing breast cancer compared to the 
general population. Women who received a higher cumulative dose were more likely to 
develop breast cancer and the risk was greatest for women exposed before they were 30 
years of age. In these patients, putative radiogenic cancer appeared at least 15 years 
after first exposure (Davis et al., 1989; Hrubec et al., 1989). Breast cancer incidence 
was twice as high in Scoliosis patients (who received numerous X-rays to monitor the 
curvature of the spine) compared to the general population and cancer risk increased 
with increased cumulative dose (Hoffman et al., 1989). Ma et al. (2008) also found that 
women exposed to 9 or more diagnostic chest X-rays for any condition were twice as 
likely to develop breast cancer relative to patients not exposed.  
A study investigating breast cancer risk following therapy for benign breast disease 
identified an ERR of 3.26 (compared to the general population) in individuals treated 
with radiotherapy compared to 1.01 for non-radiotherapy treated individuals. The risk 
was higher in women exposed to radiation under 40 years of age and remained above 
general population levels 40 years after initial exposure (Mattsson et al., 1993). 
Radiotherapy for postpartum mastitis (inflammation of the breast) also increased the 
risk of developing breast cancer 3.2 fold compared to the general population 
(Carmichael et al., 2003). 
Study of atomic bomb survivors identified a linear relationship between breast cancer 
risk and radiation dose to the breast (Tokunaga et al., 1994; Land et al., 2003; Preston et 
al., 2007), and also that risk was inversely associated with age (Land et al., 2003).  
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In summary, epidemiological study of different radiation exposed populations has 
identified some important characteristics of radiogenic breast cancer development. The 
risk of breast cancer increases with cumulative dose of radiation and decreases with 
increasing age of initial exposure; the latter may be mediated by exposure to oestrogen.  
Radiogenic breast cancer risk increases 10-15 years after initial exposure, which may 
indicate a role for acquired genetic instability as a result of an initiating genetic 
mutation. The potential role of oestrogen in radiogenic breast cancer will be discussed 
in section 1.6.  
1.6 Oestrogen and radiogenic breast cancer 
A role for oestrogen in breast cancer development has been recognised for some time 
(see Section 1.2.3). Epidemiological evidence also suggests that oestrogen plays an 
important role in radiogenic breast cancer development (Section 1.5). A number of in 
vitro and in vivo animal studies have demonstrated that concomitant exposure to 
ionising radiation and oestrogen exposure increases risk of cell transformation.  
1.6.1 Putative mechanisms of oestrogen carcinogenesis 
Two predominant mechanisms have been proposed to explain the role of oestrogen in 
breast carcinogenesis: a receptor mediated cell proliferation mechanism and a non-
receptor mediated genotoxic mechanism (Yager and Davidson, 2006; Chang, 2011).  
Receptor mediated mechanism 
Oestrogen has been shown to stimulate proliferation and inhibit apoptosis in a number 
of in vitro and in vivo studies (Cohen and Ellwein, 1990; Pike et al., 1993; Yared et al., 
2002; Travis and Key, 2003; Butt et al., 2007; Mense et al., 2008). Oestrogen interacts 
with two ligand dependant nuclear transcription factors, oestrogen receptor alpha (ERα) 
and oestrogen receptor beta (ERβ). After interaction with oestrogen, ERα and ERβ form 
homodimers which bind to oestrogen response elements in oestrogen-responsive genes 
and alter gene expression through interactions with co-activators and co-repressors 
(Yager and Davidson, 2006; Chang, 2011). Oestrogen bound receptors have also been 
identified in non-nuclear cell locations such as plasma and mitochondria implicating a 
role in mitochondrial DNA transcription (Govind and Thampan, 2003; Chen and Yager, 
2004). Cross-talk with other signal-transduction pathways such as the epidermal growth 
factor signal pathway may also occur (Levin, 2003; Liao, 2003).  
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Oestrogen-induced cell proliferation may contribute to radiogenic breast cancer 
development because increased cell proliferation causes inaccurate DNA replication and 
repair which facilitates the accumulation of transforming mutations (Bielas and Heddle, 
2000). If ionising radiation induces a mutation that increases spontaneous genetic 
instability then oestrogen-induced cell proliferation may facilitate the accumulation of 
transforming mutations. 
Genotoxic mechanism 
A non-receptor mediated mechanism of oestrogen carcinogenesis has also been 
proposed (Fig. 1.20). In this model oestrogens are metabolised by cytochrome P-450 
enzymes CYP1A1 and CYP1B1 to catechol oestrogen metabolites (Hayes et al., 1996; 
Liehr, 2000). CYP1A1 is expressed predominantly in the liver while CYP1B1 is found 
in other tissues including the breast (Chang, 2011). Oxidation of these metabolites 
produces quinones which can generate unstable DNA adducts with adenine and guanine 
that are then more prone to depurination and could lead to mutation (Cavalieri and 
Rogan, 2004; Chang, 2011). Reduction of quinones to catechol oestrogens also 
produces ROS which can cause oxidative DNA damage (Section 1.4) (Liehr, 2000; 
Yager and Davidson, 2006; Chang, 2011).  
Detoxification pathways that remove oestrogen metabolites are active in breast tissue 
(Yager and Davidson, 2006; Chang, 2011). Catechol O-methyltransferase (COMT) 
methylates catechol oestrogen metabolites to methyl catechols which are not genotoxic 
therefore preventing quinone formation. Non-genotoxic glutathione conjugates are also 
produced by reactions between quinones and glutathione mediated by glutathione S-
transferase (GST) enzymes.  
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The oxidative pathway of oestrogen metabolism resulting in the production of reactive oxygen species 
(ROS) and quinones that causes direct DNA damage. REDOX = Reduction and oxidation, P450  = 
CYP1A1 and CYP1B1 enzymes. COMT = Catechol O-methyltransferase, GST = glutathione S-
transferase enzymes. Methyl catechols and glutathione conjugates are non-toxic. The direction of the 
arrows indicates the direction of the reactions through the pathway.  
 
 
Oestrogen-associated DNA adducts have been identified in human breast cancers 
(Embrechts et al., 2003; Markushin et al., 2003) and in vivo and in vitro studies have 
demonstrated that the genotoxic activity of oestrogen and its metabolites can be 
carcinogenic. For example, oestrodiol treatment in a rat model system induced oxidative 
stress in mammary tissue and evidence of oxidative stress was found in renal tumours 
induced by oestrodiol exposure in hamsters (Mense et al., 2008). The MCF-10A and 
MCF-10F breast epithelial cell lines, which are both ERα negative and have very low 
expression of ERβ, were transformed with oestrodiol and non-steroidal oestrogenic 
agents (Liu and Lin, 2004; Fernandez et al., 2006; Russo et al., 2006; Huang et al., 
2007; Lu et al., 2007). Transformed MCF-10F cells contained mutations associated 
with breast cancer, such as LOH at the BRCA1 locus and a 5bp deletion in exon 4 of 
P53 (Fernandez et al., 2006). Further experiments with the MCF-10F cell line 
demonstrated that inhibition of COMT increased the number of DNA adducts prone to 
depurination, which is consistent with a genotoxic effect of oestrogen (Lu et al., 2007).     
Polymorphisms of genes involved in oestrogen metabolism are also associated with 
increased breast cancer risk (Ritchie et al., 2001; Mitrunen and Hirvonen, 2003; Park et 
al., 2004; Diergaarde et al., 2008). For example, a variant of CYP1B1 that has increased 
catalytic activity and thereby metabolises oestrogen more readily, was associated with 
increased breast cancer risk in postmenopausal women (Diergaarde et al., 2008). 
However, association of gene variants with breast cancer risk has been inconsistent, 
possibly due to small study size and the low penetrance of individual genetic variants 
(Yager and Davidson, 2006). 
COMT 
Oestadiol 
P450 
Catechols 
Methyl catechols 
REDOX Semi-quinones Quinones DNA adducts 
GST 
Glutathione 
conjugates 
REDOX 
ROS DNA damage 
Figure 1.20 Genotoxic mechanism of oestrogen carcinogenesis. 
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Direct DNA damage by oestrogen metabolites may contribute to radiogenic breast 
cancer development by increasing the amount genetic mutation. If ionising radiation 
induces a mutation that increases genetic instability, then the subsequent sustained 
presence of ROS or depurinating metabolites caused by prolonged oestrogen exposure 
may lead to cell transformation.  
Exposure of oestrogen receptor positive MCF-7 breast cancer cells with exogenous 
oestrogen increased cell proliferation and plating efficiency but also increased DNA 
damage (Yared et al., 2002). Proliferation of mammary tissue and an increase in 
oxidative stress in response to oestrodiol treatment was also observed in an in vivo rat 
model (Mense et al., 2008). It therefore appears that both the receptor mediated and 
genotoxic mechanisms of oestrogen carcinogenesis occur simultaneously. 
1.6.2 The role of oestrogen in radiogenic breast cancer  
A number of in vivo studies have demonstrated that mammary cancer risk is increased 
following ionising radiation exposure in the presence of exogenous oestrogens. Inano et 
al. (1995) showed that ovariectomised rats (that lack endogenous oestrogen production) 
developed more radiation-induced mammary cancers if they were injected with 
estradiol-3-benzoate than un-injected rats. Bartstra and colleagues demonstrated that 
rats exposed to a single dose of ionising radiation (maximum 2 Gγ) had increased risk 
of mammary cancer compared to un-irradiated rats. Risk declined if rats were exposed 
after 36 weeks of age (Bartstra et al., 1998b). Oestrodiol treatment 2 weeks prior to 
radiation exposure increased cancer risk further, but there was no increased risk if rats 
were older than 36 weeks (Bartstra et al., 1998a). In a fractionated dose experiment with 
sustained exogenous oestrodiol exposure from an early age, mammary cancer risk 
remained elevated up to 64 weeks of age (Bartstra et al., 2000). The authors speculated 
that the prolonged increase in cancer risk was due to continued proliferation of 
mammary cells due to sustained oestrodiol treatment. 
An in vitro study of non-transformed MCF-10F breast epithelial cells, demonstrated that 
concomitant exposure to high-LET α-particles and oestrodiol generated cell populations 
with more aggressive transformed phenotypes than radiation on its own (Calaf and Hei, 
2000). Changes in morphology, an increase in cell proliferation and anchorage 
independent growth developed in cells exposed to one or two doses of ionising radiation 
(60 cGγ). Cells irradiated and cultured in the presence of oestrodiol had enhanced 
anchorage independent growth and enhanced invasive capabilities compared to cells not 
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cultured in the presence of oestrodiol, and also produced tumours in mice (Calaf and 
Hei, 2000). As well as phenotypic changes, combined radiation and oestrogen exposed 
cells had greater allelic imbalance (expressed as microsatellite instability or LOH at 
microsatellite markers), expressed more growth factors and expressed greater levels of 
the onco-proteins c-MYC, HRAS and c-JUN than cells exposed only to radiation (Calaf 
and Hei, 2001; Roy et al., 2001a; Calaf et al., 2006). It is possible that oestrogen 
contributed to cell transformation via a genotoxic mechanism in these studies because 
MCF-10F cells are ERα negative. 
Epidemiological, in vivo and in vitro studies therefore support the notion that combined 
exposure to ionising radiation and oestrogen increases the risk of the development of 
mammary cancer than exposure to either carcinogen alone and that this relationship may 
be synergistic. Both carcinogens are able to transform cells in vitro on their own; 
however in human and animal systems it appears that exposure to oestrogen is an 
important factor in radiogenic breast cancer development. Two potential mechanisms 
for the contribution of oestrogen to radiogenic breast transformation have been 
discussed, and it is probable that both are operating. If a mutation induced by ionising 
radiation increases genetic instability, oestrogen exposure would increase the 
subsequent accumulation of transforming mutations.  
1.7 Genetic susceptibility to radiogenic breast cancer 
Inheritable genetic variants have been identified that appear to increase the risk of 
developing radiogenic breast cancer and have therefore been termed risk alleles. Risk 
alleles have been identified in a number of genes associated with DNA damage repair.   
ATM is an important regulator of DNA damage response. Bernstein et al. (2010) 
observed that individuals with constitutional deleterious variants of ATM were at greater 
risk of contralateral breast cancer following radiotherapy for a primary tumour; however 
the specific variants were only present in very small fraction of women. Individuals 
who are carriers of a low penetrance breast cancer susceptibility variant of CHEK2 
(1100delC) (which is phosphorylated by ATM during DNA damage response) were also 
observed to be at higher risk of radiogenic breast cancer (Bernstein et al., 2006). A 
similar result was found in women who had received therapeutic radiation for breast 
cancer and developed secondary contralateral breast cancer (Broeks et al., 2004). 
BRCA1 and BRCA2 mutation carriers were also identified to be at greater risk of 
radiogenic breast cancer following chest x-rays (Andrieu et al., 2006). 
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In a study by Broeks et al. (2007), a cohort of women who developed contralateral 
breast cancer following treatment for primary breast cancer were analysed for breast 
cancer risk variants of BRCA1, BRCA2, CHEK2 and ATM. Women with a pathogenic 
mutation for at least one of the genes had a significant increase in contralateral breast 
cancer risk after radiotherapy for primary breast disease compared to women who were 
not carriers of a pathogenic mutation.  
Variants of genes that are not involved in DNA damage repair have also been identified 
as risk alleles for radiogenic breast cancer. For example, variants of FGFR2 were over-
represented in Hodgkin lymphoma survivors that developed breast cancer. FGFR2 over-
expression has oncogenic effects; therefore a highly active variant may contribute to 
radiogenic breast cancer development (Ma et al., 2012). A genetic variant that reduced 
the expression of the transcriptional repressor PRDM1 also associated with Hodgkin 
lymphoma survivors that developed breast cancer compared to those who did not 
develop breast cancer following radiation exposure (Best et al., 2011). A variant of the 
miRNA gene H19 was also associated with increased breast cancer risk in American 
female radiological workers (Bhatti et al., 2008).  
Understanding the genetic susceptibility to radiation-induced cancer can help inform on 
the type of treatment an individual should have when radiotherapy is being considered 
as therapy.  
1.8 Molecular genetics of radiogenic breast cancer 
Analyses of cancer tissue from radiogenic breast cancer patients and from in vitro breast 
epithelial cell transformation models have identified few putative somatically acquired 
radiation-induced genetic alterations and gene expression profiles associated with 
radiation-induced carcinogenesis. The identification of somatically acquired genetic 
markers of radiogenic breast cancer would further understanding of the molecular 
mechanisms that drive radiation-induced carcinogenesis, and may help identify 
initiating mutation(s) that increase genetic instability. Section 1.8 will discuss 
somatically acquired genetic alterations and gene expression changes that have been 
identified in radiogenic breast cancer tissues, and somatically acquired genetic 
alterations that have been identified in radiation-induced breast epithelial cell 
transformation models.  
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1.8.1 Molecular genetic study of radiogenic breast cancer tissues 
Study of radiogenic cancer has suggested that specific radiation-induced genetic 
alterations are acquired that can drive cell transformation or are molecular markers for 
radiation-induced carcinogenesis. For example, a recent study compared chromosomal 
copy number and gene expression changes in an age matched cohorts of papillary 
thyroid carcinomas (PTC) that developed either sporadically or following exposure to 
radioactive iodine as a consequence of the Chernobyl disaster. Copy number gain on 
chromosome 7 (7q11.22-11.23) was observed in 39% of radiation-induced PTC, but 
was not seen in the sporadic cohort. Over-expression of CLIP2, which encodes a protein 
that mediates the interaction between membranous organelles and microtubules, was 
also associated with radiation induced PTC (Hess et al., 2011). Mouse models of 
radiation-induced acute myeloid leukaemia also identified consistent hemizygous loss 
on chromosome 2 which included the PU.1 gene, a candidate susceptibility gene for 
leukaemogenesis (Suraweera et al., 2005).  
To date a somatically acquired molecular genetic marker for radiogenic breast cancer 
has not been identified. Array based genetic analysis has however identified somatic 
alterations and gene expression changes common to radiogenic breast cancer 
populations. For example, sporadic and radiogenic breast cancers (developed after 
therapy for Hodgkin lymphoma) clustered separately following micro-array gene 
expression profiling. Radiogenic breast cancers were more likely to be of the HER2 or 
basal-like breast cancer subtypes (Broeks et al., 2010). Separate clustering indicated that 
radiogenic breast cancers may have specific gene expression signatures.  A recent study 
using array based comparative genomic hybridisation (aCGH) techniques to analyse 
copy number alterations in radiogenic breast cancers from atomic bomb survivors also 
reported greater genetic instability in radiation-induced cancers compared to sporadic 
disease. The study observed significantly more copy number alterations on average in 
radiation exposed individuals, although there was considerable variability between 
patients (Oikawa et al., 2011).  
Studies have attempted to identify somatically acquired genetic alterations specifically 
associated with radiogenic breast cancer. For example, Behrens et al. (2000) identified a 
greater frequency of allelic losses on chromosome 6q13-14, 9p21 and in Hodgkin 
lymphoma breast cancer cases compared to sporadic breast cancer cases. Varma et al. 
(2005) analysed copy number alterations using aCGH in breast cancer samples from 
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pre-menopausal women in New York (20 cases) and Belarus (22 cases). The authors 
hypothesised that the Belarusian cohort may have included cases with radiation 
aetiology due to exposure that resulted from the Chernobyl disaster. The two 
populations clustered separately (using somatic copy number alterations) and there were 
more copy number alterations in the Belarusian cohort compared to the New York 
cohort. Somatically acquired alterations identified in the study included copy number 
gain of MDM4 (at 1q32.1) and SULT1A3 (at 16p11.2). The authors conceded however 
that the aetiological role of radiation in the Belarusian cohort was unknown and other 
exogenous and genetic differences between the two populations may have contributed 
to the observed heterogeneity. Finally, a study by Miura et al. (2008) identified a higher 
frequency of HER2 and c-MYC amplification (2 fold increase in gene copy number 
compared to chromosome copy number) in a cohort of breast cancer cases from 
survivors of the atomic bombs at Nagasaki compared to sporadic breast cancer cases. 
The frequency of cases with amplification increased with increased radiation dose 
which was estimated by the distance the individual was from the hypocentre of the 
bomb.  
1.8.2 Molecular genetics of radiation-induced breast cell transformation 
The study of genetic changes induced by ionising radiation in cell line models is a 
useful tool for identifying genetic alterations that may contribute to radiogenic 
carcinogenesis in different tissue types (Riches et al., 1997; Gamble et al., 1999; Riches 
et al., 2001; Zitzelsberger et al., 2001; Zitzelsberger et al., 2004). 
In studies using the MCF-10F cell line (discussed in section 1.6.2) radiation- and 
oestrogen- exposed cell populations were characterised for genetic alterations. 
Chromosome 6q, 17p and 17q were analysed for LOH and microsatellite instability 
(allelic imbalance) (Roy et al., 2001a). A progressive amount of allelic imbalance was 
observed for all 3 chromosome regions as the populations analysed displayed more 
transformation phenotypes. Allelic imbalance of chromosomes 6q, 17p and 17q is 
implicated in breast cancer development and the frequency of allelic imbalance on 
regions of 6q and 17q was reported to be higher in radiogenic breast cancer compared to 
sporadic breast cancer (Behrens et al., 2000) (Section 1.8.1). A similar pattern of 
progressive allelic imbalance was observed for chromosome regions 11q15.5-15.4 and 
11q23-q24; the latter region includes the ATM gene (Roy et al., 2003; Roy et al., 2006). 
Expression analysis of 190 proto-oncogenes and tumour suppressor genes identified 
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altered expression of 49 genes in cells with transformed phenotypes compared to un-
irradiated MCF-10F (Roy et al., 2001b). Seventeen genes were differentially expressed 
in all irradiated populations that displayed transformed phenotypes. Of the 17 genes 15 
were up-regulated and 2 were down-regulated. Up-regulated genes included: c-MYC, 
IGF1R, TEL, c-JUN, PUF, MNDA, LUCA1, FRA-1, FAK, CDC25B, GSK3, c-MYC 
binding protein, E2F1, WNT-5A and c-YES. The two down regulated genes were P48 
and EB1.   
Unger and colleagues identified chromosomal rearrangements in immortalised human 
mammary epithelial cells transformed with fractionated doses of gamma irradiation to a 
cumulative dose of 40 Gγ (Unger et al., 2010), including translocations involving 
chromosomes 7, 8, 10 and 12. Genes identified in the breakpoints of these 
rearrangements included: HAS2, GRID1, RET, CPM, TBX3, TBX5, TUBA1A, WNT1 and 
ARF. Concomitant deregulation of gene expression was identified for each gene except 
TBX3 and TBX5. Rearrangements of HAS2, GRID1 and RET were identified in primary 
human breast cancer samples by fluorescent in situ hybridisation (FISH) and differential 
expression of the genes was identified in breast cancer cases by in silico expression 
analysis of a publicly available gene expression dataset. The study demonstrated that 
genetic rearrangements identified by in vitro models of radiation-induced cell 
transformation could also be identified in primary breast cancer samples.   
In summary, a limited analysis of primary human breast cancer tissues suggests that 
radiogenic cancer has a “recognisable” somatic genetic signature. This conclusion is 
also supported by data from in vitro studies using radiation-exposed cell lines. 
Identification of specific frequently acquired somatic genetic alterations could help 
diagnose breast cancer with radiation aetiology and will aid understanding of the 
molecular mechanisms of radiation-induced carcinogenesis.  
1.9 Breast epithelial cell line MCF-10A 
The present study has utilised the breast epithelial cell line MCF-10A as a model for 
radiation-induced cell transformation. The following section will therefore briefly 
introduce the characteristics of this cell line. 
The MCF-10A cell line was first described by Soule and colleagues (Soule et al., 1990) 
as an immortal, non-transformed cell line that arose spontaneously from mortal diploid 
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human mammary epithelial cells following extended culture in low calcium medium. 
MCF-10A cells are ERα negative and have very low expression of ERβ.  
MCF-10A displays numerous characteristics consistent with a non-transformed 
phenotype, including dependence upon hormones and growth factors for growth; 
contact inhibition of cell growth; anchorage dependant growth; lack of invasiveness 
across a semi-permeable membrane; inability to produce tumours in immuno-
compromised mice and acini formation in 3D matrix culture (Underwood et al., 2006). 
These characteristics make MCF-10A useful for transformation studies because their 
loss, concomitant with the acquisition of phenotypic characteristics associated with 
transformation, can be monitored. Loss of characteristics associated with the non-
transformed phenotype have been identified in MCF-10A cells transformed by various 
means, such as over-expression of proto-oncogenes and exposure to genotoxic agents 
such as benzo(a)pyrene (Maeda et al., 2005; Kim et al., 2007; Zientek-Targosz et al., 
2008; Imbalzano et al., 2009; Kim et al., 2009a; Botlagunta et al., 2010; Cho et al., 
2010; Meng et al., 2010). 
The karyotype of MCF-10A is near diploid with the major cytogenetic rearrangement a 
translocation t(3;9)(p13;p22). MCF-10A also has an unbalanced translocation of 
chromosome 5 to the derivative chromosome 9, a duplication of chromosome 8q, one 
extra copy of chromosome 1q plus a further copy of the section  chr1:198136766-qter 
and trisomy for chromosome 20 (Cowell et al., 2005).  
A study of the t(3;9)(p13;p22) translocation by FISH and aCGH analysis revealed a bi-
allelic deletion at the locus encompassing the CDKN2A/CDKN2B genes. The 
homozygous loss of CDKN2A/CDKN2B genes might be a contributing factor to the 
immortalisation of MCF-10A (Cowell et al., 2005). CDKN2A is involved in regulation 
of the cell cycle and loss of function is an established event in tumourigenesis. Loss of 
function mutations of CDKN2A are common in melanoma, head, neck, pancreatic and 
gastric cancers and are frequently seen in cancer cell lines (Liggett and Sidransky, 1998). 
Inactivation of CDKN2A
 
is suggested to be an early event in carcinogenesis due to the 
high frequency of inactivation in many primary cancers.  CDKN2A
 
heterodimerises 
with CDK4 and CDK6 which blocks downstream phosphorylation of the Rb protein, 
subsequently inhibiting release of E2F and cell proliferation (Liggett and Sidransky, 
1998). Therefore, even though MCF-10A cells are not transformed this cell line does 
contain genetic changes that are common to transformed cells. 
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1.10 Hypothesis and Aim 
Exposure to ionising radiation increases breast cancer risk, and this risk is inversely 
proportional to age at exposure. Radiogenic breast cancers often have a long latency and 
usually develop over 10 years after the initial exposure, suggesting that ionising 
radiation causes an initiating mutation in breast cells that increases genetic instability 
and predisposes to the acquisition of co-operating mutations. The molecular genetic 
mechanisms that cause radiogenic breast cancer are unclear, however some studies have 
suggested that radiogenic breast cancers share common gene expression profiles and 
may share common genetic alterations. The identification of a common specific genetic 
alteration in radiogenic breast cancer would help elucidate the molecular genetic 
mechanisms that underlie radiation carcinogenesis and would help identify breast 
cancers caused by radiation exposure.  
Hypothesis: Exposure to ionising radiation induces specific genetic alterations in breast 
epithelial cells that initiate cell transformation.  
The primary objective of this project was to investigate radiation-induced copy number 
alterations using an in vitro model of radiation-induced breast epithelial cell 
transformation, and to determine if identified alterations were common to radiogenic 
breast cancer. The strategies for achieving this were: 
 To irradiate the non-transformed breast epithelial cell line MCF-10A with 
fractionated doses of X-rays. In vitro transformation models have previously 
been shown to induce genetic alterations also seen in primary human cancers.  
 To identify copy number alterations and regions of copy neutral LOH caused by 
radiation exposure in irradiated MCF-10A cells using high density 
polymorphism arrays, and to investigate the effect of identified copy number 
alterations on gene and protein expression. 
 To compare the protein expression and copy number state of gene targets 
identified in irradiated MCF-10A cells in radiogenic and sporadic breast cancer 
tissue samples. 
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Chapter 2: Materials and Methods 
2.1 Tissue Culture 
2.1.1 Cell lines 
MCF-10A and MCF-7 cell lines were purchased from the American Type Culture 
Collection (ATCC, VA, USA). Cells were cultured in sterile tissue culture flasks from 
Corning-Costar (supplied by VWR International Ltd, Leicestershire, UK) with growth 
surface areas of 25, 75 and 175cm
2
 (T25, T75, T175).  
2.1.2 Routine cell culture 
All cell culture was carried out in a class II microbiological safety cabinet (BIOMAT-2, 
Medical Air Technology Ltd, Oldham, UK). All chemicals and reagents were purchased 
from Sigma-Aldrich Co. Ltd. (Dorset, UK) unless otherwise stated. 
MCF-10A cells were maintained in Dulbeco’s Modified Eagle’s Medium: Nutrient 
Mixture F-12 (DMEM-F12) containing 5% (v/v) horse serum, 20ng/ml epidermal 
growth factor, 0.5μg/ml hydrocortisone, 100ng/ml cholera toxin, 10μg/ml insulin and 1 % 
(v/v) penicillin/streptomycin. MCF-7 cells were maintained in Dulbeco’s Modified 
Eagle’s Medium (DMEM) containing 10% (v/v) foetal bovine serum, 1μg/ml insulin. 
Both cell lines were incubated at 37°C in a humidified 5% CO2 incubator (Heraeus 
Equipment Ltd., Essex, UK). 
To detach cells from the tissue culture flasks the cells were washed twice with 
autoclaved phosphate buffered saline (PBS) prepared from PBS tablets (Invitrogen Life 
Technologies, Paisley, UK) and incubated in a trypsin-EDTA (50mg/ml porcine 
trypsin-20mg/ml EDTA) solution (trypsinisation). MCF-7 cells were incubated in a 
trypsin-EDTA solution diluted 1:3 in PBS. Following detachment, cells were 
centrifuged for 5 minutes at 1500 rpm (Beckman Allegra X-12 R rotor SX 4750) in 
sterile BD Falcon
TM
 tubes (BD Biosciences, Oxford, UK) and seeded into new flasks at 
dilutions between 1:2 and 1:20 with fresh tissue culture medium. Cell lines were tested 
at 2 month intervals for mycoplasma by E. C. Matheson using a MycroAlert kit (Lonza 
Biologics, Slough, UK). 
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2.1.3 Cryopreservation of cells 
Cells were trypsinised and re-suspended in the appropriate freezing medium: MCF-10 - 
Horse serum supplemented with 8% (v/v) dimethyl sulphoxide (DMSO); MCF-7 – 
DMEM supplemented with 20% (v/v) foetal bovine serum and 10% (v/v) DMSO. Cell 
suspension was added to sterile polypropylene cryo-vials (Invitrogen Life Technologies, 
Pailsley, UK) in 0.5ml aliquots. Each aliquot contained an appropriate number of cells 
to be seeded onto a T25 flask. Cells were stored at -70°C for 24 hours and then 
transferred to liquid nitrogen for long term storage. 
When cryopreserved cells were needed, aliquots were rapidly thawed and transferred to 
the appropriate pre-warmed cell culture medium in T25 flasks. The medium was 
replaced 24 hours after seeding.  
2.1.4 Cell withdrawal 
MCF-10A cells were grown in phenol-red free Dulbeco’s Modified Eagle’s Medium 
(PRF-DMEM) containing 10% dextran coated charcoal-treated calf serum (DCC-CS) 
for some phenotype characterisation assays. This medium was termed ‘withdrawal 
medium’ as it was steroid depleted and contained no additional cytokines.  
2.1.5 Preparation of dextran coated charcoal-treated calf serum – (DCC-CS) 
Twenty grams of acid washed and neutralised charcoal and 0.2g of dextran T70 
(Pharmacia Biotech, Sweden) were mixed with 250ml deionised water in a 250ml 
centrifuge bottle and incubated for 10 minutes at room temperature, creating dextran 
coated charcoal (DCC). The DCC was recovered by centrifugation at 7000 rpm for 15 
minutes at 4°C (JA17 rotor, Beckman J2-21 centrifuge), re-suspended in 250ml of 
deionised water and centrifuged again under the same conditions. The DCC was then re-
suspended in 200ml of new born calf serum (Invitrogen Life Technologies, Pailsley, 
UK), transferred to 500ml conical flasks and incubated at 55°C for 40 minutes whilst 
shaking. The DCC was then removed from the serum by centrifugation at 10000 rpm 
for 30 minutes at 4°C (JA17 rotor, Beckman J2-21 centrifuge). The serum was 
transferred to clean centrifuge tubes and centrifuged again under the same conditions to 
remove any remaining charcoal. Finally the serum was filtered through a 0.45μm 
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disposable filter (Corning-Costar - supplied by VWR International Ltd, Leicestershire, 
UK) and stored at -20°C until ready for use.   
2.2 Generation of ionising-radiation exposed cell populations 
MCF-10A cells were exposed to fractionated doses of X-irradiation to generate cell 
populations that had been exposed to different cumulative doses of ionising-radiation. 
The cell populations were used in a stochastic model of the accumulation of radiation-
induced copy number alterations and cell transformation (Chapter 3).  
Cells were irradiated using a D3300 X-ray system (Gulmay Medical Ltd., Surrey, UK). 
The D3300 X-ray system was calibrated by Prof. Mike Tilby using Frike dosimetry so 
that the dose rate at the bottom of a tissue culture vessel (where adherent cells are 
present) could be calculated depending on the depth of the cell culture medium above 
the cell monolayer. These calculations were based on the cells being a set distance from 
the X-ray tube. In all irradiation conditions in the present study the depth of medium 
above the cells was 2.5 mm. The dose rate at the bottom of the tissue culture vessels 
was calculated as 2.5 Gγ/min.  
An experiment was required to determine the optimum dose to be used in the 
fractionated dose regimen. Doses were chosen depending on the extent of growth 
inhibition induced by the radiation exposure. Cells were irradiated using a D3300 X-ray 
system (Gulmay Medical Ltd., Surrey, UK).  
2.2.1 Determination of fractionated doses for dosing regimen 
MCF-10A cells were seeded in nine 6 well plates (Corning-Costar - supplied by VWR 
International Ltd, Leicestershire, UK) at 15% confluence. Cells were grown in 2.47ml 
of growth medium per well. Twenty four hours after seeding, each 6 well plate was 
exposed to different doses of ionising radiation. The doses used and the appropriate 
amount of time cells were exposed to X-rays to deliver the required dose is shown in 
table 2.1.  
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Radiation dose cells 
were exposed to (Gγ) 
Amount of time exposed to 
deliver appropriate dose (min) 
0 0 
1 0.4 
2 0.8 
5 1.9 
10 3.7 
20 7.4 
40 14.8 
60 22.2 
80 29.6 
 
Table 2.1 Doses used to determine the optimum fractionated dose.  
Radiation doses cells were exposed to and the exposure time required to deliver the appropriate dose to 
cells grown in 6 well plates in 2.47ml of growth medium or T75 flasks in 20ml of growth medium (dose 
rate 2.5 Gγ/min). 
Four days after irradiation 3 wells of each 6 well plate were tested for growth inhibition 
by cell count. Five days after radiation exposure the remaining 3 wells of each 6 well 
plate were tested for growth inhibition by DNA quantification.  
2.2.2 Growth inhibition assay – cell count 
Cells in 3 wells of each 6 well plate were trypsinised. Cells from each well were re-
suspended in 5ml of growth medium. Ten microliters of cell suspension was loaded 
onto a Neubauer haemocytometer (VWR International Ltd.) and triplicate counts of the 
number of cells from each well were recorded.  
2.2.3 Growth inhibition assay –DNA quantitation 
Cells in the remaining 3 wells of each 6 well plate were lysed with 2ml/well of 0.15M 
NaCl, 17mM sodium citrate, adjusted to pH 7.0 with NaOH (SSC) and 0.02% (w/v) 
sodium dodecyl sulphate for 30 min at 37°C on a rotary shaker (KS 250, Janke and 
Kunkel Laboratories). The DNA was sheared by passing through a 25 gauge needle 5 
times. Calf thymus DNA (stock - 1mg/ml) was dissolved in SSC-0.02%SDS solution to 
concentrations of 2.0, 1.0, 0.5, 0.25, 0.125 and 0.063μg/ml to generate a standard curve. 
One hundred microliter aliquots from each cell lysate and standard curve solution were 
placed into duplicate wells of a black 96 well plate (Grenier Bio-One, Gloucester, UK) 
and mixed 1:1 with Quant-iT PicoGreen dsDNA reagent (Invitrogen Life Technologies, 
Pailsley, UK) diluted 1:200 in Tris-EDTA (TE) buffer, pH7.5 (10 mM Tris-HCL pH 7.5, 
1 mM Na2EDTA). The plate was covered in foil and incubated for 5 minutes with 
shaking. The Quant-iT PicoGreen dsDNA reagent fluoresces when bound to DNA, and 
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is detected at 520nm following excitation with light at a wavelength of 480nm. The 
Dynex Revelation Reader spectrofluorimeter was used to excite and detect the 
fluorescent emission of Quant-iT PicoGreen stained DNA. The fluorescent values of the 
known concentrations of the calf thymus DNA were used to generate a standard curve 
and the unknown DNA concentrations were calculated from these measurements.  
2.2.4 Fractionated dose regimen 
MCF-10A cells were irradiated with fractionated doses of 5 Gγ and 10 Gγ to a 
cumulative dose of 80 Gγ. Cells were irradiated at approximately 40% confluency in 
T75 flasks that contained 20ml of medium. Dosing times are shown in table 2.1. Once 
cells began to grow again following exposure to ionising radiation, cells were 
trypsinised and seeded into a new T75 flask to allow continued cell recovery. Before 
confluence was reached in these flasks cells were trypsinised and seeded into a new T75 
flask to receive the next dose of irradiation. Cells were also seeded into a T175 flask to 
be grown for cryopreservation (section 2.1.3) so that cells were stored after each 
fractionated dose. Cell populations from the fractionated dose regimens were termed the 
‘First 5 Gγ’ and ‘First 10 Gγ’ irradiation series. An un-irradiated MCF-10A population 
was also grown to the same number of passages as cells that had received a cumulative 
dose of 80 Gγ in 5 Gγ fractionated doses to act as a reference population for acquired 
phenotypic and genetic changes. This cell population was termed the ‘passage control 
population’.    
Following the generation of the First 5 Gγ and 10 Gγ irradiation series the fractionated 
dose regimens were repeated with un-irradiated low passage MCF-10A cells, but with 
10
-8M of 17β oestrodiol added to the medium throughout cell culture. Cell populations 
from these fractionated dose regimens were termed the ‘Second 5 Gγ’ and ‘Second 10 
Gγ’ irradiation series.  A second passage control population was generated with 10-8M 
of 17β oestrodiol added to the medium throughout cell culture. When cryopreserved 
cells from the Second irradiation series were thawed for further study they were grown 
in normal MCF-10A growth medium without additional oestrodiol. 
2.3 Cell cycle analysis 
The proportion of cells in different phases of the cell cycle was analysed in sub-
confluent and confluent populations of MCF-10A and MCF-7 cells by fluorescence 
activated flow cytometry. DNA from fixed cells was stained with the intercalating dye 
53 
 
propidium iodide (PI). The amount of fluorescence emitted by PI when excited by blue 
or UV light reflects the amount of DNA within a cell and therefore what stage of the 
cell cycle the cell was in when it was fixed. For example, cells in G2 phase of the cell 
cycle have double the DNA content as cells in G0 or G1. The FACScan (Becton 
Dickenson) machine was used to excite and detect the fluorescent emission of PI stained 
cells. The ModFit LT software (Verity Software House) was used to calculate the 
percentage of cells in each phase of the cell cycle using generated cytometric data. 
2.3.1 Cell fixation and PI staining 
Cells in T25 flasks were trypsinised, washed in cold PBS and then fixed in 2ml of 70% 
(v/v) ethanol in PBS. The fixed cells were incubated for at least 24 hours at 4°C. 
Following incubation the fixed cells were pelleted and re-suspended in 500μl of staining 
buffer (10μg/μl RNase A, 40μg/μl PI in PBS). The samples were incubated for 15 
minutes at 37°C and then passed through a 23G needle to remove clumps. The samples 
were transferred to 5ml round bottomed FACS tubes (BD Biosciences, Oxford, UK) 
ready for analysis.  
2.3.2 Fluorescence activated flow cytometry 
Samples were measured using the FACScan machine (Becton Dickenson), together with 
CellQuest software (Beckton Dickenson). The FL2 detector was used to detect PI 
fluorescence. Scatter plots of FL2-A (the total fluorescence emitted from a cell) vs. 
FL2-W (the transit time of the cell through the argon laser beam) were used to optimise 
instrument settings. For each sample, 10000 events were collected. Cell aggregates and 
doublets could be identified on the FL2-A vs. FL2-W scatter plot as they have a longer 
transit time (FL2-W) through the argon laser than single cells. Aggregates and doublets 
in the 10000 events detected were excluded from subsequent analysis.  
2.3.3 Analysis 
Flow cytometric data was analysed using ModFit LT software (Verity Software House). 
Cytometric data of single cell events were used to generate cell count vs. FL2-A 
histograms. The proportion of cells in G1, S, and G2 was calculated by the software. 
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2.4 Cell phenotype assays 
Cells from the First and Second 5 Gγ series were phenotypically characterised using a 
number of in vitro assays (Chapter 3). Cell populations analysed from the First 5 Gγ 
series had received cumulative doses of 10, 25, 40, 55 and 80 Gγ of ionising radiation. 
Cell populations analysed from the Second 5 Gγ series had received cumulative doses 
of 10, 20, 40, 60 and 80 Gγ of ionising radiation. Both series were tested and analysed 
separately. For each in vitro assay described, a low passage un-irradiated MCF-10A cell 
population and the appropriate passage control population for the series tested was also 
tested. 
In all phenotype assays that utilised the PicoGreen fluorimetric DNA quantitation assay 
the protocol differed slightly from that detailed in section 2.2.3: only 1ml/well SSC-
0.02%SDS solution was used to lyse the cells and only 50μl aliquots of cell lysate was 
placed into the black 96 well plates and mixed 1:1 with Quant-iT PicoGreen dsDNA 
reagent.   
All digital photographs of cells were taken using the Visicam 5.0 (VWR International 
Ltd, Leicestershire, UK) mounted on an Olympus CK40 microscope. 
2.4.1 Cell proliferation rate assay 
Cell populations from the First 5 Gγ series were each plated in triplicate wells of 12 
well plates (Corning-Costar - supplied by VWR International Ltd, Leicestershire, UK) 
at a cell density of 2x10
4
 cells per well. Each 12 well plate corresponded to a specific 
time point. All plates were incubated at 37°C/5% CO2 and growth medium was replaced 
in every well each day of the experiment. Twenty four, 33, 48, 56, 72 and 80 hours after 
seeding, the DNA concentration of triplicate wells for each cell population was 
measured using the PicoGreen assay (section 2.2.3). Growth curves were generated for 
each population and growth rate, defined as the number of cell doublings per hour, was 
calculated from this data by exponential regression using available online software 
(http://www.doubling-time.com/compute.php).   
For the Second 5 Gγ series populations, cells were plated in 24 well plates (Corning-
Costar - supplied by VWR International Ltd, Leicestershire, UK) at a cell density of 10
4
 
cells per well, and DNA concentration was analysed after 24, 34, 48, 56 and 78 hours.  
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2.4.2 Contact inhibition assay – Cell cycle analysis 
Low passage un-irradiated MCF-10A cells and cells from the First 5 Gγ series that had 
received a cumulative dose of 80 Gγ of radiation were seeded in 21 T25 flasks at 4 x 105 
cells per flask. Forty eight hours after seeding, cells in 3 flasks per population were 
fixed for fluorescence activated flow cytometry as described in section 2.3. Three flasks 
were fixed every 24 hours thereafter for a further 6 days. MCF-10A growth medium 
was replaced in the flasks daily.  
All the fixed cell populations were stained with PI and analysed using the FACScan 
machine and CytoCell software (both Becton Dickenson) (section 2.3). The mean 
percentage of cells in each phase of the cell cycle at each time point was calculated from 
triplicate fixed cell populations using the ModFIT LT software (Verity Software House) 
(section 2.3). The percentage of cells in S-phase of the cell cycle in confluent cell 
cultures was used as an indication of how many cells were still cycling and had 
therefore lost contact inhibition.  
2.4.3 Contact inhibition assay – DNA quantitation  
Cell populations from the First 5 Gγ series were plated in triplicate wells of 12 well 
plates at a cell density of 2x10
4
 cells per well. All plates were incubated at 37°C/5% 
CO2 and growth medium was replaced in every well each day. Nine days after seeding  
DNA concentration was measured using the PicoGreen assay and the mean DNA 
concentration per population was calculated using measurements taken from triplicate 
wells.  The experiment was performed 4 times and the mean DNA concentration for 
each population was calculated using results from each experiment. DNA concentration 
for each population was expressed relative to the mean DNA concentration of the un-
irradiated MCF-10A population. Relative difference in DNA concentration was used to 
indicate whether cell populations had continued to grow after they had reached 
confluency. 
For the Second 5 Gγ series cells were plated in 24 well plates at a cell density of 104 
cells per well. 
2.4.4 Radiation resistance assay – 96-well cytotoxicity assay 
A 96 well clonogenic assay was used to assess the cytotoxicity of ionising radiation on 
cell populations from the First and Second 5 Gγ series. The technique was first used to 
56 
 
determine the mutability of suspension cell lines at low density (Furth et al., 1981) and 
was adapted for use in assessment of cytotoxicity in the present study. 
Cell populations were trypsinised, counted using a haemocytometer and re-suspended in 
MCF-10A growth medium at a cell concentration of 10
5
 cells/ml. From this, cell 
suspensions at a concentration of 10 cells/ml were prepared by 10 fold serial dilution. 
Two hundred microliters of cell suspension for each population was added to each well 
of duplicate 96-well plates, thereby seeding 2 cells/well. Twenty four hours after 
seeding one plate per population was exposed to 5 Gγ of ionising radiation by 
irradiation for 2.7 minutes while the remaining plate was used as an un-irradiated 
control.  In all cases, cells were incubated at 37°C/5% CO2 for 14 days. 
Following the 14 day growth period the number of wells that had a cell colony 
containing at least 50 cells was recorded in both the irradiated and un-irradiated plates. 
The number of wells which contained cell colonies from the irradiated plates was 
expressed as a percentage of the number of wells that contained cell colonies from the 
same population in the un-irradiated plates. The higher the percentage the less cytotoxic 
ionising radiation was for that cell population. The experiment was repeated 3 times for 
the First 5 Gγ series and twice for the Second 5 Gγ series. 
2.5 SNP array analysis 
High-density polymorphism arrays can detect both copy number alterations and copy 
neutral LOH across the whole genome using probes for single nucleotide 
polymorphisms (SNPs) and copy number variants (CNVs) hybridised to a chip. SNPs 
are single nucleotides within the genome for which two distinct bases appear in a 
significant proportion of the population. Copy number variants (CNVs) are regions of 
chromosomes that vary in copy number in humans and are used in polymorphism array 
technology to look for patterns of copy number variation (Feuk et al., 2006).  
The Affymetrix Human SNP 6.0 Array contains more than 906,600 SNP probes and 
more than 946,000 CNV probes which can be used to interrogate the entire human 
genome (McCarroll et al., 2008). When sample DNA is hybridized to the 
oligonucleotide probes on the array a fluorescent signal is emitted. Computational 
algorithms are used to calculate the relative amounts of fluorescent signal detected and 
therefore the relative amount of sample DNA that was bound to the oligonucleotides. 
Data can be generated on the genotype of a SNP (homozygous for allele “A”, 
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heterozygous or homozygous for allele “B”) and the copy number state at each probe 
hybridization site. This allows for the construction of a highly informative integrated 
map of heterozygosity and copy number state across the entire cancer genome. 
Genomic DNA from low passage MCF-10A, First 5 Gγ and 10 Gγ series, Second 5 Gγ 
and 10 Gγ series and relevant passage control populations were sent to Almac 
Diagnostics Ltd (Craigavon, UK) to be analysed using the Affymetrix Human SNP 6.0 
Array platform. Samples were sent in 3 separate batches. DNA from the low passage 
MCF-10A and First irradiation series population was sent in the first batch. DNA from 
the Second irradiation series populations was sent in the second batch and DNA from 
the passage control populations was sent in the third batch. 
2.5.1 Preparation of DNA for SNP array analysis 
Genomic DNA was extracted from low passage MCF-10A and First irradiation series 
cell populations growing in culture using the QIAmp DNA Mini Kit (Qiagen). All 
buffers were provided by the kit and buffer constitutions are unknown. All 
centrifugation was done using the Hettich Mikro 22R centrifuge. 
Cell populations were trypsinised, counted and re-suspended in MCF-10A growth 
medium at a concentration of 5x10
6
 cells/ml. One millilitre of cell suspension was 
added to a 1.5ml eppendorf tube and centrifuged for 5 minutes at 300 x g. The 
supernatant was removed and the cell pellet was re-suspended in 200μl of PBS followed 
by the addition of 20μl of proteinase K to digest proteins within the sample. To remove 
RNA, 4μl of RNaseA (stock 100mg/ml) was added to the sample. The sample was 
mixed with 200μl of lysis buffer (buffer AL) and incubated for 10 minutes at 56°C. The 
sample was mixed with 200μl of ethanol and loaded onto a QIAmp Mini spin column 
that contains a silica gel membrane to which DNA binds. The spin column was 
centrifuged for 1 minute at 6000 x g, the flow through discarded and 500μl of was 
buffer (AW1) was added to the spin column. The spin column was centrifuged for 1 
minute at 6000 x g, the flow through discarded and 500μl of a second wash buffer 
(AW2) was added to the spin column. The column was then centrifuged for 3 minutes at 
20000 x g. The column was transferred to a new 1.5ml eppendorf and 200μl of elution 
buffer (AE) (10 mM Tris-HCl, 0.5 mM EDTA, pH 9.0) was added to the spin column. 
The column was incubated for 1 minute at room temperature and then centrifuged for 1 
minute at 6000 x g to elute the DNA.  
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DNA contained in the flow through was quantified using a NanoDrop® ND-1000 
spectrophotometer which measures the absorbance of UV light at 260 nm passed 
through a 1μl aliquot of extracted DNA, and performs the necessary calculations to 
provide DNA concentration (in ng/μl). For each sample a minimum of 1μg of DNA was 
sent to Almac Diagnostics Ltd (Craigavon, UK) to be analysed using the Affymetrix 
Human SNP 6.0 Array platform.  
Genomic DNA was extracted using the same protocol for the Second irradiation and 
passage control samples, except DNA was extracted directly from pelleted 
cryopreserved cells.  
2.5.2 Data analysis 
Raw-array data was received from Almac Diagnostics Ltd (Craigavon, UK). Initial 
processing of raw data was kindly performed by Dr V. Rand (NICR) using Genotyping 
Console v4.0 software to allow subsequent copy number and LOH analysis of samples 
(Affymetrix, California, USA). Briefly, SNP genotype calls were generated by an 
unpaired comparison to 270 samples from the international Hapmap project, a dataset 
provided by Affymetrix. The birdseed v2 algorithm was used on all samples within an 
array batch to maximise efficiency of the clustering algorithm, followed by quantile 
normalisation of the data. Copy number and LOH analysis was performed using the 
software’s default settings. The detection threshold of copy number alterations was set 
to exclude regions of copy number change smaller than 100 kb and involving fewer 
than 5 markers. Quality control assessment of data was performed by determination of 
the call rate of control SNPs for each sample batch. Call rate of QC SNPs should be 
above 86%. (Batch 1 – median 95.17%, range 90.27 – 97.12; Batch 2 – median 96.16%, 
range 92.36% - 97.98%; Batch 3 – median 94.39, range 92.65 – 96.13).   
Genome copy number differences between samples was analysed using the Affymetrix 
Genotyping Console Browser (v1.1.12). Copy number data was expressed as a log2 
ratio of the relative signal intensity of each SNP. Copy number alterations smaller than 
100 kb were identified by manual interrogation of the data by scanning log2 ratio maps 
of each chromosome. Log2 ratio’s for each SNP could be exported and analysed to 
determine the putative copy number state of altered regions smaller than 100 kb.  
Regions of copy number change from a diploid state and regions of LOH identified by 
the software that were not present in the low passage un-irradiated MCF-10A genome 
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were recorded. Identified copy number alterations in irradiated populations were then 
compared with copy number alterations in the appropriate passage control population 
and any common alterations were excluded from subsequent analysis. 
2.5.3 Analysis of identified regions of copy number change 
For large regions of copy number change comprising many genes a literature search for 
links between the region of the chromosome (i.e. Chromosome 11q) and ‘cancer’, 
‘breast cancer’ and ‘radiation’ was performed using the PubMed literature database 
search engine (http://www.ncbi.nlm.nih.gov/pubmed/) 
For regions of copy number change that comprised less than 10 genes, each gene in the 
region was individually reviewed in the literature for links with ‘cancer’, breast cancer’ 
and ‘radiation’ using PubMed.  
2.6 Gene expression analysis 
The Illumina HT12 v4 expression array was used to analyse the gene expression profile 
of un-irradiated MCF-10A, First and Second 5 Gγ series and passage control 
populations. The HT12 v4 array is a whole genome direct-hybridisation BeadChip array 
which simultaneously profiles 47231 putative transcript sequences using 50-mer probe 
sequences attached to a 29-mer bead address sequence. Biotin labelled sample RNA 
binds to the probe sequences. The signal intensity for each probe is relative to the 
amount of biotin labelled RNA bound to the probe and therefore the abundance of that 
transcript sequence within the sample tested. Probe sequences were designed in silico to 
cover content from the NCBI RefSeq Release 38 including well established and 
provisional annotations of coding and non-coding transcripts. The arrays also include 
internal control sequences which analyse hybridisation efficiency and background 
signal.  
RNA was extracted from growing cell populations and sent to Gen-probe (Manchester, 
UK) who labelled the RNA with biotin and performed the arrays. Signal intensity data 
sent back from Gen-probe was analysed for expression changes between irradiated 
samples and un-irradiated MCF-10A using Ilumina® GenomeStudio V2010.3 software. 
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2.6.1 Preparation of RNA for gene expression analysis 
RNA was extracted using the RNeasy mini kit (Qiagen) according to the manufacturer’s 
instructions. All buffers were provided by the kit and buffer constitutions are unknown. 
All centrifugations were done using the Hettich Mikro 22R centrifuge. 
RNA was extracted from cell populations growing in T75 flasks. Cell populations were 
trypsinised, re-suspended in 1ml PBS and transferred to a 1.5ml eppendorf tube. The 
cell suspensions were centrifuged for 3 minutes at 300 x g to generate a cell pellet. Cell 
pellets were lysed by re-suspension in 350μl of lysis buffer (RLT). Lysate was 
homogenised by passing through a 21G needle 5 times and 350μl of 70% ethanol was 
added. The lysate was loaded onto an RNeasy spin column (which contains a silica gel 
membrane that binds RNA) to which a further 350μl of wash buffer (RW1) was added. 
The spin column was centrifuged for 15 seconds at 8000 x g and the flow through was 
discarded. To remove DNA, 80μl of a DNase I solution (10μl DNase I and 7 μl Buffer 
RDD) was added directly to the spin column membrane and incubated at room 
temperature for 15 minutes. Following incubation, 350μl of wash buffer was added to 
the spin column and centrifuged for 15 seconds at 8000 x g. The flow through was 
discarded, 500μl of a second wash buffer (RPE) was added to the spin column and 
centrifuged for 15 seconds at 8000 x g. This step was repeated but with a centrifuge 
time of 2 minutes. The RNeasy spin column was placed in a new 1.5ml eppendorf, 50μl 
of RNase free water was added directly to the spin column membrane and the RNA was 
eluted following centrifugation for 1 minute at 8000 x g. 
Eluted RNA was quantified using a NanoDrop® ND-1000 spectrophotometer which 
measures the absorbance of UV light at 260 nm passed through a 1μl aliquot of 
extracted RNA, and performs the necessary calculations to provide RNA concentration 
(in ng/μl).  
All RNA samples were sent to Gen-probe (Manchester, UK) in a volume of 25μl with a 
minimum concentration of 50ng/μl to be analysed using the Illumina HT12 v4 
expression array.  
2.6.2 Data analysis 
Raw array-generated probe intensity data files were received by Gen-probe and 
analysed using Ilumina® GenomeStudio V2010.3 software. The data was normalised 
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using quantile normalisation algorithms. All samples passed sample independent and 
sample dependant quality control assessment.   
The software calculates a detection p-value which determines the probability that the 
signal of a given probe is greater than the average signal from internal negative controls. 
Some genes are assessed by more than one probe. The undetected probe may represent a 
splice variant or represent a probe sequence that has not been experimentally verified 
and therefore doesn’t represent expression of the gene it was designed for. Lack of 
detection of one probe within a gene probe set in which all other probes were detected 
could affect subsequent differential expression analysis for that gene. Therefore all 
probes that did not have a detection p-value < 0.05 were removed from subsequent 
analysis.  
Probe intensity data from the First and Second 5 Gγ series samples and appropriate 
passage control samples were compared with probe intensity data from un-irradiated 
MCF-10A to identify any gene expression changes. The ‘Illumina Custom’ differential 
expression algorithm was used to identify differentially expressed genes. Briefly, the 
algorithm assumes that probe signal intensity is normally distributed and calculates the 
variation of signal intensity using three components: sequence specific biological 
variation, non-specific signal variation and technical error variation. The differential 
expression p-value is calculated depending on the difference in signal intensity of a 
probe between 2 samples while taking into account the signal variation of that probe in 
each sample. In the present study there were no replicate samples; therefore specific 
biological variation and technical error variation could not be estimated and variation 
could only be assessed by negative control sequences (non-specific signal variation). If 
the software was not confident that there was a difference in expression for a probe 
between the samples based on this algorithm then a differentiation p-value of 1 was 
attributed to the probe in question. If the software was confident of a difference in 
expression a p-value < 1 was attributed to the probe; however the significance of the 
difference in expression varied. 
A differentiation score was calculated for each probe by the software based on the 
confidence in the difference of expression between samples and the magnitude of this 
difference. For genes with more than one probe, the differentiation score of 
corresponding probes were averaged. A differentiation score was only attributed to 
probes that had a differentiation p-value < 1. In the present study a differentially 
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expressed gene was identified as any gene that had been attributed a differentiation 
score, regardless of the significance of this expression change.  
2.7 Functional clustering analysis 
Genes that were attributed a differentiation score in the 55 Gγ population of the First 5 
Gγ series but were not attributed a differentiation score in the passage control 
population were assessed for functionally related gene clusters using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) (Huang et al., 2009a; 
Huang et al., 2009b), an online gene function clustering tool 
(http://david.abcc.ncifcrf.gov/).  
DAVID identifies genes that share common functions as defined by gene ontology 
(GO) database annotations. Gene ontology terms have a hierarchy from broad to 
specific functional annotations. A list of differentially expressed genes form the 55 Gγ 
population was analysed against the GO FAT database (which filters out the broadest 
functional terms in the hierarchy) for gene clusters attributed to biological process (BP), 
cellular component (CC) and molecular function (MF) gene ontology annotations 
(http://www.ebi.ac.uk/QuickGO/). 
DAVID uses a modified Fisher Exact Test to calculate the probability that an identified 
functionally related gene cluster within a given gene list is not present in that gene list 
by random chance. Briefly, the software compares the proportion of genes in the given 
gene list that clusters to the biological function in question to the number of genes in the 
human genome which are related to the biological function. Gene clusters which were 
not significantly associated with a biological function were excluded from the analysis 
(p value threshold = 0.05).  
Due to the redundant nature of GO annotations in the GO database, DAVID groups GO 
annotations that share common genes between their respective gene clusters. Briefly, 
DAVID compares the clustered genes in each identified cluster with every other gene 
cluster and measures the degree of similarity between the clusters using kappa statistics. 
A score is attributed to each pair of gene clusters between 0 and 1 to indicate how 
closely the clusters agree (0 = no agreement, 1 = perfect agreement). A threshold 
similarity score of 0.85 was set in the present study. Gene clusters which fell below this 
threshold were not grouped together.  
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2.8 Fluorescent in situ hybridisation (FISH) analysis of POU2F1 and c-MYC loci 
In order to confirm copy number alterations identified by SNP array analysis in the 
irradiated series, FISH was performed on fixed cells. Low-passage un-irradiated MCF-
10 cells were assessed for both POU2F1 and c-MYC. First 5 Gγ series populations and 
the appropriate passage control population were only assessed for POU2F1 deletion, the 
Second 5 Gγ series populations and appropriate passage control population were only 
assessed for c-MYC copy number increase.  
2.8.1 POU2F1 FISH probe preparation 
A commercial FISH probe was not available for the POU2F1 locus so a probe had to be 
designed using bacterial artificial chromosome (BAC) clones purchased from the 
Roswell Park Cancer Institute (New York, USA). Appropriate BAC clones were chosen 
using the Ensemble Genome Browser. BAC clones were chosen that were within the 
deleted region on chromosome 1, encompassed the POU2F1 locus, had overlapping 
sequences and were from the 30k clone set (Fig. 2.1). The chosen clones were Chr1tp-
8H10, Chr1tp-8H11 and Chr1tp-8H12.   
Clones were received as bacterial stabs which had to be cultured so that the probe DNA 
could be extracted for labelling with an appropriate fluorochrome.  
 
Figure 2.1 BAC clones chosen to asses POU2F1 copy number  
 
2.8.2 Culture of BAC clones 
Clones were streaked using a sterile inoculation loop onto individual LB agar plates (1% 
(w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 1.5% (w/v) agar in deionised 
water) containing 12.5μg/ml chloramphenicol. The plates were incubated overnight at 
37°C. The following day a single colony was picked from each plate and inoculated in 
The image above is from the Ensemble genome browser and shows the region of chromosome 1 which 
contains POU2F1 (shown in the blue box) and the clones chosen from the 30k clone set to generate a 
FISH probe to assess POU2F1 copy number (clones chosen shown in the red box). 
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separate conical flasks containing 200ml of LB medium (1% (w/v) tryptone, 0.5% (w/v) 
yeast extract, 1% (w/v) NaCl) supplemented with 12.5μg/ml chloramphenicol. The 
cultures were incubated at 37°C overnight in a shaking incubator (C24 Incubator Shaker 
– Edison, NJ, USA).    
2.8.3 Extraction of bacterial DNA for use as FISH probes 
DNA was extracted using the NucleoBond® XtraMidi Kit (Macherey-Nagel). All 
buffers were provided by the kit and buffer constitutions are unknown. The 200ml 
bacterial cultures were split into 4 separate 50ml Falcon™ tubes and centrifuged for 15 
minutes at 5000 x g at 4°C (Heraeus Multifuge 35R+, Thermo Scientific). The 
supernatant was discarded and the cell pellet re-suspended in 4ml of re-suspension 
buffer. The contents of 2 of the tubes were then combined into one single tube resulting 
in two tubes with 8ml of re-suspended material to which 8ml of lysis buffer was added. 
The suspensions were incubated for 5 minutes at room temperature. Following 
incubation, 8ml of neutralising buffer was added to the suspensions and mixed by 
inverting the tubes 15 times. The lysates were then centrifuged at 4°C for 15 minutes at 
5000 x g (Heraeus Multifuge 35R+, Thermo Scientific).   
The lysates were passed through a nucleobond column which has a silica membrane that 
binds DNA and a filter which binds the lysed bacteria. The nucleobond column was first 
equilibrated by applying 12ml of equilibration buffer. Following centrifugation of the 
lysate the supernatant of both tubes was added to the nucleobond column and flow 
through was allowed to pass through the column by gravity flow. The column was then 
washed by applying 5ml of equilibration buffer. The column filter was removed and the 
column washed with 8ml of wash buffer. DNA was then eluted into a fresh 50ml 
Falcon™ tube using 5ml of a high salt elution buffer. 
DNA was precipitated out of the elution buffer. Isopropanol (3.5ml) was added to the 
elute and incubated for 2 minutes at room temperature. The elute was then centrifuged 
at 4°C for 30 minutes at 12000 rpm (Heraeus Multifuge 35R+, Thermo Scientific). 
Following centrifugation the supernatant was removed and 2ml of 70% ethanol (diluted 
in deionised water) was added to the pellet. The pellet was centrifuged at room 
temperature for 5 minutes at 12000 rpm (Heraeus Multifuge 35R+, Thermo Scientific). 
Following centrifugation the pellet was allowed to air dry and then reconstituted in 
200μl of distilled water.  
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2.8.4 Fluorescent labelling of extracted DNA 
DNA extracted from the BAC clones was fluorescently labelled using a Nick 
Translation Kit (Abbott Molecular, Berkshire, UK). Equal amounts of dATP, dCTP and 
dGTP were first mixed together to create a dNTP mix. dTTP was diluted separately in 
nuclease free water at a ratio of 1:2. In an eppendorf tube 10μl dNTP, 5μl dTTP, 5μl of 
NT buffer and 2.5μl of green labelled (5-Fluorescein) dUTP (Enzo Life Sciences, 
Exeter, UK) was mixed per DNA sample to be labelled. To this mix 17.5μl of extracted 
DNA was added followed by 10μl of Nick Translation enzyme mix (exact constitution 
unknown but most likely contains DNase to nick DNA strands and E.coli polymerase 1 
to add fluorescently labelled nucleotides to the nicked DNA). The mixture was 
incubated at 15°C overnight on a chilling block (PCH-1, Grant-Bio).   
The following day the reaction was stopped by the addition of 3μl of 0.5M EDTA. 
Unlabelled probe was removed by passing through quant Sephadex™ columns (GE 
Healthcare, Buckinghamshire, UK). The columns purify DNA by gel filtration which 
does not allow unbound probe to be eluted. First the resin in Sephadex™ columns was 
re-suspended by vortexing, centrifuged, and the flow through discarded. The labelled 
DNA sample (50μl) was pipetted into the centre of the resin within the column and the 
column was centrifuged for 2 minutes at 4000 rpm (Centrifuge 5419, Eppendorf). Ten 
microliters of human cot-1 DNA was then added to the eluted DNA to bind repetitive 
sequences present in the probe DNA. A 1 in 10 volume of 3M sodium acetate was 
added followed by 2.5 times the volume of ice cold ethanol. The samples were 
incubated at -20°C for 3 hours and then centrifuged for 30 minutes at 13000 rpm at 4°C 
(Centrifuge 5415, Eppendorf). The supernatant was removed and the pellet re-
suspended in 14μl of hybridisation buffer (Cytocell, Cambridge, UK) and 6μl of 
nuclease free water. The probes were then stored at -20°C until ready for use.  
2.8.5 Preparation of c-MYC and centromere 8 probes 
For copy number analysis of c-MYC the Vysis LSI SpectrumOrange Probe (Abbott 
Molecular, Berkshire, UK – Cat#:05J545-011) which hybridises a 120kb region 
spanning the c-MYC gene and the CEP8 SpectrumGreen Probe (Abbott Molecular, 
Berkshire, UK – Cat#:06J37-018) which hybridises to the 8p11.1-q11.1 region of 
chromosome 8 were used.  
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Each probe was diluted 1:5 in hybridisation buffer (delivered with each probe) and then 
mixed together in a 1:1 ratio (c-MYC/CEP8 probe mix). 
2.8.6 Preparation of POU2F1 and centromere 1 probes 
For copy number analysis of POU2F1 the 3 green fluorophore labelled probes (Chr1tp-
8H10, Chr1tp-8H11 and Chr1tp-8H12) (section 2.8) which hybridise to DNA within the 
focal deleted region on chromosome 1q and the Spectrum Red Chromosome 1 Classic 
Satellite Probe (Cytocell, Cambridge, UK – Cat#LPE001R) which hybridises to the 
centromere of chromosome 1 were used. 
The 3 green fluorophore labelled probes were mixed in equal quantitates. The Spectrum 
Red Chromosome 1 Classic Satellite Probe was diluted 1:10 with hybridisation buffer 
provided with the probe. The POU2F1 probe mix and centromere probe was then mixed 
in a 1:1 ratio ready for FISH (POU2F1 probe mix). 
2.8.7 Cell line fixation protocol 
Cells were grown to approximately 60% confluence in T25 flasks. At the time of 
fixation growth medium was replaced with 7ml of normal MCF-10A growth medium 
containing 70μl of KaryoMAX colcemid solution (10μg/ml stock concentration – 
Invitrogen, Paisley, UK) and incubated for 1 hour at 37°C/5% CO2 in an attempt to 
arrest cells in metaphase. Following incubation cells were trypsinised, centrifuged for 5 
minutes at 1500 rpm (Beckman Allegra X-12 R rotor SX 4750) and then re-suspended 
in 1 ml of 0.75M KCl. The suspension was incubated for 10 minutes at 37°C to cause 
the cells to swell, and then centrifuged for 3 minutes at 1000 rpm (Beckman Allegra X-
12 R rotor SX 4750). The supernatant was discarded and 1ml of fixative (3:1 
methanol:acetic acid) was added slowly, followed by a further 4ml of fixative. The 
fixed cells were then pelleted, re-suspended in 1ml of fixative, transferred to 2ml micro 
tubes (Sarstedt, Leicester, UK) and stored at -20°C until ready for use. 
2.8.8 Preparation of samples for FISH 
Samples were centrifuged for 2 minutes at 13000 rpm (Centrifuge 5419, Eppendorf). 
The fixative was removed and the cells re-suspended in fresh fixative (3:1 
methanol:acetic acid). Three microliters of sample was added onto a Superfrost 
microscope slide (Thermo Scientific, West Sussex, UK) and allowed to air dry for 10-
15 minutes at 60°C (REC, Digital Heating Ceramic Plate). 
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2.8.9 Probe hybridisation 
Once the cell spots had dried (section 2.9.2) 2μl of appropriate probe mix was added to 
a round coverslip (VWR International Ltd, Leicestershire, UK) and the coverslip placed 
over the cells. The edges around the coverslip were sealed with rubber cement. Slides 
were placed on a humidified hybridisation block (HYBrite™, Abbott Molecular, 
Berkshire, UK) and heated to 72°C for 5 minutes to denature the probe and nuclear 
DNA. The slides were then incubated for 24 hours (c-MYC/CEP8 probe mix) or 48 
hours (POU2F1 probe mix) in the humidified hybridisation chamber at 37°C to allow 
hybridisation of probe to its target sequence. 
2.8.10 Processing of slides following FISH 
The slides were taken from the humidified hybridisation blocks after the appropriate 
length of time and the rubber cement surrounding the coverslips removed. To remove 
the coverslips the slides were soaked in 20X SSC solution (3M NaCl, 300mM trisodium 
citrate – Invitrogen) diluted 1:10 in deionised water. The slides were then soaked in 
Wash 1 solution (2% (v/v) 20X SSC, 0.3% (v/v) NP40 in deionised water) for 2 minutes 
at 72°C followed by being soaked in Wash 2 solution (10% (v/v) 20X SSC, 0.1% NP40 
in deionised water) for a further 2 minutes at room temperature. The slides were 
removed from the wash, allowed to dry and then 3μl of DAPI (Vector Laboratories, 
Peterborough, UK) was loaded onto the slide at each cell spot as a nuclear counterstain. 
The cell spots were then covered with a cover slip ready for analysis. 
2.8.11 Analysis of FISH 
Cells were analysed using an Olympus BX61 fluorescent microscope with an X-cite 
120 mercury bulb and CytoVision camera and imaging software (Leica Microsystems, 
Newcastle Upon Tyne, UK). Filters allowing the appropriate wavelengths of light 
through to excite each probe were used to visualise probe staining and DAPI 
counterstaining (Table 2.2). 
For each sample analysed 100 nuclei were scored and the combination of probe signals 
per nuclei recorded. Blind second scoring of 6/14 samples produced results that were 
not different to the first scoring (χ2: p>0.05). Photographs were taken using the 
CytoVision image capture system (Leica Microsystems, Newcastle Upon Tyne, UK) at 
x40 magnification for use as representative images of the different genotypes observed. 
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Probe Filter 
Excitation 
wavelength 
Emission 
wavelength 
DAPI DAPI 359 461 
POU2F1 Spectrum Green 497 524 
c-MYC Spectrum Orange 559 588 
CEP8 Spectrum Green 497 524 
Centromere 1 Spectrum Orange 559 588 
Table 2.2 Excitation and emission wavelengths for each probe and counterstain used during FISH. 
2.9 G-band karyotyping and metaphase FISH 
Fixed cell preparations with metaphase chromosome spreads were generated by David 
Rowe (Institute of Genetic Medicine, Newcastle, UK) from low passage un-irradiated 
MCF-10A cells and cells from the Second 5 Gγ series that had received a cumulative 
dose of 80 Gγ. David Rowe also karyotyped the samples. 
2.9.1 Fixed cell preparation 
Briefly, growing cells were treated with colcemid and incubated for 4 hours at 37°C/5% 
CO2. The cells were then trypsinised, suspended in 0.075 KCl for 7 minutes and then re-
suspended in fixative (3:1 - methanol:acetic acid).  
Fixed cells were re-suspended in fresh fixative to a suitable cell density and a single 
drop of sample was dropped at one end of a Superfrost® microscope slide and allowed 
to run down to the end of the slide (Thermo Scientific, West Sussex, UK). For G-band 
karyotyping the slides were incubated overnight at 60°C.  
2.9.2 G-band karyotyping 
Preparations were made of banding trypsin (0.5g of trypsin powder in 10 ml distilled 
water), saline solution (0.9% (w/v) NaCl in distilled water) and staining solution (8 ml 
Giemsa stain, 0.5 ml Leishmans stain and 40 ml Gurr buffer).  
Slides were soaked and agitated in trypsin solution (2 ml banding trypsin, 25 ml saline 
solution, 25 ml Gurr buffer) for 7-10 seconds and then immediately transferred and 
twice soaked in saline solution. The slides were rinsed in distilled water and placed in 
staining solution for 3 minutes. The slides were then rinsed thoroughly in distilled water 
and mounted with a coverslip using DPX Mountant. 
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Twenty metaphase chromosome spreads were analysed for each population and the G-
band karyotypes recorded.  
2.9.3 Metaphase FISH 
Slides with metaphase chromosomes were analysed using FISH. The low-passage 
MCF-10A sample was analysed for c-MYC and POU2F1 using the protocols outlined in 
section 2.9. The Second 5 Gγ series 80 Gγ population was only analysed for c-MYC 
copy number. Twenty metaphase chromosome spreads were analysed for each 
population. 
2.10 Western transfer analysis 
Protein expression of POU2F1 was analysed in protein extracts from the First 5 Gγ 
series and c-MYC expression in protein extracts from the Second 5 Gγ series to 
determine if expression change was concomitant with change in copy number. Protein 
extracts were made from cells growing in T25 flasks. Three independent extracts were 
made per cell population analysed. Relative expression between each population was 
analysed for each extract by western transfer and densitometric analysis. Expression of 
GAPDH was analysed in each population as a protein loading control as it was not 
expected that expression of GAPDH would differ between populations.    
2.10.1 Protein extraction 
Cells were grown in T25 flasks to at least 60% confluence. Cells were first washed with 
cold PBS and then lysed with 1ml of radioimmunoprecipitation assay buffer (RIPA) 
(50mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1% (w/v) NP-40 and 0.25% (w/v) 
sodium deoxyxholate) supplemented with 1μg/ml pepstatin, 1μg/ml aprotinin, 1μg/ml 
leupeptin, 2mM sodium orthovanadate, 2mM sodium fluoride and 2mM phenyl methyl 
sulphonyl fluoride, which are protease inhibitors. After addition of the RIPA buffer 
cells were kept on ice with gentle agitation for 30 minutes. The cell lysate was 
transferred to 1.5ml centrifuge tubes (Sarstedt, Leicester, UK) and centrifuged at 14000 
rpm (Hettich Mikro 22R) for 10 minutes at 4°C. The supernatant was collected and 
stored at -70°C. 
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2.10.2 Protein quantification 
Protein concentration was measured using the Pierce® bicinchoninic acid (BCA) 
colourimetric assay. Known concentrations of protein ranging from 0.2-2mg/ml were 
prepared by re-suspending BSA in RIPA buffer and diluted 1:10 in deionised water for 
later use in generating a standard curve. Lysate aliquots of 0.5μl were also diluted in a 
1:10 ratio in deionised water. BCA assay reagents A and B (Thermo Scientific, West 
Sussex, UK) were mixed at a ratio of 50:1. Ninety five microliters of the mixture was 
added to 5μl of each protein standard and diluted lysate. The samples were incubated 
for 30 minutes at 37°C. Following incubation, samples were placed on ice and the 
absorbance at 562 nm was measured using a spectrophotometer (Beckman DU 640). A 
standard curve was generated using the protein standards and unknown protein 
concentrations of the cell lysates were interpolated using the line of best fit from the 
standard curve (correlation coefficient: R
2
 < 0.98).   
 2.10.3 Polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis was used to 
separate proteins. The acrylamide to bisacrylamide ratio was 200:1 (w/w) for the 
separating gel and contained 12% polyacrylamide (v/v), 0.5M Tris-HCl pH 8.8, 0.1% 
(w/v) SDS, 0.05% (w/v) ammonium persulphate and 0.1% (v/v) N, N, N’, N’-
tetramethylethylenediamine (TEMED). The acrylamide to bisacrylamide ratio was 20:1 
(w/w) for the stacking gel and contained 3% polyacrylamide (v/v), 125mM Tris-HCl pH 
6.8, 0.1% (w/v) SDS. The separating gel was applied to a vertical gel cast (Hoeffer) and 
allowed to polymerise for 45 minutes followed by the stacking gel which was allowed 
to polymerise for 15 minutes. A lane comb was positioned at the top of the gel cast as 
the stacking gel was applied to create lane positions in which protein sample could be 
placed. 
Cell lysate aliquots containing 10μg of protein were mixed with 10μl of 124mM Tris-
HCl, 25mM Na2EDTA, 4% (w/v) SDS, 20% (w/v) glycerol, 0.01% (w/v) bromophenol 
blue and 10% (v/v) β-mercaptoethanol pH 6.8, made up to a total volume of 20μl using 
RIPA buffer and boiled for 10 minutes. Samples were then placed in the lanes 
positioned in the stacking gel. Protein markers of known molecular mass (Full Range 
rainbow Marker – GE Life Sciences) were placed alongside samples. 
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Protein samples were electrophoresed in Mighty Small II electrophoresis chambers 
(Amersham Pharmacia) using a running buffer of 0.5M Tris-HCl, 0.38 M glycine, 0.1% 
SDS (w/v) at a constant current of 10mA per gel. 
2.10.4 Western transfer 
Proteins separated by polyacrylamide gel electrophoresis were transferred onto Westran 
0.45μM nitrocellulose membrane (VWR International Ltd, Leicestershire, UK) using a 
semi-dry transfer apparatus (S&S CarboGlas, Peglab, PerfectBlue). From anode to 
cathode the transfer sandwich comprised two sheets of Whatman 3mm chromatography 
paper soaked in 0.3M Tris, 20% (v/v) methanol, one sheet soaked in 25mM Tris, 20% 
(v/v) methanol, nitrocellulose membrane soaked in 25mM Tris, 20% (v/v) methanol, the 
polyacrylamide separating gel the proteins are bound in and three sheets of Whatman 
3mm chromatography paper soaked in 25mM Tris, 40mM 6-aminocaproic acid, 20% 
(v/v) methanol. The transfer sandwich was electrophoresed at 100mA per gel for 45-60 
minutes to allow protein transfer. 
Following transfer the membranes were dried overnight, rehydrated in deionised water 
and washed 3 times for 5 minutes in 25ml 20mM Tris-HCl, 140mM NaCl, 0.1% (v/v) 
Tween 20 (TBS-Tween). The membranes were then blocked in 5% (w/v) milk in TBS-
Tween solution for 60 minutes at room temperature with gentle shaking. Following 
blocking, membranes were washed a further 3 times for 5 minutes in TBS-Tween 
solution and then incubated with primary antibody for c-MYC (Santa Cruz 
Biotechnology, California, USA – Cat#: N-262) or POU2F1 (Santa Cruz Biotechnology, 
California, USA – Cat#: POU51097) (Table 2.3) (depending on the sample analysed) 
diluted in 5ml 5% milk (w/v) in TBS-Tween in 50ml tubes agitated on rollers overnight 
at 4°C. Following incubation with primary antibody, membranes were washed a further 
3 times in TBS-Tween and then incubated with horse-radish peroxidase conjugated 
secondary antibody (Thermo Scientific, West Sussex, UK) (Table 2.3) diluted in 5ml 5% 
milk in TBS-Tween in 50ml tubes agitated on rollers at room temperature for 90 
minutes. Following incubation with secondary antibody, membranes were washed a 
further 3 times in TBS-Tween and once in TBS.   
The membranes were incubated in Supersignal West Dura Extended Duration Substrate 
Chemiluminescent Solutions Luminol/Enhancer mixed with Peroxide buffer in a 1:1 
ratio for 5 minutes and exposed to x-ray film (Fuji, SuperRX) and developed. Exposure 
times varied (Table 2.3). 
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After analysis of POU2F1 and c-MYC expression, membranes were washed 3 times for 
5 minutes in TBS-Tween solution and then analysed for GAPDH (Santa Cruz 
Biotechnology, California, USA – Cat#: FL-335) expression following the protocol 
above (beginning at incubation in primary antibody).  
1° Antibody Dilution 2° Antibody Dilution Exposure time   
POU2F1 1:1000 Mouse 1:1000 < 5 mins 
c-MYC 1:5000 Rabbit 1:2500 < 1 min 
GAPDH 1:5000 Rabbit 1:5000 < 10 secs 
Table 2.3 Antibody dilutions and exposure times 
2.10.5 Densitometric analysis 
The x-ray film was digitally scanned and the densitometry of each protein band was 
analysed using the Lab Works 4.0 software. The background of the x-ray film was 
subtracted from the analysis. Variations in the amount of protein loaded for each sample 
was normalised using GAPDH densitometry values. Protein expression of c-MYC and 
POU2F1 for irradiated and passage control samples was expressed as the percentage of 
expression relative to un-irradiated MCF-10A. Mean expression was calculated from 
comparative densitometric analysis of 3 independent protein extracts per population.  
2.11 Genotoxic stress assays  
Growth inhibition was compared between low passage un-irradiated MCF-10A cells 
and cells from the First 5 Gγ series which had received a cumulative dose of 80 Gγ of 
radiation following treatment with different concentrations of hydrogen peroxide (H2O2) 
and doxorubicin, both of which cause DNA damage. Resazurin was used to test the 
relative amount of viable cells in each population at each concentration. These 
experiments were kindly performed by Dr N. Sunter. 
2.11.1 Growth inhibition assay with H2O2  
Cells were trypsinised, counted using a haemocytometer and re-suspended in 7ml of 
growth medium at a concentration of 4 x 10
4
 cells/ml. Ninety microliters of cell 
suspension was seeded per well in 60 wells of a 96 well plate and grown for 24 hours at 
37°C/5% CO2. A 1M H2O2 solution was prepared by addition of 102μl of 9.8 M H2O2  to 
898μl of MCF-10A growth medium and a 100mM solution was prepared from this by a 
10 fold dilution in MCF-10A growth medium. Using this dilution 9 separate 
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concentrations of H2O2 were prepared using MCF-10A growth medium and 10μl of 
each concentration was added to 6 wells per concentration (Table 2.4). 
Concentration of H2O2 (nM) Final concentration of  H2O2 (nM) per well 
4500 450 
4000 400 
3500 350 
3000 300 
2500 250 
2000 200 
1500 150 
1000 100 
500 50 
0 (growth medium) 0 
Table 2.4 Concentrations of H2O2 used in growth inhibition assay 
Plates were incubated for 24 hours at 37°C/5% CO2 and then examined by the resazurin 
assay (Section 2.12.3).     
2.11.2 Growth inhibition assay with doxorubicin  
Cells were trypsinised, counted using a haemocytometer and re-suspended in 4ml of 
growth medium at a concentration of 2 x 10
4
 cells/ml for un-irradiated MCF-10A and 3 
x 10
4
 cells/ml for cells from the First 5 Gγ series that had received a cumulative dose of 
80 Gγ. Ninety microliters of cell suspension was seeded per well in 30 wells of a 96 
well plate and grown for 24 hours at 37°C/5% CO2. A 0.1mM doxorubicin solution was 
prepared by addition of 30μl of 1mM doxorubicin to 270μl of MCF-10A growth 
medium. Four separate concentrations of doxorubicin were prepared by ten-fold serial 
dilutions of the 0.1mM solution in MCF-10A growth medium (Table 2.5). A solvent 
control was also prepared by addition of 0.1% (v/v) DMSO in growth medium as 
doxorubicin stock solution contains DMSO.  Five microliters of each doxorubicin 
concentration was added to 6 wells per concentration (Table 2.5). 
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Concentration of 
doxirubicin (nM) 
Final concentration of  
doxirubicin (nM) per well 
100000 10000 
10000 1000 
1000 100 
100 10 
DMSO 0.1% (v/v) Solvent control 
Table 2.5 Concentrations of doxirubicin used in growth inhibition assays 
Plates were incubated for 72 hours at 37°C/5% CO2 and then examined by resazurin 
assay (Section 2.12.3).     
2.11.3 Resazurin assay 
Resazurin is a non-toxic, cell permeable compound, which upon entering cells is 
reduced to resorufin. Resorufin is red in colour, is fluorescent and is released into 
growth medium by cells when it is produced. Metabolically active cells continuously 
convert resazurin to resorufin so the relative fluorescence and colour of the media 
surrounding cells can be used to compare the relative number of viable cells between 
samples.  
Ten microliters of 100μg/ml resazurin was added to each well containing cells 
following treatment with either H2O2 or doxorubicin. The cells were incubated for 4 
hours at 37°C and then fluorescence of the growth medium was analysed using a 
FLUOstar Omega microplate reader (BMG Labtech). Resofurin is excited at a 
wavelength of 560 nm and emission is detected at 580 nm. Fluorescent readings from 
multiple wells were used to calculate the mean relative amount of viable cells at each 
concentration of H2O2 or doxorubicin treatment as a percentage of the number of viable 
cells in a non-treated control. 
2.12 DNA repair gene expression analysis 
Expression of DNA repair genes was compared between low passage un-irradiated 
MCF-10A cells and cells from the First 5 Gγ series which had received a cumulative 
dose of 80 Gγ using a RT2 Profiler PCR Array (SABiosciences, Maryland, USA).   
2.12.1 RNA extraction  
RNA was extracted from cell populations growing in T75 flasks using the RNeasy mini 
kit (Qiagen) according to the manufacturer’s instructions. The extraction protocol was 
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the same as in section 2.6 except the cell lysate was homogenised by adding the lysate 
directly into a QIAshredder spin column which was centrifuged for 2 minutes at 8000 x 
g (Hettich Mikro 22R). Extracted RNA was quantified using a NanoDrop® ND-1000 
spectrophotometer. 
2.12.2 First strand cDNA synthesis 
cDNA was synthesised from extracted RNA using the RT
2
 First Strand Kit 
(SABiosciences, Maryland, USA) following manufacturer’s instructions.    
The first step was a genomic DNA elimination procedure whereby 1μg of RNA was 
mixed with 2μl of 5X genomic DNA elimination buffer, made to a final volume of 10μl 
with RNAse free water and incubated for 5 minutes at 4°C. Following incubation the 
genomic DNA elimination mixture was put directly on ice. Ten microliters of a reverse 
transcription (RT) cocktail containing RT buffer, primers and RT enzyme was added to 
the genomic DNA elimination mixture and incubated for 15 minutes at 42°C. Following 
incubation the RT reaction was stopped by heating the samples for 5 minutes at 95°C. 
The sample was then diluted in 91μl RNAse free water.  
2.12.4 DNA repair gene array 
A 96 well RT
2
 Profiler PCR Array (SABiosciences, Maryland, USA) was used to 
analyse relative expression of DNA repair genes using synthesised cDNA. The first 
strand cDNA synthesis mixture was mixed with 1350μl of SABiosciences RT2 qPCR 
Master Mix and was made to a total volume of 2700μl with water. Each well of the 96 
well RT
2
 Profiler PCR Array was loaded with 25μl of sample. The 96 well plate was 
sealed and centrifuged for 1 minute at 1000 x g (Sigma 4K15C) to remove bubbles and 
then placed on ice.  
The 7300 Real Time PCR System (Applied Biosystems, Califormia, USA) was used to 
run the real time qPCR using default baseline and threshold settings. The cycling 
programme used is shown in table 2.6. Cycle time (Ct) values were calculated 
automatically for each well of the array by the Sequence Detection Software V.1.3.1.21 
(Applied Biosystems, Califormia, USA). Data from the array was uploaded to the 
SABiosciences PCR array data analysis online portal 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) which analyses the 
array QC and compares gene expression between different arrays. Expression data from 
the low passage un-irradiated MCF-10A sample was used as the control dataset to 
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which expression data from the 80 Gγ population was compared.  Arrays for both 
populations passed Reverse Transcription QC (∆ Ct ≤ 5) and genomic DNA 
contamination QC (Ct
GDC ≥ 35). 
Stage Cycles 
Duration 
(minutes) 
Temperature 
(°C) 
1 1 10:00 95 
2 40 
00:15 95 
01:00 60 
3 1 
00:15 95 
00:30 60 
00:15 95 
Table 2.6 qPCR repair gene cycle programme. 
2.13 Breast cancer tissue samples 
A cohort of paraffin embedded breast cancer tissue samples from 18 women who had 
received radiotherapy for Hodgkin lymphoma were available from the National Cancer 
Registries of Finland (n=8) and Sweden (n=10) (radiogenic breast cancer samples) and 
were kindly provided by Prof. L.B. Travis (University of Rochester Medical Centre). 
Estimates of the radiation dose delivered to the specific location in the breast where the 
cancer developed were made following review of relevant tumour and radiotherapy 
records by a radiation oncologist (M. Gospodarowiscz, Ontario Cancer Institute) and 
radiation physicist (M. Stovall, The University of Texas M.D. Anderson Cancer Centre) 
as described by Travis et al. (2003). Briefly, dose estimates were derived using standard 
radiotherapy techniques and if tumours occurred outside the nearest measurement field, 
out-of-beam measurements using a water phantom were used (Stovall et al., 1989). Data 
on age at Hodgkin lymphoma diagnosis, age at breast cancer diagnosis, stage and 
pathology of breast cancer, quadrant of the breast the tumour developed in and any 
chemotherapy treatment received by the individual for Hodgkin lymphoma was also 
available for each case. 
An age matched cohort of paraffin embedded breast cancer tissue samples from 
individuals with no history of prior cancer or therapeutic radiation exposure were 
provided by Dr F. May (sporadic breast cancer). Age at the time of breast cancer 
diagnosis was available for these samples. 
All tissues samples used were obtained following appropriate ethical approval. 
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2.14 Protein expression analysis of breast cancer tissue samples 
Paraffin wax tissue sections of radiogenic and spontaneous breast cancer samples 
(section 2.15) were analysed for expression of c-MYC and POU2F1 by 
immunohistochemistry (IHC). Tissue section preparation and immunohistochemical 
staining using c-MYC and POU2F1 antibodies was performed by Anna Long 
(Histopathology Assistant, NICR, Newcastle University). Estimates of the percentage of 
nuclei in each section which were from tumour cells were also provided by Anna Long.  
2.14.1 c-MYC and POU2F1 IHC 
Sections were cut from formalin-fixed, paraffin-embedded tissue blocks using a Microm 
rotary microtome at 5μm thickness. The sections were floated in a water bath heated to 
50°C to flatten out the sections and then mounted on to Superfrost™ adhesion slides 
(Thermo Scientific, West Sussex, UK). The slides were dried in a slide warmer (RA-
Lamb) for 90 minutes at 60°C. Following this, slides were soaked in xylene for 5 
minutes to de-wax the sections. The slides were then soaked in absolute, 95% (v/v), 70% 
(v/v) and 50% (v/v) ethanol diluted in distilled water in sequence to re-hydrate the 
sections. The slides were pressure cooked in TE buffer (p.H 9) for 30 seconds at 125°C 
using the Menapath Antigen Access Retrieval Unit (A.Menarini Diagnostics) and 
allowed to cool at 105°C. This step breaks the crosslinks formed during formalin 
fixation and exposes the target epitopes to staining with the appropriate antibodies. The 
slides were rinsed in tap water and the sections were incubated for 10 minutes at room 
temperature in 3% (v/v) hydrogen peroxide solution. The hydrogen peroxide was rinsed 
off and the slides soaked in TBS-Tween solution (20mM Tris-HCl, 140mM NaCl, 0.1% 
(v/v) Tween 20).  
The sections were soaked in the appropriate antibody for 60 minutes to detect the target 
epitope. The c-MYC rabbit monoclonal antibody (Epitomics, California, USA – 
Cat#:1472-1) was diluted in a 1:75 ratio with TBS buffer (pH 7.6), and the POU2F1 
rabbit polyclonal antibody (Abcam, Cambridge, UK – Cat#: Ab15152) was diluted in a 
1:50 ratio with TBS buffer (pH 7.6). Following incubation in antibody the slides were 
rinsed twice in TBS-Tween for 5 minutes each and then incubated in Menapath HRP-
Polymer (A.Menarini Diagnostics) for 30 minutes at room temperature. The slides were 
rinsed in running tap water for 10 minutes and then incubated in Menapath DAB (3.3’ 
diaminobenzidine) solution for 5 minutes. The slides were once more rinsed in running 
water for 10 minutes before the sections were counter-stained in Gills II Haematoxylin 
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(Thermo Scientific, West Sussex, UK). The slides were soaked in 70% (v/v), 95% (v/v) 
and absolute ethanol diluted in distilled water in sequence to dehydrate the sections. The 
slides were finally rinsed in xylene and mounted in DPX for analysis.  
2.14.2 IHC analysis 
Sections stained with antibody specific to POU2F1 were assessed by Anna Long and 
samples were designated as POU2F1 positive or negative depending if staining 
appeared in cancer cell nuclei. 
Sections stained with antibody specific to c-MYC were also assessed by Anna Long. 
Nuclei of 500 cancer cells across 5 independent fields (100 cells per field) per sample 
were analysed for c-MYC staining. Each nuclei analysed was attributed a score between 
0 and 3 depending on the expression of c-MYC. A score of 0 represented no c-MYC 
staining; a score of 1 represented weak staining for c-MYC; a score of 2 represented 
moderate staining for c-MYC; and a score of 3 represented strong staining for c-MYC. 
A histoscore was then calculated for each sample analysed as the sum of the expression 
scores given to each nucleus within a sample. Results from blind second scoring of 30% 
of samples were not different compared to results from the first scoring (χ2: p>0.05). 
Images of stained sections were captured using the PALM Microbeam System 
(P.A.L.M. Microlaser Technologies GmbH, Germany) in conjunction with the Zeiss 
Axio Observer inverted microscope (Carl Zeiss Ltd., Welwyn Garden City, UK). The 
microscope was fitted with PALM RoboStage II for precise slide movement and a CCD 
camera (Hitachi Kokusai Electric Europe GmbH).  All components were controlled by 
the PALM RoboSoftware (version 4.0.0.10). The magnification used for all images was 
X40. 
2.15 FISH in breast cancer tissue samples 
In order to determine if copy number increase at the c-MYC locus was common to 
radiogenic breast cancer, FISH was performed on nuclei isolated from paraffin wax 
tissue sections of radiogenic and spontaneous breast cancer samples (Section 2.15).  
2.15.1 Preparation of whole nuclei from paraffin wax tissue sections 
Nuclei were isolated from paraffin tissue sections by Dr S. Crosier of the Cellular 
Pathology Department at the Royal Victoria Infirmary, Newcastle, UK. 
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Twenty micrometre paraffin curls were cut from paraffin blocks and placed into 
separate tubes (Reichart Jung microtome). The curls were de-paraffinised by two, 5 
minute incubations in Xylene (VWR International Ltd, Leicestershire, UK). The 
paraffin curls were rehydrated by three 1 minute incubations in 100% ethanol. The 
alcohol was drained off and the sample was re-suspended in molecular grade distilled 
water and incubated for 10 minutes at room temperature. The molecular grade distilled 
water was aspirated off and the sample was re-suspended in 0.5 ml proteinase K 
solution and incubated for 30 minutes at 37°C to digest proteins surrounding the nuclei 
(0.005% proteinase K in 0.05M Tris-HCl pH 7.5, 0.01M EDTA, 0.01M NaCl). The 
protease digestion was stopped by adding 1ml of 2X PBS. Aggregates were broken up 
by gentle pipetting and then 1ml of molecular grade methanol was added. The samples 
were placed on a plate shaker for 10 minutes to disaggregate the samples further. One 
hundred microliters of sample was placed into a cytospin cartridge and cytospun for 5 
minutes at 1000 rpm onto labelled superfrost microscope slides. The slides were stored 
at 4°C until required. 
2.15.2 Protease treatment of isolated nuclei 
A further protease pre-treatment of the cytospun isolated nuclei was required in order to 
expose target sequence to FISH probes. Two protocols were used in the present study. 
All samples were tested by FISH using both pre-treatment protocols. FISH only worked 
in 20 out of 33 isolated nuclei slides from sporadic breast cancer samples and 9 out of 
18 isolated nuclei slides from radiogenic breast cancer samples. 
2.15.3 Protease pre-treatment – protocol 1 
All 20 of the sporadic and 3 out of 9 of the radiogenic samples for which c-MYC FISH 
worked were pre-treated with protocol 1. All washes and incubations were in coplin jars, 
unless otherwise stated, with no more than 6 slides per coplin jar. 
Slides were soaked in 70% (v/v) acetic acid diluted in distilled water for 20 seconds The 
slides were then immediately soaked in Methanol for 10 minutes after which the slides 
were air dried. RNAse (100μg/ml in 2X SSC) was loaded onto the nuclei, covered with 
a cover slip and incubated for 30 minutes at 37°C in a humidified hybridisation chamber 
(HYBrite™, Abbott Molecular, Berkshire, UK). Following incubation, slides were 
washed twice in 2X SSC for 5 minutes each and the cover slips were removed. The 
slides were then washed for 2 minutes each in 70% (v/v), 90% (v/v) and 100% (v/v) 
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ethanol diluted in distilled water, after which the slides were air dried. Pepsin at a 
concentration of 1mg/ml in 0.01M HCl was loaded onto the nuclei, covered with a 
cover slip and incubated for 30 minutes at 37°C in a humidified hybridisation chamber 
(HYBrite™, Abbott Molecular, Berkshire, UK). Following incubation, slides were 
washed three times in 50mM MgCl2 diluted in PBS for 2 minutes each and the cover 
slips removed. The slides were then washed for 2 minutes each in 70% (v/v), 90% (v/v) 
and 100% (v/v) ethanol diluted in distilled water, after which the slides were air dried 
ready for FISH. 
2.15.4 Protease pre-treatment – protocol 2 
Only 6 out of 9 of the radiogenic samples produced clearer probe staining after pre-
treatment with protocol 2 compared to protocol 1. All washes and incubations were in 
coplin jars with no more than 6 slides per coplin jar. 
Slides were soaked in 0.2M HCl for 20 minutes and then washed in water for 3 minutes. 
Slides were washed in 2X SSC for 3 minutes before being soaked in 1M NaSCN diluted 
in water for 30 minutes at 80°C. Following incubation, slides were washed in water for 
1 minute and then twice in 2X SSC for 5 minutes each. Pepsin was added to saline 
solution (0.9% NaCl (w/v) in distilled H2O) to make a final concentration of 4mg/ml. 
Slides were incubated in the pepsin/saline solution for 15 minutes at 37°C. Following 
incubation slides were washed twice in 2X SSC for 5 minutes each and air dried ready 
for FISH. 
2.15.5 c-MYC FISH on pre-treated isolated nuclei 
The Vysis LSI SpectrunOrange Probe (Abbott Molecular, Berkshire, UK) and CEP8 
SpectrumGreen Probe (Abbott Molecular, Berkshire, UK) were each diluted 1:10 in 
hybridisation buffer provided with each probe. Each probe was analysed separately for 
each nuclei sample as analysis of the c-MYC/CEP8 probe mix (section 2.9) did not 
produce strong enough signal for the probes to be analysed together.  
Following dilution of the FISH probes, 2μl of probe was added to a round coverslip 
(VWR International Ltd, Leicestershire, UK) and the coverslip placed over the nuclei. 
The edges around the coverslip were sealed with rubber cement. Slides were placed in a 
humidified hybridisation chamber (HYBrite™, Abbott Molecular, Berkshire, UK) and 
heated to 85°C for 30 minutes to denature the probe and nuclear DNA. The slides were 
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then incubated for 48 hours in the humidified hybridisation chamber at 37°C to allow 
hybridisation of probe to its target sequence. 
The c-MYC/CEP8 probe mix (section 2.9) was loaded onto samples SPO15, SPO2, 
SPO28, SPO18, RAD9 and RAD10 following the same denature and hybridisation 
protocol as described above to be analysed using the CytoVision image capture system 
(Leica Microsystems, Newcastle Upon Tyne, UK).  
2.15.6 Analysis of FISH 
Cells were analysed using the same equipment and filters as cell line samples (section 
2.9). For each sample analysed 100 nuclei were scored for each probe and the number 
of probe signals per nuclei recorded. Blind second scoring of 9/29 samples analysed 
produced results that were not significantly different to the initial scoring (χ2: p>0.05). 
For samples that were analysed using the c-MYC/CEP8 probe mix, nuclei were not 
scored but representative images of the different genotypes in the cell population were 
captured. The CytoVision image capture system (Leica Microsystems, Newcastle Upon 
Tyne, UK) was sensitive enough to detect the signals for digital photography but was 
not a viable option for genotype scoring.  
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Chapter 3: Development of in vitro radiation-induced breast epithelial 
cell transformation models 
3.1 Introduction 
Exposure to ionising radiation has been shown to be associated with an increased breast 
cancer risk in a number of epidemiological studies. These have included studies of: 
female survivors of the atomic bombs dropped in World War II (Tokunaga et al., 1994; 
Land, 1995; Land et al., 2003), women who have been exposed to ionising radiation 
through their occupation (Rafnsson et al., 2001; Doody et al., 2006), women who have 
received multiple therapeutic and diagnostic X-rays (Davis et al., 1989; Hoffman et al., 
1989; Mattsson et al., 1993; Ma et al., 2008) and women who have received radiation 
therapy for Hodgkin lymphoma (Hancock et al., 1993; Travis et al., 2003; van Leeuwen 
et al., 2003).  
The relative risk of breast cancer increases as dose of ionising radiation increases. Also, 
younger women exposed to ionising radiation are at greater risk of breast cancer than 
older women exposed to the same level of radiation. This difference is evident 
particularly in women under the age of 30; women exposed to radiation over the age of 
30 have no increased relative risk of breast cancer (Travis et al., 2003; van Leeuwen et 
al., 2003). 
Ionising radiation causes DNA strand breaks which lead to genetic mutations. Increased 
radiation dose increases the amount of genetic damage caused to a cell and therefore 
increases the potential for oncogenic mutations. 
It has been suggested that the increased risk in younger women compared to in older 
women is due to the increased levels of oestrogen in younger women. Oestrogen is a 
known carcinogen that may cause cancer through an oestrogen receptor-mediated 
mechanism or a genotoxic mechanism (Russo and Russo, 2006; Yager and Davidson, 
2006; Mense et al., 2008). It has therefore been hypothesised that ionising radiation and 
oestrogen act synergistically to drive malignant transformation of the breast in young 
women.  
The molecular genetic mechanisms which underlie radiation-induced breast cell 
transformation are currently unclear. In vitro models provide a means to investigate 
radiation-induced breast cell transformation and the genetic alterations which underpin 
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this transformation. The MCF-10A cell line (Section 1.19) is a suitable immortalised 
non-transformed, non-tumourigenic breast epithelial cell line with which to investigate 
radiation-induced transformation (Soule et al., 1990). The cell line is near diploid and 
the largest rearrangement is a translocation t(3;9)(p13;p22). Study of the t(3;9)(p13;p22) 
translocation by FISH and CGH array  analysis revealed that it resulted in deletion of 
the CDNK2A/CDNK2B genes on chromosome 9. The same genes had also been deleted 
from the normal chromosome 9 (Cowell et al., 2005). The loss of both 
CDNK2A/CDNK2B genes is suggested to contribute to the immortalisation of the MCF-
10A cells. 
3.1.1 Aim 
The aim of the work described in this chapter is the development of in vitro 
transformation models from the MCF-10A cell line. Previous studies with the MCF-10F 
cell line (Section 1.6) and in vivo rat models have shown that ionising radiation can 
transform mammary epithelial cells and that concomitant radiation and oestrogen 
exposure is more effective than either on their own (Calaf and Hei., 2000; Roy et al., 
2001; Calaf et al., 2006; Bartstra et al., 1998a; Bartstra et al., 1998b). Therefore two 
transformation models were developed. A model which used fractionated doses of X-
irradiation was created first, followed by a model in which cells were grown continually 
in the presence of additional oestrogen in cell culture medium and were exposed to the 
same fractionated dose regimen. The development and phenotypic characterisation of 
each model are described. The cell line model derived without additional oestrogen in 
the medium will be called the “First” in vitro model and the cell line model derived with 
additional oestrogen in the medium will be called the “Second” in vitro model in the 
remainder of the thesis. 
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3.2 Development of the in vitro models. 
3.2.1 Determination of fractionated doses for dosing regimen. 
A fractionated dose regimen was designed with which to develop a model of the 
progression of breast epithelial cell transformation induced by the accumulation of 
genetic alterations caused by ionising radiation. The aim was to irradiate MCF-10A 
cells with fractionated X-ray doses to a cumulative dose of 80 Gγ. The optimal dose for 
the fractionated dose regimen would cause genetic damage to MCF-10A cells but not to 
a lethal level. This optimal dose would be determined by demonstration of growth arrest 
from which the cells were able to recover sufficiently to receive further doses of 
ionising radiation. Growth arrest occurs following exposure to irradiation and other 
DNA damaging agents due to cell cycle arrest in the G1 phase of the cell cycle which 
allows effective DNA repair before the cell re-enters the cell cycle. A cell which has 
undergone DNA damage that is too extensive to be repaired becomes senescent and is 
induced to apoptose.  
MCF-10A cells were plated in T75 flasks and 6 well plates and grown to a confluence 
of 50%. The cells were irradiated with 0, 1, 2, 5, 10, 20, 40, 60 and 80 Gγ of X-
irradiation. Five days following irradiation, the morphology of the cells in the T75 
flasks was observed to allow for qualitative evaluation of cell recovery (Fig. 3.1).  
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   0 Gγ - 100% Confluent         1 Gγ – 95% Confluent         2 Gγ – 95% Confluent 
 
  5 Gγ – 85-95% Confluent     10 Gγ – 60-70% Confluent   20 Gγ – 60-70% Confluent 
 
  40 Gγ – 60-70% Confluent   60 Gγ – 60-70% Confluent   80 Gγ – 60-70% Confluent 
Figure 3.1Effect of ionising radiation on the morphology of MCF-10A cells. 
 
 
 
 
 
 
 
 
 
MCF-10A cells were grown to 40-50% confluency in T75 flasks then either left un-irradiated (0 Gγ) or 
irradiated with either: 1, 2, 5, 10, 20, 40, 60 or 80 Gγ of X-rays. The cells were incubated for 5 days and 
then the morphology was assessed. The photomicrographs show the morphology of the cells at x40 
magnification. The confluency of the cells in the T75 flasks was estimated and is shown beneath the 
corresponding photomicrographs.    
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The un-irradiated cells were small, round cells with a cobblestone-like appearance 
which is the normal morphology of healthy MCF-10A cells. After five days in culture, 
the cells were 100% confluent and had stopped growing presumably due to contact 
inhibition. The 1 and 2 Gγ cell populations nearly reached 100% confluency and had a 
similar morphology to the un-irradiated cells which indicated that these cells had 
recovered from the initial growth arrest. For cells which had received 5 Gγ and above, 
the cells appeared to be larger and flatter which is indicative of cell hypertrophy and are 
characteristics of senescent cells. The cells were sub-confluent which indicated that the 
cells were still in a stage of growth arrest. The 5 Gγ cell population contained cells that 
had begun to round up and was slightly more confluent than the population that had 
received 10 Gγ and above, which indicated that these cells had undergone limited 
recovery from growth arrest five days after treatment.  
Cells that were irradiated in 6 well plates were counted four days after irradiation and 
the DNA content of cells irradiated in 6 well plates was measured five days after 
irradiation (Fig. 3.2). Reduced cell numbers and DNA concentration would indicate 
reduced cell division. The results indicated that the greater the radiation dose the longer 
the period of growth arrest (Fig. 3.2a) . Up to 5 Gγ this relationship was linear. There 
was no detectable cell growth after 4 days of cells that had been irradiated with between 
5 and 80 Gγ as cell numbers were very similar for each dose within this range. Cell 
numbers for cells irradiated with 5 Gγ were slightly higher than for cells which had 
received 10 Gγ and above which may have indicated the beginning of cell growth; 
however this difference was not significant. Cell numbers were significantly different 
from un-irradiated cells after 2 Gγ of ionising radiation (Students t-test: p=0.002).  
The results also indicated that irradiation of cells gave rise to growth inhibition in a 
dose-dependent manner (Fig 3.2b). The DNA content for cells irradiated with 5 Gγ was 
higher than for cells which received 10 Gγ and above which indicated that by day 5 
growth recovery had begun in the 5 Gγ dosed cell population (Paired t-test with 10 Gγ 
sample: p=0.040). Overall, the results showed that cell growth was inhibited by 
irradiation doses between 1 – 80 Gγ after irradiation. The length of time it took for cell 
growth to recover was dose dependant.   
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Figure 3.2 Effect of ionising radiation on MCF-10A cell growth. 
 
 
 
MCF-10A cells were grown to 40-50 % confluency in 6 well plates and then irradiated with either: 0, 1, 2, 
5, 10, 20, 40, 60 or 80 Gγ of X-rays. Four days after irradiation three wells were trypsinised and the cells 
counted in triplicate (a). The number of cells for the irradiated cells at each dose was calculated as a 
percentage of the mean un-irradiated number of cells. Five days after irradiation the cells in the remaining 
three wells of the 6 well plates were lysed and their DNA content measured using a fluorescent pico-
green assay (b). The DNA concentration for each radiation dose was expressed as a percentage of the 
DNA concentration for the un-irradiated cells. Mean percentages +/- SEM of triplicate samples within 
one experiment are shown. 
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The MCF-10A cells exposed to 1 and 2 Gγ appeared to recover fully within the five 
days of the experiment. It was decided that there was probably not enough DNA 
damage induced to cause cell transformation at these doses and that they would not be 
suitable for the fractionated dose schedule. Cells exposed to 5 Gγ had shown signs of 
cell recovery within the five days of the experiment and had recovered fully to have a 
normal MCF-10A cell morphology after seven days. Cells which received 10 Gγ of X-
irradiation recovered after two weeks in culture; they lost their quiescent phenotype and 
returned to a normal MCF-10A morphology. Cells which received X-irradiation 
between 20 – 80 Gγ did not recover and remained in a state of cell senescence. 
It was decided therefore that MCF-10A cells would undergo fractionated doses of both 
5 and 10 Gγ of ionising radiation until they had received a cumulative dose of 80 Gγ. 
The dosing regimen outlined in figure 3.3 allowed for future step-wise analysis of 
genetic alterations and phenotypic changes that had occurred because the cells were 
frozen after each fractionated dose. During the dosing regimen, the 5 Gγ fractionated 
dose populations took 5 days to recover and 7 – 9 days elapsed between irradiations. 
The 10 Gγ fractionated dose populations took 7 days to recover and 10-12 days elapsed 
between irradiations. MCF-10A cells were grown to the same passage number as the 
cells that received a cumulative dose of 80 Gγ of ionising radiation in the 5 Gγ 
fractionated dose series (passage control population). This cell population then acted as 
reference for any phenotypic changes and genetic alterations observed in the irradiation 
series.  
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Figure 3.3 Flow diagram for dosing regimens. 
 
 
 
 
 
 
 
Cells were given an initial X-ray dose of 5 or 10 Gγ in the absence and presence of additional oestrogen 
in their medium in T75 flasks. Cells underwent growth arrest followed by a period of recovery. Once the 
cells had started to recover they were plated in T75 flasks to allow them space to grow and recover fully. 
Following full recovery, cells were trypsinised and plated in T75 flasks to receive another dose of X-
radiation. Cells were cryopreserved at this stage. Re-irradiation continued until a cumulative dose of 80 
Gγ was reached. n=number of re-irradiations needed to achieve a cumulative dose of 80 Gγ. This was 15 
for the 5 Gγ schedule and 7 for the 10 Gγ schedule.  
MCF-10 A 
X-irradiation 
Cell quiescence 
Cell recovery 
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3.3 Phenotypic characterisation of the First 5 Gγ irradiated series 
Several cellular phenotypes are accepted as being characteristics of transformed cells 
and indicative of cell transformation in vitro. Examination of the phenotypic 
characteristics of the irradiated cells might therefore indicate if the cells had been 
transformed, and any altered characteristics could be correlated with genetic alterations 
identified. Phenotypes of the irradiated series were analysed in the 5 Gγ fractionated 
dose populations. The cumulative dose populations analysed had received 10, 25, 40, 55 
and 80 Gγ of irradiation. The remainder of this section describes analysis of cell 
morphology, proliferation rate, contact inhibition and radiation sensitivity in the First 5 
Gγ series.  
3.3.1 Changes in cell morphology of the First 5 Gγ irradiated populations 
MCF-10A cells had a morphology typical of breast epithelial cells which was 
characterised by a tight cellular monolayer with a cobblestone like appearance (Fig. 
3.4a). Proliferating MCF-10A cells grew in clusters and lamellipodia were often seen 
which indicated that the cells were motile. Cells from the 40 Gγ population and above 
had a distinctly different cell morphology to that of un-irradiated MCF-10A cells at both 
high and low cell density. Cells appeared to cluster into dense cellular islands that 
retained a cobblestone appearance but had very defined borders and fewer motile cells 
were visible (Fig. 3.4b). Cells which had received 40 Gγ cumulative dose and above 
also detached more quickly than un-irradiated MCF-10A cells when incubated in 
trypsin and appeared to detach more readily when grown in growth factor-depleted 
medium.  
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  a                                     b   
     
Figure 3.4 Cell morphology of the First 5 Gγ Series 
3.3.2 Differences in growth rate of the First 5 Gγ irradiated populations 
 
Increased cell proliferation rate has been considered to be indicative of cell 
transformation. It was noted that the growth rate appeared to slow down as cumulative 
dose increased and that the 25 Gγ cumulative population had a notably slower growth 
rate than the other cell populations. The growth rate of the passage control population 
did not appear to be different from the un-irradiated MCF-10A population. The growth 
rates of the selected cumulative dose populations of the First 5 Gγ series were analysed 
in a single experiment. Cells were plated in triplicate wells in 12 well plates and the 
DNA content of the wells was analysed at specific time points over a period of 4 days.  
Growth curves generated for each population indicated that the un-irradiated MCF-10A 
and 10 Gγ populations had similar growth rates whereas the 25 Gγ population had the 
slowest growth rate (Fig. 3.5a). The 40, 55 and 80 Gγ populations had similar growth 
rates which were slower than un-irradiated MCF-10A cells but faster than the 25 Gγ 
cumulative dose population. 
Growth rates for each cell populations, as defined by the number of cell doubling per 
hour, were determined from the growth curves by exponential regression (Fig. 3.5b). 
The un-irradiated MCF-10A cell population had the fastest growth rate of 0.048 cell 
doublings per hour. The trend of the experiment indicated that as cumulative dose 
increased, growth rate decreased (compared to that of un-irradiated MCF-10A). The 25 
Gγ population had a significantly reduced growth rate compared to the un-irradiated and 
10 Gγ populations of 0.034 cell doublings per hour (Turkey’s test: Un-irradiated MCF-
Images shown: un-irradiated MCF-10A cells (a) and cells from the First 5 Gγ series which had received a 
cumulative dose of 55 Gγ (b). Cells from the 55 Gγ population appear to cluster into tight cellular clusters 
with defined borders and appear less motile that un-irradiated MCF-10A.    
92 
 
10A - p=0.04, 10 Gγ population - p=0.022). This growth rate was the lowest of all the 
cell populations which agreed with observations during cell culture. The growth rate of 
the 40 Gγ population increased again to 0.043 cell doubling per hour which was lower 
than un-irradiated MCF-10A but not to a significant level. The growth rate of the 80 Gγ 
population reduced to 0.038 cell doublings per hour which was significantly lower than 
the un-irradiated MCF-10A cells (Turkey’s test: p=0.048)    
Overall results indicated that there may have been two separate events which affected 
growth rate. The first, which decreased growth rate, may have occurred between the 10 
and 25 Gγ cumulative dose populations; the second, which increased growth rate, may 
have occurred between the 25 and 40 Gγ cumulative dose populations. Further events 
may have occurred after 40 Gγ cumulative dose which caused the continued gradual 
reduction in growth rate throughout the remainder of the irradiation series.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
               a 
Hours
0 20 40 60 80 100
D
N
A
 c
o
n
c
e
n
tr
a
ti
o
n
 (

g
/m
l)
0
2
4
6
8
10
12
14
16
18
20
Un-Irradiated MCF-10A
10 GCumulative Dose
25 G Cumulative Dose
40 GCumulative Dose
55 GCumulative Dose
80 Gy Cumulative Dose
 
                  b 
 Cell population (cumulative dose)
Un-Irradiated 10 Gy 25 Gy 40 Gy 55 Gy 80 Gy
G
ro
w
th
 r
a
te
 (
d
o
u
b
lin
g
s
/h
o
u
r)
0.00
0.01
0.02
0.03
0.04
0.05
0.06
MCF-10A
 
Figure 3.5 Growth rate of the First 5 Gγ series. 
 
Cells from each population were plated in 3 wells of a 12 well plate at a cell density of 2x10
4
 cells per 
well. Cell culture medium was replaced in the wells each day of the experiment. Cells were lysed for 
DNA measurement at specific time points over 4 days from 24 hours after plating. The mean DNA 
concentration of the triplicate samples at each time point was used to calculate growth rate. The DNA 
concentration from triplicate samples +/- SEM for each cell population at each time point from one 
experiment normalised to the DNA concentration of the un-irradiated MCF-10A cell population (a). 
Growth rate, defined as the number of cell doublings per hour, determined from this data (b).  
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3.3.3 Changes to contact inhibition of the First 5 Gγ irradiated cell populations 
Contact inhibition is the inhibition of cell growth that results when cells are in contact 
with other cells. In normal tissues, contact inhibition helps to prevent uncontrolled cell 
growth and the loss of this ability is indicative of cell transformation. MCF-10A cells 
displayed contact inhibition and stopped growing when they had formed a confluent 
monolayer. Transformed cell lines, such as the breast cancer cell line MCF-7, have lost 
contact inhibition and continue to proliferate in culture after they have reached 100% 
confluency which results initially in cells occupying a smaller area and eventually in the 
cells being piled-up on top of each other.  
Cells that display contact inhibition arrest in the G1 phase of the cell cycle (Kuppers et 
al., 2010). Cell cycle analysis of confluent cell populations therefore provides an 
indication of whether or not cells are contact-inhibited. Cells which are contact-
inhibited will be largely in G0 or G1 phase of the cell cycle.  Cell populations which 
have lost contact inhibition will continue replicating and therefore contain cells in the S-
phase of the cell cycle.  
Flow cytometric analysis of MCF-10A and MCF-7 cells from 100% confluent 
populations are shown in figure 3.6. There were fewer MCF-10A cells compared to 
MCF-7 cells in S-phase of the cell cycle. This difference was evident in both the scatter-
graphs (Fig. 3.6 a and b) and subsequent histograms (Fig. 3.6 c and d). The majority of 
cells in the MCF-10A population were in the G1 phase of the cell cycle which indicated 
that they had undergone cell cycle arrest and is consistent with the observation that 
MCF-10A cells displayed contact inhibition when 100% confluent. MCF-7 cells had 
lost contact inhibition and continued to replicate after they had reached 100% 
confluency. The loss of contact inhibition was demonstrated by the presence of cells in 
all phases of the cell cycle. 
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Figure 3.6 Cell cycle analysis of confluent MCF-10A and MCF-7 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
MCF-10A (a and c), and MCF-7 (b and d) cells were grown to confluence in T25 flasks and prepared for 
propidium iodide flow cytometric analysis. Ten thousand events were recorded for each cell population. 
(a and b). Areas of the scatter-graphs which represent cells in G1, S and G2 are circled. Cells within these 
areas are shown in the histograms to demonstrate the proportion of cells in each phase of the cell cycle (c 
and d).   
b. 
c. d. 
a. 
MCF-10A 
MCF-10A 
MCF-7 
MCF-7 
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Un-irradiated MCF-10A cells and cells from the First 5 Gγ series that had received a 
cumulative dose of 80 Gγ were analysed using flow-cytometry on the day the cell 
populations reached 100% confluency and each day for the subsequent 5 days. Figure 
3.7 shows the flow cytometric analyses 24 and 48 hours after cells reached 100% 
confluency. There were more cells in S-phase of the cell cycle in the 80 Gγ population 
than the un-irradiated population at both time points, which indicated that more of the 
80 Gγ cells were replicating and therefore had reduced contact inhibition. The 
proportion of cells in S-phase appeared to reduce between 24 and 48 hours for the 80 Gγ 
cumulative dose population but still remained higher than for un-irradiated MCF-10A 
cells. 
  
 
       
          
Figure 3.7 Cell cycle distribution of un-irradiated MCF-10A cells and First 5 Gγ series cells that 
have received a cumulative dose of 80 Gγ. 
 
Un-irradiated cells (a and c) and cells from the First 5 Gγ series which have received a cumulative dose of 
80 Gγ (b and d) were plated out in T25 flasks at 4x105 cells per flask. Cell populations were trypsinised 
and fixed for flow cytometry once 100% confluency was reached and at 24 hour intervals for the 
following 5 days. Growth medium was replaced in all flasks not fixed. Scatter-graphs for the 24 hour time 
point (a and b) and the 48 hour time point (c and d) are shown. Areas of the scatter-graphs which 
represent cells in G1, S and G2 phase of the cell cycle are circled. 
b. a. 
c. d. 
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The percentage of cells in S-phase of the cell cycle was calculated for each population 
at each time point (Fig. 3.8). The 80 Gγ cumulative dose population had a larger 
percentage of cells in S-phase when they reached 100% confluency than un-irradiated 
cells. The percentage of cells in S-phase continued to be higher than in un-irradiated 
cells after 24 hours. Thereafter the difference was smaller but remained significant. 
These results indicated that the 80 Gγ cumulative dose cells had reduced contact 
inhibition compared to un-irradiated MCF-10A cells.  
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Figure 3.8 Percentage of cells in S-Phase of Un-Irradiated MCF-10A cells and First 5 Gγ Series 
cells that have received a cumulative dose of 80 Gγ. 
The percentage of cells in S-Phase of the cell cycle was calculated with ModFit LT software. Day 0 
represents the day when the populations reached 100% confluency. The mean percentages +/- SEM from 
triplicate analyses are shown. The statistical significance between each population below the 5% 
confidence level at each time point was tested (Students T-test): Day 0 p=0.021, Day 1 p=0.001, Day 2 
p=0.003, Day 3 p=0.014, Day 4 p<0.001, Day 5 p=0.002 
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The percentage of cells in G2 and M phase of the cell cycle was also analysed (Fig 3.9).  
The 80 Gγ cell population had significantly fewer cells in G2 and M phase of the cell 
cycle when the cells reached 100% confluency. A greater proportion of cells in the 80 
Gγ population continued to replicate at this time point (Fig. 3.8) which indicated that 
the 80 Gγ cells were moving through the G2/M checkpoint faster than un-irradiated 
MCF-10A cells. The day after they had reached 100% confluency, the number of cells 
in G2 and M phases of the cell cycle in the un-irradiated population was significantly 
lower than for the 80 Gγ population. This difference was most likely because fewer 
cells were entering S-phase as they had been arrested in G1 phase of the cell cycle. The 
increased proportion in cells in G2 and M phases of the cell cycle in the 80 Gγ 
population compared to un-irradiated MCF-10A was observed throughout the remainder 
of the experiment. 
 
Figure 3.9 G2/M phase cell cycle analysis of Un-Irradiated MCF-10A cells and First 5 Gγ Series 
cells that have received a cumulative dose of 80 Gγ. 
The percentage of cells in G2/M-Phase of the cell cycle was calculated with ModFit LT software. Day 0 
represents the day when the populations reached 100% confluency. The mean percentages +/- SEM of 
triplicate samples are shown. The statistical significance between each population below the 5% 
confidence level at each time point was tested (Students T-test): Day 0 p=0.001, Day 1 p=0.015, Day 2 
p=0.024, Day 3 p=0.105, Day 4 p=0.007, Day 5 p<0.001. 
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To test for loss of contact inhibition in all the cumulative dose populations in the First 5 
Gγ series, cell populations were allowed to grow in 12 well plates for 5 days after they 
had reached 100% confluency. Figure 3.10 shows representative images of the First 5 
Gγ series cell populations 5 days after they had reached 100% confluency. It appeared 
that as cumulative dose increased, more cells were piling on top of each other which 
indicated that the populations were continuing to replicate. The 80 Gγ cumulative dose 
population also showed cells that were piling up and then detaching from the other cells. 
The passage control population showed a similar phenotype to un-irradiated MCF-10A 
cells (image not shown). 
 
   
0 Gγ            10 Gγ          25 Gγ 
 
   
                    40 Gγ         55 Gγ       80 Gγ   
Figure 3.10 The effect of confluency on the First 5 Gγ series. 
 
 
 
 
 
 
Cells from each cumulative dose population were plated in 3 wells of a 12 well plate at a cell density of 
2x10
4
 cells per well. The medium was replaced on the cells each day for 9 days. Photomicrographs were 
taken of each cell population after 9 days at x10 magnification. Cumulative dose that had been received 
by each cell population is indicated below each image. 
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The DNA concentration of the cells was measured 5 days after they had reached 100% 
confluency and the relative concentration compared to un-irradiated MCF-10A cells 
was calculated (Fig. 3.11). If cells had lost contact inhibition then they would have 
continued to replicate, more cells would be present and therefore the DNA 
concentration would be higher than un-irradiated MCF-10A.  
The DNA concentration of the 80 Gγ cumulative dose population was 2.14 fold higher 
than un-irradiated MCF-10A and was the only DNA concentration different from un-
irradiated MCF-10A (Turkey’s test: p=0.002). The relative DNA concentration of the 
80 Gγ cumulative dose population was also significantly higher than the 10, 25, 40 Gγ 
and passage control cell populations (Turkey’s test: p=0.008, 0.004, 0.15 and 0.002, 
respectively). This increased cell number indicated that the 80 Gγ cumulative dose 
population had reduced contact inhibition compared to the other cell populations. The 
55 Gγ cumulative dose population had a 1.47 fold increase in DNA concentration 
compared to un-irradiated MCF-10A but this did not reach significance (Turkey’s test: 
p=0.490). There was an increase in DNA concentration for the 10, 25 and 40 Gγ 
cumulative dose populations compared to un-irradiated MCF-10A (1.15, 1.07 and 1.21 
fold respectively) but again this was not significant. The passage control population did 
not differ from un-irradiated MCF-10A (p=1.00). 
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Figure 3.11 DNA concentration of the First 5 Gγ Series 5 days after 100% confluency was reached. 
 
These results, coupled with images of increasing numbers of cells appearing to pile on 
top of each other as cumulative dose increases (Fig. 3.10), and the difference in the cell 
cycle profile of confluent un-irradiated and 80 Gγ cumulative dose populations 
indicated that cells from the First 5 Gγ series had reduced contact inhibition. The 
passage control population did not display these phenotypes and therefore loss of 
contact inhibition was not likely to be passage related.   
 
 
 
 
 
Cells from each cumulative dose populations were plated in triplicate wells of a 12 well plate at a cell 
density of 2x10
4
 cells per well. The medium was replaced on the cells each day for 9 days. The DNA 
content of the cells was measured with pico-green after 9 days.  The mean DNA concentration from 
triplicate wells relative to the mean DNA concentration of un-irradiated MCF-10A cells +/- SEM from 
four experiments is shown. Statistical significance for each population within the experiments below the 5% 
confidence level was tested (ANOVA): p=0.002.  
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3.3.4 Radiation resistance of the First 5 Gγ irradiation populations 
As a cell population receives fractionated doses of ionising irradiation there may be 
selection for genetic alterations which make the cells more resistant to the effects of 
ionising radiation. Cells with such alterations would no longer undergo growth arrest 
induced by ionising radiation, or would recover earlier from growth arrest.  Radiation 
resistant cells would therefore become the dominant cell population. During the 
development of the First 5 Gγ series it did not appear that cells were becoming more or 
less radiation-resistant. Cells from the First 5 Gγ series were tested explicitly to 
investigate if they had become radiation-resistant.  
Single cells of the First 5 Gγ series populations were irradiated and the proportion of 
cells which survived the irradiation and grew into multi-cellular colonies was evaluated. 
The rational was that the number of single cells which could produce cell colonies after 
irradiation reflects the radiation-resistance of the cell population. Cells from the chosen 
cumulative dose populations were plated at 2 cells per well in 96 well plates and either 
not irradiated or irradiated with 5 Gγ of X-rays. The number of wells which contained 
cell colonies from cells which had received 5 Gγ was counted and expressed as a 
percentage of the number of wells with colonies formed from cells of the same 
population which had not been irradiated. If the percentage of recovered cells was lower 
for any of the First 5 Gγ series populations than for the un-irradiated MCF-10A 
population then this would indicate that the cells had become less radiation resistant.  
The un-irradiated MCF-10A cells, 10 Gγ cumulative dose cells and passage control 
cells had between 35% and 40% of radiation-recovered colonies and therefore had a 
similar radiation-resistance (Fig 3.12). Cell populations which had received between 25 
and 80 Gγ cumulative doses of X-irradiation all had a significantly lower percentage of 
radiation recovered colonies than un-irradiated MCF-10A which indicates that they 
were less radiation-resistant than un-irradiated MCF-10A cells (Turkey’s test: 25 Gγ - 
p=0.009, 40 Gγ - p=0.002, 55 Gγ - p=0.015, 80 Gγ - p=0.029). The 40 Gγ cumulative 
dose population had a lower radiation-resistance than the 10 Gγ and passage control 
populations (Turkey’s test: 10 Gγ: p=0.023, Passage control: p=0.024). The 25-80 Gγ 
cumulative dose populations had between 11% and 20% of radiation recovered colonies 
and were not significantly different from each other.  
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Figure 3.12 Radiation resistance of the First 5 Gγ Series. 
Cells from each cumulative dose population were plated at 2 cells per well in two 96 well plates in 200μl 
of medium. Cells received either no irradiation or were irradiated with 5 Gγ of X-rays. The cells were 
cultured for a further 14 days and then the number of wells which contained a distinct colony of cells was 
counted in each 96 well plate. The number of wells with colonies from cells of each population which had 
received 5 Gγ of irradiation was expressed as a percentage of the number of wells with colonies from 
cells of the same population which had received no irradiation. Mean values from four experiments for 
un-irradiated cells, three experiments for the First 5 Gγ series and two experiments for the passage control 
+/- SEM are shown (ANOVA: p=0.001).  
 
Results therefore indicated that cell populations which had received a cumulative dose 
of 25 Gγ of ionising radiation and above were more radiation-sensitive than un-
irradiated MCF-10A cells and the 10 Gγ cumulative dose cell population. The reduction 
in radiation-resistance was not observed during the development of the First 5 Gγ series; 
the cells appeared to recover at the same rate throughout the dosing regimen. The 
increase in radiation-sensitivity did not appear to be passage-related.           
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3.4 Development and phenotypic characterisation of the Second in vitro model  
For the Second in vitro model 10
-8 M of 17β oestrodiol was present in the medium for 
the duration of the dosing regimen. An oestrodiol concentration of 10
-8 
M is used 
frequently to stimulate maximal oestrogen response in vitro and is equivalent to the high 
concentrations of oestrogen reached in the plasma of adolescent females (Styrt and 
Sugarman, 1991). Because MCF-10A cells are ERα negative, any carcinogenic role of 
oestrogen in these cells will most likely be via a genotoxic rather than a receptor 
mediated mechanism. To provide a reference cell population for the Second 5 Gγ series, 
MCF-10A cells were grown in the presence of 10
-8 M 17β oestrodiol but without 
irradiation for the same number of passages as were required to reach a cumulative dose 
of 80 Gγ of ionising radiation (passage control population). 
Initially, during the Second dosing series, the 5 Gγ populations took approximately 5 
days to recover and 7 – 9 days elapsed between irradiations. After 50 Gγ cumulative 
dose the cells took only 3-5 days to recover. For the 10 Gγ series, cell recovery took 7 
days and 10-12 days elapsed between irradiations; cells did not recover faster as the 
cumulative dose increased. 
Phenotypes of the Second in vitro model were analysed in the 5 Gγ irradiation series. 
The cumulative dose populations analysed were 10, 20, 40, 60 and 80 Gγ. The 
following sections of this chapter describe cell morphology, proliferation rates, contact 
inhibition and radiation-sensitivity of this series.  
3.4.1 Changes in cell morphology of the Second 5 Gγ irradiated populations 
The cell morphology of the Second 5 Gγ series was characteristic of cells undergoing 
epithelial to mesenchymal transition (EMT), which occurs during epithelial cell 
transformation. Cells which have undergone EMT have a spindle-like or fibroblastic 
appearance, less tight cellular junctions with adjacent cells and are more motile. 
Previous studies have indicated that at low density MCF-10A cells have morphological 
and gene expression properties similar to cells that are undergoing EMT; however these 
similarities are lost at high density (Maeda et al 2005; Sarro et al. 2008). Figure 3.13a 
shows un-irradiated MCF-10A cells at low density. There were some spindle like cells 
and other cells were clustered into cell cobblestone-like islands typical of epithelial cells. 
Cells from the Second 5 Gγ series showed a similar morphology however the spindle 
cell morphology was more prominent and there was less evidence of the cobblestone 
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morphology (Figure 3.13b). As cell density increased, un-irradiated MCF-10A cells lost 
the spindle cell morphology and had traditional epithelial cell morphology (Figure 
3.20c). More cells from the Second 5 Gγ series at high density however maintained 
spindle morphology, and compared to un-irradiated MCF-10A there was a reduced 
cobblestone appearance to the cell population. The maintenance of EMT-like cell 
morphology at high cell density may therefore be an indication of cell transformation of 
the Second 5 Gγ series. 
 
a                 b 
     
c                  d 
     
Figure 3.13 Cell morphology of the Second 5 Gγ Series 
Cells were plated in T75 flasks and grown to different cell densities. Cell morphology was assessed at 
x10 magnification. The cell populations shown are: un-irradiated MCF-10A cells at cell confluency of ~ 
40% (a) and ~ 90% (c) and cells from the Second 5 Gγ series which have received a cumulative dose of 
60 Gγ at cell confluency of ~ 40% (b) and ~ 90% (d). Examples of spindle-like or fibroblastic cell 
morphology in the Second 5 Gγ series are shown by black arrows. 
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3.4.3 Growth rate of the Second 5 Gγ irradiated populations 
The proliferation rates in the Second 5 Gγ series populations did not differ obviously 
from each other during routine cell culture. To compare proliferation rates, cells were 
plated in 24 well plates and the DNA content of the cells was measured over 3 days 
before the cells had become confluent. There were no apparent differences in growth 
rate between the different cell populations (Fig.3.14a). 
The growth rates of the cell populations were compared by exponential regression. The 
growth rate was approximately 0.05 cell doublings per hour for un-irradiated MCF-10A 
cells. The cells grew in all cell populations at similar rates (ANOVA: p=0.144).  
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Figure 3.14 Growth rate of the Second 5 Gγ Series. 
 
 
 
Cells from each population were plated in 3 wells of a 24 well plate at a cell density of 1x10
4
 cells per 
well. Cell culture medium was replaced in the wells every day. Cells were lysed for DNA measurement at 
the indicated times after plating. The mean DNA concentrations of triplicate samples +/- SEM for each 
cell population was normalised to the DNA concentration of the un-irradiated MCF-10A cell population 
(a). Growth rate, which is expressed as the number of cell doublings per hour was determined from this 
data (b).  
a 
b 
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3.4.4 Contact inhibition of the Second 5 Gγ irradiated populations 
The extent to which the Second 5 Gγ series demonstrated contact inhibition was 
analysed. Cell populations from un-irradiated MCF-10A cells and from chosen 
cumulative dose populations of the Second 5 Gγ series were allowed to grow in 24 well 
plates past the point of 100% confluency. Un-irradiated MCF-10A cells, 10 Gγ, 20 Gγ, 
40 Gγ, 60 Gγ and 80 Gγ and equivalent high passage MCF-10A cells (data not shown) 
all appeared as a crowded monolayer with no evidence of cells growing on top of other 
cells five days after confluency had been reached (Fig 3.15). The observation indicated 
that all the cell populations had retained contact inhibition.  
   
                  0 Gγ                           10 Gγ                 20 Gγ 
   
                40 Gγ     60 Gγ             80 Gγ   
Figure 3.15 Images of the Second 5 Gγ Series 5 days after 100% confluency was reached. 
 
 
 
 
 
 
 
Cells from each cumulative dose population were plated in 3 wells of a 24 well plate at a cell density of 
1x10
4
 cells per well. The medium was replaced on the cells each day for 9 days. Photomicrographs were 
taken of each cell population after 9 days at x10 magnification. Cumulative dose that had been received 
by each cell population is indicated below each image. 
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To confirm these observations the DNA concentration of cells was measured 5 days 
after they had reached 100% confluency. The DNA concentration was similar in un-
irradiated cells and in all cumulative dose cell populations (Fig. 3.16) which 
demonstrated that the cells did not replicate after they had reached 100% confluence 
and had not lost contact inhibition. There was a slight increase in DNA content as 
cumulative dose increased but the difference was not significant (ANOVA: p=0.427).  
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Figure 3.16 DNA content of the Second 5 Gγ Series 5 days after 100% confluency was reached. 
 
 
3.4.5 Radiation resistance of the Second 5 Gγ irradiation populations 
After 10 fractionated doses cells from the Second 5 Gγ series appeared to recover faster 
from irradiation. This more rapid recovery was not due to an increased growth rate 
because the growth rate did not change as the cumulative dose increased (Section 3.4.3) 
and may be indicative of increased radiation-resistance. Cells from the Second 5 Gγ 
series were therefore tested to investigate if they had become radiation-resistant.   
The Second 5 Gγ series populations were plated at low density in 96 well plates and the 
proportion of single cells which survived irradiation and grew into multi-cellular 
colonies was evaluated as described in section 3.3.4.  
There appeared to be a decrease in radiation resistance as cumulative dose increased, 
which is contrary to what had been inferred from the cell recovery during the 
Cells from each cumulative dose population were plated in triplicate wells of a 24 well plate at a cell 
density of 1x10
4
 cells per well. The medium was replaced on the cells each day for 9 days. The DNA 
content of the cells was measured with pico-green after 9 days.  The mean DNA concentration from 
triplicate samples expressed relative to the mean DNA concentration of un-irradiated MCF-10A cells +/- 
SEM from one experiment is shown.  
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development of the series (Fig. 3.17). It is also noteworthy that the equivalent high 
passage MCF-10A cells appeared to have reduced radiation resistance compared to the 
un-irradiated MCF-10A population. The decrease in radiation resistance between the 
un-irradiated MCF-10A cells and cells from the Second 5 Gγ series did not reach the 5% 
confidence level (ANOVA: p=0.092) 
Cell Population
Un-Irradaited 10 Gy 20 Gy 40 Gy 60 Gy 80 Gy Passage
N
u
m
b
e
r 
o
f 
c
e
ll 
c
o
lo
n
ie
s
 (
%
)
0
10
20
30
40
50
MCF-10A Control
 
Figure 3.17 Radiation resistance of the Second 5 Gγ series. 
 
 
 
 
 
 
 
Cells from each cumulative dose population were plated at 2 cells per well in two 96 well plates in 200 μl 
of medium. Cells received either no irradiation or were irradiated with 5 Gγ of X-rays. The cells were 
cultured for a further 14 days and then the number of wells which contained a distinct colony of cells was 
counted in each 96 well plate. The number of wells with colonies from cells of each population which had 
received 5 Gγ of irradiation was expressed as a percentage of the number of wells with colonies from 
cells of the same population which had received no irradiation. Mean values from two experiments +/- 
SEM are shown.  
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3.5 Discussion 
The molecular genetics that underlie radiogenic breast cancer are unclear and there are 
currently no reliable somatically acquired genetic markers that distinguish radiation-
induced breast cancer. The development of in vitro models which aim to replicate 
conditions that lead to cell transformation should allow the molecular genetic signatures 
caused by different mutagens or carcinogens to be discerned. We have developed 
models of irradiated breast epithelial cells with the non-transformed breast epithelial 
cell line MCF-10A to investigate the genetic alterations caused by ionising radiation. 
Four in vitro models of irradiated breast epithelial cells have been developed. The in 
vitro models are divided into two series. In the “First” irradiation series, cells received 
fractionated doses of X-rays of either 5 Gγ or 10 Gγ to a cumulative dose of 80 Gγ to 
create two separate in vitro models. Cells in the “Second” irradiation series underwent 
the same fractionated dosing regimens but with 10
-8
 M 17-β oestrodiol present in the 
cell culture medium throughout the dosing schedule. Epidemiological evidence has 
suggested that younger women exposed to ionising radiation have a greater risk of 
developing breast cancer than older women (Hrubec et al., 1989; Land et al., 2003; 
Travis et al., 2003). It has been hypothesised that this may be due to the increased levels 
of oestrogen present in younger women (van Leeuwen et al., 2003). The presence of 
high levels of oestrogen when cells are exposed to ionising radiation may therefore be a 
relevant factor when developing a radiation exposed in vitro model.  
This chapter has described the phenotypic characterisation of the First 5 Gγ irradiation 
series and the Second 5 Gγ irradiation series. Changes in phenotype would indicate that 
the cell populations have undergone genetic alterations and could provide evidence of 
cell transformation. Cell morphology, growth rate, radiation sensitivity and contact 
inhibition were analysed. 
3.5.1 First 5 Gγ Series 
Cells in the First 5 Gγ series display differences from normal MCF-10A cells in all of 
the phenotypes analysed. These changes do not appear to be passage related and are 
therefore consequences of genetic alterations caused by the radiation regimen. Because 
the irradiated MCF-10A cell populations are heterogeneous, the genetic alterations that 
lead to phenotypic changes are likely to have occurred in sub-populations of cells which 
have subsequently become established throughout the population. The establishment of 
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cell populations with phenotypic changes could occur through chance or because the 
new phenotype causes a selective advantage to the cells.  
3.5.2 Cell morphology 
Cells from the First 5 Gγ series appear to become more densely packed and to be less 
motile than un-irradiated MCF-10A cells. These changes in cell phenotype are observed 
first in the 40 Gγ cumulative dose cell population. Varied cell morphologies have been 
reported for transformed MCF-10A cells but the cells often become more spindle-like, 
lose their normal epithelial-like cobblestone appearance and appear more motile than 
non-transformed MCF-10A cells (Maeda et al., 2005; Kim et al., 2007; Botlagunta et 
al., 2008; Kim et al., 2009a; Botlagunta et al., 2010; Cho et al., 2010; Meng et al., 
2010). Most studies which describe this altered cell morphology have used targeted cell 
transformation approaches such as increased expression of oncogenes or growth factors 
known to stimulate EMT. Cells which have undergone EMT have a spindle-like cell 
morphology (Maeda et al., 2005; Kim et al., 2007; Kim et al., 2009a; Cho et al., 2010; 
Meng et al., 2010).  
Exposure to ionising radiation is not a specific or single gene alteration approach and 
the phenotypes induced might be expected to be more varied. Transformation of MCF-
10A cells with the ICR191 mutagen, which is also not a specific or single gene  
approach, did not induce a spindle-like cell morphology but the cells did form tumours 
in immune-compromised mice (Zientek-Targosz et al., 2008). A spindle like cell 
morphology may therefore be indicative of MCF-10A cell transformation but is not a 
pre-requisite for cell transformation.  Likewise, cells transformed by transfection with 
the HRAS oncogene did not have a spindle-like morphology but they did form tumours 
in immune-compromised mice. Subsequently cells cultured from the tumours had a 
spindle-like morphology (Imbalzano et al., 2009). In the present study, there is the 
potential for there to be transformed cells within the cell populations, although cells 
have not been selected for transformation status. 
3.5.3 Growth rate 
Cells from the First 5 Gγ series show a gradual reduction in growth rate compared to 
un-irradiated MCF-10A cells as the cumulative dose received by the cells increases. 
This pattern is interrupted at the 25 Gγ cumulative dose population which has a 
significant reduction in growth rate but the growth rate increases again by the 40 Gγ 
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cumulative dose population. Growth rate does not reduce to a significant level again 
compared to un-irradiated MCF-10A cell population until the 80 Gγ cumulative dose 
population. The growth rate results indicate that more than one genetic event which 
affects growth rate has occurred in the First 5 Gγ series. Multiple genetic alterations are 
expected during a fractionated dose regimen which means that a given phenotype may 
be altered more than once and potentially in different directions throughout an 
irradiation series.  
Both increases and decreases in growth rate of transformed MCF-10A cells have been 
reported. Cell populations transformed by HER2 transfection and IGF-IR transfection 
both had a reduced growth rate (Kim et al., 2007; Meng et al., 2010). MCF-10A cells 
transformed by transfection with HRAS or by exposure to ionising radiation combined 
with cigarette smoke had an increased growth rate (Imbalzano et al., 2009; Botlagunta 
et al., 2010). Populations of MCF-10A cells transformed by treatment with the ICR191 
mutagen had both increased and reduced growth rates. These cells were capable of 
growing as tumours in immune-compromised mice irrespective of whether their growth 
rate was increased or decreased (Zientek-Targosz et al., 2008). Cumulatively, these 
results indicate that the growth rate of MCF-10A cells may not be a reliable indicator of 
cell transformation. 
3.5.4 Radiation-resistance  
Individuals with cancer who have undergone radio-therapy often acquire resistance to 
irradiation and show evidence of accelerated re-population of the tumours between 
fractionated doses of irradiation (Phillips et al., 2006). In the present study, we 
investigated whether the fractionated X-ray dose regimen would select for a radiation-
resistant cell population. The First 5 Gγ series showed increased radiation-sensitivity 
compared to the un-irradiated MCF-10A and equivalent passage number populations. 
Increased radiation sensitivity was observed in cell populations that had received 25 Gγ 
cumulative dose of X-rays and above. A current favoured hypothesis for radiation 
resistance in vivo is that radiation-resistant cancer stem cells are present in the tumour 
cell population and that these cells allow re-growth and repopulation of tumours 
following ionising radiation therapy (Vlashi et al., 2009). Studies of these cells in a 
number of cancer types have reported increased activity of DNA damage checkpoint 
genes (Rich, 2007), increased expression of the developmental pathway proteins, 
JAGGED-1 and NOTCH-1 (Phillips et al., 2006), and over-expression of the WNT/β-
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CATENIN pathway (Woodward et al., 2007). These changes in activity and expression 
have been reported to be involved in increased radiation-resistance. These studies used 
cancer cell lines or primary tumour cell populations to confirm that fractionated doses 
of irradiation enrich the cell populations for cells with radiation-resistant cancer stem 
cell properties. Results in the present study are consistent with absence of a cancer stem 
cell population in the original MCF-10A cell population and that cells with cancer stem 
cell properties were not developed during the dosing schedule.  
An increase in radiation sensitivity could be caused by genetic alterations that affect the 
DNA damage response or DNA damage repair. Loss or altered function of genes 
involved in these processes would cause cells to become more radiation sensitive. For 
example, loss of function of a number of DNA damage checkpoint genes such as ATM 
(Collis et al., 2003) and CHEK1 (Koniaras et al., 2001) have been shown to cause an 
increase in radiation sensitivity (Pawlik and Keyomarsi, 2004). Loss of DNA repair 
genes such as RAD54 in a mouse study (Essers et al., 1997) and RAD51 in an 
osteosarcoma in vitro study (Du et al., 2010a) have also resulted in elevated radiation 
sensitivity.  
Disruption of the G2/M checkpoint has also been shown to cause increased sensitivity 
to radiation (Strunz et al., 2002). In the present study there were fewer cells in G2/M 
phase of the cell cycle in the 80 Gγ cumulative dose population than in the un-irradiated 
MCF-10A cell population (Section 3.3.3). This finding indicates that the 80 Gγ 
cumulative dose cells pass through the G2/M checkpoint faster than un-irradiated MCF-
10A cells and provides some evidence of G2/M checkpoint disruption. Genetic 
alterations in genes involved in maintenance of the G2/M checkpoint may therefore be 
the cause of increased radiation sensitivity in the First 5 Gγ series. 
3.5.5 Contact inhibition 
The First 5 Gγ series displayed gradual loss of contact inhibition, as represented by an 
increase in the number of cells present in confluent cell populations, which reached 
statistical significant in the 80 Gγ population. There was also evidence of loss of contact 
inhibition in the 40 Gγ and 55 Gγ cumulative dose cell populations, demonstrated by 
cells growing on top of each other after they have become confluent. This phenotype 
became more pronounced as the cumulative dose increased. The loss of contact 
inhibition phenotype observed in the present study differs slightly than those reported in 
other MCF-10A studies. In the present study, cells appeared to pile on top of each other 
115 
 
evenly across the whole cell population when confluent which indicates that cells with 
reduced contact inhibition are distributed evenly throughout the population. 
Transformed cells in other MCF-10A studies formed foci of cells within the cell 
population (Caruso et al., 2001; Kim et al., 2007; Zientek-Targosz et al., 2008; Meng et 
al., 2010).  
A study by Kim et al. (2009b) reported that contact inhibition in MCF-10A cells is 
mediated by a balance between the level of growth stimulation by EGF and level of 
growth inhibition by E-Cadherin mediated cell contact. The study reported that at low 
EGF concentrations, cell replication was observed only at the edge of low density cell 
clusters. At higher EGF concentrations, replicating cells were observed uniformly 
throughout the cell clusters. In densely packed cell clusters, cell replication was 
observed only at the edge of clusters even at high EGF concentrations. After E-Cadherin 
expression had been silenced, cell replication was observed uniformly throughout the 
densely packed cell clusters. The authors concluded that a balance exists between EGF 
concentration and cell-cell contact that determines whether or not cells grow. In the 
present study, high EGF concentrations were maintained throughout the experiment and 
cells were packed very densely at confluence. It is therefore possible that the evenly-
distributed piling up of cells observed in irradiated cell populations in the present study 
may be due to a reduction in cell-cell contact compared to in un-irradiated MCF-10A 
cells. 
3.5.6 Second 5 Gγ Series 
Cell populations in the Second 5 Gγ series displayed fewer phenotypic changes 
compared to un-irradiated MCF-10A cells than those of the First 5 Gγ series. The only 
phenotypic change observed was in cell morphology. The lack of phenotypic changes 
indicates that fewer genetic alterations have occurred in the Second 5 Gγ series than in 
the First 5 Gγ series. This result is not consistent with the conclusions from previous 
studies which have reported that radiation and oestrogen exposure together caused 
greater allelic imbalance and more phenotypic changes in cells than exposure with 
either on their own (Bartstra et al., 1998b; Bartstra et al., 1998a; Calaf and Hei, 2000; 
Roy et al., 2001a). 
Cells from the Second 5 Gγ irradiation series appeared to have less tight cellular 
junctions at high cell densities, did not form epithelial-like cobblestone islands and were 
more spindle-like in appearance than un-irradiated MCF-10A cells. This cell 
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morphology is akin to cells undergoing EMT which is an accepted stage in cell 
transformation (Huber et al., 2005) and has been observed in transformed MCF-10A 
cells in numerous studies (Maeda et al., 2005; Kim et al., 2007; Botlagunta et al., 2008; 
Kim et al., 2009a; Botlagunta et al., 2010; Cho et al., 2010; Meng et al., 2010). EMT 
has been shown to be induced by expression of oncogenes such as c-MYC, HRAS and 
HER2 (Kim et al., 2009a; Liu et al., 2009; Cho et al., 2010) and by treatment with 
growth factors such as insulin-like growth factors (IGFs) and transforming growth 
factor-β (TGF-β) (Morali et al., 2001; Maeda et al., 2005; Kim et al., 2007). 17-β 
oestrodiol has been shown also to induce EMT transition in MCF-10F cells (Huang et 
al., 2007). The change in cell morphology in the Second 5 Gγ series indicates that 
genetic alterations have occurred and may be indicative of cell transformation.  
3.5.3 Conclusion 
Changes to cell phenotypes in the X-ray treated in vitro models analysed suggest that 
genetic alterations have been caused by the ionising radiation regimen.  The loss of 
contact inhibition by the First 5 Gγ is a transformed phenotype. Other phenotypic 
changes in the First 5 Gγ series were not typical of the phenotypes of transformed MCF-
10A cells reported in the literature. A spectrum of changes is observed in transformed 
MCF-10A cells and lack of a particular transformed phenotype does not necessarily 
indicate cells are not transformed. It should be noted however that there is little 
evidence that the cells in the First 5 Gγ series are transformed.  
The findings in this chapter also suggest that the First 5 Gγ series has undergone more 
phenotypic changes and hence more genetic alterations that the Second 5 Gγ series. This 
difference is surprising as the literature suggests that the conditions of the Second 
irradiation regimen should cause more genetic alterations. The Second 5 Gγ series does 
display cell morphology similar to cells which have undergone EMT.  Cells which have 
undergone this transition are more motile and invasive and investigation of these 
phenotypes in the Second 5 Gγ series would be interesting (Huber et al., 2005).  
Overall, evidence for cell transformation of the in vitro models is in-conclusive. There 
is however compelling evidence that radiation-induced genetic alterations have occurred. 
Analysis of these genetic alterations could provide information on the genetic basis for 
the phenotypic changes observed, and may identify potential radiation-induced genetic 
alterations. 
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Chapter 4: Gene copy number analysis of radiation-treated MCF-10A 
cells using a high-density polymorphism array 
4.1 Introduction 
Ionising radiation causes DNA damage which can lead to mutation following incorrect 
DNA repair or DNA replication without DNA repair. Ionising radiation can cause 
damage to individual nucleotides or induce single and double DNA strand breaks 
(Section 1.4). Damage to nucleotides and single strand breaks can normally be 
effectively repaired by mechanisms such as base excision repair (Zharkov, 2008). 
Double strand breaks can be repaired by non-homologous end joining and homologous 
recombination (Mahaney et al., 2009; Barker and Powell, 2010).  
Incorrect repair of DNA double strand breaks can lead to chromosome rearrangements 
and translocations, and regions of chromosome/gene deletion or duplication (Section 
1.4). Some of the main genetic alterations caused by ionising radiation are therefore 
gene copy number alterations. Loss or gain of copies of genes can subsequently change 
the level of expression which, depending on the function of the gene, can contribute to 
cell transformation. For example, copy number loss of a tumour suppressor gene could 
reduce protein expression and activity which could lead to cancer due to 
haploinsufficiency. Copy number loss could also induce a state of LOH whereby only 
one version of the allele remains. Unmasking recessive mutations can contribute to 
cellular transformation. Alternatively, copy number gain of an oncogene could lead to 
increased protein expression and activity which again could lead to cancer.  
Ionising radiation-induced DNA damage can also induce copy neutral LOH, where a 
deleted allele can be re-constituted from a homologous chromosome. This process re-
establishes the diploid state (copy neutral) but the affected region becomes homozygous. 
Recessive mutations can also be unmasked through this process and can also contribute 
to cellular transformation, and has been identified as a mechanism operating in human 
cancers, such as acute myeloid leukaemia (Gupta et al., 2008; O'Keefe et al., 2010).  
High-density polymorphism arrays can detect both copy number alterations and copy 
neutral LOH across the whole genome using markers for single nucleotide 
polymorphisms (SNPs) and copy number variants (CNVs). The Affymetrix Human 
SNP 6.0 Array contains more than 906,600 SNP probes and more than 946,000 CNV 
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probes which can be used to interrogate the entire human genome (McCarroll et al., 
2008) (Section 2.5). 
4.1.1 Aim 
The aim of the work described in this chapter was to analyse copy number alterations 
and copy neutral LOH in the un-irradiated MCF-10A cell population and populations 
from the “First” and “Second” irradiation series (described in chapter 3.1) using the 
Affymetrix Human SNP 6.0 Array. The pathogenesis of radiation-induced breast cancer 
remains to be fully elucidated, and somatically acquired genetic alterations that 
contribute to disease development following radiation exposure have yet to be identified. 
As such, the in vitro model of breast epithelial cells exposed to ionising radiation will 
be used to identify putative radiation-induced genetic alterations.  
4.2 Copy number analysis of parental MCF-10A 
In order to identify ionising radiation-induced copy number alterations, the copy 
number profile of MCF-10A cells before irradiation was analysed. The global copy 
number state of MCF-10A was determined using Genotyping Console software 
following data generation using the Affymetrix Human SNP 6.0 Array (Figure 4.1). 
Some copy number alterations and chromosome rearrangements have previously been 
published for MCF-10A and these were confirmed by the SNP 6.0 array analysis. 
However, previously unreported copy number alterations were also identified using this 
array platform. 
4.2.1 Published copy number alterations in MCF-10A  
The MCF-10A cell line is a near diploid cell line but its genome contains several 
established somatic genetic alterations, previously identified using metaphase FISH and 
aCGH (Cowell et al., 2005).  
MCF-10A cells have an extra copy of chromosome 1q (including chromosome 1 
centromere) plus a duplication of the region 198136766-qter to create an overall copy 
number of 4 for this region (Cowell et al., 2005). This alteration was confirmed by SNP 
6.0 data analysis, although the duplicated region is shown to be 199265027-qter (Fig 
4.2a).  
SNP 6.0 analysis also confirmed previously described copy number gains on 
chromosome 5q (Chr 5: 118383183-qter) and chromosome 8q (Chr 8: 100271658-qter) 
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to give a copy number of 3 (Fig 4.2b and 4.2c). Copy number gain of chromosome 5q 
has previously been identified as arising due to a nonreciprocal translocation with a 
derivative of Chromosome 9 (which will be discussed in section 4.2.2) (Cowell et al., 
2005). Previously unreported alterations identified by the SNP 6.0 array will be 
discussed in section 4.2.3. 
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Figure 4.1 Copy number analysis of MCF-10A. 
An overview of the copy number alterations identified by the Genome Console software of the parental MCF-10A genome. Blue arrows indicate regions of chromosomes with a 
copy number greater than 2 and red arrows indicate regions of chromosomes with a copy number less than 2. Regions of the chromosome covered by a block of blue indicate that 
this whole region has a copy number greater than 2. 
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The copy number profiles of Chromosome 1 (a), Chromosome 5 (b), and Chromosome 8 (c) are shown. The log2 ratio of each marker as calculated by the Genotyping Console 
software is shown for each chromosome. The calculated copy number of each region of the chromosome is shown above each log2 ratio map. Regions which are not diploid are 
indicated by a red arrow. A representation of each chromosome along with chromosome position is below each log2 ratio map.  
Figure 4.2 Previously reported major alterations of MCF-10A. 
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G-band karyotyping of un-irradiated MCF-10A cells by David Rowe (Institute of 
Genetic Medicine, Newcastle upon Tyne, UK) provided further detail of the somatic 
alterations identified by the SNP array (Fig. 4.3). The karyotype was defined as 47, XX, 
i(1)(q10),+del(1)(q12q32), der(3)t(3;9)(p14;p21), der(8)t(8;8)(q22;p23),  
der(9)t(3;9;5)(p14;p21;q23). The chromosome 1 rearrangement incorporated an 
isochromosome of 1q which provides the extra copy of 1q identified by the SNP array. 
A derivative chromosome 1, +del(1)(q12q32), with a deletion between regions q12 and 
q32 provides the fourth copy of the 199265027-qter region identified by the SNP array 
(Fig 4.3). SNP array data shows that MCF-10A has 3 copies of the chromosome 1 
centromere. The +del(1)(q12q32) chromosome does not have a centromere and it was 
not identified in any other location; therefore the i(1)(q10) may be dicentric.  
The duplication of the chromosome 8q region (Chr 8: 100271658-qter) is positioned on 
the end of the p arm of the derivative chromosome 8 (Fig. 4.3). The 8q duplication and 
rearrangement has been described as a translocation in the karyotype definition but in 
reality the mechanism is unknown. The rearrangement between chromosomes 3, 9 and 5 
are as previously described in the literature and will be discussed in section 4.2.2 
(Cowell et al., 2005). 
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Chromosomal rearrangements constitutive to MCF-10A are labelled with the chromosomal regions that 
constitutes the rearrangement and the karyotype definition of the chromosome. Two derivatives of 
chromosome 1 and derivative chromosomes 3, 8 and 9 are labelled. 
Figure 4.3 G-banding karyotyping of un-irradiated MCF-10A metaphase chromosomes. 
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4.2.2 t(3;9) affecting cyclin-dependant kinase inhibitor 2A (CDKN2A) 
The major MCF-10A genomic rearrangements described by Cowell et al (2005) include 
a reciprocal translocation between chromosomes 3 and 9 and a non-reciprocal 
translocation of the end of the q arm of chromosome 5 to the derivative chromosome 9. 
The site of the reciprocal translocation on chromosome 9 is in the p21.3 region and 
resulted in a 3.2Mb mono-allelic deletion, reducing the copy number state to 1 (Fig 
4.4a). Cowell and colleagues also identified a deletion on the non-translocated 
chromosome 9 located within the larger area of mono-allelic deletion which contains the 
MTAP, CDKN2A and CDKN2B loci, which gave rise to bi-allelic deletion of these loci 
in MCF-10A.  
Cowell et al. (2005) suggested the breakpoint of the reciprocal translocation on 
chromosome 3 to be within the FAM19A1 gene and showed that expression of this gene 
is lost in MCF-10A. However, the aCGH approach used in their study was not 
sufficiently sensitive to identify the exact area of the deletion. SNP analysis in the 
present study identified a putative mono-allelic deletion of approximately 35Kb in the 
second intron of FAM19A1 which may be the sight of the breakpoint suggested by 
Cowell et al (Fig. 4.4b).  
Validation of previously described MCF-10A copy number alterations in the present 
study confirms that the cell line being used is MCF-10A. The benefit of using high 
density SNP arrays is demonstrated by the identification of the putative chromosome 3 
breakpoint in the t(3:9) rearrangement. 
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Log2 ratio map of markers in the regions containing the postulated breakpoints of the reciprocal translocation between chromosome 9 (a) and chromosome 3 (b). The copy 
number of each region is shown above each log2 ratio map. Non-diploid regions are indicated by a red arrow. A representation of the exons (green boxes) and introns (green 
lines) of any genes in the affected regions are positioned under each log2 ratio map. CDKN2A is indicated by a red box surrounding the gene (a). A representation of the region of 
the chromosome and chromosome base position is displayed under each log2 ratio map. The region on Chromosome 3 is shown at a higher magnification than Chromosome 9.  
  
Figure 4.4 Analysis of the breakpoints of t(3:9) in MCF-10A cells. 
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4.2.3 Previously unreported copy number alterations in MCF-10A  
Affymetrix Human SNP 6.0 Array analysis identified previously unreported copy 
number alterations in MCF-10A. Copy number alterations over 100Kb were identified 
by the Genotyping Console software and alterations under 100Kb were identified via 
manual interrogation of the data. Previously unreported regions which have a copy 
number greater or less than 2 are shown in Table 4.1. Some regions with altered copy 
number state appear not to include any coding sequence but may include regulatory 
regions, such as microRNA’s. Only regions that include known coding sequences have 
been included in Table 4.1.  
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Regions of the MCF-10A genome which are not diploid were detected by the Genotyping Console software and by manual interrogation of the log2 ratio data of each 
chromosome. Only copy number altered regions affecting known coding sequence are shown. Alterations identified by manual interrogation of the data are indicated by an (*) in 
the “Chromosome” column. For manually identified alterations. if the copy number state of all the markers in the region is not conclusive then the two potential copy number 
states are given in the “Copy Number State” column. If the number of genes in an altered region is under 5 they have been named, otherwise the number of genes in the region 
has been given.  
N.B. GSTT1 on chromosome 22 is known to be deleted in a high percentage of the population, with 20% of Caucasians being homozygous for the deletion (Nelson et al 1995). 
Table 4.1 Previously unreported regions of the MCF-10A genome which are not diploid. 
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4.3 Copy number analysis of the First 5 Gγ series 
To identify novel copy number alterations and areas of LOH induced by ionising 
radiation, MCF-10A populations from the First irradiation series were analysed using 
the Affymetrix Human SNP 6.0 Array and copy number state was compared to un-
irradiated MCF-10A.  
Cell populations which had received a cumulative dose of 10, 25, 40, 55 and 80 Gγ 
were analysed from the 5 Gγ fractionated series and populations which had received a 
cumulative dose of 10, 20, 40 and 80 Gγ were analysed from the 10 Gγ fractionated 
series. An MCF-10A cell population which had been cultured to the same passage as the 
cells that received a cumulative radiation dose of 80 Gγ in the 5 Gγ irradiation series 
was also analysed as a reference population (passage control population). 
Copy number alterations identified in the First 5 Gγ series, First 10 Gγ series and 
passage control populations which were not present in the un-irradiated MCF-10A 
genome are shown in Table 4.2, 4.3 and 4.4, respectively. Many of the alterations were 
large scale and contained many genes; therefore only genes in focal alterations (fewer 
than 10 genes affected) have been named. 
The same genomic region can undergo multiple copy number alterations during a 
fractionated dosing regimen. Therefore, for each copy number alteration the copy 
number state of the region in the un-irradiated MCF-10A population, the population 
prior to when the alteration is identified and the population the alteration was identified 
in is displayed. This enables the temporal acquisition of successive copy number 
changes to be discerned.  
Complex copy number alterations can develop when a single large copy number change 
encompasses a region of a chromosome which contains multiple pre-existing smaller 
and presumably independent regions of different copy number state. In these instances 
those regions which were altered due to the same single large copy number change are 
grouped together in red. Table 4.2 shows four instances where this has occurred, on 
chromosome 1, 5, 11 and 15. The complexity of the alterations on chromosome 1, 5 and 
11 will be discussed in section 4.3.2. Chromosomal deletions which extend to the ends 
of chromosomes are indicated by green shading in Table 4.2. 
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Copy number alterations identified by the Genotyping Console software and by manual interrogation of the array data. The table shows the position of the copy number 
alterations on each chromosome affected and information of the markers used to detect the copy number alteration. Red shaded rows indicate copy number alterations which span 
a number of regions with different copy number states. Green shaded rows indicate copy number losses affecting telomeric regions. For green shaded copy number alterations the 
start base position is the position of the first marker on that particular chromosome. Base positions are based upon the annotation build hg18.  
Table 4.2 Copy number alterations of the First 5 Gγ series. 
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Copy number alterations identified by the Genotyping Console software and by manual interrogation of the array data. The table shows the position of the copy number 
alterations on each chromosome affected and information of the markers used to detect the copy number alteration.  Red shaded areas indicate copy number alterations which 
span a number of regions with different copy number states. Base positions are based upon the annotation build hg18.  
Copy number alterations identified by the Genotyping Console software and by manual interrogation of the array data. Base positions are based upon the annotation build hg19.  
  
Table 4.3 Copy number alterations of the First 10 Gγ series. 
Table 4.4 Copy number alterations of the high passage MCF-10A cells (passage control population). 
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Following a cumulative dose of 80 Gγ the First 5 Gγ series had accumulated 24 separate 
copy number alterations compared to 11 in the First 10 Gγ series. The decision was 
made to pursue alterations in the First 5 Gγ series rather than the 10 Gγ series due to the 
increased number of targets for subsequent investigation and the fact that the First 5 Gγ 
series had undergone in vitro phenotypic characterisation (Chapter 3).  
Irradiated cell populations were also interrogated for areas of copy neutral LOH. In the 
First 5 Gγ series and passage control populations there were no areas of copy neutral 
LOH that were not constitutional to the un-irradiated MCF-10A genome. 
4.3.1 Passage related copy number alterations in the First 5 Gγ Series 
The passage control population had 5 copy number alterations (Table 4.4), two of which 
were also found in the First 5 Gγ series: these were a mono-allelic gain of Chromosome 
20 and a mono-allelic deletion of EP300 (Table 4.1). It can therefore be concluded that 
these alterations are passage related rather than induced by ionising radiation. It should 
also be noted that both of these alterations were present in the First 10 Gγ series (Table 
4.2). The fact that the same alterations were seen in irradiated and passage control 
populations suggests that passage of the cells can either induce these alterations, 
presumably due to underlying genomic instability, or that the alterations were already 
present within a sub-population of un-irradiated MCF-10A cells. Selection during 
passage would suggest that these alterations conferred a growth advantage.  
4.3.2 Complex copy number alterations 
There were a number of large scale copy number alterations in the First 5 Gγ series 
which encompassed millions of bases and many genes. Some of these large scale copy 
number alterations were complex with more than one event occurring in the same 
genomic region at independent time points. Complex alterations were identified in 
Chromosome 1q, 5q and 11q (Table 4.2).  
As stated previously, chromosome 1q includes regions of triploidy and tetraploidy 
constitutional to MCF-10A cells (Fig 4.5a). Two apparently independent mono-allelic 
deletions were observed in the triploid region of chromosome 1q in the 40 Gγ 
cumulative dose population (Fig. 4.5b), reducing the copy number state to 2. These 
were a relatively focal 602Kb deletion (termed “40 Gγ-Deletion 1”) between positions 
165154658:165756926, and a 16631 kb deletion (termed “40 Gγ-Deletion 2”) between 
positions 176867954:193499072.  
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A large scale mono-allelic deletion was subsequently identified in the 80 Gγ population 
between positions 1431883331:184109080 (termed “80 Gγ-Deletion”) (Fig. 4.5c). This 
deletion spanned 40 Gγ-Deletion 1 and encompassed 7241 kb of 40 Gγ-Deletion 2 
which further reduced the copy number states of these regions to 1. Centromeric regions 
not previously affected in the 40 Gγ population but subsequently affected by the 80 Gγ-
Deletion reduced copy number state from 3 to 2. 
SNP 6.0 array analysis does not inform which allele each copy number alteration 
occurred on. It can however be concluded that the 80 Gγ-Deletion must have occurred 
on a different allele than either of the deletions observed in the 40 Gγ population. If the 
80 Gγ-Deletion had occurred on the same allele of either of the 40 Gγ deletions then the 
copy number state of these regions would have remained at 2.  
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The copy number profile of chromosome 1q for the un-irradiated MCF-10A (a), 40 Gγ cumulative dose (b) and 80 Gγ cumulative dose (c) populations of the First 5 Gγ series. 
The copy number of each region of chromosome 1q is shown above each log2 ratio map. Black arrows indicate a region which has not changed from the un-irradiated MCF-10A 
population. Red arrows indicate copy number alterations that were first identified in the 40 Gγ population. The green arrows indicate copy number alterations that were first 
identified in the 80 Gγ population. Above the copy number states is an arrow indicating the copy number change event(s) identified in each population (Del = deletion). A 
representation of the q arm of Chromosome 1, including base positions, is at the bottom of the log2 ratio maps.     
Figure 4.5 Complex copy number alterations– Chromosome 1q. 
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Figure 4.6 shows the progression of the complex alteration on chromosome 5q. A 
mono-allelic copy number gain was identified in the 40 Gγ cumulative dose population 
between positions 93621043-qter (Fig 4.6b). The start position of this copy number gain 
was centromeric of a triploid region on chromosome 5 (118383183-qter), which is 
constitutive to the un-irradiated MCF-10A population. The copy number gain therefore 
increased the constitutional triploid region to a copy number state of 4 and the 
constitutional diploid region (93621043:118427111) to a copy number state of 3. An 
additional mono-allelic deletion was identified in the 55 Gγ cumulative dose population 
between positions 129632118-qter (Fig 4.6c). The deletion restored the copy number of 
this region from 4 down to 3. Finally, a small region of copy number gain was observed 
in the 80 Gγ cumulative dose population between positions 112200585:112380304 
encompassing the SRP19, REEP5 and DCP2 loci, which was within the triploid region 
identified in the 40 Gγ cumulative dose population (Fig 4.6d). This increased the copy 
number state of this smaller region to 4. It is not discernible from the SNP 6.0 data 
which alleles were affected by these alterations.  
Deletions on chromosome 5q have been linked with a number of cancers including ER 
negative breast cancers and AML (Loo et al., 2004; Wang et al., 2004b; Fang et al., 
2011; Sekeres et al., 2011). Genes located in this region have therefore been suggested 
to be involved in cancer, such as EGR1 (Ronski et al., 2005). Copy number gains, as 
seen in this in vitro model, have not been linked with cell transformation; yet large scale 
copy number alterations do suggest an increase in chromosomal instability which often 
characterises transformed cells (discussed in section 4.5). 
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The copy number profile of chromosome 5q for the un-irradiated MCF-10A (a), 40 Gγ cumulative dose (b), 55 Gγ cumulative dose (c) and 80 Gγ cumulative dose (d) 
populations of the First 5 Gγ series. The copy number of each region of chromosome 5q is shown above each log2 ratio map. Black arrows indicate a region which has not 
changed from the un-irradiated MCF-10A population. Red arrows indicate copy number alterations that were first identified 40 Gγ population. The green arrows indicate copy 
number alterations that were first identified in the 55 Gγ population. . The blue “*” above the log2 ratio map for the 80 Gγ population (d) represents a small gain to a copy 
number state of 4. Above the copy number states is an arrow indicating the copy number change event identified in each population (Del = Deletion). A representation of 
Chromosome 5q, including base positions, is below the log2 ratio maps.     
Figure 4.6 Complex copy number alterations– Chromosome 5q. 
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Figure 4.7 shows the progression of the complex copy number alteration on 
chromosome 11. A mono-allelic deletion between positions 103769002:116689124 was 
observed in the 40 Gγ cumulative dose population which reduced the copy number state 
of this region to 1 (Fig. 4.7b). A larger mono-allelic gain between positions 62318238-
qter which spanned the mono-allelic deletion observed in the 40 Gγ population was then 
detected in the 55 Gγ population (Fig. 4.7c). The copy number state of the 40 Gγ mono-
allelic deleted region was unaffected by this gain, while the rest of the region increased 
to a copy number state of 3, indicating that the copy number gain must have occurred on 
the same allele as the 40 Gγ deletion.  
Loss of heterozygosity in this area of chromosome 11 is common in a number of 
cancers, including 40% of primary breast cancers (Carter et al., 1994; Lee et al., 2000; 
Nagahata et al., 2002; Zhang et al., 2005b). It has also been shown that ionising 
radiation can induce LOH in this region of chromosome 11 (Roy et al., 2006; Du et al., 
2010a). Candidate tumour suppressor genes or loci with a putative role in 
carcinogenesis located in this region include CADM1 and CUL5 (Fay et al., 2003; 
Murakami, 2005). DNA damage signal and repair genes on chromosome 11, such as 
ATM, MRE11A and H2AFX, have also been linked with transformation (Shiloh, 2003). 
ATM, CADM1 and CUL5 are found in the region of deletion identified in the present 
study. The relevance and potential consequences of deletion of these genes, and 
deletions of genes in other copy number affected regions, will be discussed in section 
4.5. 
There was also evidence of shortened telomeres in the First 5 Gγ series indicated by 
mono-allelic loss of telomeric regions on chromosomes 4p, 16p, 19p and 20p (Table 4.2, 
highlighted in green).  Shortened telomeres can cause chromosomal instability, or in 
itself be an indication of chromosomal instability (Gollin, 2005; Sabatier et al., 2005; 
Jefford and Irminger-Finger, 2006). Again, the relevance of these alterations will be 
discussed in section 4.5. 
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The copy number profile of chromosome 11q for the un-irradiated MCF-10A (a), 40 Gγ cumulative dose (b) and 55 Gγ cumulative dose (c) populations of the First 5 Gγ series. 
The copy number of each region of chromosome 11q is shown above each log2 ratio map. Black arrows indicate a region which has not changed from the un-irradiated MCF-
10A population.  Red arrows indicate copy number alterations that were first identified the 40 Gγ population. The green arrows indicate copy number alterations that were first 
identified in the 55 Gγ population. Above the copy number states is an arrow indicating the copy number change event identified in each population (Del = deletion). The hashed 
part of the arrow above the log2 ratio map of the 55 Gγ population indicates a region of the chromosome not affected by the copy number change event, in this case because the 
deleted region is on a different allele. A representation of Chromosome 11q, including base positions, is below the log2 ratio maps.     
Figure 4.7 Complex copy number alterations– Chromosome 11q. 
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4.3.3 Identification of genes in focal regions for further investigation 
In order to prioritize candidate genes for further investigation only loci in relatively 
focal regions of copy number change (<10 affected genes) were considered. Following a 
literature review of genes within these regions (as described in section 2.5.3) POU2F1 
was chosen for further investigation. POU2F1 (OCT-1) is located within the mono-
allelic 602Kb deletion on Chromosome 1q (Section 4.3.2). This 602Kb region contains 
6 loci in total: C1orf32, MAEL, GPA33, DUSP27, POU2F1 and CD247 (Fig. 4.8). As 
described in section 4.3.2, a mono-allelic deletion of this region was first identified in 
the 40 Gγ cumulative dose population (Fig. 4.9b). The region is located within a 
constitutional trisomic region of chromosome 1q in MCF-10A and successive deletion 
events reduced the copy number state of POU2F1 from 3 to 1 (Fig. 4.9c). An overview 
of the copy number alterations on chromosome 1q can be seen in figure 29.  
Briefly, POU2F1 is a transcription factor which has a role as a stress sensor and 
transcriptional regulator of stress response genes (Tantin et al., 2005). POU2F1 also has 
specific roles in BRCA1 mediated transcriptional regulation of DNA repair genes and 
genes involved in DNA damage response (Jin et al., 2001; Fan et al., 2002; Maekawa et 
al., 2008; Saha et al., 2010). The fact that POU2F1 is involved in these processes and 
was focally deleted in the First 5 Gγ series makes it an interesting gene to investigate 
further. Further investigation of POU2F1 will be discussed in chapter 6.    
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The log2 ratio map of a region on Chromosome 1q in the 80 Gγ cumulative dose population genome which contains a 602Kb deletion. The red arrow above the log2 ratio map 
indicates the position of the 602Kb deletion. The deleted region contains the loci for POU2F1, C1orf32, MAEL, GPA33, DUSP27 and CD247. Underneath the log2 ratio map is a 
representation of the genes within the region. Green boxes represent the exons and green lines represent the introns of the genes. Underneath the genes is a representation of the 
chromosome arm and base positions of the region.  
Figure 4.8 602Kb mono-allelic deletion of Chromosome 1q. 
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The copy number profile of the region of chromosome 1q containing POU2F1 for the un-irradiated MCF-10A (a), 40 cumulative dose (b) and 80 Gγ cumulative dose (c) 
populations of the First 5 Gγ series. The copy number of each region is shown above each log2 ratio map. The red arrow indicates a 602Kb mono-allelic deletion containing 
POU2F1 identified in the 40 Gγ population. A larger mono-allelic deletion spanning the 602Kb deletion is then identified in the 80 Gγ cumulative dose population which reduces 
the copy number state of the 602Kb deletion to 1 and flanking regions to 2. Underneath the log2 ratio maps is a representation of the genes within the region. POU2F1 is 
highlighted by the red box. A representation of the chromosome arm, including base positions, is below the gene representations.  
Figure 4.9 Progression of the POU2F1 copy number alteration in the First  5Gγ Series. 
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4.4 Copy number analysis of the Second 5 Gγ Series (Oestrogen) 
Cells from the Second Irradiation series (section 3.5) were also analysed using the 
Affymetrix SNP 6.0 Array. Cells which had received a cumulative dose of 10, 20, 40, 
60 and 80 Gγ of ionising radiation in the presence of exogenous oestrogen were 
analysed for both the 5 Gγ and 10 Gγ fractionated dosing regimens. Copy number state 
in these cell populations was compared to un-irradiated MCF-10A cells and an 17β-
oestrodiol treated passage control population, to identify copy number alterations 
caused by ionising radiation.  
There were considerably fewer copy number alterations in the Second Irradiation series 
compared to the First Irradiation series. There were no observed copy number 
alterations in the Second 10 Gγ series and only 5 copy number alterations in the Second 
5 Gγ series. The passage control population on the other hand had 6 copy number 
alterations. All of the alterations in the passage control population were whole 
chromosome copy number gains of one extra copy, involving chromosomes 7, 8, 11, 13, 
19 and 20. As in the First Irradiation series there were no areas of copy neutral LOH 
detected in the Second Irradiation series or passage control population which were not 
constitutional to the un-irradiated MCF-10A genome. 
Two of the alterations acquired in the Second 5 Gγ series were trisomy of chromosome 
20 and mono-allelic deletion of EP300, which were also identified in the First 5 Gγ 
series. Furthermore, both of these alterations were identified in the passage control 
population of the First Irradiation series. As such, evidence suggests that these 
alterations were selected for during passage of the cells and were not in fact caused by 
ionising radiation. 
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4.4.1 Novel copy number alterations of the Second 5 Gγ series 
Three novel copy number alterations were identified in the Second 5 Gγ series. Two 
were focal alterations that each affected only one gene. Specifically, these were a mono-
allelic deletion of BMPR1A and a copy number gain of c-MYC. A large copy number 
gain on chromosome 8q which affected the c-MYC locus was also identified.  
BMPR1A is located on Chromosome 10 and the mono-allelic deletion occurs between 
positions 88501217:88649027. Mono-allelic deletion of BMPR1A is first identified in 
the 40 Gγ cumulative dose population. The deletion reduces the copy number state from 
2 to 1 (Fig. 4.10). The function of BMPR1A and its potential role in cancer will be 
briefly discussed in section 4.5. 
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The copy number profile of chromosome 10 for the un-irradiated MCF-10A cell population (a). The region containing BMPR1A is highlighted by a red box and magnified 
underneath for the un-irradiated MCF-10A, 40 Gγ cumulative dose, 60 Gγ cumulative dose and 80 Gγ cumulative dose populations (b). The copy number state of each region is 
shown above each log2 ratio map. Red arrows indicate the area of mono-allelic deletion containing BMPR1A. Underneath the magnified log2 ratio maps is a representation of the 
genes within the region. BMPR1A is highlighted by a red box. A representation of the chromosome arm, including base positions, is below each log2 ratio map.  
  
Figure 4.10 Progression of the BMPR1A copy number alteration in the Second 5Gγ Series. 
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The copy number gain of c-MYC occurred within a constitutionally trisomic region of 
Chromosome 8q (described in section 4.2.1) between positions 127621008:130125337 
and was first identified in the 40 Gγ cumulative dose population (Fig. 4.11b). The copy 
number state of c-MYC increased from 3 to 4.  
A large region of copy number gain was identified on 8q in the 60 Gγ population 
between positions 71160976:130125337 which increased the constitutionally diploid 
and triploid regions to a copy number state of 3 and 4 respectively (Fig 4.11c). The 
large region of copy number gain ended at the telomeric position of the c-MYC copy 
number gain which therefore increased the copy number state of c-MYC above 4. Both 
copy number alterations on chromosome 8q appeared to share a breakpoint which 
implied that this point was fragile to double strand breaks in the Second 5 Gγ series. It 
also appeared that both alterations become more prominent as cumulative dose 
increased, which indicated that the proportion of cells the alterations were present in 
increased with cumulative dose (Fig. 4.11). It is impossible to discern from the 
polymorphism array whether both alterations occurred on the same chromosome and 
therefore the mechanisms which led to the alterations are unclear. Other techniques will 
be utilised to investigate the cytogenetic nature of the alterations and their relative 
abundance in the different irradiated cell populations (described in Chapter 7). The 
passage control population also had a single copy number increase of c-MYC but this 
was via a whole chromosome copy number gain.  
c-MYC is an established proto-oncogene which plays a role in a number of different 
cellular processes including cell proliferation and apoptosis (Xu et al., 2010). Copy 
number increase of c-MYC, converting it to an oncogene, is an established event in cell 
transformation and amplification has been reported in 15% of putative sporadic breast 
cancers (Deming et al., 2000). Furthermore, c-MYC amplification was reported in breast 
cancers that developed in radiation-exposed survivors of the Hiroshima and Nagasaki 
atomic bombs (Miura et al., 2008). The fact that c-MYC is focally altered in the present 
study and has previously been linked with radiation induced breast cancer makes it an 
interesting gene for further investigation (Chapter 7).  
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Copy number profile of chromosome 8q for the un-irradiated MCF-10A (a), 40 Gγ cumulative dose (b) 60 Gγ cumulative dose (c) and 80 Gγ cumulative dose (d) populations of 
the Second 5 Gγ series. The copy number of each region of chromosome 8q is above each log2 ratio map. Black arrows indicate a region which has not changed from the un-
irradiated MCF-10A population. Red arrows indicate copy number alterations that were first identified in the 40 Gγ population. The green arrows indicate copy number 
alterations that were first identified in the 60 Gγ population. Above the copy number states is an arrow indicating the copy number change event(s) identified in each population. 
A representation of the q arm of Chromosome 8, including base positions, is at the bottom of the log2 ratio maps.     
Figure 4.11 Copy number alterations – Chromosome 8q 
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4.5 Discussion 
The genetic alterations that contribute to breast cancer development following radiation 
exposure have yet to be identified. In the present study we have used the breast 
epithelial cell line MCF-10A to develop two in vitro models of radiation-induced breast 
epithelial cell transformation. The “First” model exposed MCF-10A cells to fractionated 
doses of 5 Gγ and 10 Gγ of ionising radiation up to a cumulative dose of 80 Gγ allowing 
for cell recovery between fractionated doses. The 5 Gγ fractionated dose series 
displayed evidence of phenotypic changes including: changes to cell morphology, 
reduction of growth rate, loss of contact inhibition and increased sensitivity to ionising 
radiation. The “Second” model exposed MCF-10A cells to the same radiation dosing 
regimen but in the presence of exogenous 17-β oestrodiol (10-8 M). The 5 Gγ 
fractionated dose series only displayed changes in cell morphology, with the 
development of an epithelial to mesenchymal transition (EMT) morphological 
phenotype.  
4.5.1 First irradiation Series 
The 5 Gγ fractionated dose series had more than twice the number of copy number 
alteration events compared to the 10 Gγ fractionated dose series. The amount of DNA 
damage caused by ionising radiation in a cell is proportional to the dose of radiation 
received (Chadwick and Leenhouts, 2011). A high dose of ionising radiation causes 
more genetic damage and is therefore more likely to be lethal to the cell. Lower doses of 
radiation can cause sub-lethal DNA damage which allows recovery and repopulation of 
cells which may then fix DNA damage as genetic mutations (Boice et al., 1987; Allan 
and Travis, 2005; Chadwick and Leenhouts, 2011). The higher cytotoxicity of the 10 Gγ 
fractionated dose regimen may therefore have not allowed cells to accumulate sub-lethal 
DNA damage, resulting in fewer overall copy number alteration events in the irradiated 
populations. The 5 Gγ series had been phenotypically characterised in the previous 
chapter therefore only alterations in the 5 Gγ series were analysed further. 
The First 5 Gγ series had radiation-induced copy number alterations on chromosome 1p, 
1q, 2p, 2q, 4p, 5q, 7q, 10p, 11q, 12q, 14q, 15q, 16p, 18q, 19p, 20p and chromosome X 
(Table 4.2, section 4.3). High density polymorphism array analysis allows the whole 
genome to be interrogated for copy number alterations. Previous studies have analysed 
specific chromosome regions and have identified LOH and microsatellite instability 
(MSI) on chromosomes 6q, 11q and 17p in a radiation-induced in vitro breast 
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transformation model (Roy et al., 2001a; Roy et al., 2006), and on chromosomes 6q, 9p 
and 17p in breast and lung cancer tissue samples from Hodgkin lymphoma patients 
(Behrens et al., 2000). Interestingly no copy number alterations or areas of copy neutral 
LOH were identified on chromosome 6q or 17p in the present study. These regions are 
known to contain important tumour suppressor genes such as IGF2R, BRCA1 and P53 
which are commonly affected in breast cancer (Niederacher et al., 1997; Rodriguez et 
al., 2000). 
All of the radiation-induced copy number alterations in the First 5 Gγ series were 
identified after a cumulative dose of 40 Gγ, and these were generally large regions of 
deletion or copy number gain, which is a hallmark of chromosomal instability (Jefford 
and Irminger-Finger, 2006). Two models could explain the apparent lack of copy 
number alterations between 0 and 25 Gγ of irradiation: 
i) Copy number alterations had occurred before 25 Gγ of irradiation but were not 
in a large enough population of cells to be identified by the SNP array software. 
SNP analysis of heterogeneous cell populations only identifies copy number 
alterations which are present in the majority of cells. Therefore a sub-population 
which accumulated copy number alterations and was gradually clonally selected 
for would not be detected until later in the irradiation series (Fig. 4.12a) 
ii) Between 0 and 25 Gγ of irradiation the DNA damage repair mechanisms were 
successful in repairing or killing cells with DNA damage. A mutation may have 
occurred between the 25 Gγ and 40 Gγ populations which led to an increase in 
chromosomal instability and/or dysregulation of DNA damage response. This 
led to a rapid clonal selection of a cell population with numerous chromosomal 
alterations (Fig. 4.12b).  
A combination of the two models is also possible.  
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Two models to explain the apparent rapid accumulation of copy number alterations identified between the 25 Gγ and 40 Gγ populations. The figure shows a representation of the 
genetically heterogeneous MCF-10A cell population with green and blue sub-populations. In the gradual clonal selection model (a), mutation or mutations occur relatively early 
in the irradiation series (red cell). The mutations confer a modest but discernible growth advantage and the sub-population(s) grows as cumulative dose increases until it is of 
sufficiently high proportion for acquired copy number alterations to be detected by the SNP 6.0 array. In the rapid clonal selection model (b), mutations are not fixed in the cell 
population until temporally later during the irradiation series (red cell) and the acquired mutation(s) confer a strong selective growth advantage. The sub-population which 
acquired the mutations is therefore rapidly selected for and comprises a sufficiently high population for acquired copy number alterations to be detected by the SNP 6.0 array. A 
combination of these models may occur in which mutations are acquired early in the irradiation series, but are not detected, followed by a mutation which causes rapid growth and 
accumulation of copy number alterations. 
Figure 4.12 Model of copy number accumulation in irradiated MCF-10A cells. 
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The mono-allelic loss of chromosome 11q22.3-23.3 identified in the 40 Gγ population 
contains the gene ATM, which encodes a protein kinase involved in DNA damage 
response and plays an important role in regulating chromosome stability (Shiloh, 2003; 
Gollin, 2005). The deletion of this region may therefore contribute to the accumulation 
of copy number alterations in the First 5 Gγ series. ATM was discovered by the 
identification of inactivating mutations in patients with the genetic disorder ataxia-
telangiectasia (Savitsky et al., 1995). Individuals that have the disorder display high 
levels of genomic instability and sensitivity to double strand break-inducing agents such 
as ionising radiation (Crawford, 1998; Shiloh, 2003). Briefly, ATM protein kinase 
rapidly initiates cell-cycle arrest and activation of cell-cycle checkpoints in G1, S and 
G2 phase of the cell cycle in response to double strand breaks. ATM mediates this 
activation by phosphorylation of a number of substrates, the full extent of which has not 
yet been determined. Phosphorylation can directly stimulate or inhibit the action of 
these proteins, which function as mediators of cell cycle checkpoint activation (Shiloh, 
2003). (Fig. 4.13).  
ATM has also been implicated as a direct activator of DNA repair. Loss of ATM causes 
sub-optimal assembly of protein complexes involved in homologous recombination and 
ATM has been shown to directly bind to sites of double strand breaks (Andegeko et al., 
2001; Shiloh, 2003; Shiloh, 2006). ATM is also functionally linked to the maintenance 
of telomere length and integrity and is involved in the apoptotic response to shortened 
telomeres (Pandita, 2001; Pandita, 2002; Shiloh, 2003; Silva et al., 2004). The First 5 
Gγ series had areas of mono-allelic loss at the telomeres of chromosomes 4p, 16p, 19p 
and 20p. Shortened telomeres can cause end-to-end fusions which can initiate 
chromosome breakage and increase chromosome instability, giving rise to gene deletion 
and amplification (Jefford and Irminger-Finger, 2006). Three of the four chromosomes 
affected by telomere shortening were not identified until the 80 Gγ cumulative dose 
population, therefore earlier acquired genetic events, such as ATM loss, may promote 
the survival of cells with shortened telomeres.  
The loss of one copy of ATM does not significantly increase the risk of cancer if a 
functioning allele remains (Gatti et al., 1999). However, under conditions of repeated 
exposure to ionising radiation and the resultant DNA strand breaks, reduced expression 
of ATM through haploinsufficiency may attenuate repair function and predispose cells 
to chromosomal damage. A reduced capacity to effectively deal with elevated levels of 
double strand breaks via ATM haploinsufficiency may explain the increased sensitivity 
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to ionising radiation shown by the First 5 Gγ series (section 3.3.4). It remains to be 
determined whether the remaining copy of ATM produces functioning protein.  
 
Figure 4.13 ATM mediated activation of cell cycle checkpoints following DNA damage 
 
 
 
ATM mediates the activation of G1, S and G2 cell cycle checkpointing in reaction to double strand 
breaks. The figure above shows each of these phases of the cell cycle. An approximation of at which 
point in each phase of the cell cycle the checkpoints are activated in is shown. The temporal direction of 
each phase of the cell cycle is from left to right. ATM mediates checkpointing via phosphorylation of a 
number of target proteins which can either activate (black arrows) or inhibit (red T shapes) the action of 
that protein. The activating or inhibitory affect of these target proteins on other proteins in the checkpoint 
pathway is also shown. The figure is adapted from Shiloh (2003).  
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ATM is not the only interesting gene in the region of chromosome 11 affected by mono-
allelic deletion. The putative tumour suppressor genes CUL5 and CADM1 were also 
affected in the present study. Expression of CUL5 was shown to be approximately 2.2 
times lower in primary breast cancer cases compared to matched normal tissue, 
indicating it as a potential tumour suppressor (Fay et al., 2003). The tumour suppressor 
role of this protein has so far not been fully determined but over-expression of the gene 
has been shown to inhibit cell proliferation in several cell lines (Lewis et al., 2011).   
CADM1 has both extra-cellular and cytoplasmic binding domains. The protein plays an 
important role in cell-cell adhesion via its extra-cellular domain (Masuda et al., 2002; 
Liang et al., 2011). Reduction in cell-cell adhesion in cancer can lead to cell invasion 
and metastasis, and loss of CADM1 promotes transformation to an invasive phenotype 
(Goto et al., 2005; Murakami, 2005; Liang et al., 2011). Cells in the First 5 Gγ series 
display reduced contact inhibition which may be due to reduced cell-cell adhesion 
mediated by loss of CADM1. A direct link between contact inhibition specifically and 
CADM1 has not been reported but loss of CADM1 abrogates recruitment of E-cadherin 
to cell-cell attached sites and E-cadherin cell-cell contact is an important mediator of 
contact inhibition (Kim et al., 2009a; Sakurai-Yageta et al., 2009).   
CADM1 has also been shown to act as a tumour suppressor via its cytoplasmic binding 
domain. CADM1 modulates cell cycle progression (Sussan et al., 2005), inhibits tumour 
growth by inducing cell cycle arrest (Lung et al., 2006), induces apoptosis after re-
expression in CADM1
-
/
-
 cells (Mao et al., 2004), and is also involved in modulating 
immunological surveillance (Murakami, 2005; Liang et al., 2011). Reduced expression 
of CADM1 has been reported in a wide variety of cancers including non-small cell lung 
cancer, breast cancer, nasoasophageal, esophageal, gastric, prostate, pancreatic, 
colorectal and cervical cancer (Liang et al., 2011). CADM1 protein expression is also 
inversely proportional to the stage of many of these cancers (Uchino et al., 2003). Loss 
or reduced expression of CADM1 via promoter silencing due to hyper-methylation can 
occur in many cancer cases but not all. For example, 70% of primary breast cancers in 
the study by Takahashi et al. (2011) had low CADM1 expression but only 46% of 
cancers displayed promoter methylation. Therefore, copy number loss of CADM1 may 
represent an alternative and important mechanism by which CADM1 expression is lost 
in some cancers. It is also possible that LOH and methylation of the promoter of 
CADM1 co-operate to reduce CADM1 expression.  
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Loss of heterozygosity at the deleted region of chromosome 11 has been reported in a 
number of malignancies, including breast cancer (40% of cases), colorectal cancer, head 
and neck squamous cell carcincoma and cervical cancer (Carter et al., 1994; Lee et al., 
2000; Nagahata et al., 2002; Zhang et al., 2005b; Parikh et al., 2007). Loss of 
heterozygosity at this region, and reduced expression of tumour suppressor genes 
therein, may therefore be a key event in tumour development. Ionising radiation has 
also been shown to induce LOH in this region in in vitro studies (Roy et al., 2006; Du et 
al., 2010b). The region may therefore be vulnerable to copy number loss due to ionising 
radiation.  
Other areas of large copy number alteration identified in the present study also contain 
genes which have been identified as potentially having a role in cancer. LOH on 
Chromosome 4p has been reported in a number of cancers (Polascik et al., 1995; 
Shivapurkar et al., 1999a; Shivapurkar et al., 1999b; Zheng et al., 2008). SLIT2, a 
putative tumour suppressor gene on chromosome 4p and is silenced or has reduced 
expression in a number of cancers, including breast cancer (Dallol et al., 2002; Kim et 
al., 2011b). Ectopic expression of SLIT2 inhibits tumour cell proliferation, suggesting 
that loss could promote tumour cell division (Kim et al., 2008; Tseng et al., 2010). 
SLIT2 is located in the area of mono-allelic deletion identified in the present study 
(Table 4.2). 
LOH on chromosome 18q has been heavily linked with colorectal cancer (Fearon et al., 
1990; De Angelis et al., 1999; Migliore et al., 2011). Chromosome 18q contains the 
putative tumour suppressor gene DCC, which is implicated in cell apoptosis and whose 
expression is lost in the majority of colorectal cancers (Fearon et al., 1990; Mehlen and 
Fearon, 2004; Shin et al., 2007; Castets et al., 2011).  DCC was affected in the region of 
mono-allelic deletion on 18q identified in the present study (Table 4.2).  
Hundreds of genes were affected in the large chromosomal alterations observed in the 
First 5 Gγ series. Copy number alteration of a subset of these genes will have had an 
effect on cell transformation and the acquired phenotypic changes (driver mutations), 
while the effect of alteration on the majority of genes will have been neutral (carrier 
mutations). A few genes that have been affected by copy number alteration that may 
play a role in cell transformation have been discussed. To focus the direction of the 
study, only genes in focally affected regions were considered for further investigation. 
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Following a literature review of potential gene targets POU2F1 was chosen for more 
detailed analysis. 
4.5.2 POU2F1 
POU2F1 is a member of the POU domain transcription factors. The protein binds to the 
octamer motif “5’ATGCAAAT3’” through the DNA binding POU domain (Herr et al., 
1988; Klemm et al., 1994). The octamer motif is found in the promoters of a number of 
genes such as: H2B (Fletcher et al., 1987), immunoglobulin genes expressed in B cells 
(Jenuwein and Grosschedl, 1991), TIE2 (Fadel et al., 1999), GnRH (Eraly et al., 1998), 
the von Willebrand factor gene (Schwachtgen et al., 1998) and the vascular cell 
adhesion molecule gene (Iademarco et al., 1992). POU2F1 is involved in transcriptional 
regulation of these genes and either activates or represses gene expression depending on 
the gene.  
Tantin et al. (2005) showed that expression of the housekeeping gene H2B was not 
altered in POU2F1 deficient fibroblasts, suggesting that POU2F1 was not essential for 
basal gene expression. POU2F1 deficient fibroblasts did however respond abnormally 
to cellular and genotoxic stress. The cells were hypersensitive to ionising radiation, 
hydrogen peroxide and doxorubicin, had increased levels of reactive oxygen species, 
increased incidence of double strand breaks and displayed dysregulation of genes 
involved in oxidative and metabolic stress pathways Tantin et al. (2005), suggesting a 
role for POU2F1 as a stress sensor and modulator of stress related genes. Previous 
studies had indicated that DNA damaging exposures such as ionising radiation, ultra-
violet (UV) radiation and methyl methanesulfonate induced increased POU2F1 protein 
levels (Meighan-Mantha 1999; Zhao 2000). DNA damage did not alter mRNA levels of 
POU2F1 and therefore the induction of POU2F1 was postulated to be mediated via 
post-translational modification. The promoter binding activity of POU2F1 was also 
enhanced after DNA damage (Zhao 2000).  
Following induction of DNA double strand breaks POU2F1 can be post-translationally 
modified by DNA-PK (Schild-Poulter et al., 2003; Schild-Poulter et al., 2007). The 
DNA-PK complex is activated following strand breakage, and is composed of a 
KU70/80 heterodimer and catalytic subunit (DNA-PKcs) required for DNA repair by 
non-homologous end joining (Mahaney et al., 2009). DNA-PK phosphorylates 13 serine 
and threonine residues on the NH2 terminus of POU2F1 which stabilizes the protein to 
allow protein accumulation (Schild-Poulter et al., 2007). Phosphorylated POU2F1 plays 
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a crucial role in p53 mediated transcriptional regulation of the cell cycle checkpoint 
gene CDKN1A following ionising radiation, and also functions to repress the function of 
H2B as a mediator of cell cycle arrest, allowing DNA repair to take place (Schild-
Poulter et al., 2003). POU2F1 expression is not up-regulated following ionising 
radiation in cells deficient for KU70/80 or DNA-PK indicating that phosphorylation by 
the DNA-PK complex is needed for POU2F1 to promote cell survival transcriptional 
modifications following double strand breaks (Schild-Poulter et al., 2003). This 
interaction was also confirmed in vivo (Kang et al., 2009). There is also evidence that 
POU2F1 might directly play a role in non-homologous end joining as it was observed 
that a POU2F1/KU complex can associate with DNA ends (Schild-Poulter et al., 2001). 
DNA-PK is activated in response to double strand breaks but POU2F1 activity is also 
induced following other forms of DNA damage. Wang and Jin (2010) showed that the 
oxidising agent hydrogen peroxide caused an increase in levels of nuclear POU2F1 and 
stimulated the kinase activity of DNA-PK and JNK. As such, DNA-PK or JNK 
complexes may phosphorylate POU2F1 in response to genotoxic stress other than 
double strand breaks.  
POU2F1 plays a major role in transcriptional regulation mediated by BRCA1. BRCA1 is 
a tumour suppressor gene which is mutated in 40-50% of hereditary breast cancers 
(Miki et al., 1994). BRCA1 has many functions such as a direct role in cell cycle 
regulation, apoptosis, DNA damage response and also functions as a transcriptional 
regulator of genes involved in these processes (Rosen et al., 2006). POU2F1 has a 
crucial role in BRCA1-mediated regulation of GADD45 following induction by DNA 
damaging agents (Jin et al., 2001; Fan et al., 2002; Maekawa et al., 2008). GADD45 
promotes genetic stability of cells following DNA damage and can be induced in a 
TP53 dependant and independent manor (Liebermann and Hoffman, 2008). POU2F1 
along with NF-YA is required for TP53 independent induction of GADD45 by BRCA1 
following DNA damage. Depletion of BRCA1 or POU2F1, or disruption of POU2F1 
binding sites abrogates GADD45 induction (Jin et al., 2001; Fan et al., 2002).  
POU2F1 was also shown to interact with BRCA1 to transcriptionally regulate genes in 
the base excision repair (BER) pathway (Saha et al., 2010). Following oxidative DNA 
damage BRCA1 induced the expression of BER genes: OGG1, NTHL1, APEX1 and 
XRCC1. Reduced expression of BRCA1 inhibited BER activity following oxidative 
damage. RNA interference of POU2F1 abrogated induction of OGG1, NTH1, APEX1 
and XRCC1 by BRCA1, indicating the important role POU2F1 has in this process. 
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Impaired induction of BER following oxidative damage would result in impaired DNA 
repair and promote the acquisition of mutations. POU2F1 is also important in BRCA1 
mediated induction of the spindle checkpoint gene MAD2, whose loss causes 
chromosomal abnormalities and genetic instability (Wang et al., 2004a), and the 
transcription of ERα (Hosey et al., 2007; Harte et al., 2010). 
Loss or reduced expression of POU2F1 may therefore have an effect on many cellular 
processes, but in particular on response to genotoxic stress. Dysregulation of stress 
response could result in genetic instability and incorrect repair of DNA damage which 
could result in oncogenic mutations. The fact that POU2F1 is involved in these 
processes and was focally deleted in the First 5 Gγ series makes it an interesting gene to 
investigate further (Chapter 6 and Chapter 8).  
4.5.3 Second irradiation series 
The Second irradiation series had comparatively fewer copy number alterations than the 
First irradiation series after both the 5 Gγ and 10 Gγ fractionated dose regimens, which 
correlates with fewer phenotypic changes observed in the Second 5 Gγ series compared 
to the First 5 Gγ series (Chapter 3). Whole chromosome copy number increases were 
identified for 6 chromosomes in the oestrogen exposed passage control population, 
however only 3 copy number alterations were identified for the irradiated populations. 
Fewer chromosomal alterations imply that concomitant 17β-oestrodiol and ionising 
radiation exposure had a protective effect against DNA damage that could initiate copy 
number alterations. This however contradicts in vitro, in vivo and epidemiological 
evidence which suggests that exposure to increased levels of both ionising radiation and 
oestrogen is more genotoxic than either on their own (reviewed in Chapter 1).  
It remains possible that mutations in genes which promote chromosome instability had 
not occurred in the Second irradiation series and therefore few chromosomal alterations 
were generated in these cell populations. However, considering the genotoxicity of both 
ionising radiation and oestrogen exposure this seems unlikely. It is also possible that 
mutations early on in the irradiation series may have conferred a resistance to DNA 
damage; for example up-regulation of DNA repair genes or genes which remove ROS. 
Ultimately however, it is unknown why the Second 5 Gγ series had relatively few copy 
number alterations.  
156 
 
Radiation/oestrodiol-induced copy number alterations identified in the Second 5 Gγ 
series were restricted to a mono-allelic deletion of BMPR1A on chromosome 10q, a 
copy number increase of c-MYC on chromosome 8q and copy number gain of a large 
region of chromosome 8q. Both focal alterations were identified in the 40 Gγ 
cumulative dose population and the large alteration was identified in the 60 Gγ 
cumulative dose population. The focal c-MYC copy number gain and large region of 
copy number gain on chromosome 8q appeared to share a breakpoint position. 
Cytogenetic study of these alterations and the relevance of a common breakpoint will be 
discussed in Chapter 7. 
Bone morphogenic protein receptor type 1 (A) (BMPR1A) is a membrane bound 
receptor which heterodimerizes with type 2 BMPR’s on binding with bone morphogenic 
proteins (BMP’s). Ligand bound BMPR1A phosphorylates downstream molecules 
SMAD1, 5 and 8 which in turn bind to SMAD4 promoting interaction with transcription 
factors to regulate expression of downstream target genes. BMP signalling plays a role 
in a number of functions such as bone and cartilage formation and neural crest 
development (Chen et al., 2004). 
Dysregulated BMP signalling has been implicated in promotion of a number of cancers, 
such as breast cancer, colon cancer and B-cell chronic lymphocytic leukaemia (Helms et 
al., 2005; Katsuno et al., 2008; Dzietczenia et al., 2010; Slattery et al., 2012), although 
there is evidence that BMPs can also function as tumour suppressors in other tissues 
(Edson et al., 2010; Shirai et al., 2011). Mutations in BMPR1A have been implicated in 
colon cancer and juvenile polyposis (Nieminen et al., 2011; Dahdaleh et al., 2012). The 
molecular mechanisms of BMP signalling are complex and its role in malignant 
transformation remains to be fully elucidated.  
4.5.4 c-MYC 
c-MYC is a well-established proto-oncogene which is amplified or over-expressed in a 
number of cancers, including, but not exclusively: Burkitt’s lymphoma, Non-Burkitt’s 
lymphoma, breast cancer, prostate cancer, gastrointestinal cancer, melanoma and small 
cell lung cancer (Nesbit et al., 1999). c-MYC is a transcription factor which regulates 
up to 15% of all human genes (Dang et al., 2006). c-MYC has a helix-loop-helix 
leucine zipper domain at the C-terminal region and binds to form a heterodimer with the 
protein MAX. This heterodimer binds specifically to E-box elements with the consensus 
sequence ‘CACGTG’ to positively or negatively regulate target gene expression 
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(Blackwood and Eisenman, 1991). Transcriptional activation involves the recruitment 
of co-activators to the E-box elements, however the mechanism of transcriptional 
repression is not well understood (Adhikary and Eilers, 2005).  
c-MYC is involved in regulating many different cell processes (Dang et al., 2006). 
Over-expression of c-MYC can lead to deregulation of these processes and to cell 
transformation and cancer. Over-expression of c-MYC results in increased proliferation 
by inhibiting cell cycle checkpoint genes and CDK inhibitors, such as GADD45 and 
p21
Cip1
 and activating cyclins D/D2/E1,A2, CDK4, CDC25A, E2F1 and E2F2, which 
induces G1 to S phase transition (Obaya et al., 1999; Meyer and Penn, 2008; Xu et al., 
2010). c-MYC overexpression has also been reported to block cell differentiation (Wu 
et al., 2003; Meyer and Penn, 2008), lead to cell immortalization by activation of 
telomerase reverse transcriptase (TERT) (Wu et al., 1999), promote angiogenesis by 
regulation of vascular endothelial growth factor VEGF expression (Baudino et al., 
2002), and induce apoptosis in the absence of survival factors by activation of p53 
apoptotic pathways (Evan et al., 1992; Zindy et al., 1998). Overcoming the apoptotic 
effects of c-MYC is an essential step in c-MYC induced cell transformation (Xu et al., 
2010).  
c-MYC overexpression has also been implicated in increasing genetic instability in vitro 
by the induction of ROS and DNA strand breaks (Vafa et al., 2002; Prochownik and Li, 
2007). Increased c-MYC copy number does not appear to have increased genetic 
instability in the present study but this characteristic may be relevant for radiogenic 
breast cancer development.  
Over-expression of c-MYC has been associated with increased c-MYC copy number 
(Chrzan et al., 2001a; Blancato et al., 2004), however overexpression can also occur in 
breast cancers without a c-MYC copy number increase, suggesting other mechanisms 
responsible for c-MYC overexpression (Chrzan et al., 2001a). TGF-β represses 
transcription of c-MYC via a SMAD3, SMAD4, E2F4, E2F5, DP-1 and p107 protein 
complex at the gene promoter (Frederick et al., 2004). The RAS/RAF/MAPK pathway 
antagonises TGF-β repression, stabilises the c-MYC protein and represses c-MYC 
degradation by inhibition of GSK-3β (Sears et al., 1999; Adhikary and Eilers, 2005; 
Sekimoto et al., 2007). Increased activity by the RAS/RAF/MAPK pathway can 
therefore increase c-MYC protein levels.  
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c-MYC is also a downstream target of both the WNT/β-CATENIN signalling and 
NOTCH signalling pathways, activation of which results in increased c-MYC expression 
(Xu et al., 2010). The relationship between WNT/β-CATENIN signalling and cancer 
has been investigated and established in colorectal cancer and increased β-CATENIN 
expression has been observed in breast carcinomas with a poor prognosis (He et al., 
1998; Khramtsov et al., 2010; Lopez-Knowles et al., 2010). c-MYC also works in a 
positive feedback loop with the WNT/β-CATENIN signalling pathway as c-MYC 
suppresses the WNT inhibitors DKK1 and SFRP1 (Cowling and Cole, 2007; Cowling et 
al., 2007). The association between the NOTCH signalling pathway and c-MYC 
expression has been studied in less detail but it has been shown that the c-MYC 
promoter is a direct target of the transcriptional activator NICD, which is released 
during NOTCH signalling (Klinakis et al., 2006; Xu et al., 2010). NICD accumulates in 
breast carcinoma cells and one study reported that up-regulation of c-MYC was 
observed in NICD-induced murine mammary cancer (Klinakis et al., 2006; Stylianou et 
al., 2006). 
Amplification of c-MYC is an established event in breast carcinogenesis. A meta-
analysis of 29 breast cancer c-MYC amplification studies by Deming et al. (2000) 
classified an amplification of c-MYC as at least a 2-fold increase in copy number. The 
analysis reported that 15.7% of breast cancers were c-MYC amplified and that 
amplification had a weak association with tumour grade and prognosis. Subsequent 
studies have also reported associations between c-MYC amplification with high tumour 
grade and poor prognosis, and that c-MYC amplification is more common in invasive 
breast carcinoma than carcinoma in situ (Deming et al., 2000; Robanus-Maandag et al., 
2003; Schlotter et al., 2003; Al-Kuraya et al., 2004; Blancato et al., 2004).  
There is some evidence in the literature that there is an association between exposure to 
ionising radiation and amplification of c-MYC. Studies of secondary angiosarcoma (AS) 
which arose after radiotherapy for primary cancers, such as breast cancer, indicated a 
high incidence of c-MYC amplification (55% - 100% of cases) compared to no evidence 
of c-MYC amplification in primary AS (Manner et al., 2010; Guo et al., 2011). c-MYC 
amplification was also reported in AS that developed following lymphoedema in 
patients not exposed to radiation, so a direct link with ionising radiation cannot be made.   
A study of Japanese atomic bomb survivors compared the incidence of c-MYC 
amplified breast cancer in radiation-exposed women and a control group of Japanese 
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women without exposure (Miura et al., 2008). c-MYC amplification was identified in 
56.5% of cases from women exposed to high doses of irradiation, 29.4% from women 
exposed to a lower dose and 14.3 % of women not exposed to ionising radiation. 
Moreover, c-MYC was reported in breast cancers with a concomitant HER2 
amplification. The results from this study therefore suggest that c-MYC amplification 
can be induced by ionising radiation. The focal c-MYC copy number increase in MCF-
10A reported in the present study, and the increased incidence of c-MYC amplified 
breast cancers in radiation-exposed atomic bomb survivors, identifies c-MYC 
amplification as a putative marker of radiation-induced breast carcinogenesis.  
4.5.4 Conclusion 
High density SNP array analysis of ionising radiation treated MCF-10A cells (with and 
without added oestrogen) has identified regions of copy number change which may be 
linked to radiation-induced breast epithelial cell transformation. These include a mono-
allelic deletion of a region on chromosome 11, a focal deletion of the stress response 
gene POU2F1 and a copy number increase of the proto-oncogene c-MYC. 
Further phenotypic characterisation of POU2F1-deleted MCF-10A cells, and the 
prevalence of POU2F1 deletion in sporadic and radiation-induced breast cancer will be 
investigated in Chapter 6 and Chapter 8. Likewise, further genotypic characterisation of 
c-MYC-amplified MCF-10A cells will be investigated in chapter 7, along with an 
assessment of c-MYC amplification in sporadic and radiation-induced breast cancer 
tissue samples (Chapter 8). 
First however, the effect of the acquired copy number alterations in the First and Second 
5 Gγ series on gene expression will be discussed (Chapter 5).  
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Chapter 5: Genome-wide expression analysis of irradiated MCF-10A 
populations 
5.1 Introduction 
High-density polymorphism analysis of the First and Second 5 Gγ series identified copy 
number alterations in both irradiation series. Copy number alterations can alter the 
expression of those genes directly affected by the copy number change and also genes 
which are transcriptionally regulated by directly affected genes. The First 5 Gγ series 
had extensive copy number alterations and the expression profile of these irradiated cell 
populations is predicted to be different to un-irradiated MCF-10A as a consequence. 
The Second 5 Gγ series only had three copy number alterations, but genes affected by 
these alterations (c-MYC and BMPR1A) are known to transcriptionally regulate 
numerous downstream target genes. The exogenous oestrogen added to the culture 
media during irradiation of the Second 5 Gγ series can also cause oxidative DNA 
damage and therefore mutations that can alter gene expression. Analysing the 
expression profile of cells from the First and Second 5 Gγ series will help to understand 
the effect of ionising radiation. 
In order to investigate the effect of radiation-induced genetic alterations on gene 
expression the Illumina HT12 v4 expression array was used to analyse RNA extracted 
from un-irradiated MCF-10A cells and radiation-treated cells from the First and Second 
5 Gγ series. Briefly, the array uses 50-mer oligonucleotide probe sequences which are 
designed, in silico, to hybridise with transcript sequences of genes in the human genome. 
When transcript sequence is bound to the probes a signal for the probe can be detected. 
The signal intensity for each probe corresponds to the amount of gene-specific transcript 
that is present in the sample and therefore the relative expression of that gene. For some 
genes there are multiple probes which are specific to different regions of the gene or to 
splice variants of the gene. Therefore, within the same gene some probes can generate a 
signal while others probes might not, depending on which splice variants are transcribed 
or if the probe sequence is present in the transcript of the gene within that sample.  
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5.1.1 Aim 
The aim of the work described in this chapter was to investigate the expression of genes 
affected by copy number alteration in irradiated MCF-10A cells (described in Chapter 
4), which genes were most differentially expressed and whether differentially expressed 
genes can be grouped according to cellular function.  
5.2 Gene expression analysis of the First 5 Gγ series 
The Illumina HT12 v4 expression array was used to analyse RNA extracted from un-
irradiated MCF-10A, First 5 Gγ series and passage control cell populations. Expression 
data was not available for the 10 Gγ and 80 Gγ cumulative dose populations, which 
limited the subsequent analysis. Expression data was analysed using the Illumina 
Genome Studio software which compares the signal intensity of each probe in each 
population to a chosen control population. A differentiation p-value was calculated 
based on the difference in signal intensity between the test and control samples and the 
variation of internal controls, which in turn was computed into a Differentiation Score 
for each probe (section 2.6.2). For probes where the software was not confident of a 
difference between the test and control samples a Differentiation Score was not given. 
Some probes which were attributed a differentiation score had differentiation p-values > 
0.05. Due to the lack of replicates for the gene expression analysis the differentiation p-
value was artificial and therefore may not have reflected the true significance of any 
expression difference. As such, for subsequent analyses the attribution of a 
differentiation score was used as the sole indicator of differential expression, regardless 
of the differential p-value. From here on, when the term differentially expressed is used 
it refers to genes which have been attributed a differentiation score. 
It should be noted that due to the lack of repeats and the caveats discussed above that 
the data is limited and has to be analysed with some caution. Nevertheless, comparisons 
between gene expression, copy number and phenotypic changes are still possible.   
5.2.1 Expression analysis of specific copy number altered genes from the First 5 Gγ 
series 
Genes affected by copy number changes (described in section 4.3) were analysed for 
concomitant changes in gene expression. Genes analysed were: CADM1, CUL5, ATM, 
SLIT2, DCC and POU2F1 (Table 5.1). For each probe, Genome Studio calculates a 
detection p-value which indicates whether the signal from that gene is detected above 
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background as determined by negative controls on the array.  Two of the four probes for 
ATM were not detected above background in un-irradiated MCF-10A cells and were 
therefore discarded from subsequent analysis. 
Gene Chromosome 
Copy number change 
by SNP analysis 
Resulting number 
of copies 
Number of expression 
probes 
Number of probes detected 
POU2F1 1q -1 2 1 1* 
SLIT2 4p -1 1 1 1 
CADM1 11q -1 1 1 0 
CUL5 11q -1 1 1 1 
ATM 11q -1 1 4 2 
DCC 18q -1 1 1 0 
Table 5.1 Genes affected by copy number alteration analysed for changes in gene expression. 
Genes affected by copy number changes which were highlighted in Chapter 4. The chromosomal location 
of the selected loci and the overall copy number change in the 55 Gγ cell populations relative to un-
irradiated MCF10-A is shown (-1 = mono-allelic loss of the gene). The number of probes on the array and 
the number of probes detected above background for each locus are also detailed.* The POU2F1 probe 
was not detectable above background in 55 Gγ MCF10-A cells, and only marginally detectable above 
background in un-irradiated MCF-10A. 
 
Expression of ATM, CUL5 and SLIT2 was over 2 fold lower in the 40 Gγ and 55 Gγ 
populations compared to the un-irradiated MCF-10A cell population (Fig. 5.1). Mono-
allelic deletion of these loci was detected in the 40 Gγ and 55 Gγ populations (chapter 
4), suggesting that expression of these genes was reduced due to allelic loss. Expression 
of each selected locus was similar in passage control and un-irradiated MCF-10A cell 
populations. 
CADM1, POU2F1 and DCC were each represented by only one probe in the array. 
Probe signal for CADM1 and DCC were not detected above background in un-irradiated 
MCF-10A (Detection p-value > 0.05), and signal for POU2F1 was only slightly higher 
than background. Non-detection of these probes may indicate that the target transcript 
was not expressed, or expressed at very low level. However, as the probes are designed 
in silico and have not all been validated in a laboratory setting it could be that some do 
not hybridise to their target transcripts as expected. It has also been shown that some of 
the Illumina probe sets hybridise to non-target genomic regions, including intergenic 
regions (Barbosa-Morais et al., 2010). As only one probe matches to each of these 
genes, a defective or un-informative probe would give the false impression of absent 
expression of target transcript. As such, there is a lack of information for these genes 
rather than definitive proof of lack of expression. 
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Figure 5.1 Expression analysis of ATM, CUL5 and SLIT2 in the First 5 Gγ series. 
 
 
 
 
 
 
 
 
 
 
The mean signal intensity of probes which hybridise to transcripts of ATM, CUL5 and SLIT2 in un-
irradiated MCF-10A, 25 Gγ, 40 Gγ, 55 Gγ and passage control populations is shown. For genes which 
have more than one probe which hybridises to the gene transcript the average signal intensity is shown. 
Probe signal intensity that is at least 2 fold lower than that seen in un-irradiated MCF-10A is indicated by 
an * on the graph.  
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5.2.2 Analysis of differentially expressed genes of the First 5 Gγ series 
Genes that were differentially expressed (attributed with a differentiation score) in the 
First 5 Gγ series and passage control populations compared to the un-irradiated MCF-
10A cell population were identified following analysis with Genome Studio. Probes 
which were not detected above background (Detection p-value > 0.05) in un-irradiated 
MCF-10A cells were discarded from the analysis.  
Differentially expressed genes in each irradiated population that were also differentially 
expressed in the passage control population were deemed to be passage related 
expression changes. Differentially expressed genes that were not identified in the 
passage control population were deemed to be radiation-induced expression changes. 
The number of radiation-induced and passage related differentially expressed genes in 
each irradiated population are shown in figure 5.2. The proportion of passage related 
expression changes reduced as cumulative dose increased, from 44% in the 25 Gγ 
population, to 24% and 18% in the 40 and 55 Gγ populations, respectively. Genes that 
were differentially expressed in both radiation-treated and passage control cell 
populations relative to un-irradiated MCF-10A were removed from subsequent analysis 
of the First 5 Gγ series in order to focus on radiation-induced alterations. 
There was a 10 fold increase in the number of radiation-induced differentially expressed 
genes in the 40 Gγ population compared to the 25 Gγ population, which approximately 
corresponded with the observed increase in the number of copy number alterations 
(discussed in section 4.3) (Fig. 5.2). There was a further increase in the number of 
radiation-induced differentially expressed genes in the 55 Gγ population, which again 
approximately corresponded with an increase in the number of copy number alterations. 
Copy number alterations may directly affect gene expression, as seen for ATM, CUL5 
and SLIT2 (section 5.2.1), but may also indirectly affect expression of other genes via 
deletions or amplifications of genes which regulate gene transcription or DNA 
methylation, for example. Also, copy number alterations will not account for all gene 
expression changes. Non-copy number related alterations such as point mutations in 
promoter regions of genes for example will also affect the expression of genes, although 
these and other mechanisms have not been investigated in this study. 
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Figure 5.2 Number of differentially expressed genes in the First 5 Gγ series. 
 
 
 
 
 
 
 
 
 
The number of genes which are differentially expressed in the 25 Gγ, 40 Gγ, 55 Gγ and passage control 
populations compared to un-irradiated MCF-10A. The number of differentially expressed genes which are 
also identified in the passage control population are represented by black bars (passage related expression 
changes). The number of differentially expressed genes in radiation-exposed MCF-10A, but not affected 
in the passage control cells, are represented by grey bars (radiation-induced expression changes). The 
total number of differentially expressed genes is above each pair of bars for each population. The 
percentage of differentially expressed genes which were passage related for each population was:     25 
Gγ – 44%, 40 Gγ – 24%, 55 Gγ – 18%.  
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The 55 Gγ population had the highest number of differentially expressed genes and had 
received the highest cumulative dose of irradiation. Therefore only differentially 
expressed genes from the 55 Gγ population were used in subsequent analysis. The 55 
Gγ population had over 200 down-regulated genes and over 150 up-regulated genes 
compared to the un-irradiated MCF-10A population (Fig. 5.3). In order to reduce the 
number of genes to analyse in more detail, only the top 10 most differentially expressed 
genes (according to differentiation score) in each expression group were used in 
subsequent analysis (Table 5.2a and 5.2b).  
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Figure 5.3 The number of down-regulated and up-regulated genes in the First 5 Gγ series. 
 
 
 
 
 
 
The number of genes which are down-regulated (black bars) and up-regulated (grey bars) in the 25 Gγ, 40 
Gγ, 55 Gγ and passage control populations compared to the un-irradiated MCF-10A cell population. The 
number of differentially expressed genes for the 25 Gγ, 40 Gγ and 55 Gγ populations does not include 
genes which were also differentially expressed in the passage control population. The total number of 
differentially expressed genes displayed on the graph is shown above each pair of bars for each 
population. 
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Reduced Expression 
Gene Name 
Differentiation 
Score 
Copy Number Change 
by SNP Analysis 
Resulting Number 
of Copies 
Gene Function 
FLJ12684 -51.79 None 2 Calcium uptake in mitochondria 
ASAP3 -30.88 None 2 Promotes cell proliferation 
BCL6 -30.88 None 2 Transcriptional repressor 
C14orf147 -27.44 None 2 Unknown 
SNCA -27.26 None 2 Regulation of dopamine release and transport 
SIDT2 -24.78 -1 1 Unknown 
IFI44L -24.65 None 2 Unknown 
MGMT -24.46 None 2 DNA repair: Repairs alkylated guanine 
HADH -22.02 None 2 Mitochondrial oxidation of short chain fatty acids 
SMOX -21.86 +1 3 Catalyzes the oxidation of spermin to spermidine 
 
 
Increased Expression 
Gene Name 
Differentiation 
Score 
Copy Number Change 
by SNP Analysis 
Resulting 
number of copies Gene Function 
CCND2 66.12 None 2 
Regulates progression between G1 and S phase of 
the cell cycle 
LOC100008589 39.25 None 2 
Un-annotated gene coding a ribosomal RNA 
repeating unit 
LOC100133565 34.38 None 2 Un-annotated gene 
AKAP12 30.46 None 2 Anchoring protein 
LOC441763 27.75 None 2 Un-annotated gene 
SRP19 25.29 +1 3 Part of the signal-recognition-particle complex 
IL24 23.98 None 3 Induces apoptosis in various cancer cells 
CHORDC1 22.66 +1 3 
Chaperone protein: regulates centrosome 
duplication 
LMTK3 22.45 None 2 
Phosphorylates ERα leading to tamoxifen 
resistance 
ADRB2 21.39 None 3 
Beta-2-andrenic receptor: smooth muscle 
relaxation 
Table 5.2 Top 10 differentially expressed genes in the 55 Gγ cumulative dose population. 
The top 10 down-regulated (a) and top 10 up-regulated genes (b) (as determined by differentiation score) 
in the 55 Gγ population compared to the un-irradiated MCF-10A population were identified using 
Genome Studio. The name and differentiation score (as calculated by Genome Studio: Section 2.6.2) for 
each of the 20 genes is shown in the table. Negative differentiation scores indicate a reduction in 
expression and positive differentiation scores indicate an increase in expression. The more 
negative/positive a score, the larger the difference in expression compared to un-irradiated MCF-10A. 
The copy number change between the un-irradiated MCF-10A and 55 Gγ population as determined by the 
SNP 6.0 array is also shown for each gene. None = no change, +n = number of copies gained and -n = 
number of copies lost. The resulting copy number state of the gene in the 55 Gγ population is also shown. 
Genes to be discussed further in section 5.4 are highlighted in red.    
 
 
 
 
a 
b 
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Of the 20 most differentially expressed genes only 3 had a gene copy number change 
which correlated with a reduction or increase in expression (SIDT2, SRP19, CHORDC1; 
Table 5.2a and b). SMOX is in a region of copy number increase but expression of the 
gene decreased. The lack of correlation between gene expression change and copy 
number change in the 20 gene cohort suggests that other mechanisms affecting gene 
expression may be operating. 
Genes in the 20 gene cohort that may be relevant to cell transformation or alterations in 
cell phenotype observed in the First 5 Gγ series included ASAP3, BCL6, MGMT, 
CCND2 IL24, and LMTK3. Change in expression of these genes throughout the First 5 
Gγ series was analysed as a function of cumulative radiation dose (Fig. 5.4 and Fig. 5.5). 
Both ASAP3 and BCL6 were differentially expressed in the 40 Gγ and 55 Gγ cell 
populations, however there was also a modest decrease in expression in the 25 Gγ 
population (Figure 5.4). The expression of ASAP3 was also reduced in the passage 
control population but was not identified as differentially expressed by Genome Studio. 
The expression of MGMT dropped substantially between the 40 Gγ and 55 Gγ 
populations indicating that a genetic event between these two populations caused the 
decrease in expression (Figure 5.4). 
CCND2 expression was differentially increased in all of the irradiated populations 
analysed compared to un-irradiated MCF-10A (Figure 5.5). IL24 expression was only 
differentially expressed in the 55 Gγ population however there is a smaller increase in 
expression in the 40 Gγ population also. LMTK3 expression increased more than 4 fold 
between the 25 Gγ and 40 Gγ populations indicating that a genetic event between these 
two populations may have caused a sudden increase in expression. 
The implications and relevance of altered expression of these genes will be discussed in 
section 5.4.3. 
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Figure 5.4 Gene expression of ASAP3, BCL6 and MGMT in the First 5 Gγ series. 
The average signal intensity of probes which hybridise to transcripts of ASAP3, BCL6 and MGMT, in the 
un-irradiated MCF-10A, 25 Gγ, 40 Gγ, 55 Gγ and passage control population is shown. For genes which 
have more than one probe which hybridises to the gene transcript the mean signal intensity of the probes 
is shown. Cell populations whose probe signal intensity is differentially expressed compared to the un-
irradiated MCF-10A population as calculated by GenomeStudio is identified by an * on the graph. 
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Figure 5.5 Gene expression of CCND2, IL24 and LMTK3 in the First 5 Gγ series. 
 
 
 
 
 
 
 
 
 
 
The average signal intensity of probes which hybridise to transcripts of CCND2, IL24 and LMTK3 in the 
un-irradiated MCF-10A, 25 Gγ, 40 Gγ, 55 Gγ and passage control population is shown. For genes which 
have more than one probe which hybridises to the gene transcript the mean signal intensity of the probes 
is shown. Cell populations whose probe signal intensity is differentially expressed compared to the un-
irradiated MCF-10A population as calculated by GenomeStudio is identified by an * on the graph. 
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5.2.3 Functional clustering analysis of the First 5 Gγ series 
Radiation-induced gene expression changes identified in the 55 Gγ cumulative dose 
population were used to elucidate biological processes that were enriched for 
differentially expressed genes. To identify affected processes an online gene function 
clustering tool (The Database for Annotation, Visualization and Integrated Discovery -
DAVID) was used to cluster differentially expressed genes into functionally related 
groups defined by Gene Ontology (GO) Database annotations (Huang et al., 2009a; 
Huang et al., 2009b). DAVID calculated the probability that identified gene clusters 
were not present in the differentially expressed gene list by chance (Section 2.7). 
Cellular pathways significantly enriched for differentially expressed genes were more 
likely to be affected by gene expression changes. DAVID also grouped together gene 
clusters that shared genes and had similar biological functions.   
DAVID identified 10 functional groups which contained multiple gene clusters that 
were significantly enriched for differentially expressed genes from the 55 Gγ population 
(p<0.05) (Table 5.3). The gene cluster with the lowest p-value within each functionally 
related group is shown in table 5.3. Changes to these 10 processes may have affected 
the phenotypes observed in the First 5 Gγ series. The specific consequence of the 
changes to the processes identified cannot be determined as it is unclear whether the 
activity of the process would be reduced or enhanced by the expression changes. 
Nevertheless, changes in the expression of genes in these pathways can be considered in 
the context of the phenotypic changes observed in the First 5 Gγ series. Cellular 
pathways likely to have been affected by expression changes include: cell death (with 3 
of the 10 processes outlined in table 5.3 being related to apoptosis), cell migration, cell 
growth and cellular response to steroid hormones. The potential implications of changes 
to these processes in relation to the First 5 Gγ series will be discussed in section 5.4.4.  
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Database Resource Gene Group Function (Annotation Term) 
Number 
of Genes 
p value 
GOTERM_BP_FAT GO:0008219~cell death 27 0.0015 
GOTERM_BP_FAT GO:0042981~regulation of apoptosis 28 0.0036 
GOTERM_BP_FAT GO:0048545~response to steroid hormone stimulus 12 0.0013 
GOTERM_MF_FAT GO:0004252~serine-type endopeptidase activity 9 0.0101 
GOTERM_BP_FAT GO:0045926~negative regulation of growth 8 0.0054 
GOTERM_BP_FAT GO:0043065~positive regulation of apoptosis 16 0.0199 
GOTERM_BP_FAT GO:0016485~protein processing 7 0.0213 
GOTERM_BP_FAT GO:0016477~cell migration 12 0.0184 
GOTERM_BP_FAT GO:0007599~hemostasis 7 0.0182 
GOTERM_BP_FAT GO:0008585~female gonad development 5 0.0349 
Table 5.3 Biological processes enriched for differentially expressed genes from the 55 Gγ population 
of the First irradiation series. 
Functional clustering results for genes which were differentially expressed in the 55 Gγ population given 
by the online functional annotation tool DAVID (http://david.abcc.ncifcrf.gov/). Gene clusters that share 
a common cellular function and are unlikely to be present in the differentially expressed gene list by 
chance (p < 0.05) are shown. The lower the p value the more probable the associated functional group is 
affected in the assayed cell population. The number of differentially expressed genes associated to each 
biological process is given. The nomenclature in the Database Resource column refers to the nature of the 
biological function: BP = Biological process, MF = Molecular Function (Section 2.7). The annotation 
term relates to a description of the biological function that the gene group is attributed to in the Gene 
Ontology (GO) database (http://www.ebi.ac.uk/QuickGO/).  
It should be noted that some of the biological processes may have overlapping genes within their gene 
clusters. 
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5.3 Gene expression analysis of the Second 5 Gγ series 
The Illumina HT12 v4 5.3 expression array was used to analyse RNA extracted from 
the Second 5 Gγ series (irradiated with the addition of exogenous oestrogen). The 10 Gγ, 
20 Gγ, 40 Gγ, 60 Gγ and 80 Gγ cumulative dose populations of the Second 5 Gγ series 
were analysed for gene expression, as was the exogenous oestrogen exposed passage 
control population. 
5.3.1 Expression analysis of specific copy number altered genes from the Second 5 Gγ 
series 
Genes identified by the SNP 6.0 array which had an altered copy number state 
compared to un-irradiated MCF-10A (c-MYC and BMPR1A, section 4.4) were 
specifically analysed for changes in gene expression.  
A focal copy number increase of c-MYC was identified in the 40 Gγ cumulative dose 
population (section 4.4.2). A second larger copy number gain on chromosome 8q 
increased the copy number of c-MYC further in the 60 Gγ and 80 Gγ populations. Copy 
number of the c-MYC locus also increased in the passage control population due to a 
whole chromosome copy number gain of chromosome 8. c-MYC was not attributed a 
differentiation score in any of the populations compared to un-irradiated parental MCF-
10A. However, there was a trend for an increase in signal intensity for these probes in 
the 40 Gγ population compared to un-irradiated MCF-10A which continued to increase 
as cumulative dose increased, which is consistent with increasing copy number in these 
cell populations (Fig 5.6a). 
Mono-allelic deletion of BMPR1A was observed in the 40 Gγ, 60 Gγ and 80 Gγ 
populations using SNP array analysis. However, BMPR1A was not attributed a 
differentiation score in any of the populations compared to un-irradiated MCF-10A (Fig 
5.6b). Again a trend was observed that the signal intensity of the probe was reduced in 
the 40 Gγ, 60 Gγ and 80 Gγ populations. 
Taken together, these data suggest that an increase in c-MYC copy number and mono-
allelic deletion of BMPR1A may be associated with increased and reduced expression 
respectively. 
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Figure 5.6 Expression of c-MYC and BMPR1A in the Second 5 Gγ series. 
 
 
 
The average signal intensity of probes which hybridise to transcripts of c-MYC (a) and BMPR1A (b) in 
the un-irradiated MCF-10A, 10 Gγ, 20 Gγ, 40 Gγ, 60 Gγ, 80 Gγ and passage control population is shown. 
For genes which have more than one probe which hybridises to the gene transcript the mean signal 
intensity of the probes is shown. The genes were not differentially expressed in any population compared 
to un-irradiated MCF-10A. 
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5.3.2 Analysis of differentially expressed genes of the Second 5 Gγ series 
As described in section 5.2.2, probes which were not expressed above background in 
un-irradiated parental MCF-10A cells were discarded from the analysis. The SNP 6.0 
data indicated that there were only 2 focal copy number alterations and 1 large copy 
number gain in the Second 5 Gγ series not present in un-irradiated MCF-10A cells. In 
contrast, there were 5 whole chromosome copy number gains in the passage control 
population (section 4.4). The relative number of genes affected by copy number 
alterations in the irradiated cell populations and passage control cells was reflected in 
the number of differentially expressed genes identified by Genome Studio in these 
populations. Specifically, in total there were 1540 differentially expressed genes in the 
passage control population, 857 of which were up-regulated and 683 which were down-
regulated. In contrast, the total number of differentially expressed genes in the 80 Gγ 
population was 46. The passage control population had novel copy number gains of 
chromosomes 7, 8, 11, 13, and 19. The majority of the differentially up-regulated genes 
compared to un-irradiated MCF-10A were located on those chromosomes affected by 
trisomy (Fig. 5.7a).  Conversely, these chromosomes carried relatively few 
differentially down-regulated genes (Fig. 5.7b). The large numbers of genes which 
increased in copy number in the passage control population may have also had an 
indirect effect on expression of other genes in the genome. 
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b Number of down-regulated genes 
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Figure 5.7 Location of differentially expressed genes in the passage control population of the 
Second 5 Gγ series. 
 
 
 
 
 
 
 
 
 
The number of genes which were up-regulated (a) and down-regulated (b) on each chromosome of the 
passage control population compared to the un-irradiated MCF-10A population. Trisomic chromosomes 
identified by the SNP 6.0 array in the passage control population are highlighted in red.  
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Differentially expressed genes identified in the passage control population were 
removed from subsequent analysis of the Second 5 Gγ series in order to concentrate on 
genes whose expression was affected by alterations specific to the irradiated populations. 
The number of radiation-induced differentially expressed genes increased 3 fold 
between the 20 Gγ and 40 Gγ populations (Fig. 5.8). Amplification of c-MYC and 
mono-allelic deletion of BMPR1A were both first identified in the 40 Gγ population. c-
MYC and BMPR1A are both transcriptional regulators which may partly explain the 
observed increase in the number of differentially expressed genes. An elevated number 
of differentially expressed genes compared to un-irradiated MCF-10A were maintained 
in the 60 Gγ and 80 Gγ populations (Fig. 5.8). As there are relatively few differentially 
expressed genes in the 60 Gγ and 80 Gγ populations, genes identified from both of these 
populations were analysed further. Specifically, there were 31 differentially expressed 
genes in total between the two populations. Thirteen genes were differentially expressed 
in both populations (Fig. 5.9a), 12 genes were only differentially expressed in the 60 Gγ 
population (Fig. 5.9b) and 6 genes were only differentially expressed in the 80 Gγ 
population (Fig. 5.9c). Differentiation score rather than signal intensity is shown for 
each gene in figure 5.9. It is noteworthy that none of these genes were affected by copy 
number alterations. 
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Figure 5.8 Number of differentially expressed genes in the Second 5 Gγ series. 
  
The number of genes which were differentially expressed in the 10 Gγ, 20 Gγ, 40 Gγ, 60 Gγ and 80 Gγ 
populations compared to un-irradiated MCF-10A. The number of differentially expressed genes for the 
irradiated populations does not include genes which were also differentially expressed in the passage 
control population. The number of differentially expressed genes displayed on the graph is shown above 
each bar for each population.  
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a. Differentially expressed genes in both the 60 Gγ and 80 Gγ populations 
 
 
   b. 60 Gγ population   c. 80 Gγ population 
  
Figure 5.9 Differentially expressed genes of the 60 and 80 Gγ cumulative dose populations. 
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Genes differentially expressed in both the 60 Gγ (black bars) and 80 Gγ (grey bars) cumulative dose 
populations (a), only in the 60 Gγ population (b) and only in 80 Gγ population (c) compared to the un-
irradiated MCF-10A cell population. Genes are ordered from left to right by differentiation score. In the 
graph displaying genes differentially expressed in both populations (a) genes are ordered from left to right 
by differentiation score in the 80 Gγ population. A positive score indicates up-regulation of a gene and a 
negative score indicates down-regulation of a gene relative to un-irradiated MCF-10A. The more 
positive/negative the score, the greater the difference in expression of the gene compared to the un-
irradiated MCF-10A population.  
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A number of the expression changes identified in the 60 Gγ population correlate with 
expression changes in cells which undergo epithelial mesenchymal transition (EMT). 
For example, one very well established marker for EMT is down-regulation of CDH1 
(E-cadherin) which is often concomitant with up-regulation of CDH2 (N-cadherin). 
CDH1 was down-regulated in the 60 Gγ population (Fig 5.9b), and CDH2 showed 
increased expression compared to un-irradiated MCF-10A but was not attributed a 
differentiation score (Fig. 5.10). CDH1 was not down-regulated in the 80 Gγ population 
and the expression of CDH2 did not increase compared to un-irradiated MCF-10A 
either (Fig. 5.10).  
Other genes which are down-regulated in cells undergoing EMT and were also down-
regulated in the 60 Gγ population include KRT14, PI3, FGFBP1, KRT17P3 and CD24 
(Thiery, 2003; Vincent-Salomon and Thiery, 2003; Huber et al., 2005; Higashikawa et 
al., 2008; Mani et al., 2008; Cho et al., 2010; Micalizzi et al., 2010; Asiedu et al., 2011; 
Hanahan and Weinberg, 2011) (Fig. 5.9a and b). Down-regulation of CD24 is also a 
marker for cancer stem cells which are highly tumourigenic (Reya et al., 2001; Al-Hajj 
et al., 2003), and which share properties with cells undergoing EMT (Mani et al., 2008). 
KRT14 and FGFBP1 were also down regulated in the 80 Gγ population (Fig. 5.9a).  
SERPINE1, which is an expression marker for EMT and is up-regulated in a number of 
cancers was also up-regulated in both 60 and 80 Gγ cell populations (Samarakoon et al., 
2009; Hesling et al., 2011) (Fig 5.9a).  
The identification of some EMT expression markers in the 60 Gγ population and not the 
80 Gγ population may be natural fluctuations in the expression profile of these genes or 
may reflect other molecular processes that are affecting the EMT expression profile 
(discussed in section 5.4.2).  
Other genes which were differentially expressed in the 60 Gγ or 80 Gγ populations and 
have putative roles in cancer include H19, LEPREL1, CCL20 and EYA2; each of which 
will be discussed in section 5.4.2.  
Due to the small number of genes that were differentially expressed in the Second 5 Gγ 
series it was not appropriate to use gene function clustering analysis.  
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Figure 5.10 Expression analysis of CDH2 in the Second 5 Gγ series. 
 
5.4 Discussion 
High density SNP array analysis of irradiated MCF-10A populations detected numerous 
copy number alterations induced by ionising radiation. Change in gene copy number 
can affect cellular phenotype by affecting gene expression. As such, a genome-wide 
expression array was used to generate a gene expression profile of the First and Second 
5 Gγ series. This approach could be used to identify cellular functions affected in 
irradiated cells, and which might be responsible for radiation-induced phenotypic 
changes. Furthermore, expression array analysis was also used to investigate the 
expression of those genes specifically affected by gene copy number alterations.  
5.4.1 First 5 Gγ series 
Three hundred and ninety putative radiation-induced differentially expressed genes 
were identified in the 55 Gγ population compared to un-irradiated MCF-10A. The 
number of differentially expressed genes increased as cumulative dose increased which 
approximately corresponded to an increase in the number genes with an altered copy 
number state. This association therefore indicates that copy number alterations directly 
affect gene expression in the First 5 Gγ series. Similar associations have been made in 
other in vitro studies which have analysed the gene expression profile of cell 
populations with differing amounts of copy number alteration (Russo and Russo, 2006).  
The average signal intensity of the single probe which hybridises to the transcript of CDH2 in the un-
irradiated MCF-10A, 60 Gγ and 80 Gγ populations.  
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ATM, CUL5 and SLIT2, which underwent mono-allelic deletion in the First 5 Gγ series 
(Chapter 4), showed a concomitant loss of expression. The potential relevance of loss or 
reduced function of these genes was discussed in section 4.5. Other deleted genes 
identified in chapter 4 (CADM1, DCC and POU2F1) were not detected above 
background in the array and therefore changes in expression could not be analysed. As 
stated in section 5.2.1, non-detection of probes designed to hybridise to specific 
transcripts may indicate low expression of the gene, or conversely, that the probes may 
not bind to the relevant transcript (Barbosa-Morais et al., 2010).   
Reduced gene expression often results in reduced protein product. Whether the potential 
reduction of ATM, CUL5 and SLIT2 transcript is biologically significant in the present 
study is unknown. The presence of only one functioning copy of ATM has been reported 
to have no effect on cancer risk in mice (Spring et al., 2002); however the functionality 
of the remaining gene in the present study is unknown. Loss or reduced function of 
ATM may explain the sudden accumulation of copy number alterations in the 40 Gγ 
population of the First 5 Gγ series (section 4.5). 
Due to the large number of differentially expressed genes in the First 5 Gγ series only 
the top 10 differentially up-regulated and down-regulated genes (based on their 
differentiation score) were analysed further. The differentiation score is not a direct 
representation of the amount of differential expression but is based on the probability 
that the difference in expression between the test and control samples is real. The 
probability is however dependant on the difference in signal intensity of the probes 
between samples (section 2.6.2).  
5.4.2 Alternative mechanisms affecting gene expression 
Only 3 of the top 20 differentially expressed genes had a concomitant copy number 
alteration. Therefore 85% of the genes were differentially expressed via other 
mechanisms. For example, expression or functional changes to transcriptional 
regulatory proteins such as transcription factors, or epigenetic regulatory proteins can 
potentially affect the expression of numerous downstream target genes not directly 
affected by copy number alterations (Sharma et al., 2010; Kanwal and Gupta, 2011). 
Changes to the methylation profile of the genome which can affect gene expression 
have been observed in vivo and in vitro following exposure to ionising irradiation 
(Raiche et al., 2004; Pogribny et al., 2005; Aypar et al., 2011). Possible radiation-
induced alterations to the methylation profile of cells in the present study may therefore 
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have contributed to expression changes of genes not directly affected by copy number 
alterations.  
Point mutations or small deletions/insertions, which cannot be detected by the SNP 6.0 
array, in gene transcription regulatory regions could also affect gene expression. 
Ionising radiation exposure generates ROS cells which can cause point mutations via 
oxidative damage. Mutations in promoter regions or other cis-regulatory elements may 
therefore affect gene expression in the First 5 Gγ series.  
Chromosomal translocations can also cause up-regulation or down-regulation of genes 
while not affecting gene copy number by positioning genes under the influence of 
strong promoter regions. Translocation of cis-acting transcriptional regulatory elements 
or translocation breakpoints positioned in non-coding regions which contain cis-acting 
transcriptional regulatory elements may also affect gene expression (Harewood et al., 
2010). Balanced translocations would not be detected by the SNP 6.0 array and it is 
unknown if cis-regulatory elements have been affected by copy number alterations in 
non-coding regions of the genome in the present study. Either of these mechanisms 
could therefore contribute to differential expression of genes not directly affected by 
copy number change. 
5.4.3 Differentially expressed genes in the First 5 Gγ series 
Genes of interest in the 20 most differentially expressed genes identified in the First 5 
Gγ series included ASAP3, BCL6, MGMT (down-regulated) CCND2 IL24 and LMTK3 
(up-regulated).   
ASAP3 is a member of the ARF GTP-ase activating protein (GAP) family, which are 
involved in the regulation of different cytoskeletal structures important for cell 
migration and invasion (Randazzo et al., 2007). Reduced expression of ASAP3 was 
shown to reduce cell migration and invasion (Ha et al., 2008). Down-regulation of this 
gene may therefore contribute to the apparent reduction in cell migration observed in 
the First 5 Gγ series (Chapter 3).  
BCL6 is a transcriptional repressor that is important for normal antibody response in B 
and T lymphoid cells (Wagner et al., 2011). BCL6 has at least 500 transcriptional 
targets (Parekh et al 2007) and can interact with at least 61 other proteins (Miles et al., 
2005). Expression of BCL6 is also observed in 68% of high grade ductal breast 
carcinomas and was shown to have an anti-apoptotic role in these cells (Logarajah et al., 
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2003). Reduced expression of this transcription factor may have affected expression of 
those genes identified as differentially expressed in the present study, but which were 
not affected by copy number alterations. A significant reduction in BCL6 is first 
identified in the 40 Gγ population, which correlates with a 10 fold increase in 
differentially expressed genes.  
MGMT plays a role in defence against alkylating agents which can form DNA lesions 
such as O
6
-methylguanine (O
6
MeG) and O
4
-methylthymine (O
4
MeT). The O
6
MeG and 
O
4
MeT DNA adducts are mispaired during replication and can induce point mutations, 
sister chromatid exchange and chromosomal aberrations when not effectively repaired 
(Kaina et al., 2007). MGMT repairs these lesions via non-enzymatic transfer of the 
methyl group from DNA to a cysteine residue within its own structure, which 
inactivates MGMT (Kaina et al., 2007). Reduced expression of MGMT is predicted to 
reduce the number of MGMT molecules available for repair of DNA methyl lesions, 
and could facilitate the accumulation of point mutations. Furthermore, reduced MGMT 
expression could also contribute to the accumulation of copy number alterations by 
invoking futile DNA mismatch repair of un-repaired O
6
MeG lesions, which is thought 
to induce DNA double strand breaks (Ochs and Kaina, 2000).  
Expression of CCND2 was increased in all analysed irradiated populations relative to 
un-irradiated MCF-10A. CCND2 (cyclin D2) is involved in regulating progression 
between G1 and S phase of the cell cycle. D cyclins activate CDK4/6 to phosphorylate 
retinoblastoma (RB) which releases repression of the transcription factor E2F. 
Downstream transcriptional targets of E2F in turn stimulate progression of the cell cycle 
(Ortega et al., 2002). Overexpression of D-type cyclins can therefore accelerate the 
G1/S transition of the cell cycle (Quelle et al., 1993). Increased expression of CCDN2 
has been observed in cancers such as lymphocytic leukaemia and gastric cancer, but is 
not seen in the majority of breast cancers (Takano et al., 1999; Igawa et al., 2011). 
Interestingly, CCND2 expression is negatively regulated by BCL6 (Shaffer et al., 2000), 
and the observed reduced expression of BCL6 may therefore have contributed to 
increased expression of CCND2. 
IL24 is a putative tumour suppressor gene which is known to inhibit growth and 
invasive capabilities and induce apoptosis and radio-sensitivity in cancer cells, 
including breast cancer cells (Gupta et al., 2006; Patani et al., 2010). Increased 
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expression of IL24 may therefore contribute to the radiosensitive phenotype reported in 
high cumulative dose populations of the First 5 Gγ series (Chapter 3). 
LMTK3 has recently been identified as a kinase whose overexpression leads to 
increased ERα mediated transcription and protection of ERα from proteosomal 
degradation (Giamas et al., 2011). The protein is over expressed in more aggressive 
breast cancers and inversely correlates with survival and sensitivity to ERα targeting 
cancer therapy (Giamas et al., 2011; Stebbing et al., 2011). In the present study the 
activity of LMTK3 may not be relevant as MCF-10A cells are reported to be ERα 
negative and ERα gene expression was not detected above background in the expression 
array (data not shown). However, one hypothesis suggests that ionising radiation and 
oestrogen synergise to induce breast cancer in young women. If ionising radiation does 
increase LMTK3 expression the subsequent effect on ERα activity could be important in 
this relationship. 
5.4.4 Biological processes affected by gene expression changes 
Although potentially interesting genes were identified in the 20 gene cohort it is quite 
hard to infer what effect altered expression would have on biological process in the First 
5 Gγ series. All of the identified radiation-induced differentially expressed genes in the 
55 Gγ population were therefore used in clustering analysis which identified 10 
biological processes potentially affected by gene expression changes.  Three of these 
biological processes were involved in regulation of apoptosis. Dysregulation of 
programmed cell death is a well-established hallmark of cancer (Lowe and Lin, 2000; 
Hanahan and Weinberg, 2011). Dysregulated apoptosis allows cells to continue to 
proliferate when normally they would die, for example at high cell density, and also 
allows the accumulation of sub-lethal mutations. In the First 5 Gγ series contact 
inhibition was lost at high cell density and populations accumulated numerous copy 
number alterations (chapter 3 and chapter 4). Although the direct effect of gene 
expression change on the apoptotic processes identified by cluster analysis is not 
determined, loss of contact inhibition provides evidence that cells of the First 5 Gγ 
series may have acquired a pro-survival phenotype.    
Other biological processes potentially affected by expression changes that may be 
relevant to cell transformation or responsible for the phenotypes observed in the First 5 
Gγ series include:  
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i) Response to steroid hormone and insulin stimulus - The irradiated cell 
populations appeared to be less tolerant of growth factor withdrawal than un-
irradiated MCF-10A. Altered response to steroid hormones and insulin in the 
First 5 Gγ series may have caused the MCF-10A cells to be more dependent on 
these stimuli for growth. 
ii) Cell migration - The irradiated populations appeared to be compromised in their 
migratory capabilities compared to un-irradiated MCF-10A cells. 
iii) Negative regulation of cell growth - The irradiated populations had a slower rate 
of growth than un-irradiated MCF-10A cells. 
Overall, expression analysis of the First 5 Gγ series has demonstrated that the 
accumulation of copy number alterations affected the expression of numerous genes. 
Regulatory mechanisms controlling gene expression may have been affected in the First 
5 Gγ series, indicated by the accumulation of differentially expressed genes not directly 
affected by copy number change. Some of the most differentially expressed genes have 
roles in cancer and potential phenotypic consequences in the First 5 Gγ series were 
suggested. The biological processes potentially affected by altered gene expression that 
may also have had phenotypic consequences in the First 5 Gγ series were also discussed. 
Alterations to genes involved in DNA repair such as ATM, MGMT and POU2F1, and 
dysregulation of programmed cell death may have contributed to the observed 
accumulation of copy number alterations. The effect of copy number loss on POU2F1 
expression could not be determined from the expression array but will be assessed in 
chapter 6.  
5.4.5 Second 5 Gγ Series 
The Second 5 Gγ series had remarkably fewer differentially expressed genes that the 
First 5 Gγ series. This is likely due to fewer copy number alterations in the Second 5 Gγ 
series than the First 5 Gγ series (section 4.5). The oestrogen treated passage control 
population had a large number of differentially expressed genes which reflects the large 
number of genes which have changed copy number state due to trisomy involving 
several chromosomes. Other regulatory mechanisms of gene expression (discussed in 
section 5.4.2) will undoubtedly have been affected in the passage control population 
also. The large number of differentially expressed genes in the passage control 
population may have caused an under-estimation of radiation-induced changes in the 
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Second 5 Gγ series, as changes seen in both irradiated and passage control populations 
were removed from the analysis. 
The two focal copy number alterations identified in the Second 5 Gγ series were a 
mono-allelic deletion of BMPR1A and a copy number gain of c-MYC. Altered 
expression of these genes was consistent with the observed copy number change of the 
gene, however neither genes were attributed a differentiation score. Both BMPR1A and 
c-MYC are involved in transcriptional regulation (Chen and Yager, 2004; Dang et al., 
2006). Altered expression of these genes may therefore impact on expression of their 
transcriptional targets. The increase in the number of differentially expressed genes in 
the 40 Gγ population coincides with the first appearance of copy number changes to 
both BMPR1A and c-MYC.  
Of the 32 differentially expressed genes in the 60 Gγ and 80 Gγ populations, 7 were 
expression changes that have been reported to be differentially expressed during EMT, 
including down-regulation of CDH1, KRT14, PI3, FGFBP1, KRT17P3 and CD24 and 
up-regulation of SERPINE1 (Thiery, 2003; Vincent-Salomon and Thiery, 2003; Huber 
et al., 2005; Higashikawa et al., 2008; Ke et al., 2008; Mani et al., 2008; Sarrio et al., 
2008; Samarakoon et al., 2009; Cho et al., 2010; Micalizzi et al., 2010; Asiedu et al., 
2011; Hanahan and Weinberg, 2011; Hesling et al., 2011). Overexpression of c-MYC 
has been shown to induce EMT in MCF-10A cells (Liu et al., 2009; Cho et al., 2010). 
Differential expression of genes which associate with EMT may therefore have been 
due to the copy number increase of c-MYC observed in irradiated populations in the 
present study. The identification of a copy number increase of c-MYC, which has been 
shown to induce EMT in vitro, strengthens the hypothesis from chapter 3 that cells in 
the Second 5 Gγ series were undergoing EMT (Cowling and Cole, 2007; Liu et al., 
2009; Smith et al., 2009; Cho et al., 2010).  
5.4.6 Epithelial to mesenchymal transition in the Second 5 Gγ series 
Epithelial to mesenchymal transition is the cellular switch between a polarised epithelial 
phenotype to a motile fibroblastic mesenchymal phenotype and is an important process 
during embryonic development (Thiery, 2002; Huber et al., 2005). EMT is required for 
morphogenic movements, endoderm formation, gastrulation and the formation of organs 
and tissues (Thiery, 2002; Huber et al., 2005). EMT is also important during 
tumourigenesis as it allows cells to invade and metastasise to other areas of the body 
and has been observed in many cancer types, including breast cancer (Thiery, 2002; 
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Thiery, 2003; Vincent-Salomon and Thiery, 2003; Huber et al., 2005; Micalizzi et al., 
2010; Hanahan and Weinberg, 2011). EMT is characterised by the loss of epithelial cell 
markers, the most widely reported being E-Cadherin (CDH1), the acquisition of 
mesenchymal cell markers such as N-Cadherin (CDH2), Vimentin (VIM) and 
Fibronectin (FIN), a transition from an epithelial cobblestone appearance to a spindle 
morphology, increased cell motility and increased invasion capability (Thiery, 2002; 
Thiery, 2003; Vincent-Salomon and Thiery, 2003; Huber et al., 2005; Micalizzi et al., 
2010; Hanahan and Weinberg, 2011). EMT is not instantaneous and intermediate 
phenotypes and expression profiles are observed depending on the model system used 
and the factors inducing the EMT switch (Figure 5.11) (Huber et al., 2005; Kalluri and 
Weinberg, 2009; Hanahan and Weinberg, 2011). Numerous proteins and signalling 
pathways have been identified which induce EMT in cell line studies including, RAS 
(Liu et al., 2009), TGF-β (Zavadil and Bottinger, 2005), WNT (Kim et al., 2002), 
SNAIL (Huber et al., 2005), SLUG (Savagner et al., 1997) and TWIST (Yang et al., 
2004). None of these genes underwent a copy number alteration in the Second 5 Gγ 
series. 
c-MYC can also induce EMT in vitro and in vivo (Cowling and Cole, 2007; Trimboli et 
al., 2008; Liu et al., 2009; Smith et al., 2009; Cho et al., 2010). Specifically, 
overexpression of c-MYC induces the EMT morphological phenotype, down-regulates 
the epithelial marker CDH1, up-regulates EMT inducers SNAIL and TWIST, and also 
up-regulates mesenchymal markers VIM and FIN (Liu et al., 2009; Smith et al., 2009; 
Cho et al., 2010). SNAIL transcriptionally represses CDH1 by binding to E-boxes in the 
promoter region of the gene (Huber et al., 2005). c-MYC was shown to directly induce 
transcription of SNAIL1 (SNAIL) through co-operation with DNA bound SMAD 
proteins following TGF-β induction (Smith et al., 2009), and also through activation of 
ERK and NF-κB which activates GSK-3β mediated activation of SNAIL (Cho et al., 
2010). CDH1 was down-regulated in the 60 Gγ population in the present study however 
the expression of SNAIL1 was not detected above background (although this does not 
necessarily mean SNAIL1 was not expressed).  
c-MYC is a relatively poor at inducing EMT and very high expression of c-MYC was 
required to induce a full complement of gene expression and phenotypic changes (Liu et 
al., 2009; Cho et al., 2010). Therefore although it has been demonstrated c-MYC 
expression can drive EMT, the amount of c-MYC expressed in the Second 5 Gγ series 
may not have been enough to induce full transition to the EMT phenotype. Intermediate 
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phenotypes and gene expression profiles exist during EMT (Fig. 5.11), so it is possible 
that cells in the Second 5 Gγ series have been induced into entering EMT by c-MYC but 
are at an early stage of the transition.  
Only 3 expression markers of EMT were identified in the 80 Gγ population compared to 
7 in the 60 Gγ population. If functional c-MYC expression had reduced in the 80 Gγ 
population through inactivating mutations or changes to other genes involved in 
translation or protein stability then a reversal of the EMT expression profile may be 
explained. The relative levels of c-MYC expression in the Second 5 Gγ series will be 
investigated in chapter 7. 
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The transition from an epithelial cell phenotype to a mesenchymal cell phenotype is not instantaneous and there are intermediate stages between the two cell states. The gradual 
loss of expression of epithelial cell genes such as CDH1 and gain of expression of mesenchymal genes such as VIM (Vimentin) and FIN (Fibronectin) mediate the gradual 
acquisition of the mesenchymal phenotype. Some cells can therefore acquire a partial EMT-like phenotype without completing the transition. Figure adapted from Kaluri and 
Weinberg, 2009. 
Figure 5.11 Epithelial mesenchymal transition. 
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5.4.7 Non-EMT related differentially expressed genes of the Second 5 Gγ series 
Other genes which were differentially expressed in the 60 Gγ and 80 Gγ populations of 
the Second 5 Gγ series which have been implicated in cancer are H19, EYA2, CCL20 
and LEPREL1. Although these genes are not reported to be directly related to EMT 
some of their cellular functions may relate to the EMT phenotype. 
H19 was the most differentially up-regulated gene in the 80 Gγ population but was only 
slightly up-regulated in the 60 Gγ population. H19 is a non-coding RNA that has been 
heavily linked with increased tumourigenicity and acquisition of transformed 
phenotypes in vitro (Lottin et al., 2002). Conversely, knockdown of H19 reduces 
clonegenicity and anchorage dependant growth (Barsyte-Lovejoy et al., 2006).  
Consistent with a role as a putative oncogene, H19 is also up-regulated in a number of 
cancers, including breast, lung, endometrial, bladder and colorectal cancer (Ariel et al., 
2000; Tanos et al., 2004; Barsyte-Lovejoy et al., 2006; Tsang et al., 2010).  
c-MYC directly induces H19 transcription and c-MYC/H19 transcript levels were 
strongly correlated in breast and lung cancer samples (Barsyte-Lovejoy et al., 2006).  
Up-regulation of H19 in the present study may therefore have been due to c-MYC copy 
number increase. It is also noteworthy that H19 was the highest differentially expressed 
gene and TWIST1 the second highest expressed gene in tumours derived from metastatic 
cancer cell lines (Yang et al., 2004). As discussed previously, increased TWIST 
expression and the acquisition of an invasive phenotype are key characteristics of cells 
undergoing EMT; therefore up-regulation of H19 may also be an expression marker of 
EMT. This finding, and the transcriptional link between H19 and c-MYC, further 
enhances the case that c-MYC has induced EMT in the present study.    
EYA2 is a member of a family of transcriptional co-activators which have key roles in 
mediating SIX1 transcriptional activation (Farabaugh et al., 2012). SIX1 can induce 
EMT and stem cell-like phenotypes by up-regulating TGF-β signalling pathways 
(McCoy et al., 2009; Micalizzi et al., 2010). Loss of EYA2 abrogates SIX1 up-
regulation of TGF-β signalling, EMT and stem cell phenotypes in the breast cancer cell 
line MCF-7 indicating that EYA2 is a critical co-activator of SIX1 induced EMT 
(Farabaugh et al., 2012). EYA2 has been reported to be over expressed in a number of 
cancers including ovarian cancer (Zhang et al., 2005a; Farabaugh et al., 2012). Over 
expression of EYA2 can increase proliferation, migration, invasion and metastasis in 
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mammary carcinoma cells (Pandey et al., 2010). Up-regulation of EYA2 observed in the 
present study may therefore also be an expression marker of EMT.  
CCL20 is a chemokine ligand which binds to the chemokine receptor CCR6. CCL20 
was up-regulated in the 60 Gγ population and is also up-regulated in a number of 
cancers including colorectal cancer and prostate cancer (Beider et al., 2009; Ghadjar et 
al., 2009; Rubie et al., 2010). Up-regulation of CCL20 has been implicated in increased 
cell proliferation and acquisition of a metastatic phenotype (Ghadjar et al., 2009). Up-
regulation of CCL20 has not been implicated in breast cancer or EMT directly, but its 
established role in mediating metastasis suggests a role in the EMT phenotype. 
LEPREL1 is required for collagen synthesis and assembly (Vranka et al., 2004). 
LEPREL1 was reported to be epigenetically silenced in breast cancer cell lines, but not 
in other epithelial cancer cell lines, and was down-regulated in the 80 Gγ population in 
the present study (Shah et al., 2009). Loss of collagen expression is important in the 
invasive properties of epithelial cancer (Ikeda et al., 2006). Reduced expression of 
LEPREL1, and therefore impaired assembly of collagen, may also play a role in the 
invasive or metastatic phenotype. Again there is no direct link to EMT, however loss of 
LEPREL1 is potentially implicated in acquisition of phenotypic characteristics of cells 
undergoing EMT. 
Expression analysis of the Second 5 Gγ series provides strong evidence that irradiated 
MCF-10A cells have at least initiated EMT, and that this transition is likely to be 
mediated by the copy number increase of c-MYC. Specifically, expression markers of 
EMT have been identified in the 60 Gγ and 80 Gγ populations concomitant with 
increased c-MYC copy number. Differentially expressed genes implicated in 
carcinogenesis but not currently related to EMT could also putatively play a role in 
EMT as there is a common link with cell invasion and metastasis in their functions. The 
present study may have therefore identified new putative markers for EMT. 
5.4.8 c-MYC, EMT and stem cell phenotypes 
Mani et al. (2008) recently reported a link between EMT and stem cells. Stem cells can 
self-renew while also being able to differentiate and generate progenitor cells. Cells 
with stem cell characteristics have been found in a number of tumours, including breast 
cancer, and are termed cancer stem cells (Reya et al., 2001). Stem cells are identified by 
surface expression of CD44 and reduced surface expression of CD24 (CD24
-/low
/CD44
+
) 
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(Al-Hajj et al., 2003). Mani et al. (2008) showed that populations which have been 
induced to undergo EMT become enriched for CD24
-/low
/CD44
+ 
cells and that these 
cells share properties with normal and cancer stem cells. The CD24
-/low
/CD44
+ 
cells 
generated also had an EMT expression profile. The study reported that isolated murine 
and human stem cells which had not been generated by induced EMT shared phenotypic 
and gene expression characteristics with EMT cells. The study concluded that EMT 
promotes the generation of cancer stem cells. CD24 was down-regulated in the 60 Gγ 
population while CD44 expression remained unaffected. Whether the down-regulation 
of CD24 resulted in reduced expression of its protein product in the present study is 
unknown; however it is possible that cells in the Second 5 Gγ series which have been 
induced to undergo EMT by c-MYC may share some characteristics with stem cells.  
Stem-cell phenotypes include ionising radiation-resistance and a reduction of mutations 
and double strand breaks induced by ionising radiation (Phillips et al., 2006; Diehn et 
al., 2009; Vlashi et al., 2009). Diehn et al. (2009) showed that stem cells had fewer 
intracellular ROS than non-stem cells. Stem cells also had increased expression of anti-
oxidant and ROS metabolism genes, as well as increased expression of transcription 
factors which regulate these genes. Following ionising radiation, which increases 
intracellular ROS and induces DNA double strand breaks, stem cells had lower levels of 
ROS and therefore fewer double strand breaks (Diehn et al. 2009; Phillips et al. 2006). 
Cells in the Second 5 Gγ series had few copy number alterations, which may be partly 
due to the acquisition of a stem cell DNA damage resistant phenotype conferred by c-
MYC-induced EMT. Increased c-MYC copy number may therefore be implicated in 
acquired radiation DNA damage resistance. 
5.4.3 Conclusion 
The expression analysis of the First and Second 5 Gγ is somewhat limited by the lack of 
repeats for each sample in the array and the problems this causes when identifying 
biologically relevant gene expression changes. If expression changes due to radiation 
exposure were to be investigated further in these populations then further repeats would 
be needed. Methods such as qPCR could also be used for specific gene targets. 
Nevertheless, expression analysis of both the First and Second 5 Gγ series has shed 
some light on the expression changes which may have contributed to phenotypic 
changes observed in the different cell populations. Importantly, the expression analysis 
provides one possible explanation for the disparity in acquired copy number alterations 
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between the First and Second 5 Gγ series. The First 5 Gγ series appears to have 
acquired copy number and expression changes which have caused increased 
chromosomal instability, for example alterations to DNA repair genes and to apoptosis 
pathways; however the Second 5 Gγ series acquired a specific copy number alteration at 
the c-MYC locus which may have promoted development of a phenotype similar to that 
seen in stem cells, and which includes resistance to ionising radiation-induced DNA 
damage.  
Acquisition of a radiation-resistance phenotype may also have implications for the 
mechanism by which breast cells are transformed by radiation in vivo. If ionising 
radiation induces c-MYC amplification, and the evidence from atomic bomb survivors 
supports this assumption (Miura et al. 2008), then the acquisition of a radiation-resistant 
phenotype is predicted to result in the enrichment of c-MYC amplified cells with 
subsequent radiation exposure. c-MYC amplification on its own may not be sufficient to 
transform the cells but gene amplification will increase the proportion of cells at risk of 
acquiring secondary and higher order mutations required for complete transformation. 
As such, the probability of breast cancer developing in a radiation exposed individual 
would now be greater as fewer additional mutations would be required for 
transformation. Increased oestrogen levels in young women with an enrichment of c-
MYC amplified cells would further increase the chance of transforming “hits” due to its 
carcinogenic effects; which may explain the putative synergistic relationship seen 
between ionising radiation and oestrogen.  
Chosen genes from each irradiation series (POU2F1 – First 5 Gγ series; c-MYC – 
Second 5 Gγ series) will be analysed further to assess what significance the copy 
number and expression changes had on protein level and to assess the relative 
abundance of each copy number alteration within the heterogeneous cell populations 
(chapter 6 and chapter 7). The relevance of these alterations in sporadic and radiation-
induced breast cancer samples will also be investigated (chapter 8).  
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Chapter 6: Investigation of the deleted transcription factor POU2F1 
in irradiated MCF-10A (First 5 Gγ series) 
6.1 Introduction 
The POU2F1 locus is located in a constitutively trisomic region of chromosome 1q in 
the un-irradiated MCF-10A genome. Mono-allelic deletion of a 602 Kb region on 
chromosome 1q which included the POU2F1 locus was detected in the 40 Gγ 
cumulative dose population of the First 5 Gγ series. A second deletion on chromosome 
1q, which also included the POU2F1 locus, in the 80 Gγ population resulted in bi-
allelic loss of this gene, reducing copy number state from 3 to 1 in the First 5 Gγ series.  
POU2F1 is a member of the POU domain transcription factors and is involved in 
transcriptional regulation of a number of genes including regulation of stress response 
genes (Tantin et al., 2005). DNA damaging agents which cause oxidative damage, 
single and double strand breaks induce increased expression of POU2F1 protein levels 
and enhanced DNA binding activity (Meighan-Mantha et al., 1999; Zhao et al., 2000). 
POU2F1 regulates promoter binding of BRCA1, and expression of its downstream 
target genes. Specifically, POU2F1 and BCRA1 co-operate to regulate GADD45 
expression following DNA damage (which helps to maintain genetic stability), and base 
excision repair (BER) genes following oxidative stress (Jin et al., 2001; Fan et al., 2002; 
Maekawa et al., 2008; Saha et al., 2010). These findings indicate that POU2F1 plays a 
major role in cellular response to genotoxic stress. Dysregulation of stress response 
could result in genetic instability, incorrect repair of DNA damage and the acquisition 
of oncogenic mutations. The fact that POU2F1 is involved in DNA damage response 
and that its locus was focally deleted in the First 5 Gγ irradiated series makes it an 
interesting candidate for further investigation. If POU2F1 deletion is prevalent in breast 
cancer that develops following ionising radiation it would identify this lesion as 
potentially important in the molecular pathogenesis of radiogenic breast disease.  
6.1.1 Aim 
The aim of the work described in this chapter was to confirm the copy number state of 
POU2F1 in cell populations from the First 5 Gγ series using fluorescent in situ 
hybridisation (FISH) and to investigate the effect that gene deletion has on protein level 
using western transfer. Given that POU2F1 plays a role in DNA damage response, and 
in particular BRCA1 mediated transcriptional regulation of BER genes, the response of 
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cells from the First 5 Gγ series to oxidative stress was investigated.  The expression of 
DNA repair genes in the 80 Gγ population was also investigated to see what effect, if 
any, loss of POU2F1 had on BER and other DNA repair pathways.  
6.2 In vitro confirmation of POU2F1 copy number state in the First 5 Gγ series 
POU2F1 copy number was investigated in the First 5 Gγ series using FISH. A red 
fluorescent chromosome 1 centromere probe and a green fluorescent probe  mix 
consisting of 3 BAC probes which map to POU2F1 were used for cytogenetic analysis 
(section 2.8). Confirmation that these probes map to the correct chromosome and in the 
correct region was shown using metaphase chromosomes, prepared by David Rowe 
(Institute of Genetic Medicine, Newcastle upon Tyne, UK), from un-irradiated MCF-
10A cells (Fig. 6.1). Specifically, the green centromere probe hybridised to the 
centromere of chromosome 1 and the POU2F1 probe hybridised to a region at the 
centromeric end of 1q. FISH analysis confirmed that the i(1)(q10) chromosome in 
MCF-10A was a dicentric chromosome (section 4.2.1). 
Figure 6.2a shows the percentage of cells which have 3, 2 and 1 copies of POU2F1 in 
each cell population as determined by counting 100 cells for each population. Over 95% 
of the cells in each cell population displayed 3 chromosome 1 centromere probes 
consistent with the established copy number state in un-irradiated MCF-10A. The 
centromere counts are therefore not included on the graph. Standard FISH scoring 
protocols classify alterations that are seen in less than 5% of all cells scored as “not 
reportable,” and such alterations have therefore not been included in Figure 6.2. FISH 
images illustrating POU2F1 copy number in the un-irradiated MCF-10A, 40 Gγ 
cumulative dose and 80 Gγ cumulative dose cell populations are shown in figure 6.2 b, 
c, and d. 
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Figure 6.1 Cytogenetic analysis of POU2F1 in MCF-10A cells. 
 
 
 
 
 
 
 
 
 
 
FISH probes are specific to the centromere of chromosome 1 (red) and the POU2F1 locus (green). 
Metaphase chromosomes of un-irradiated MCF-10A were counterstained with DAPI. The probe for 
POU2F1 hybridises to the q arm of the same chromosomes as the centromere 1 probe, specifically on a 
normal chromosome 1 and the dicentric i(1)q(10) chromosome, which is consistent with its position in the 
genome.  
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Figure 6.2 Cytogenetic analysis of POU2F1 in the First 5 Gγ series. 
 
 
 
 
 
 
The probes are specific to the centromere of chromosome 1 (red) and the POU2F1 locus (green) and the 
cells was counterstained with DAPI. Following FISH on cells in the First 5 Gγ series the percentage of 
cells with 1 (green bar), 2 (red bar) and 3 (black bar) copies of POU2F1 could be calculated from counts 
of 100 cell nuclei in each cell population (a). Examples of FISH of the dominant sub-populations   in the 
un-irradiated MCF-10A (b), 40 Gγ cumulative dose (c), and 80 Gγ cumulative dose cell populations (d) 
are also shown. 
198 
 
FISH data agrees with copy number data generated using the SNP 6.0 array. 
Specifically, in the un-irradiated cell populations and those established following 10 Gγ 
and 25 Gγ cumulative doses, cells with 3 copies of POU2F1 represent the dominant cell 
population, comprising 98%, 86% and 66% of all cells, respectively. In the 40 Gγ 
cumulative dose population, cells with 2 copies of POU2F1 represent the dominant 
population (86% of all cells). The proportion of cells with this genotype persists until 
the 80 Gγ cumulative dose population when cells with one copy of POU2F1 represent 
the dominant population (92% of all cells). The passage control population has 
approximately equal amounts of cells with 3 and 2 copies of POU2F1, which reflects 
the large mono-allelic deletion on chromosome 1q encompassing the POU2F1 locus 
(Table 4.4).  
FISH results also illustrate the heterogeneity of the cell populations and the potential for 
selection of sub-populations with certain genotypes. For example, mono-allelic deletion 
of POU2F1 was first identified in the 40 Gγ population by the SNP 6.0 array, however 
12% of cells had two copies of POU2F1 in the 10 Gγ population which rose to 33 % in 
the 25 Gγ population. These data demonstrate that the mono-allelic deletion of POU2F1 
carried by the majority of cells in the 40 Gγ population may have actually occurred 
earlier and was then subsequently selected for, and is consistent with the gradual clonal 
selection model described in section 4.5 and illustrated in figure 4.12. However, it 
cannot be conclusively determined that the sub-populations with 2 copies of POU2F1 in 
the 10 Gγ and 25 Gγ populations contain the same specific POU2F1 deletion as 
identified in the 40 Gγ population, because FISH does not discriminate between 
deletions affecting the same locus but with different breakpoints. As such, it is possible 
that the POU2F1 deletion identified in the 40 Gγ population is unique to that population. 
Similarly, bi-allelic deletion of POU2F1 was first identified in the 80 Gγ population by 
the SNP 6.0 array, however 7% of cells in the 40 Gγ population also had only one copy 
of POU2F1. A rapid increase in the number of cells with one copy of POU2F1 at the 80 
Gγ population indicates that either the population observed in the 40 Gγ population was 
selected was for or that the bi-allelic deletion of POU2F1 identified in the 80 Gγ 
population is unique to that population. 
FISH analysis demonstrates that each cell population is genetically heterogeneous. 
Without SNP analysis data of all sub-populations it is hard to map the true genesis of a 
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copy number alteration and its subsequent selection, which would require sub-
populations to be sorted and purified.  
SNP analysis measures the mean copy number of the entire population. Overall the SNP 
genotype of the POU2F1 locus in each cell population agrees with the dominant 
genotype identified by FISH in each population of the First 5 Gγ series.  
6.3 Protein expression of POU2F1 in the First 5 Gγ series 
In order to determine the effect of POU2F1 copy number on protein expression 
POU2F1 protein levels in un-irradiated MCF-10A, First 5 Gγ series and passage control 
cells were analysed by western transfer and immunoblot (section 2.10). Representative 
images of the immunoblot analysis are shown in figure 6.3a and b. A strong band of the 
correct mass for POU2F1 (95 kDa) was observed in the un-irradiated MCF-10A cell 
population. POU2F1 expression in the First 5 Gγ series was reduced in the 40 Gγ and 
55 Gγ cumulative dose cells compared to the un-irradiated, 10 Gγ and 25 Gγ cells, and 
is almost undetectable in the 80 Gγ cells (Fig. 6.3a).  POU2F1 expression is also 
noticeably lower in the passage control cells compared to un-irradiated MCF-10A, 
consistent with mono-allelic deletion in a significant fraction of the cells (Fig. 6.3b; 
Turkey’s Test: p=0.042).  
POU2F1 expression was quantified by densitometric analysis of 3 independent 
experiments and normalised using GAPDH expression (Fig. 6.3c). Expression of 
POU2F1 in the 40 Gγ and 55 Gγ cell populations is more than two fold lower than 
expression in un-irradiated MCF-10A cells (Turkey’s Test: p=0.017; p=0.006). In the 
80 Gγ population expression of POU2F1 has fallen to 2% of the level in un-irradiated 
MCF-10A cells (Turkey’s Test: p<0.001).  
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Figure 6.3 POU2F1 expression in the First 5 Gγ series. 
 
 
Western transfer analysis of the First 5 Gγ series (a) and passage control population (b) with antibodies 
specific for the 95kDa protein POU2F1 and 37kDa protein GAPDH. Densitometric analysis of 3 
independent western transfers was used to quantify the expression of POU2F1 for each cell population as 
a percentage of the expression of POU2F1 in un-irradiated MCF-10A cells (which was set at 100% 
expression) (c). U-I = un-irradiated MCF-10A and P.C = passage control in cell population lane 
identifiers below each image in (a) and (b). 10 μg of protein was used for each cell population in each 
experiment. Although irradiated and passage control populations were analysed separately the same un-
irradiated MCF-10A protein extracts were used and expression was expressed as a percentage of the 
expression of c-MYC in un-irradiated MCF-10A cells within these experiments. To calculate the relative 
protein expression of POU2F1, band intensity was normalised against GAPDH band intensity within each 
experiment. Difference in expression between populations below the 5% confidence level was tested 
(ANOVA: p<0.001). A post hoc Turkey’s test was then used to assess the difference in expression 
between individual populations below the 5% confidence level. (*) indicates populations whose POU2F1 
protein expression was significantly different from un-irradiated MCF-10A.  
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The reduction in POU2F1 expression corresponds to when the deletions of POU2F1 are 
detected in the SNP 6.0 Array. This relationship indicates that the amount of POU2F1 
protein expressed is directly affected by the copy number state of the gene. The 80 Gγ 
cumulative dose cells have 1 copy of POU2F1 which almost completely removes 
POU2F1 expression. Complete loss of expression may indicate that loss of only one 
POU2F1 allele in cells diploid for POU2F1 is sufficient to almost completely abrogate 
POU2F1 expression, or that the protein is unstable at low concentrations. The dramatic 
reduction in POU2F1 expression may also be due to other mutations, either in POU2F1 
itself or other genes, which affect POU2F1 transcription, transcript stability or protein 
stabilisation.  
6.4 Response of cells from the First 5 Gγ Series to DNA damage 
POU2F1 plays a role in response to DNA damage caused by numerous DNA damaging 
agents (Meighan-Mantha et al., 1999; Zhao et al., 2000; Jin et al., 2001; Fan et al., 2002; 
Tantin et al., 2005; Maekawa et al., 2008). In particular, POU2F1 deletion has been 
shown to dysregulate oxidative stress response genes (Tantin et al., 2005) and is directly 
involved in BRCA1 mediated transcriptional induction of BER genes in response to 
oxidative damage (Saha et al., 2010). The 80 Gγ cumulative dose cell population 
expresses negligible amounts of POU2F1 and therefore response to oxidative damage 
may be compromised. In order to test this, the response of un-irradiated MCF-10A cells 
and 80 Gγ cumulative dose cells to oxidative damage by hydrogen peroxide (H2O2) was 
tested. Cells were seeded at 4x10
3
 cells per well in 96 well plates and treated with 0-450 
μM of hydrogen peroxide. Twenty-four hours after hydrogen peroxide treatment, the 
number of cells in each well was determined using the Resazurin assay for cell viability 
(Section 2.11). The mean number of hydrogen peroxide treated cells was expressed as a 
percentage of the mean number of vehicle-only treated cells over the same time period 
(Fig. 6.4). Reduced cell number after hydrogen peroxide treatment would indicate 
reduced cell growth and therefore increased sensitisation to oxidative stress. 
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Figure 6.4 Response of un-irradiated MCF-10A cells and 80 Gγ cumulative dose cells (First 5 Gγ 
series) to hydrogen peroxide. 
Cells were treated with 1-450uM H2O2 for 24 hours. The surviving cell number for each concentration of 
H2O2 is expressed as a percentage of the number of vehicle-only treated cells. Mean values of surviving 
cell numbers from multiple experiments are expressed +/- SEM (un-irradiated MCF-10A n=5; 80 Gγ 
cumulative dose n=4). An ANOVA test was used to assess statistical significance of cell number 
percentage between each H2O2 concentration within each cell population: un-irradiated MCF-10A 
p<0.001; 80 Gγ cumulative dose p<0.001. A post-hoc Turkey’s test was used to asses at which 
concentrations cell number percentage was significantly different within the same cell population. A 
paired T-test was used to test for significant differences in growth inhibition at each concentration of 
H2O2: 0 μM p=1; 50 μM p=0.005; 100 μM p=0.020; 150 μM p=0.001; 200 μM p-0008; 250 μM p=0.025; 
300 μM p=0.028, 350 μM p=0.352; 400 μM p=0.846; 450 μM p=0.579.  
In both populations cell number reduced as hydrogen peroxide concentration increased. 
Significant reduction in cell number occurred after treatment with 50 μM of hydrogen 
peroxide in the 80 Gγ population (Turkey’s test: p<0.001) and after 100 μM in the un-
irradiated MCF-10A population (Turkey’s test: p<0.001). The working range of the 
assay does not go below approximately 98% growth inhibition (2% cell number). Both 
populations reached this threshold after treatment with 350-450 μM of hydrogen 
peroxide. The 80 Gγ population had fewer cells compared to the un-irradiated MCF-
10A population 24 hours after treatment with 50-300 μM of H2O2 (Paired T-Test: p < 
0.050) (Un-irradiated MCF-10A GI50 = 135 μM, GI90 = 254 μM; 80 Gγ population 
GI50 = 101 μM, GI90 = 157 μM). The difference was most pronounced after treatment 
with 250 μM of H2O2 (6.5 fold difference in cell number). The results indicate that the 
80 Gγ cumulative dose cell population was more sensitive to hydrogen peroxide than 
the un-irradiated MCF-10A cell population.  
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The response of un-irradiated MCF-10A cells and 80 Gγ cells to DNA damage by 
doxorubicin was also investigated (Fig. 6.5). Doxorubicin undergoes redox cycling 
which generates reactive oxygen species and induces DNA damage similar to that 
induced by hydrogen peroxide. However, its main cytotoxic mechanism is through 
interference with topoisomerase II which generates DNA strand breaks. There was a 
doxorubicin dose-dependent reduction in cell growth in both cell populations, with 
significant reductions in cell number following treatment with 100-1000 μM 
doxorubicin (Turkey’s test: p<0.001). The 80 Gγ cell population was significantly more 
sensitive to 100 μM doxorubicin than un-irradiated MCF-10A cells (Paired T-test: 
p=0.029), although the difference in sensitivity was relatively modest (Un-irradiated 
MCF-10A GI50 = 340 μM; 80 Gγ population GI50 = 112 μM). The 80 Gγ cumulative 
dose population therefore appeared to be more sensitive to doxorubicin than the un-
irradiated MCF-10A cell population but the sensitivity was not as pronounced as with 
hydrogen peroxide treatment.  
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Figure 6.5 Response of un-irradiated MCF-10A cells and 80 Gγ cumulative dose cells (First 5 Gγ 
series) to doxorubicin. 
 
Cells were treated with 1-1000uM doxorubicin for 72 hours The surviving cell number for each 
concentration of doxorubicin is expressed as a percentage of the number of vehicle-only treated cells. 
Mean values from multiple experiments are expressed +/- SEM (un-irradiated MCF-10A n=5; 80 Gγ 
cumulative dose n=4). An ANOVA test was used to assess statistical significance of cell number 
percentage between each doxorubicin concentration within each cell population: un-irradiated MCF-10A 
p<0.001; 80 Gγ cumulative dose p<0.001. A post-hoc Turkeys test was used to asses at which 
concentrations cell number percentage was significantly different within the same cell population. A 
paired T-test was used to test for significant differences in growth inhibition at each concentration of 
doxorubicin: 0 μM p=1; 1 μM p=0.600; 10 μM p=0.264; 100 μM p=0.029; 1000 μM p-0078. 
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6.5 Expression of DNA repair genes in the 80 Gγ cumulative dose population of the 
First 5 Gγ series 
Sensitivity to the cytotoxic effects of hydrogen peroxide and doxorubicin in the 80 Gγ 
population (section 6.4) suggests a deficiency in DNA repair and in particular base 
excision repair of oxidative DNA lesions. In order to test whether DNA repair 
expression is affected in POU2F1-deleted cells a Real-Time PCR array of DNA repair 
genes was used to analyse basal gene expression of un-irradiated MCF-10A cells and 80 
Gγ cumulative dose cells. BER genes known to be transcriptionally regulated by 
POU2F1 and BRCA1 were also specifically investigated (section 6.5.3).  
6.5.1 Expression of DNA repair genes in the 80 Gγ cumulative dose population 
DNA repair genes that have a minimum two fold increase or decrease in gene 
expression in the 80 Gγ cumulative dose population compared to the un-irradiated 
MCF-10A population under basal conditions are shown in table 6.1. Fold decreases are 
shown in blue and fold increases in red. The copy number changes of the genes between 
the un-irradiated MCF-10A cell population and the 80 Gγ cumulative dose cell 
population are also shown. 
Gene expression changes may occur due to changes in the copy number of that gene, 
changes in the transcriptional mechanisms/regulation of the gene or mutations in the 
genes themselves which dysregulate transcription (for review see section 5.4). Two 
genes identified by the DNA repair gene array show gene expression changes and a 
corresponding copy number alteration; these are ATM which has been discussed 
previously (section 4.5) and MPG, which encodes a 3-methladenine DNA glycosylase. 
Specifically, mono-allelic deletion of MPG (located on chromosome 16p), is associated 
with a three-fold reduction in gene expression (Table 6.1), suggesting a direct 
association between copy number and expression. Conversely, however, a single copy 
gain at the locus for NEIL1 on chromosome 15q is inconsistent with the observed two-
fold decrease in gene expression.  
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Of the 12 genes listed in table 6.1, only MGMT and ATM showed differential gene 
expression in other cell populations of the First 5 Gγ series following analysis with the 
Illumina HT12 v4 expression array (chapter 5).  Specifically, MGMT had reduced in 
expression in the 55 Gγ population and ATM had reduced expression in both the 40 and 
55 Gγ populations. There was also reduced expression of PARP3 in the 55 Gγ 
population but this was not attributed a differentiation score (data not shown). Four of 
the remaining 9 genes were not detected above background by the Illumina HT12 v4 
expression array (MPG, MSH4, NEIL1 and MLH3).  For genes detected above 
background (RAD50, RAD51D, NTHL1, NEIL3 and RPA3) expression did not change 
between the 25 Gγ and 55 Gγ populations compared to un-irradiated MCF-10A; it is 
therefore likely that genetic alterations between the 55 Gγ and 80 Gγ populations 
affected expression of these genes. 
6.5.2 Expression of BER genes transcriptionally regulated by POU2F1 and BRCA1 
Saha et al. (2010) showed that POU2F1 was essential for BRCA1 mediated up-
regulation of the BER genes NTHL1, APEX1, XRCC1 and OGG1 following oxidative 
damage; however complete loss of POU2F1 expression only affected basal expression 
of NTHL1, whereas a reduction in expression of BRCA1 reduced basal expression of all 
four genes. Saha and colleagues concluded that BRCA1 was the limiting factor of 
NTHL1, APEX1, XRCC1 and OGG1 basal expression, but that POU2F1 was an 
Genes which show at least a 2 fold increase or decrease in expression in the 80 Gγ population compared 
to the un-irradiated MCF-10A population are listed. Decrease in expression is shown in blue and increase 
is shown in red. The copy number change of the gene in the 80 Gγ population compared to the un-
irradiated MCF-10A population is also shown. none = no change, +n = number of copies gained and -n = 
number of copies lost. The resulting copy number state in the 80 Gγ population is also displayed.  
Gene  Fold Increase/Decrease Copy Number Change  Resulting copy number of 
copies in 80 Gγ population 
MGMT -4.5065 none 2 
RAD50 -3.487 none 3 
MPG -3.0147 -1 1 
MSH4 -2.9322 none 2 
NEIL1 -2.7741 +1 3 
RAD51D -2.5704 none 2 
MLH3 -2.5175 none 2 
ATM -2.3817 -1 1 
PARP3 -2.2377 none 2 
NTHL1 -2.0028 none 2 
NEIL3 2.0111 none 2 
RPA3 2.0534 none 2 
Table 6.1 Differentially expressed DNA repair genes in the 80 Gγ cumulative dose cells compared to 
un-irradiated MCF-10A cells. 
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essential component of the BRCA1 complex that induces up-regulation of these genes 
in response to genotoxic stress. The basal expression of NTHL1, APEX1, XRCC1, 
OGG1 and BRCA1 was assessed in the POU2F1-deleted 80 Gγ population (Table 6.4).  
 
 
 
 
 
Only NTHL1 had at least a 2 fold decrease in basal expression although the expression 
of APEX1 was also close to a 2 fold reduction. Expression of NTHL1 and APEX1 was 
not affected in other populations of the First 5 Gγ series (data not shown). The 
difference in basal expression of XRCC1, OGG1 and BRCA1 between the un-irradiated 
MCF-10A and 80 Gγ population was relatively small. The expression profile of NTHL1, 
APEX1, XRCC1 and OGG1 under basal conditions in the POU2F1 deleted 80 Gγ 
population therefore agreed with the findings by Saha et al. (2010); however data from 
the present study also suggested that basal expression of APEX1 may be affected by 
POU2F1 loss. 
6.6 Discussion 
POU2F1 is a transcription factor involved in regulation of genes following genotoxic 
stress; including DNA repair and other genes involved in maintaining genetic stability 
(Meighan-Mantha et al., 1999; Zhao et al., 2000; Jin et al., 2001; Fan et al., 2002; 
Schild-Poulter et al., 2003; Wang et al., 2004a; Maekawa et al., 2008; Saha et al., 2010) 
(Reviewed in section 4.5.2).  A focal mono-allelic deletion of the POU2F1 locus was 
detected using SNP array analysis in the 40 Gγ cumulative dose population of the First 
5 Gγ series (chapter 4). The POU2F1 locus is in a constitutively triploid region of 
chromosome 1q in MCF-10A cells, therefore the focal deletion reduced the copy 
number state of POU2F1 to 2. A further non-focal deletion on chromosome 1q was 
detected in the 80 Gγ population which reduced the copy number state of POU2F1 to 1.  
The following sections will discuss the relevance of POU2F1 deletion and concomitant 
loss of protein expression on DNA damage response and the accumulation of DNA 
damage in the First 5 Gγ series. 
The fold decrease in gene expression of NTHL1, APEX1, XRCC1, OGG1 and BRCA1 in the 80 Gγ 
cumulative dose population compared to expression in the un-irradiated MCF-10A population. 
Gene Fold Increase/Decrease 
NTHL1 -2.0028 
APEX1 -1.9346 
XRCC1 -1.3213 
OGG1 -1.0367 
BRCA1 -1.3213 
Table 6.2 Relative expression of BER genes transcriptionally regulated by POU2F1 and BRCA1. 
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6.6.1 POU2F1 copy number state and protein expression 
FISH analysis of the POU2F1 locus confirmed that in every population of the First 5 Gγ 
series where SNP data suggested a deletion, a deleted genotype was present in the 
dominant sub-population. FISH analysis also implied that the deletions of POU2F1 may 
have occurred earlier in the irradiation series than when detected by the SNP 6.0 array 
and those sub-populations with POU2F1 deletions were subsequently selected for, 
although it is not possible to determine whether POU2F1 deletion directly conferred a 
growth advantage. Further, it cannot be confirmed that the deletions of POU2F1 
detected by FISH in the non-dominant sub-populations of the First 5 Gγ series were the 
same specific deletions detected by the SNP 6.0 array in the 40 Gγ and 80 Gγ 
populations.  
Expression analysis of POU2F1 by the Illumina HT12 v4 expression array was un-
informative as the probe representing POU2F1 was only marginally detected above 
background in un-irradiated MCF-10A cells (chapter 5). Protein expression analysis by 
Western transfer and immunoblot however confirmed that POU2F1 is expressed in 
MCF-10A cells and that reduced expression is concomitant with deletion of the gene. 
Almost complete loss of expression in the 80 Gγ cells implies that either transcription 
from a single allele is not sufficient to maintain significant expression levels (possibly 
due to protein instability at low levels), or that a further mutation occurred in the 80 Gγ 
population which affected expression of the remaining allele.  
Saha et al. (2010) showed that the expression of the BER gene NTHL1 was only 
reduced in POU2F1
-/-
 fibroblasts and not in cells with approximately 60 % reduced 
protein concentration. In the present study a Real-Time PCR array, used to compare 
basal expression of DNA repair genes in the un-irradiated MCF-10A and 80 Gγ cell 
populations, identified a unique 2 fold reduction in expression of NTHL1 in the 80 Gγ 
population. Other genetic alterations may have affected NTHL1 expression but the 
result indicates that expression of POU2F1 in the present study may have conferred the 
same effect as seen in null (POU2F1
-/-
) cells, and therefore provides further evidence 
that POU2F1 expression was effectively lost in the 80 Gγ population.  
The amount of POU2F1 expressed under basal conditions may be a limiting factor in 
POU2F1-mediated response to genotoxic stress as loss of protein expression under basal 
conditions has been shown to attenuate the DNA damage response. For example, 
reduced basal expression of POU2F1 attenuates induction of CDNK1A transcription 
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following ionising radiation (Nenoi et al., 2009). Studies have also shown that increase 
in POU2F1 levels after genotoxic stress is not mediated by an increase in transcription 
but by kinase-mediated post-translational stabilization of the protein (Meighan-Mantha 
et al., 1999; Zhao et al., 2000; Tantin et al., 2005; Schild-Poulter et al., 2007; Wang and 
Jin, 2010). For example, POU2F1 induction after DNA damage induced by ionising 
radiation is abrogated when the kinase activity of DNA-PK is lost (Schild-Poulter et al., 
2007), although this has no effect on basal levels of POU2F1 (Schild-Poulter et al., 
2007). Loss of POU2F1 expression in the present study may therefore have attenuated 
DNA damage response. The concentration of POU2F1 directly after ionising radiation 
treatment would need to be assessed in the First 5 Gγ series to investigate whether 
reduced basal expression affected protein induction following ionising radiation 
however. 
6.6.2 POU2F1 and DNA damage response 
As described previously, POU2F1 expression is essential for the BRCA1 mediated up-
regulation of the BER genes NTHL1, APEX1, XRCC1 and OGG1 (Saha et al., 2010). 
Loss of BRCA1/POU2F1 induction of these genes increased sensitivity to oxidative 
damage by hydrogen peroxide. Increased sensitivity to oxidative stress in cells with 
reduced POU2F1 activity has been observed in a number of other studies (Tantin et al., 
2005; Wang and Jin, 2010). An increase in sensitivity to hydrogen peroxide and 
doxorubicin in the present study has been demonstrated, which could be due to POU2F1 
loss.  
Reduced POU2F1 activity also leads to increased sensitivity to ionising radiation (Zhao 
et al., 2000; Tantin et al., 2005). Loss of POU2F1 could affect BER of oxidative 
damage caused by ROS generated following radiation exposure. POU2F1 has also been 
implicated as having a direct role in non-homologous end joining, which is responsible 
for repairing double strand DNA breaks (Schild-Poulter et al., 2001). The gradual 
reduction in loss of POU2F1 in the First 5 Gγ series may therefore have contributed to 
the apparent increase in radio-sensitivity in irradiated populations (chapter 3).  
POU2F1 is also part of a BRCA1/NF-κB complex which is an important transcriptional 
regulator of p53 independent induction of GADD45 following DNA damage (Jin et al., 
2001; Fan et al., 2002; Maekawa et al., 2008). Loss of POU2F1 activity reduced 
transcription of GADD45A following genotoxic stress (Jin et al., 2001; Fan et al., 2002). 
GADD45A coordinates numerous cellular responses through interactions with partner 
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proteins in response to genotoxic stress, including DNA damage repair, cell cycle arrest 
and activation of stress response kinases (Liebermann and Hoffman, 2008). GADD45A
-
/-
 mice developed mammary tumours and displayed increased mutation frequency in 
response to ionising radiation (Liebermann and Hoffman, 2008). Loss of GADD45A 
induction due to POU2F1 loss may therefore increase DNA damage, mutation and 
genetic instability. POU2F1 also plays a role in BRCA1-mediated transcription of the 
spindle checkpoint gene MAD2 (Wang et al., 2004a). The spindle checkpoint is 
important for maintaining chromosomal integrity. Loss of MAD2 expression abrogates 
the spindle checkpoint, promotes chromosome mis-segregation and therefore the 
accumulation of DNA damage.  
Loss of POU2F1 expression in the present study may therefore have contributed to the 
accumulation of copy number alterations and gene expression changes identified in the 
First 5 Gγ series following ionising radiation treatment (chapter 4 and 5). The increase 
in genetic instability and accumulation of potentially advantageous mutations may have 
led to the apparent selection of cell sub-populations with a POU2F1 deletion identified 
by FISH analysis. 
It should also be noted that there was a two-fold change in the expression of 12 DNA 
damage repair genes which may also have contributed to the increased sensitivity to 
genotoxic stress and the accumulation of copy number alterations and gene expression 
changes in the First 5 Gγ series.  
Genes which showed reduced expression included: MGMT which repairs the O
6
-
alkylguanine DNA lesion caused by alkylating agents (discussed in section 5.4.1), 
MSH4 and MLH3 which have roles in DNA mismatch repair (Santucci-Darmanin et al., 
2002; Jaafar and Flores-Rozas, 2009), RAD50 which is involved in DNA double strand 
break response, RAD51D which plays a role in homologous recombination and telomere 
maintenance (D'Amours and Jackson, 2002; Shiloh, 2006; Czornak et al., 2008) and 
ATM which is also involved in double strand break stress response (Shiloh, 2003). 
Reduced expression of RAD50, RAD51D and ATM may have contributed to the 
accumulation of copy number alterations, increase in radiation sensitivity and telomere 
loss due to the abrogation of DNA double strand break repair and telomere maintenance. 
Of the genes with increased expression NEIL3 is implicated in BER (Liu et al., 2010) 
and RPA3 is postulated to have a role in repair of single strand DNA (Salas et al., 2009).   
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Four of the 10 down-regulated genes have a role in the BER pathway (MPG, NEIL1, 
PARP3, and NTHL1). Reduction in the basal levels of expression of MPG, NEIL1, 
PARP3, and NTHL1 may therefore play a role in increased sensitivity to oxidative DNA 
damage in the 80 Gγ population (Section 6.4). 
Reduced expression of at least 6 of the genes was unique to the 80 Gγ population which 
indicates that a genetic mutation between the 55 Gγ and 80 Gγ cell populations affected 
their expression. It is possible that loss of POU2F1 expression in the 80 Gγ population 
could have affected expression of these DNA repair genes considering the established 
role of POU2F1 in DNA damage response. Both ATM and NTHL1 have previously been 
shown to be down-regulated in cells with reduced POU2F1 expression (Tantin et al., 
2005; Saha et al., 2010). Regulation of the DNA damage repair genes by POU2F1 could 
be confirmed by reconstitution of POU2F1 expression in the 80 Gγ population to assess 
if DNA repair gene expression is restored. Techniques such as ChIP, which would 
assess if POU2F1 is part of transcriptional complexes which regulate these genes, could 
also be used to investigate this hypothesis further. 
6.6.4 Conclusion 
In summary, a focal deletion of POU2F1 was identified in the First 5 Gγ series 
following exposure to ionising radiation. This deletion was confirmed by cytogenetic 
analysis and caused a concomitant loss in protein expression. POU2F1 has known roles 
in response to genotoxic stress and a POU2F1-deleted population in the present study 
displayed increased cytotoxicity due to oxidative stress and reduced expression of a 
number of DNA repair genes. However, current data has not conclusively proved that 
loss of POU2F1 expression caused these changes. Due to the known function of 
POU2F1 in maintaining genetic stability and the radiation-mediated deletion of the 
gene in MCF-10A, POU2F1 expression will be investigated in a cohort of radiogenic 
and sporadic breast cancer tissue samples to assess if loss of expression is a feature of 
radiogenic breast cancer (chapter 8).   
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Chapter 7: Investigation of the copy number increase of c-MYC in the 
Second 5 Gγ series 
7.1 Introduction 
c-MYC is a transcription factor which regulates up to 15 % of all human genes and is 
involved in cell growth, proliferation, metabolism, differentiation and apoptosis (Dang 
et al., 2006). Increased c-MYC expression is an established event in cancer 
development and progression and can cause uncontrolled cell proliferation, 
immortalisation of cells, epithelial to mesenchymal transition, angiogenesis, reduced 
cell differentiation and ultimately cell transformation (Xu et al., 2010). c-MYC 
amplification (2 fold increase in c-MYC copy number over chromosome 8 copy number) 
is associated with over-expression of mRNA and protein product and it is reported to 
occur in 15% of all breast cancers (Deming et al., 2000).  
The c-MYC locus is in a constitutively trisomic region of chromosome 8q in the un-
irradiated MCF-10A genome. A focal copy number increase of c-MYC was detected in 
the 40 Gγ cumulative dose population of the Second 5 Gγ series. A larger region of 
copy number increase on chromosome 8, ending at the telomeric breakpoint of the focal 
alteration, was detected in the 60 Gγ population and further increased the copy number 
state of c-MYC (section 4.4.2).  Gene expression analysis of the Second 5 Gγ series 
identified expression changes in genes transcriptionally regulated by c-MYC, including 
the putative oncogene H19 and genes involved in epithelium to mesenchymal transition 
(chapter 5). The incidence of c-MYC amplification has been reported to be higher in 
breast cancer cases from individuals exposed to ionising radiation during the atomic 
bombs of Hiroshima and Nagasaki compared to breast cancers in the general population 
(Miura et al., 2008). The established oncogenic properties of amplified c-MYC and the 
previous links with radiogenic cancer therefore make the copy number increase event 
identified in MCF-10A cells a high priority candidate for investigation in radiogenic 
breast cancer. 
7.1.1 Aim  
The aim of the work described in this chapter was to investigate c-MYC copy number 
alterations in cells from the Second 5Gy series using fluorescent in situ hybridisation 
(FISH), and to investigate the effect increased copy-number has on c-MYC expression 
using western transfer and immunoblot.  
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7.2 In vitro confirmation of c-MYC copy number alterations  
c-MYC copy number alterations were investigated in the Second 5 Gγ series using FISH. 
A commercially available green fluorescent chromosome 8 centromere probe and a 
commercially available orange fluorescent probe which maps to c-MYC were used for 
cytogenetic analysis (section 2.8). Confirmation that these probes map to the correct 
chromosome and in the correct region was made using metaphase chromosomes, 
prepared by David Rowe (Institute of Genetic Medicine, Newcastle upon Tyne, UK), 
from un-irradiated MCF-10A cells (Fig. 7.1). As expected, the green centromere probe 
hybridised to the centromere of the constitutively normal chromosome 8 and the 
der(8)t(8;8)(q22;p23) chromosome. The c-MYC probe hybridised to the q arm of these 
two chromosomes in positions consistent with the MCF-10A karyotype described in 
section 4.2.1.  
 
Figure 7.1 Cytogenetic analysis of c-MYC in un-irradiated MCF-10A cells. 
 
 
FISH probes are specific to the centromere of chromosome 8 (green) and the c-MYC locus (red) and the 
metaphase chromosomes of un-irradiated MCF-10A were counterstained with DAPI. The probe for c-
MYC hybridises to the q arm of the same chromosomes as the centromere 8 probe, specifically on a 
normal chromosome 8 and the der(8)t(8;8)(q22;p23) chromosome, which is consistent with its established 
position in the genome. 
213 
 
7.2.1 c-MYC copy number alterations in the 80 Gγ population determined using 
metaphase cells 
Copy number alterations of the c-MYC locus were investigated using metaphase 
chromosomes from the 80 Gγ cumulative dose population from the Second 5 Gγ series. 
Metaphase chromosome spreads were not available for the other populations of the 
Second 5 Gγ series.  
G-band analysis of the 80 Gγ population identified that the large region of copy number 
gain on chromosome 8q (between positions 71160976:130125337; section 1.4.2) was 
attached to the end of the constitutively normal chromosome 8q, creating the derivative 
chromosome dup8(q12-q24) (Fig. 7.2). All 20 cells analysed by G-band karyotyping 
contained the dup8(q12-q24) chromosome. SNP 6.0 analysis showed that the c-MYC 
locus was at the telomeric end of the duplicated region (section 1.4.2). FISH analysis of 
metaphase chromosomes from the 80 Gγ population showed that the c-MYC locus was 
at the telomeric end of the dup8(q12q24) chromosome q arm which confirmed that the 
duplicated region was not inverted (Fig 7.3a).  
Sub-populations were identified that had multiple copies of c-MYC on the q arm of the 
dup8(q12q24) chromosomes (Fig 7.3 b and c). Multiple copies of c-MYC appeared to be 
present at the c-MYC locus on both constitutive 8q and the duplicated region. The c-
MYC genotype observed in this sub-population most likely represented the focal c-MYC 
amplification identified by the SNP 6.0 array (Section 4.4.2).  
Despite all chromosomes analysed by G-band karyotyping containing the dup8(q12-q24) 
chromosome, alternative karyotypes with different alterations that incorporated the c-
MYC locus were also observed by FISH analysis (albeit at a much lower frequency than 
the dup8(q12q24) alterations). For example a translocation of c-MYC to an unknown 
chromosome was identified in cells which did not contain the dup8(q12-q24) 
chromosome (Fig 7.3d). Cells containing a second duplication on the dup8(q12q24) 
chromosome and a duplication on one of the q arms of the constitutive 
der(8)t(8;8)(q22;p23) were also observed (Fig 7.3e and f).  
In summary it appeared that numerous chromosome rearrangements occurred on 
chromosome 8q that involved the c-MYC locus and that the focal amplification of c-
MYC only occurred on the dup8(q12q24) chromosome.  
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Figure 7.2 G-band karyotyping of metaphase chromosomes from the 80 Gγ population of the 
Second 5 Gγ series. 
 
 
 
 
 
 
 
Chromosomes which display chromosomal rearrangements are labelled with the chromosomal regions 
that constitute the rearrangement and the karyotype definition of the chromosome. All rearrangements are 
constitutive to the MCF-10A cell line except the dup8(q12-q24) chromosome which is circled. The 
dup8(q12-q24)  chromosome is unique to the Second 5 Gγ series. 
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Figure 7.3 Copy number alterations of c-MYC in the 80 Gγ population (Second 5 Gγ series). 
 
 
FISH probes are specific to the centromere of chromosome 8 (green) and the c-MYC locus (red) and the metaphase chromosomes were counterstained with DAPI. Examples of 
different chromosome alterations which incorporate the c-MYC locus on metaphase chromosomes from cells of the 80 Gγ population (Second 5 Gγ series) are circled in red: 
duplication of the 8q21-q24 region with the c-MYC locus positioned at the telomeric end of the duplicated region (a), multiple copies of c-MYC at the c-MYC locus on the 
constitutive 8q arm and duplicated region of the dup(8)(q21-q24) chromosome (b) and (c), a translocation of the c-MYC locus to an unknown chromosome (d), a second duplication 
on the q arm of the dup(8)(q21-q24) chromosome (e) and a duplication of a region of 8q incorporating the c-MYC locus on one arm of the constitutive der(8)t(8;8)(q22;p23) 
chromosome.  
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7.2.2 c-MYC copy number alterations in the Second 5 Gγ series determined using 
interphase cells. 
FISH analysis of interphase cell populations identified 3 distinct c-MYC genotypes in 
sub-populations from the Second 5 Gγ series. These were:  
i. 2 copies of chromosome 8 and 3 copies of c-MYC; representing the genotype of 
un-irradiated MCF-10A cells which has a region of constitutional trisomy on 
chromosome 8q (section 4.2.1) (Fig. 7.4a). 
ii. 2 copies of chromosome 8 and 4 distinct copies of c-MYC. Two copies of c-
MYC appeared to consistently localise to each centromere probe in this cell 
population indicating that each chromosome now had two copies of c-MYC (Fig. 
7.4b); 
iii. 2 copies of chromosome 8 and multiple copies of c-MYC (Figure 7.4c). The 
nature of the staining of the c-MYC locus by the FISH probe meant that cells 
with multiple copies of c-MYC were easy to identify but the exact number of 
copies of c-MYC was sometimes hard to discern. Cells with this pattern of 
staining were therefore grouped together as c-MYC amplified cells (copy 
number > 4).  
There was no evidence of focal c-MYC amplification in the passage controls cells. 
Rather, the dominant c-MYC genotype in the passage control cells was 3 copies of 
chromosome 8 and 4 copies of c-MYC, consistent with acquired Trisomy 8 (section 4.4). 
Only 9% of passage control cells had the un-irradiated MCF-10A c-MYC genotype (2 
centromere 8 and 3 c-MYC signals). There was no indication of focal c-MYC 
amplification. 
The percentage of cells in each cell population with each of the 3 identified c-MYC 
genotypes was calculated after scoring 100 cells in populations of the Second 5 Gγ 
series (Fig. 7.4d, e and f). Standard FISH scoring protocols classify alterations that are 
seen in less than 5% of all cells scored as not reportable; therefore such alterations have 
not been included in the analysis. The proportion of cells with 2 copies of chromosome 
8 and 3 copies of c-MYC reduced as cumulative radiation dose increased. Reduction in 
the proportion of cells with this genotype indicated that the un-irradiated MCF-10A 
genotype was selected against.  The proportion of cells with this genotype had reduced 
almost 3 fold by the 60 Gγ population compared to un-irradiated MCF-10A (Fig. 7.4d).  
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Cells with 2 copies of chromosome 8 and 4 copies of c-MYC were not observed in the 
un-irradiated MCF-10A cell population. This genotype was observed in 12% of cells in 
the 10 Gγ population and increased as cumulative dose increased. There was however a 
reduction in the percentage of cells with this genotype in the 60 Gγ population although 
the percentage increased again in the 80 Gγ population (Fig. 7.4e).  
No cells contained c-MYC amplification in the un-irradiated MCF-10A or 10 Gγ cell 
populations; however 7% of cells contained c-MYC amplification in the 20 Gγ 
population (Figure 7.4f). The percentage of cells with a c-MYC amplification increased 
as cumulative dose increased, becoming the dominant genotype in the 60 Gγ population 
comprising 46% of all cells. However the number of c-MYC amplified cells reduced 
again to 36 % in the 80 Gγ population. The increasing proportion of cells with c-MYC 
amplification as cumulative dose increased indicated that these cells had been selected 
for. The reduction in the percentage of c-MYC amplified cells in the 80 Gγ population 
and increase of cells with 2 copies of chromosome 8 and 4 copies of c-MYC indicated 
that a mutation may have occurred which conferred a selective advantage on cells with 
the latter genotype.  
In summary, FISH analysis of the Second 5 Gγ series confirmed that populations of the 
Second 5 Gγ series were genetically heterogeneous and that the proportion of cells with 
an increased c-MYC copy number increased with cumulative dose. Although the 
percentage of cells with c-MYC amplification reduced in the 80 Gγ population 
compared to the 60 Gγ population, the percentage of cells with any increase in c-MYC 
copy number compared to the un-irradiated MCF-10A genotype increased.  
Speculation as to which c-MYC genotypes represented which sub-population observed 
in the metaphase analysis of the 80 Gγ population will be discussed in section 7.4. 
Potential mechanisms by which the alterations may have arisen, at what stage of the 
irradiation series alterations occurred and how this correlates with data form the SNP 
6.0 analysis will also be discussed in section 7.4. 
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Figure 7.4 c-MYC copy number gains in the Second 5 Gγ series 
 FISH probes specific to the centromere of chromosome 8 (green) and the c-MYC locus (red) were used to analyse c-MYC copy number in populations of the Second 5 Gγ series. Cells 
were counterstained with DAPI. Examples of the three dominant c-MYC genotypes in cells of the Second 5 Gγ series are shown: 2 copies of chromosome 8 with 3 copies of c-MYC 
(a), 4 copies of c-MYC (b) and greater than 4 copies of c-MYC (c). Underneath the image of each genotype is a graph displaying the percentage of cells with that genotype calculated 
from counts of 100 nuclei from each cell population: 2 copies of chromosome 8 with 3 copies of c-MYC (d), 4 copies of c-MYC (e) and  greater than 4 copies of c-MYC (f). 
219 
 
7.3 c-MYC protein expression in the Second 5 Gγ series 
Western transfer and immunoblot was used to determine what effect c-MYC copy 
number had on c-MYC protein levels in un-irradiated MCF-10A, Second 5 Gγ series 
and passage control cells. Representative images of the immunoblot analysis are shown 
in figure 7.5a and b. A strong band at the correct mass for c-MYC (67 kDa) was 
observed in the un-irradiated MCF-10A cell population. c-MYC expression in the 
Second 5 Gγ series was reduced in the 20 Gγ cumulative dose cells compared to un-
irradiated MCF-10A cells. Expression increased in the 40 Gγ, 60 Gγ and 80 Gγ cells 
and was higher than in un-irradiated MCF-10A cells (Fig. 7.5a). Expression of c-MYC 
appeared to be higher in the passage control population than in un-irradiated MCF-10A 
cells also (Fig. 7.5b).  
c-MYC expression was quantified by densitometric analysis of 3 independent 
experiments from 3 independent protein extracts and normalised using GAPDH 
expression (Fig. 7.5c). Expression appeared to reduce in the 20 Gγ population compared 
to un-irradiated MCF-10A; however the difference was not significant (Turkey’s Test: 
p=0.477). Cell populations with an increased c-MYC copy number identified by SNP 
6.0 analysis (40 Gγ, 60 Gγ, 80 Gγ and passage control populations) had increased 
expression of c-MYC compared to un-irradiated MCF-10A; however only the 60 Gγ 
population had significantly increased expression (Turkey’s Test: p=0.002). 
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Figure 7.5 c-MYC protein expression in the Second 5 Gγ series 
 
 
 
Western transfer analysis of the Second 5 Gγ series (a) and passage control population (b) with antibodies 
specific for the 67kDa protein c-MYC and 37kDa protein GAPDH. Densitometric analysis of 3 
independent western transfers using 3independant protein extracts was used to quantify the expression of 
c-MYC for each cell population as a percentage of the expression of c-MYC in un-irradiated MCF-10A 
cells (which was set at 100% expression) (c). U-I = un-irradiated MCF-10A and P.C = passage control in 
cell population lane identifiers below each image in (a) and (b). 10 μg of protein was used for each cell 
population in each experiment. Although irradiated and passage control populations were analysed 
separately the same un-irradiated MCF-10A protein extracts were used and expression was expressed as a 
percentage of the expression of c-MYC in un-irradiated MCF-10A cells within these experiments. To 
calculate the relative protein expression of c-MYC the densitometry results for each sample were 
normalised with densitometry of GAPDH within each experiment. Difference in expression between 
populations below the 5% confidence level was tested (Kruskal-Wallis: p=0.006). A post hoc Turkey’s 
test was then used to assess the difference in expression between individual populations below the 5% 
confidence level. * indicates populations whose c-MYC protein expression was significantly different 
from un-irradiated MCF-10A. 
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The fluctuations of c-MYC expression in the 40 Gγ, 60 Gγ, 80 Gγ and passage control 
populations do not directly correlate with the increase in c-MYC copy number identified 
by SNP 6.0 array and FISH analysis. For example, the comparable level of expression 
in the 40 Gγ and 80 Gγ populations was not expected as the 80 Gγ population had a 
higher proportion of cells with increased c-MYC copy number. It was interesting 
however that c-MYC expression was highest in the 60 Gγ population as this population 
had the highest frequency of cells with c-MYC amplification (section 7.2.2, Fig. 7.4f).  
The apparent fluctuations in c-MYC expression may be due to the inaccuracies of 
western densitometry which is only semi-quantitative. It is also possible however, that 
those genes which regulate the expression or stabilisation of c-MYC may have been 
altered or were acting in different ways in the different cell populations and 
subsequently caused different levels of expression. The relationship between c-MYC 
copy number and c-MYC expression may therefore not be a simple one. Overall 
however, the trend in the Second 5 Gγ series was that increased c-MYC copy number in 
the majority of cells led to an overall increase in c-MYC expression. 
7.4 Discussion  
The incidence of c-MYC amplification is increased in breast cancers following exposure 
to ionising radiation, and chromosomal rearrangements involving the 8q24.2 region 
have been reported in breast epithelial cells transformed with γ rays (Miura et al., 2008; 
Unger et al., 2010). It is therefore possible that genetic alterations on chromosome 8q, 
including c-MYC amplification, are common following radiation exposure. The 
numerous chromosomal re-arrangements of 8q observed in the present study, including 
c-MYC amplification, is consistent with this model and suggests that 8q is particularly 
susceptible to radiation-induced instability. The present study also confirmed 
concomitant increase of c-MYC expression with increase in the proportion of cells 
containing c-MYC copy number gains. Section 7.4.1 will discuss putative mechanisms 
by which copy number alterations incorporating the c-MYC locus occurred on 
chromosome 8q, followed by discussion of the relevance elevated c-MYC protein 
expression has on the transformation process. 
7.4.1 Copy number alterations on chromosome 8q in the Second 5 Gγ series 
Translocation of the c-MYC locus was identified in a sub-population of the 80 Gγ 
population. A reciprocal translocation of c-MYC to a location close to enhancers of IgH 
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on chromosome 14 is a well-established driver of transformation in Burkitt lymphoma 
(Boxer and Dang, 2001). Translocation breakpoints in relation to c-MYC in Burkitt 
lymphoma include sites within, immediately 5’ and distant to the gene (Boxer and Dang, 
2001). Breakpoints for the observed translocations in the present study have not been 
determined. Further large copy number gains incorporating the c-MYC locus on the 
dup8(q12q24) and der(8)t(8;8)(q22;p23) chromosomes were also observed. The 
genomic regions involved in these rearrangements are also unknown. 
The two dominant alterations incorporating c-MYC in the 80 Gγ population identified 
by both SNP analysis and FISH analysis of the 80 Gγ population were a focal 
amplification of c-MYC and a duplication of the q21-q24 region of chromosome 8. SNP 
array analysis of these two alterations indicated that they share a common breakpoint 
(section 4.4.2).  
Amplification of c-MYC appeared to only occur on the dup8(q12q24) chromosome and 
was identified at the c-MYC locus on both the constitutive q arm and on the duplicated 
region (Fig. 7.3b and c). It therefore appears that both the duplication and amplification 
were initiated on the same chromosome and that the amplification occurred before the 
duplication. This model correlates with the temporal acquisition of the genetic 
alterations identified by the SNP 6.0 array which first identified the focal amplification 
in the 40 Gγ population and the duplication in the 60 Gγ population (section 4.4.2).  
The molecular mechanisms generating the derivative chromosome are likely to be 
complex; however a model has been proposed which could generate this rearrangement 
(Fig. 7.6). Early in the irradiation series a radiation-induced double strand break at the 
telomeric end of the focal amplification may have induced a BFB cycle (described in 
section 1.4.2) which caused focal c-MYC copy number increase (Fig 7.6 a-f). At a later 
point a second double strand break centromeric to the amplification caused a chromatid 
rearrangement to the end of the sister chromatid at the site of the focal amplification, 
creating the dup8(q12q24) chromosome (Fig 7.6 g-h). At some point during subsequent 
cell division a chromosome 8 telomere was added to the end of the dup8(q12q24) 
chromosome, perhaps via homologous recombination repair using the 
der(8)t(8;8)(q22;p23) chromosome as a template (Fig 7.6 i).  Cells with the amplified 
dup8(q12q24) chromosome were then subsequently selected for.  
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Figure 7.6 Potential mechanism generating the c-MYC amplified dup(8)(q21-q24) chromosome. 
 
 
A radiation-induced double strand break occurs telomeric to the c-MYC locus (a), which removes the 8q telomere (b). Replication of the chromosome results in two broken sister 
chromatids (c). The chromatids fuse to form a dicentric chromosome (d). Mitotic segregation of the centromeres results in a second break centromeric to the c-MYC locus , creating 
a chromosome with 2 copies of c-MYC (e). The derivative chromosome replicates and this cycle could continue creating multiple copies of c-MYC. In the above figure however 
only one cycle is shown. A second potentially radiation-induced double strand break occurs on one chromatid of the replicated chromosome prior to sister chromatid fusion (f – g). 
The broken fragment of the chromatid containing the c-MYC amplification attaches to its sister chromatid creating a tandem duplication with c-MYC at the terminal end of the 
chromosome arm (h). Acquisition of a telomere, potentially via homologous recombination with the der(8)t(8;8)(q22;p23) chromosome halts further breakage fusion bridge cycles 
(i). 
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The proposed model would derive alterations which appear to have the same breakpoint. 
No telomere deletion would be detected in chromosome 8q by SNP array analysis as the 
proportion of cells with the telomere deletion would represent too small a percentage of 
cells early in the irradiation series. Amplification caused by BFB cycles are identified 
by a series of inverted repeats (Hastings et al., 2009). Sequence analysis of the c-MYC 
locus in amplified chromosomes could therefore confirm if BFB cycles generated the 
amplification.  
There is some evidence that the duplication event may have occurred before the focal 
amplification. For example: some dup(q12q24) chromosomes did not appear to contain 
multiple copies of c-MYC, suggesting that duplication occurred prior to amplification 
(Fig. 7.3a); FISH analysis of the Second 5 Gγ series identified a genotype of 2 
chromosome 8 centromeres and 4 distinct copies of c-MYC in a substantial proportion 
of cells in certain populations; and the first copy number increase of c-MYC identified 
by FISH in the Second 5 Gγ series was a single distinct copy number gain in the 10 Gγ 
population, implying a duplication event (section 7.2.2). It should be noted that some of 
the cells observed with 4 distinct c-MYC copies may actually contain alternative 
alterations which incorporate c-MYC, or may in fact be c-MYC amplified cells in which 
the resolution of the FISH staining is not good enough to identify multiple c-MYC 
copies close together in the cell. This latter point could relate to both metaphase and 
non-metaphase FISH.    
It is theoretically possible that the duplication could have occurred before the focal 
amplification but be detected subsequent to the amplification by the SNP 6.0 array. The 
duplication was only a single copy number gain, therefore in heterogeneous cell 
populations this alteration may be masked when not present in over 50% of cells. The 
focal amplification on the other hand appears to be an increase of multiple copies. This 
would cause a relatively large increase in signal intensity at the c-MYC locus and may 
be detected by the SNP array even when in a minor sub-population of cells. This could 
therefore lead to a situation whereby the focal amplification occurs after the duplication 
event, but is detected first. 
Two double strand break events in the same chromatid or in a sister chromatid could 
generate the dup(q12q24) chromosome (Fig 7.7). A translocation from the 
der(8)t(8;8)(q22;p23) could also cause the duplication but won’t be described in this 
example. Double strand break events in the same chromatid would lead to c-MYC being 
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positioned at the terminal end of the chromosome which could lead to BFB cycles and 
therefore c-MYC amplification (Fig. 7.7a). Separate double strand break events would 
allow a telomere to be positioned at the end of the dup(q12q24) chromosome and c-
MYC amplification would require a further strand break event and most likely occur by 
an alternative mechanism (Fig 7.7b). The position of the telomere is unclear from G-
band analysis of the 80 Gγ population.  
Examples of alternative amplification mechanisms include: non-allelic homologous 
recombination (NAHR) (described in section 1.4.2) which relies on a measure of 
sequence homology either side of the amplified region (Hastings et al., 2009), double 
rolling circle replication, or fold-back priming which both rely on inverted repeats either 
side of the amplified region (Rattray et al., 2005; Watanabe and Horiuchi, 2005). The 
“duplication first” model however would not explain the observation that both loci of c-
MYC on the dup(q12q24) chromosome appeared to have amplified regions. 
In summary, with the data currently available it is very difficult to determine a 
mechanism by which the genetic alterations on chromosome 8q were generated in the 
Second 5 Gγ series. It is very possible that mechanisms other than those proposed 
resulted in focal c-MYC amplification and q21-q24 duplication. Metaphase analysis of 
early populations of the Second 5 Gγ series may help determine the temporal 
acquisition of the alterations; however this analysis was not possible. Overall, the 
spectrum of alterations incorporating the c-MYC locus seen in the present study 
indicates a series of complex rearrangements of chromosome 8q which were induced by 
ionising radiation exposure; therefore suggesting that this region of chromosome 8 
contains one or more sites sensitive to radiation-induced breakage. 
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Figure 7.7 Potential mechanisms of the “duplication first model”. 
 
 
Simultaneous radiation-induced DSB events on the same chromatid (a) or on different chromatids of the same chromosome (b) could generate two slightly different dup(8)(q21q24) 
chromosomes. (a): DSB’s on the same chromatid at the breakpoints of the 8q21q24 duplication would create a chromatid fragment which could position itself onto the q arm of a 
constitutively normal chromatid resulting in the telomere being positioned at an intra-chrmosomal region. A non-telomeric region at the end of this region could conceivably 
therefore induce a BFB cycle. (b): DSB’s on different chromatids at the breakpoints of the 8q21q24 duplication would create two broken chromatids that could rearrange so that the 
centromeric breakpoint of one fragment attaches to the telomeric breakpoint of the other fragment. This could create a tandem duplication with a telomere at the end of the 
chromosome. Amplification of the c-MYC locus would then occur at a later point of the irradiation series.  
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7.4.2 Potential mechanisms linking c-MYC amplification and ionising radiation 
The following section will briefly discuss two potential mechanisms which could cause 
preferential chromosomal arrangements, including c-MYC amplification, on 
chromosome 8q after exposure to ionising radiation. The role of these potential 
mechanisms is purely speculative and they have not been shown to affect c-MYC or 
radiation induced alterations in radiogenic breast cancer. 
Common fragile sites with a particular propensity to undergo breakage during 
replication stress (inefficient DNA replication that causes replication to progress slowly 
or to stall) are known to exist in the human genome (Arlt et al., 2006). Two known 
common fragile sites, FRA8C and FRA8D, flank the c-MYC locus and have been 
implicated in chromosomal rearrangements in cervical cancer and Burkitt lymphoma 
(Ferber et al., 2004). It has also been suggested that the FRA8C and FRA8D sites may 
actually represent one large fragile site and common chromosome breaks at these sites 
represent peak fragile regions (Arlt et al., 2006). Radiation-induced genotoxic stress, 
which in turn induces replication stress, has been shown to induce breaks at fragile sites 
in rats (Camats et al., 2006). Breakage of common fragile sites at the c-MYC locus may 
therefore be indirectly induced by ionising radiation exposure which could lead to c-
MYC amplification in radiogenic breast cancer. This has not been analysed or shown in 
previous studies however.  
The fragile site mechanism may have contributed to the alterations on chromosome 8q 
observed in the Second 5 Gγ series. A fragile site would potentially explain how both 
the focal amplification and duplicated region appeared to share a common breakpoint. 
The common breakpoint in the present series was positioned between the FRA8C and 
FRA8D fragile sites. A common fragile breakpoint could explain the spectrum in 
chromosomal alterations observed in the Second 5 Gγ series. 
Transcriptionally active regions of the chromosome (euchromatin) have been shown to 
be more susceptible to chromosome aberrations due to ionising radiation exposure than 
transcriptionally inactive regions (heterochromatin) (Nagasawa et al., 2010). For 
example, radiation-induced genetic alterations were shown to be more common on 
chromosome 2 in a radiation-susceptible AML strain of mice than radiation-resistant 
AML strains (Darakhshan et al., 2006). It has been suggested that this was due to 
differences in chromatin organisation in the different strains of mice (Nagasawa et al., 
2010). Differences in chromatin structure on chromosome 8q may therefore make the 
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region encompassing the c-MYC locus particularly susceptible to radiation-induced 
DNA damage.  
Oestrogen has been shown to induce chromatin modifications to facilitate 
transcriptional activation of target genes (Green and Carroll, 2007). As discussed in 
chapter 1, breast epithelial cells are hormone sensitive and oestrogen exposure is an 
important risk factor for radiogenic breast cancer. c-MYC is transcriptionally activated 
by oestrogen bound ERα and histone modifiers have been shown to facilitate oestrogen 
dependant transcription (Kawazu et al., 2011; Wang et al., 2011); therefore exposure to 
oestrogen in the breast of young women may cause chromatin modifications at the c-
MYC locus which may make it susceptible to radiation damage. Alterations of 
chromosome 8q in the present study were only observed in cells with oestrogen added 
to the medium. The MCF-10A cell line is ERα negative, but does express ERβ which is 
96% homologous to ERα at the DNA binding domain (Yager and Davidson, 2006). It is 
therefore conceivable that chromatin modification due to oestrogen exposure may have 
affected chromatin structure at the c-MYC locus rendering it susceptible to DNA 
damage. It should be re-iterated however that the effect of oestrogen on radiation-
induced alterations of chromosome 8q is speculative, and development of this 
hypothesis would require further experimentation.  
7.4.2 c-MYC expression 
Previous chapters have discussed potential phenotypic and gene expression changes that 
may be related to a copy number increase of c-MYC (chapter 3 and chapter 5). In 
particular, induction of EMT has been discussed in relation to the Second 5 Gγ series. 
Phenotypic changes potentially induced by c-MYC copy number increase rely on the 
assumption that copy number gain of c-MYC increases c-MYC expression. Protein 
expression analysis confirmed that expression increased in cell populations with an 
identified c-MYC copy number increase. 
Densitometric analysis indicated that expression of c-MYC fluctuated throughout the 
irradiation series; however this may be due to the semi quantitative nature of the 
analysis. Therefore speculation as to how fluctuations in expression may have affected 
different populations of the Second 5 Gγ series has to be appropriately circumspect.  
c-MYC expression was highest in the 60 Gγ population. This population was shown to 
differentially express more markers of EMT following gene expression analysis than 
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any other population in the Second 5 Gγ series (section 5.3.2). Expression of c-MYC in 
the 80 Gγ population reduced compared to the 60 Gγ population. A reduction in the 
number of differentially expressed EMT markers between the 60 Gγ and 80 Gγ 
populations was also observed (section 5.3.2). Together these data support the 
hypothesis that c-MYC can induce gene expression changes that can drive EMT, and 
that reduction of c-MYC expression can reverse these gene expression changes (section 
5.4.6).  
Potential mechanisms for c-MYC expression changes in the Second 5 Gγ series include 
a reduction in the number of cells with c-MYC copy number gains, or changes to c-
MYC regulation and stabilisation throughout the Second 5 Gγ series. FISH analysis of 
the Second 5 Gγ series implied that the 60 Gγ population had a larger proportion of cells 
with focal amplification of c-MYC than the 80 Gγ population, which had a larger 
proportion of cells with only a single copy number increase. At face value it is possible 
that a reduction in c-MYC amplified cells and an increase in cells with only a single 
copy number increase of c-MYC in the 80 Gγ population could have caused an overall 
reduction in c-MYC expression. However, as was discussed in section 7.4.1 accurate 
analysis of the FISH data is difficult. 
As discussed in section 4.5.4 different pathways and proteins can control expression of 
c-MYC and stabilisation of c-MYC protein. For example: the TGF-β complex, the 
RAS/RAF/MAPK pathway, GSK-3β and the WNT and NOTCH signalling pathways 
(Sears et al., 1999; Frederick et al., 2004; Adhikary and Eilers, 2005; Sekimoto et al., 
2007; Xu et al., 2010). There is no indication by SNP array or gene expression analysis 
that any of the genes involved in c-MYC expression or stabilisation were altered in the 
80 Gγ population; however functional and expression changes of proteins involved in 
these processes could in theory have been affected and may explain fluctuation in c-
MYC expression.    
7.4.3 Conclusion 
In summary, genetic alterations identified by SNP array analysis that affect the c-MYC 
loci have been confirmed in the Second 5 Gγ series using cytogenetic techniques. The 
mechanisms by which these alterations were generated remain to be determined. 
Alterations affecting the c-MYC locus which were not identified by SNP array analysis 
were also identified in the 80 Gγ population using FISH which provides further 
evidence that chromosome 8q may be prone to genetic rearrangement. Increased c-
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MYC expression concomitant with increasing c-MYC copy number indicates that 
phenotypic and gene expression changes of the Second 5 Gγ series may have been 
induced by c-MYC.  
Considering these results c-MYC copy number and c-MYC expression will be analysed 
in radiogenic and sporadic breast cancer samples to assess if amplification of c-MYC 
and concomitant increase in expression is a feature of radiogenic breast cancer (chapter 
8). 
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Chapter 8: POU2F1 expression and c-MYC amplification in sporadic 
and radiation-induced primary breast cancer tissues 
8.1 Introduction 
The established increased risk of breast cancer following exposure to ionising radiation 
is believed to occur through the gradual accumulation of transforming mutations 
following an initiation event induced by ionising radiation (Allan and Travis, 2005). 
Oestrogen and its metabolites are believed to play a role in the accumulation of 
mutations via genotoxic and receptor mediated mechanisms following initiation (van 
Leeuwen et al., 2003; Yager and Davidson, 2006). The discovery of a molecular genetic 
alteration which is common in radiogenic breast cancer may identify early mutation 
events induced by ionising radiation and would facilitate the understanding of 
radiogenic breast transformation.  
A focal deletion of POU2F1 has been identified following exposure to ionising 
radiation in MCF-10A cells and reduced protein expression concomitant with copy 
number loss has been demonstrated. Previous studies have demonstrated that POU2F21 
is an important regulator of DNA damage response genes and sensitivity to genotoxic 
exposures in POU2F1-deficient cells has been demonstrated in the present study 
(Meighan-Mantha et al., 1999; Zhao et al., 2000; Jin et al., 2001; Fan et al., 2002; 
Schild-Poulter et al., 2003; Tantin et al., 2005; Maekawa et al., 2008; Saha et al., 2010; 
Wang and Jin, 2010). Reduced DNA damage response is an established mechanism of 
cell transformation due to the concomitant increase in genetic instability and 
accumulation of potentially oncogenic mutations. Deletion of POU2F1 and subsequent 
reduction in expression is therefore a candidate early genetic event in radiogenic breast 
carcinogenesis.  
A radiation-induced focal amplification of c-MYC and further alterations of 
chromosome 8q which incorporate the c-MYC locus in radiation exposed MCF-10A 
cells have been identified and a concomitant increase in protein expression has been 
demonstrated. c-MYC is an established oncogene, is overexpressed in a number of 
cancers, is implicated in cell transformation and data from this study has linked copy 
number increase of c-MYC with epithelial to mesenchymal transition (Dang et al., 2006; 
Meyer and Penn, 2008; Xu et al., 2010). Incidence of c-MYC amplification has also 
been reported to be higher in breast cancer cases from survivors of the atomic bomb at 
Nagasaki who were exposed to ionising radiation compared to individuals not exposed 
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to radiation (Miura et al., 2008). The identification of a radiation-induced copy number 
increase in the present study and previous links with radiogenic breast cancer therefore 
makes c-MYC copy number gain a strong candidate for an early genetic event in 
radiogenic breast transformation. 
8.1.1 Aim 
The aim of the work described in this chapter was to compare protein expression of both 
POU2F1 and c-MYC in spontaneous and radiation-induced breast cancer tissue samples 
by immunohistochemistry. The copy number state of c-MYC was also investigated to 
determine if c-MYC copy number increase is a common event in radiogenic breast 
cancer. 
8.2 Spontaneous and radiation-induced breast cancer cohorts 
Two cohorts of paraffin embedded breast cancer tissue samples were available to 
investigate the role of POU2F1 and c-MYC in sporadic and ionising radiation-induced 
breast cancer.  
Material was available from 18 women who developed breast cancer after treatment 
with ionising radiation for Hodgkin lymphoma (“radiogenic breast cancers”) and 33 
women who developed apparent sporadic breast cancer without any antecedent 
therapeutic radiation exposure (“sporadic breast cancers”).  
The link between ionising radiation and increased breast cancer risk in Hodgkin 
lymphoma survivors has been extensively reviewed (chapter 1). Briefly, women who 
receive ionising radiation treatment for Hodgkin lymphoma have an increased risk of 
breast cancer which is dose dependant (van Leeuwen et al., 2003). The risk is also 
dependant on the age of the individual, with a number of studies claiming that there is 
no increase in relative risk of breast cancer in women who have received ionising 
radiation treatment for Hodgkin lymphoma over the age of 30 (Travis et al., 2003; van 
Leeuwen et al., 2003). Treatment with alkylating agents during radiotherapy for 
Hodgkin lymphoma attenuates the risk of breast cancer, potentially through ablation of 
ovarian function which reduces circulating oestrogen levels (van Leeuwen et al., 2003).  
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8.2.1 Radiogenic breast cancer cohort 
A summary of the characteristics of the radiogenic breast cancer cases is outlined in 
table 8.1. The mean cumulative radiation dose received by patients for Hodgkin 
lymphoma was 19.2 Gγ (Median, 19.2 Gγ; Range, 1.2 Gγ - 42.7 Gγ), the mean age of 
diagnosis of Hodgkin lymphoma was 21.73 years (Median, 21 years: Range 16 – 29 
years), the mean age of breast cancer diagnosis was 37.89 years (Median, 37.89 years; 
Range 30 – 47 years) and the mean latency between Hodgkin lymphoma diagnosis and 
breast cancer diagnosis was 15.33 years (Median, 14 years; Range, 7 – 24 years). Most 
patients developed infiltrating ductal carcinoma (11/18, 61%). There were 2 cases each 
of infiltrating lobular carcinoma and comedocarcinoma, and 1 case of tubular carcinoma. 
Breast cancer in the remaining 2 cases was unspecified. Most breast cancers arose in the 
upper outer quadrant of the breast (12 of 18), 2 arose in the lower outer quadrant, 2 in 
the lower inner quadrant and 1 in the upper inner quadrant. Half of the cases were stage 
IIA breast cancers, 5 were stage I, 3 were stage IIB and 1 was stage IIIA. Only 6 of the 
18 Hodgkin lymphoma patients received alkylating agents as part of combined modality 
therapy. 
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Table 8.1 Data for paraffin embedded radiation-induced breast cancer tissue cases. 
  
HL = Hodgkin lymphoma, BC = Breast cancer  
IDC = infiltrating ductal carcinoma, ILC = infiltrating lobular carcinoma, NOS = Cancer type not specified 
LOQ = Lower Outer Quadrant, UOQ = Upper Outer Quadrant, LIQ = Lower Inner Quadrant, UIQ = Upper Inner Quadrant 
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There was no correlation between the radiation dose received and age of diagnosis of 
Hodgkin lymphoma (Pearson’s coefficient = 0.226; p = 0.368) or between radiation 
dose received and age of diagnosis of breast cancer (Pearson’s coefficient = -0.270; p = 
0.279). There was however a moderate inverse correlation between radiation dose 
received and latency in years between diagnosis of Hodgkin lymphoma and breast 
cancer (Pearson’s coefficient = -0.459; p = 0.055) (Fig. 8.1).  
 
Figure 8.1 Relationship between latency of breast cancer diagnosis following Hodgkin lymphoma 
and radiation dose received during radiotherapy for Hodgkin lymphoma. 
HL = Hodgkin lymphoma, BC = Breast cancer 
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There was no correlation between the age of Hodgkin lymphoma diagnosis and latency 
between Hodgkin lymphoma and breast cancer diagnosis (Pearson’s coefficient = -
0.220; p>0.05). There was however a positive correlation between age of Hodgkin 
lymphoma diagnosis and age of breast cancer diagnosis (Pearson’s coefficient = 0.546; 
p = 0.019) and between age of breast cancer diagnosis and latency between diagnosis of 
Hodgkin lymphoma and breast cancer (Pearson’s coefficient = 0.0675; p = 0.002). 
These correlations were expected as the younger a patient is diagnosed with Hodgkin 
lymphoma the younger they are likely to develop breast cancer and the younger a 
patient will develop breast cancer the lower the latency between diagnoses (Fig 8.2 a 
and b). 
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a 
 
b 
 
Figure 8.2 Relationship between age of diagnosis of Hodgkin lymphoma and breast cancer (a) and 
latency between diagnoses and age of breast cancer diagnosis (b). 
HL = Hodgkin lymphoma, BC = Breast cancer 
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There was no significant difference in the age of Hodgkin lymphoma diagnosis, age of 
breast cancer diagnosis, or latency between cases treated with radiation monotherapy 
and those treated with combined modality (T-test: p>0.050). Within the group of 
patients who received methylating chemotherapy there was no significant correlation 
between either the cumulative dose of methylating agent received (Procarbazine dose 
per m
2
) or number of cycles of chemotherapy and age of Hodgkin lymphoma diagnosis, 
age of breast cancer diagnosis and latency between the diagnoses (Pearson’s coefficient: 
p>0.050). However, the small size of the patient cohort limits the statistical power to 
detect significant associations. 
8.2.2 Sporadic breast cancer cohort 
A summary of the data for the sporadic breast cancer cases is outlined in table 8.2. An 
attempt was made to match the radiogenic and sporadic cases by age of diagnosis of 
breast cancer. The mean age of breast cancer diagnosis in the radiogenic cohort was 
37.9 years old with a range between 28 and 47 years. The mean age of breast cancer 
diagnosis in the sporadic cases was 40.6 years old (Median, 41) with a range between 
28 and 49 years. Most cases included areas of infiltrating ductal carcinoma (29 of 33, 
88%), 6 cases had areas of ductal carcinoma in situ, 3 cases had areas of 
comedocarcinoma, 2 cases had areas of infiltrating lobular carcinoma, 2 cases had areas 
of fibrocystic disease and 2 cases had mammary Paget’s disease; which is a malignant 
condition that forms in the skin of the nipple. Information on stage and breast quadrant 
site was not available for these cases. 
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Sample ID Age of BC Diagnosis (years) Breast Cancer Pathology 
SPO1 43 IDC 
SPO2 43 IDC 
SPO3 36 comedocarcinoma 
SPO4 44 IDC 
SPO5 39 IDC + DCIS 
SPO6 46 IDC 
SPO7 42 IDC+DCIS 
SPO8 44 IDC 
SPO9 38 IDC 
SPO10 37 IDC+comedocarcinoma 
SPO11 44 IDC 
SPO12 47 IDC+FCD 
SPO13 35 IDC 
SPO14 47 IDC 
SPO15 43 IDC 
SPO16 38 IDC 
SPO17 37 IDC 
SPO18 41 ILC + FCD 
SPO19 47 IDC + DCIS 
SPO20 32 comedocarcinoma 
SPO21 49 IDC 
SPO22 47 IDC 
SPO23 48 IDC 
SPO24 33 ILC + IDC 
SPO25 32 IDC + DCIS 
SPO26 41 IDC 
SPO27 34 IDC 
SPO28 45 IDC 
SPO29 37 IDC 
SPO30 39 IDC 
SPO31 28 mammary Paget's disease + DCIS 
SPO32 39 IDC + mammary Paget's disease + DCIS 
SPO33 45 IDC 
Table 8.2 Data for paraffin embedded sporadic breast cancer tissue cases. 
 
 
 
 
 
 
IDC = infiltrating ductal carcinoma, ILC = infiltrating lobular carcinoma, DCIS = ductal carcinoma in 
situ, FCD = fibrocystic disease. 
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8.3 Expression of POU2F1 in sporadic and radiogenic breast cancer 
Sections of paraffin embedded tumours (detailed in section 8.2) were analysed for 
expression of POU2F1 by immunohistochemistry (section 2.14). Only nuclei in 
malignant areas of the sections (identified following pathological review) were assessed 
for POU2F1 expression. POU2F1 staining was relatively polarised, with nuclei either 
staining very strongly or not at all. All sporadic breast cancer cases (33/33, 100%) and 
17/18 (94%) radiogenic breast cancer cases were strongly positive for POU2F1 
expression (Fig. 8.3). There was therefore no significant difference in POU2F1 
expression between radiation-induced and sporadic breast cancer cases (Fisher exact 
test: p = 0.353).  Tissue from a single radiogenic breast cancer case, RAD7, (table 8.1) 
was negative for POU2F1 expression (Fig. 8.4). Immunohistochemistry was performed 
twice for this sample, and showed no expression on both occasions. Sections were 
simultaneously stained for c-MYC with positive expression seen in sample RAD7 
indicating that immunohistochemistry did work on this particular sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
241 
 
 
Figure 8.3 Expression of POU2F1 in sporadic and radiogenic breast cancer. 
 
 
Figure 8.4 POU2F1 negative breast cancer sample. 
 
Sections of sporadic and radiogenic breast cancers were tested for POU2F1 expression by 
immunohistochemistry. Both sporadic and radiogenic breast cancer cases displayed strong expression of 
POU2F1 in tumour cell nuclei. Example samples shown ar x40 magnification: SPO18, SPO49, RAD12 
and RAD13. 
Sections of sporadic and radiogenic breast cancers were tested for POU2F1 expression by 
immunohistochemistry. Only RAD7 was negative for POU2F1 expression, indicated by no staining in 
tumour cell nuclei (a). The sample showed positive staining for c-MYC expression in tumour cell nuclei 
(b) which indicated that negative staining of POU2F1 was not due to the sample being unreceptive to 
immunohistochemistry. Images were taken at x40 magnification. 
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8.4 c-MYC expression in radiation-induced and sporadic breast cancer 
Paraffin embedded tumour sections (detailed in section 8.2) were analysed for 
expression of c-MYC by immunohistochemistry (Section 2.14). Only tumour nuclei 
were analysed for c-MYC expression (identified following pathological review). c-
MYC staining was variable within individual tumour sections and heterogeneous 
between patient samples, necessitating the development of an appropriate scoring 
system. Five hundred nuclei from 5 independent fields (100 nuclei per field) were 
analysed for each case. Each nucleus was given a score from 0 - 3 depending on c-MYC 
staining (0 = no expression, 1 = weak expression, 2 = moderate expression, 3 = strong 
expression) (Fig. 8.5). A sample was deemed to be negative for c-MYC expression if 90% 
or more of the nuclei analysed were given an expression score of 0.  Eight of the 
radiation-induced cohort (8/18, 44%) and 16 of the sporadic cohort (16/33, 48%) did not 
express c-MYC in at least 10% of nuclei counted (χ2: p = 0.986). Exposure to ionising 
radiation was not therefore associated with c-MYC-positivity in the cohort of breast 
cancer patients described in this study. Examples of samples with different levels of c-
MYC expression are shown in figure 8.6.  
An overall histoscore was calculated for each sample as a quantitative representation of 
expression. Briefly, the histoscore is the sum of the expression scores given to each 
nuclei within each sample. Taking all cases together, including those with c-MYC 
expression in fewer than 10% of nuclei, expression of c-MYC was higher in the 
radiation-induced cohort than the sporadic cohort (Figure 8.7a) but the difference was 
not statistically significant (Mann-Whitney test: p=0.072). When samples with c-MYC 
expression in fewer than 10% of nuclei were removed from the analysis, expression of 
c-MYC was significantly higher in the radiation-induced cohort (Figure 8.7b) (Mann-
Whitney test: p=0.002).  
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Figure 8.5 c-MYC immunohistochemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sections of sporadic and radiation-induced breast cancers were tested for c-MYC expression by 
immunohistochemistry. An example of a sample with heterogeneous levels of c-MYC expression in 
nuclei of tumour cells is shown (Sample  RAD11). Nuclei with no expression (Expression score = 0: 
black arrow) weak expression (Expression score = 1: purple arrow), moderate expression (Expression 
score = 2: yellow arrow) and strong expression (Expression score =3: red arrow) of c-MYC are shown. 
The image is at x40 magnification. 
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Figure 8.6 c-MYC immunohistochemistry in radiogenic samples. 
 
Sections of sporadic and radiation-induced breast cancers were tested for c-MYC expression by 
immunohistochemistry. Sample RAD13 has no c-MYC expression in nuclei of tumour cells (a) and is 
therefore c-MYC negative. Sample RAD9 (b) shows weak staining and therefore weak c-MYC 
expression in a number of cell nuclei (Histoscore = 70.4). Sample RAD6 (c) shows moderate to strong 
staining in the majority of cell nuclei and therefore has relatively high expression of c-MYC (Histoscore 
= 158.8).    
a RAD13 
b RAD9 
c RAD6 
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Figure 8.7 c-MYC expression in sporadic and radiogenic breast cancers. 
Sections of sporadic (n=33) and radiogenic breast cancers (n=18) were tested for c-MYC expression by 
immunohistochemistry. The overall histoscore for each sample was calculated and the histoscores 
between the cohorts were compared (a). The histoscores between the cohorts after the removal of samples 
which were negative for c-MYC expression (< 10% of nuclei positive for c-MYC) were also compared 
(b). Horizontal bars represent the median values, the boxes represent the 25
th
 and 75
th
 percentiles of the 
data, the error bars represent the 10
th
 and 90
th
 percentiles and the black dots represent values outside the 
10
th
 and 90
th
 percentile. 
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Although the proportion of cases positive for c-MYC expression was not significantly 
different between the radiogenic and sporadic breast cancer cases, the mean c-MYC 
expression level was higher in radiogenic cases. For the purpose of the analysis samples 
were split into 4 groups which represented: no c-MYC expression (histoscore = 0), 
weak expression (histoscore: 1-50), moderate expression (histoscore: 50-100) and high 
expression (histoscore > 100). The proportion of samples with weak, moderate or high 
c-MYC expression was calculated (Fig. 8.8). Three fold more radiogenic samples had 
high c-MYC expression than sporadic samples and 5.5 fold more sporadic samples had 
weak c-MYC expression compared to radiogenic samples. The difference in the 
proportion of samples with different scores of c-MYC expression between the two 
cohorts was significant (χ2: p = 0.045). The results therefore indicated that mean 
expression of c-MYC was higher in radiation-induced breast cancer. 
Histoscore
0 1-50 51-100 >100
P
ro
p
o
rt
io
n
 o
f 
s
a
m
p
le
s
 (
%
)
0
20
40
60
80
100
Sporadic breast cancer
Radiogenic breast cancer
14
7 14
2 3
3
2
6
 
Figure 8.8 Proportion of sporadic and radiogenic breast cancers with different levels of c-MYC 
expression. 
The proportion of samples which have a c-MYC histoscore of: 0, 1-50, 50-100 and >100 in the sporadic 
(n=33) and radiation-induced cohorts (n=18). Above each bar is the number of samples represented in 
that group from each cohort.  
   
 
χ2: P = 0.021 
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There was no correlation between c-MYC expression (histoscore) and age of breast 
cancer diagnosis in the sporadic cohort (Pearson’s coefficient: p = 0.644). There was 
also no correlation between c-MYC expression and age of Hodgkin lymphoma 
diagnosis, age of breast cancer diagnosis or latency between diagnoses in the radiogenic 
cohort (Pearson’s coefficient: p>0.050). There was also no relationship between c-MYC 
expression and pathology of the cancer in either of the cohorts and no relationship 
between expression and stage of the breast cancer in the radiogenic cohort.  
There was however a weak positive correlation between c-MYC expression and 
radiation dose received during radiotherapy (Fig. 8.9a) (Pearson’s coefficient = 0.414; p 
= 0.078). When samples which were deemed negative for c-MYC expression were 
removed from the analysis the correlation between radiation dose received and c-MYC 
expression strengthened but was also of borderline significance (Fig. 8.9b) (Pearson’s 
coefficient = 0.544; p = 0.076).  
In summary, analysis of c-MYC expression in radiogenic and sporadic breast cancer in 
the present study suggests that exposure to ionising radiation does not influence the 
proportion of breast cancers positive for c-MYC expression, but prior exposure to 
radiation associates with higher mean c-MYC expression level; an association which 
may be radiation dose dependent.   
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Figure 8.9 Correlation between radiation dose and c-MYC expression in radiogenic breast cancers. 
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c-MYC expression is expressed against radiation dose received during radiotherapy for Hodgkin 
lymphoma in all tumours of the radiation-induced cohort (a) and only in tumours which expressed c-
MYC (>10% of nuclei positive for c-MYC expression) (b).  
 P= 0.078 
 P= 0.076 
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8.5 c-MYC copy number in radiogenic and sporadic primary breast cancer 
c-MYC copy number was analysed in isolated nuclei from paraffin embedded tissues by 
FISH. A green fluorescent probe (Abbott Molecular, Berkshire, UK) which mapped to 
the centromere of chromosome 8 and an orange fluorescent probe (Abbott Molecular, 
Berkshire, UK) which mapped to c-MYC were used for cytogenetic analysis on slides of 
isolated nuclei (section 2.15). FISH was successful in 9 out of 18 radiogenic breast 
cancer cell nuclei samples and 20 out of 33 sporadic breast cancer cell nuclei samples. 
Hybridisation of both FISH probes on the same slide produced very weak signals in a 
large proportion of the samples which made reliable simultaneous assessment of c-MYC 
and chromosome 8 copy numbers impossible. However, separate hybridisation of the 
probes on independent slides from the same tissue sample produced stronger signals 
which could be counted. The disadvantage of this method of analysis was that the c-
MYC/chromosome 8 status could not be determined in an individual nucleus.  
One hundred nuclei were counted for each probe in each sample (Table 8.3). Copy 
number is indicated at the top of table 8.2 and the number of nuclei which have that 
particular copy number for each probe is shown underneath. Copy number analysis for 
c-MYC is indicated by red shaded numbers and copy number analysis for chromosome 8 
by green shaded numbers. The intensity of the shading indicates the number of nuclei 
which contain that particular copy number. 
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 Copy number of probe 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
SPO2 
5 53 8 6 21 5 2               
38 62                         
SPO5 
7 82 10 1                     
7 79 9 5                     
SPO6 
16 77 4 3                     
17 79 3 1                     
SPO7 
8 44 13 29 3 3                 
8 48 12 25 3 2 1     1         
SPO10 
7 88 3 1   1                 
7 80 9 1 1 1 1               
SPO11 
  62 5 5 14 9 2 2 1           
  66 7 11 8 6       1 1       
SPO13 
16 74   10                     
4 88 6 2                     
SPO15 
10 89 1                       
9 88 3                       
SPO17 
4 56 10 14 8 3 5               
3 49 8 19 13 4 3 1             
SPO18 
10 66 18 6                     
7 66 21 6                     
SPO21 
10 62 12 4 5 4 1 2             
7 62 23 7   1                 
SPO22 
15 76 4 4 1                   
17 76 5 2                     
SPO24 
5 70 15 8 2                   
14 71 13 2                     
SPO26 
9 39 36 16                     
4 50 43 2 1                   
SPO27 
8 67 20 1 2 2                 
13 71 12 3   1                 
SPO28 
4 48 30 18                     
7 83 9 1                     
SPO29 
5 38 15 42                     
6 44 7 43                     
SPO30 
15 73 9 3                     
40 52 6 2                     
SPO31 
12 76 10 1     1               
7 77 14 2                     
SPO32 
7 83 6 4                     
17 67 14 2                     
               
RAD1 
  45 8 32 2 11 2 1             
7 44 16 18 8 4 3               
RAD2 
4 92 2 2                     
9 84 4 3                     
RAD3 
1 48 48 3                     
17 48 35                       
RAD4 
5 92 1 2                     
4 94 2                       
RAD5 
  56 4 32 9                   
2 63 25 9 1                   
RAD8 
1 22 11 40 17 5 1 1 1 1         
9 35 9 40 2 2 2 1             
RAD9 
  41 3 15 22 7 7 2   2     1   
13 79 4 4                     
RAD10 
  53     3 5 1 8 13 6 5 5   1 
11 74 9 5 1                   
RAD17 
2 56 4 6 20 12                 
2 64 5 14 18      1             
Number 
of nuclei 
          
0-5 6-20 21-50 51-75 75-100 
          
0-5 6-20 21-50 51-75 75-100 
Table 8.3 Copy number analysis for c-MYC and chromosome 8 in radiogenic and sporadic breast 
cancer samples. 
 
The number of copies of each probe is indicated at the top of the table. For each sample the number of 
nuclei which contain a particular copy number for c-MYC (red) and chromosome 8 centromere (green) is 
shown. The intensity of each colour is an indicator of the number of nuclei with that particular copy 
number. The number of nuclei which corresponds to each shade is shown by the key at the bottom of the 
table, where darker shades represent higher counts. SPO = sporadic; RAD = radiogenic. 
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A summary of the information in table 8.3 is shown in table 8.4. One of the caveats of 
copy number analysis using isolated nuclei is that it is not possible to determine whether 
the nuclei being counted are from tumour or non-malignant breast cells in any particular 
tissue sample. As an aid to data interpretation, an estimate of the tumour content of each 
tissue sample was made from histopathalogical analysis of the paraffin embedded tissue 
blocks. Twenty four of twenty nine (83%) tissue samples had a tumour content of at 
least 50% and 15/29 (52%) tissue samples had a tumour content of at least 75% (Table 
8.4). The mean tumour content in the sporadic breast cancer series (62.5%) was not 
significantly different from that in the radiogenic breast cancer series (76.6%) (T-test: 
p=0.080). An estimate of tumour content in each tissue samples is available as a 
reference but the copy number counts were not adjusted in subsequent analysis using 
this value. 
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Sample 
Mean c-MYC 
copy number 
Mean  
chromosome 8 
copy number 
Ratio between c-MYC 
and chromosome 8 
copy number 
% of nuclei c-MYC 
copy number ≥ 3 
% of nuclei 
chromosome 8 
copy number ≥ 3 
% of tumour nuclei 
in each sample 
SPO2 3.08 1.62 1.90 42.00 0.00 80 
SPO5 2.05 2.12 0.97 11.00 14.00 55 
SPO6 1.94 1.88 1.03 7.00 4.00 70 
SPO7 2.84 2.84 1.00 48.00 44.00 70 
SPO10 2.02 2.16 0.94 5.00 13.00 85 
SPO11 3.22 2.95 1.09 38.00 34.00 75 
SPO13 2.04 2.06 0.99 10.00 8.00 90 
SPO15 1.94 1.91 1.01 1.00 3.00 45 
SPO17 2.95 3.19 0.92 40.00 48.00 80 
SPO18 2.20 2.26 0.97 24.00 27.00 50 
SPO21 2.58 2.34 1.10 28.00 31.00 70 
SPO22 2.00 1.92 1.04 9.00 7.00 50 
SPO24 2.32 2.03 1.14 25.00 15.00 65 
SPO26 2.59 2.46 1.05 52.00 46.00 75 
SPO27 2.28 2.09 1.09 25.00 16.00 55 
SPO28 2.62 2.04 1.28 48.00 10.00 35 
SPO29 2.94 2.87 1.02 57.00 50.00 80 
SPO30 2.00 1.70 1.18 12.00 8.00 45 
SPO31 2.05 2.11 0.97 12.00 16.00 20 
SPO32 2.07 2.01 1.03 10.00 16.00 50 
       
RAD1 3.38 3.00 1.13 55.00 49.00 75 
RAD2 2.02 2.01 1.00 4.00 7.00 85 
RAD3 2.50 2.18 1.15 51.00 35.00 90 
RAD4 2.00 1.98 1.01 3.00 2.00 30 
RAD5 2.95 2.44 1.21 45.00 35.00 90 
RAD8 3.87 3.10 1.25 77.00 56.00 80 
RAD9 3.49 1.99 1.75 59.00 8.00 90 
RAD10 5.28 2.11 2.51 47.00 15.00 65 
RAD17 3.22 2.91 1.11 42.00 38.00 85 
Table 8.4 Copy number analysis for c-MYC and chromosome 8 in radiogenic and sporadic breast 
cancer samples – summary table. 
 
 
 
For each sample the mean copy number for c-MYC and chromosome 8 was calculated. A mean copy 
number score greater than 2 indicated that there were nuclei with more than 2 copies of c-MYC or 
chromosome 8. The ratio between these values was calculated by dividing mean c-MYC copy number 
score by mean chromosome 8 copy number score. The percentage of nuclei which have a c-MYC and 
chromosome 8 copy number ≥ 3 was also calculated. The estimated percentage of tumour nuclei counted 
in each sample was determined following histopathalogical examination of the paraffin embedded tissue 
samples that the nuclei were extracted from. Green shaded samples show no evidence of a c-MYC copy 
number increase with fewer than 10% of nuclei counted having a c-MYC copy number ≥ 3, and red 
shaded samples show evidence of focal c-MYC amplification. 
253 
 
Although probing nuclei samples with two probes at the same time did not allow 
accurate copy number analysis by eye, some nuclei had strong enough signal for both 
probes to be detected by digital photography. Dual probe analysis was therefore 
performed on selected nuclei samples (SPO15, SPO2, SPO28, SPO18, RAD 9 and RAD 
10) to obtain example images of c-MYC/chromosome 8 copy number status. 
Samples that showed no amplification of c-MYC could be easily identified following 
analysis of the raw and summary copy number data. For samples that did not show 
evidence of c-MYC amplification (shaded green in table 8.4) the mean copy number of 
c-MYC and chromosome 8 was close to 2 and the ratio between the mean copy number 
values was close to 1. Fewer than 10% of the nuclei in these samples had a c-MYC copy 
number ≥ 3. An example of dual probe hybridisation for the non-amplified sample 
SPO15 is shown in figure 8.10. 
  
Figure 8.10 Dual probe FISH of sample SPO15. 
Nuclei which are diploid for chromosome 8 (green probe) and c-MYC (red probe) are circled red. 
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Samples that showed evidence of a specific, intra-chromosomal, c-MYC copy number 
increase (shaded red in table 8.4) had a mean c-MYC copy number greater than 2 which 
was also greater than the mean copy number for chromosome 8. The ratio between the 
mean copy number values was greater than one and the proportion of nuclei which had 
a c-MYC copy number ≥ 3 was more than double that for chromosome 8. Examples of 
nuclei which show a specific copy number increase of c-MYC in samples SPO2, SPO28, 
RAD 9 and RAD 10 are shown in figure 8.11. These samples could be deemed to 
contain cells with a specific c-MYC amplification.  
SPO2 appeared to have a monosomy of chromosome 8 and multiple copies of c-MYC. 
Examples of nuclei with 5 and 6 copies of c-MYC are shown in figure 8.11a. There was 
also a population which was diploid for chromosome 8 and had 4 copies of c-MYC in 
sample SPO2. The majority of nuclei from sample SPO28 were diploid for chromosome 
8 and had either 3 or 4 copies of c-MYC (Fig. 8.11b). 
Specific c-MYC amplified samples from the radiogenic breast cancer cohort (RAD9 and 
RAD10) had many more copies of c-MYC than the specifically amplified sporadic 
breast cancer samples (SPO2 and SPO28). RAD9 had a range between 4 and 13 copies 
of c-MYC per cell diploid for chromosome 8 (Table 8.4). Figure 8.11c shows nuclei 
with increasing copies of c-MYC from left to right in nuclei diploid for chromosome 8. 
The majority of RAD10 amplified nuclei had c-MYC copy numbers above 5 and up to 
14 copies (Table 8.4). Figure 8.11d shows a range of nuclei diploid for chromosome 8 
which have c-MYC amplification in this sample. 
Many of the breast cancer samples are highly heterogeneous in terms of somatic c-MYC 
and chromosome 8 centromere copy number. This is particularly apparent in the 
radiogenic breast cancer samples where the number of copies of c-MYC varied greatly 
within the same nuclei population.  
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Figure 8.11 Dual probe FISH of samples SPO2, SPO28, RAD9 and RAD10. 
 
 
 
 
Nuclei that show examples of specific, intra-chromosomal, c-MYC copy number increase for samples 
SPO2 (a), SPO28 (b), RAD9 (c) and RAD 10 (d). The chromosome 8 FISH probe is green and the c-
MYC FISH probe is red.  The samples all show heterogeneity within the c-MYC amplified cell 
populations with regard to c-MYC copy number. The images are therefore arranged left to right for 
each sample from lowest c-MYC copy number to highest c-MYC copy number. 
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Numerous samples can be characterised by an increase in both c-MYC and chromosome 
8 centromere copy number (un-shaded samples table 8.4). As such, the c-MYC copy 
number increase observed in these samples, such as SPO7, SPO17, SPO18 and SPO29, 
is likely due to chromosome 8 aneuploidy rather than specific c-MYC amplification. An 
example of dual probe hybridisation of SPO18 which contains a population with 3 
copies of chromosome 8 and 3 copies of c-MYC is shown in figure 8.12. 
 
Figure 8.12 Dual probe FISH of sample SPO18. 
 
 
 
 
 
 
 
 
 
Nuclei which are diploid for chromosome 8 (green probe) and c-MYC (red probe) are circled in red, 
nuclei which have 3 copies of chromosome 8 and c-MYC are circled in green. The un-circled nucleus in 
the middle of the image appears to have lost a copy of chromosome 8 and therefore a copy of c-MYC. 
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Some of the samples which displayed aneuploid c-MYC copy number gains also 
displayed evidence of specific c-MYC copy number increase, including RAD5 (41% of 
nuclei had greater than 3 copies of c-MYC compared to 10% for chromosome 8) and 
RAD8 (26 % of nuclei had greater than 4 copies of c-MYC compared to 7% for 
chromosome 8). The nature of the c-MYC copy number increase is ambiguous in these 
samples and without data from analysis using both probes in the same nuclei it is 
difficult to be confident of the mechanisms underlying the increase in c-MYC copy 
number.  
Although dual scoring analysis was not available to determine the exact copy number 
increase mechanism of each sample, the ratio between mean c-MYC copy number and 
mean chromosome 8 copy number alluded to the relative contribution of specific and 
aneuploid copy number increase within each sample. A ratio of 1 indicated that any 
increase in c-MYC copy number was directly proportional to the copy number of 
chromosome 8 in the cell population. A ratio above one indicated that there were more 
copies of c-MYC than chromosome 8 and therefore potentially specific c-MYC 
amplification in a sub-population of the cells. Samples identified as having specific c-
MYC amplifications (SPO2, SPO28, RAD9 and RAD10) had the highest c-
MYC/chromosome 8 ratios (Table 8.4).  
For the purposes of analysis, samples were split into 3 groups depending on the c-
MYC/chromosome 8 ratio. A ratio ≤1.04 was used to identify samples with no evidence 
of specific c-MYC amplification in the sample, a ratio between 1.05-1.14 identified 
samples with some evidence of specific c-MYC amplifications and a ratio ≥1.15 
identified samples where there was strong evidence of specific c-MYC amplification 
within the cell population. The proportion of samples in each cohort which had a c-
MYC/chromosome 8 ratio of ≤1.04, 1.05-1.14 and ≥1.15 was calculated (Fig. 8.13). The 
radiogenic breast cancer cohort had 38% fewer samples with a c-MYC/chromosome 8 
ratio of ≤1.04 and 40 % more samples with a ratio ≥1.15 than the sporadic breast cancer 
cohort. The difference between the two cohorts did not reach statistical significance but 
the small sample size will have limited the power of this analysis (χ2: p = 0.062). 
Nevertheless, these data suggest that there were a higher proportion of samples focally 
amplified at the c-MYC locus in the radiogenic breast cancer cohort compared to the 
sporadic breast cancer cohort.  
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Figure 8.13 c-MYC/chromosome 8 ratio analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The graph shows the percentage of cells in each cohort which have a c-MYC/chromosome 8 ratio of: 
<1.04, 1.05-1.14 and >1.15. Above each bar is the number of samples represented in that group from each 
cohort.  
 χ2: P = 0.078 
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An increase in c-MYC copy number would be biologically relevant regardless of the 
mechanism of amplification. As such, the difference in c-MYC copy number between 
the two cohorts was statistically analysed. A sample was deemed to contain a cell 
population with a particular c-MYC copy number if at least 10 % of the nuclei had that 
number of copies. The percentage of samples which had cell populations with ≥ 3, 4, 5, 
6 or 7 copies of c-MYC in each cohort is shown in figure 8.14. For both cohorts 
approximately 80% of the samples contained cell populations with ≥ 3 copies of c-MYC. 
The proportion of radiogenic samples with populations containing ≥4, 5 and 6 copies 
however was 15%, 30% and 40% higher than the sporadic breast cancer cohort, 
respectively. No sporadic breast cancer samples contained populations with ≥7 copies of 
c-MYC whereas 20% of the radiogenic cohort had cell populations with at least 7 copies 
of c-MYC. This analytical approach is affected by the proportion of malignant and non-
malignant cells in each tissue sample. However, there was no difference in the mean 
tumour cell content between the samples from the two cohorts (T-test: p=0.079). As 
such, samples from the radiogenic breast cancer cohort appeared to have copy number 
gain events which lead to a higher number of copies of c-MYC compared to the sporadic 
breast cancer cohort; however the difference in the proportion of samples was only 
significant at ≥ 6 copies of c-MYC (Fisher Exact Test: p = 0.022).  
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Figure 8.14 The proportion of samples which contained increasing copies of c-MYC. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage of samples in which at least 10% of the nuclei counted contained ≥3, 4, 5, 6 and 7 copies 
of c-MYC from both the sporadic (n=20) and radiation-induced (n=9) breast cancer cohorts. Above each 
group is the Fisher Exact Test p value indicating the difference in the proportion of cases between the two 
cohorts. Above each individual bar is the number of cases for each cohort within that group. Significant 
differences between the two cohorts is represented by an *. 
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The difference in the mean c-MYC copy number per nuclei between the two cohorts was 
also analysed. The radiogenic breast cancer cohort had a higher mean c-MYC copy 
number than the sporadic breast cancer cohort which again indicated that exposure to 
ionising radiation increased the number of c-MYC copies in breast cancer cells. (Mann-
Whitney test: p = 0.030) (Figure 8.15) 
 
Figure 8.15 Mean c-MYC copy number in the sporadic and radiogenic breast cancer cohorts. 
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A comparison was made between the mean c-MYC copy number per nuclei in samples from the sporadic 
(n=20) and radiogenic (n=9) breast cancer cohorts. Horizontal bars represent the median values, the boxes 
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There was no correlation in either cohort between the mean c-MYC copy number and 
age of breast cancer diagnosis (Pearson’s coefficient: Radiation-induced p = 0.130; 
Sporadic p = 0.411). There was also no correlation between mean c-MYC copy number 
and radiation dose received during radiotherapy, age of diagnosis of Hodgkin 
lymphoma or latency in years between Hodgkin lymphoma and breast cancer diagnosis 
(Pearson’s coefficient: p>0.050 for all analyses).  
Analysis of both cohorts combined revealed that there was no correlation between mean 
c-MYC copy number and c-MYC expression (Pearson’s coefficient: p = 0.141) (Table 
8.5). However when the samples were separated into those which had a mean c-MYC 
copy number ≥  3, and those which had a mean c-MYC copy number < 3 there appeared 
to be an association with c-MYC expression (Figure 8.16). Seven samples which had a 
mean c-MYC copy number ≥ 3 had a c-MYC histoscore of 64.26 (Median = 63.4) 
compared to 22.10 (Median = 1) in 22 samples which had a mean c-MYC copy number 
< 3; however the difference was not significant (Mann-Whitney: p = 0.115). It is 
noteworthy that some samples, such as RAD 8, have evidence for increased c-MYC 
copy but are null for c-MYC expression, and others, such as RAD 4, which have no 
increase in c-MYC copy number but have high c-MYC expression. 
In summary, those cancers that developed following exposure to therapeutic ionising 
radiation had a greater proportion of specific copy number increase of c-MYC compared 
to sporadic breast cancers. Exposure to ionising radiation also appeared to increase the 
absolute number of copies of c-MYC however the influence this has on expression of c-
MYC is unclear. The implications of these findings will be discussed in section 8.5. 
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Sample c-MYC Score Histoscore 
SPO2 3.08 147.6 
SPO5 2.05 0 
SPO6 1.94 2 
SPO7 2.84 0 
SPO10 2.02 0 
SPO11 3.24 12.2 
SPO13 2.04 6.6 
SPO15 1.94 0 
SPO17 2.95 47 
SPO18 2.20 0 
SPO21 2.58 29.8 
SPO22 2.00 0 
SPO24 2.32 0 
SPO26 2.59 0 
SPO27 2.28 27.8 
SPO28 2.62 0 
SPO29 2.94 17.2 
SPO30 2.00 72.2 
SPO31 2.05 64.2 
SPO32 2.07 0 
   
RAD1 3.37 156.2 
RAD2 2.02 0 
RAD3 2.53 35.2 
RAD4 2.00 131.5 
RAD5 2.94 52.6 
RAD8 3.87 0 
RAD9 3.89 70.4 
RAD10 5.28 63.4 
RAD17 3.17 0 
Table 8.5 c-MYC copy number and c-MYC expression results of samples from the sporadic and 
radiogenic breast cancer cohorts. 
 
 
 
 
 
Displayed are the calculated mean c-MYC copy number scores and c-MYC expression histoscores of 
samples which were analysed by FISH in the sporadic and radiogenic breast cancer cohorts. SPO = 
Sporadic breast cancer samples; RAD = Radiogenic breast cancer samples. 
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Figure 8.16 Comparison of c-MYC expression between cohorts with different mean c-MYC copy 
number states. 
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8.6 Discussion 
In this chapter the expression of POU2F1 and c-MYC, and the copy number state of c-
MYC, between cohorts of radiogenic and sporadic breast cancer has been compared in 
an attempt to identify a molecular genetic marker of radiogenic breast cancer.  
8.6.1 Breast cancer cohorts 
Material was available from 18 patients who developed breast cancer following 
radiotherapy for Hodgkin lymphoma and 33 age-matched patients who developed 
sporadic breast cancer. 
The mean age of breast cancer diagnosis was 37.89 years in the radiation-induced 
cohort and 40.6 years in the sporadic cohort. In the United Kingdom 81% of breast 
cancer cases occur in women aged 50 years and over (Office for National Statistics, 
Edition: MB1 39). Breast cancer in younger women tends to be more aggressive and 
invasive with approximately 70 % of cancers being infiltrating ductal carcinomas 
(Axelrod et al., 2008). In the present study, 87 % of sporadic breast cancer cases 
contained areas of infiltrating ductal carcinoma, which is consistent with the pathology 
of breast cancer in younger women. There was no information available other than the 
age of breast cancer diagnosis and pathology of the cancer for the sporadic cases. 
As stated previously, the link between ionising radiation therapy for Hodgkin 
lymphoma in young women and the subsequent increased risk of breast cancer is well 
established (reviewed in Chapter 1). The radiogenic breast cancer cohort used in the 
present study had characteristics consistent with similar cohorts used in previous studies. 
For example, for the majority of cases, cancer developed following mantle field 
radiotherapy in the upper outer quadrant of the breast, as this region of the breast is 
exposed to the largest dose of ionising radiation (Christie et al., 1998). In the present 
study 66 % of breast cancers in the radiogenic cohort developed in this region and is 
therefore consistent with previous reports.  
The latency between exposure to ionising radiation and development of cancer is a key 
characteristic of radiation-induced carcinogenesis, and is most likely due to radiation-
induced genetic instability which causes subsequent accumulation of cell transforming 
mutations over time (Allan and Travis, 2005). The mean latency between age of 
diagnosis of Hodgkin lymphoma and breast cancer in the present study was 15.33 years 
and was consistent with the mean latency reported in other studies (15-20 years) 
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(Hancock et al., 1993; Tinger et al., 1997; Travis et al., 2003; van Leeuwen et al., 2003; 
Wahner-Roedler et al., 2003; Basu et al., 2008; De Bruin et al., 2009; Elkin et al., 
2011).   
Precise estimates of dose to the affected area of the breast allow detailed analysis of the 
effects of ionising radiation on breast transformation. In the present study, a borderline 
significant inverse linear relationship between radiation dose received at the affected 
area of the breast and latency between radiotherapy for Hodgkin lymphoma and breast 
cancer diagnosis was identified. Travis et al. (2003) showed that 60 % of individuals 
who had received < 4 Gγ of ionising radiation to the affected area of the breast 
developed breast cancer more than 20 years after exposure to ionising radiation; 
however 65.6 % of individuals who had received ≥ 4 Gγ of ionising radiation to the 
affected area of the breast developed breast cancer within 20 years of exposure to 
ionising radiation. The present study was the first study to identify a putative linear 
relationship between radiation dose and latency of breast cancer development following 
radiotherapy for Hodgkin lymphoma. 
Higher radiation doses increase the amount of DNA damage in cells (Chadwick and 
Leenhouts, 2011). The probability of a cell acquiring multiple mutations therefore 
increases with increasing radiation dose. Moreover, the probability of inactivating a key 
gene in a cellular pathway that controls spontaneous mutation frequency also 
presumably increases as a function of increasing radiation dose. Cells that acquire a 
mutator phenotype take less time to acquire genetic alterations required for 
transformation. Taken together, these observations provide a plausible explanation for 
the inverse relationship between dose and latency in radiogenic cancer. 
In the case of mantle field radiotherapy for Hodgkin lymphoma, higher radiation dose 
also means a greater number of fractionated doses of irradiation (approximately 2 Gγ 
per fractionated dose) (Hancock et al., 1993; De Bruin et al., 2009). Fractionated dosing 
is established as a mechanism for selecting cells with a mutator phenotype (Hampson et 
al., 1997), further promoting and accelerating transformation to the malignant state.   
In summary, the radiogenic breast cancer cohort utilised in the present study display 
characteristics which are consistent with radiation-induced breast cancer. 
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8.6.2 POU2F1 
POU2F1 was an interesting candidate for a molecular genetic marker of radiogenic 
breast cancer as it was focally deleted following exposure to ionising radiation in MCF-
10A cells had with a concomitant reduction in protein expression, and has an 
established role in cellular DNA damage response (Meighan-Mantha et al., 1999; Zhao 
et al., 2000; Jin et al., 2001; Fan et al., 2002; Schild-Poulter et al., 2003; Tantin et al., 
2005; Schild-Poulter et al., 2007; Maekawa et al., 2008; Saha et al., 2010; Wang and 
Jin, 2010). In particular, the role played by POU2F1 as a transcriptional regulator of 
BER genes following oxidative damage was intriguing as both radiation and oestrogen 
metabolites (which synergise to promote breast transformation) can both induce 
oxidative DNA damage (Yager and Davidson, 2006). It can therefore be speculated that 
POU2F1 deletion, and subsequent reduction in protein expression, may make young 
women exposed to ionising radiation at greater risk of developing breast cancer.  
No spontaneous breast cancer samples lost POU2F1 expression, yet 1 radiation-induced 
sample (RAD7) displayed complete loss of expression. This sample had received the 
sixth highest dose of radiation (31.1 Gγ), was from the youngest individual diagnosed 
with breast cancer (28 years), had only a latency of 10 years between Hodgkin 
lymphoma and breast cancer diagnosis, was an infiltrating ductal carcinoma and was a 
low stage cancer (Stage I). However, the identification of only 1 breast cancer case with 
no POU2F1 expression indicates that loss of POU2F1 expression is not a common event 
in radiogenic breast cancer.  
It is possible that reduced, but not lost, expression of POU2F1 would increase genetic 
instability in cells. For example, loss of only 60% of basal POU2F1 expression was 
enough to abrogate BER gene induction (Saha et al., 2010). Due to the strong staining 
of the IHC antibody in the present study it was only possible to positively or negatively 
assess POU2F1 expression. It would be interesting to use other methods of protein 
quantification, or to reanalyse the samples by IHC using different dilutions of the 
antibody, to assess if more subtle differences in POU2F1 expression between the 
radiogenic and spontaneous breast cancer cohorts existed. It would also be interesting to 
assess the incidence of POU2F1 deletion between radiogenic and spontaneous breast 
cancer. Irradiated MCF-10A cells showed almost complete loss of POU2F1 expression 
even though one allele of POU2F1 remained; however it is also possible that other 
mutations affected expression of the protein. It is possible that mono-allelic deletion of 
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POU2F1 in a diploid cell may reduce POU2F1 expression to a mutagenic but non-lethal 
level through a mechanism involving haploinsufficiency. Unfortunately, due to poor 
probe hybridisation (data not shown) it was not possible to assess the copy number state 
of POU2F1 by FISH analysis in primary patient material in the present study.  
8.6.3 c-MYC copy number  
A focal amplification of c-MYC and an associated increase in c-MYC expression in 
MCF-10A cells following exposure to exogenous oestrogen and ionising radiation was 
identified in the present study. Amplification of c-MYC has previously been linked with 
radiation-carcinogenesis and in particular has been identified in breast cancer 
developing in atomic bomb survivors (Felber et al., 1992; Miura et al., 2008; Manner et 
al., 2010; Guo et al., 2011). c-MYC is an established oncogene which initiates cell 
transformation and increases genetic instability (Prochownik and Li, 2007; Xu et al., 
2010). Amplification of c-MYC is therefore a strong candidate as an early genetic event 
and molecular marker of radiogenic breast cancer. 
c-MYC copy number state was analysed in isolated nuclei from radiogenic and sporadic 
breast cancer tissues. One of the caveats of copy number analysis using isolated nuclei 
is that it is not possible to determine whether the nuclei being counted are from tumour 
or non-malignant breast cells in any particular tissue sample. Adjusting copy number 
counts according to relative tumour content would rely on the assumption that only 
nuclei from malignant cells contain a c-MYC copy number increase. Field cancerization 
theory has demonstrated that non-malignant and malignant cells adjacent to each other 
in a tissue can share genetic alterations as both cell populations are descended from the 
same non-transformed, but mutated, cellular ancestor (Slaughter et al., 1953; Braakhuis 
et al., 2003; Heaphy et al., 2009). If c-MYC amplification is an early event in breast 
carcinogenesis, nuclei from pre-malignant tissue may also contain copy number 
increase of c-MYC. One approach to test this hypothesis is to use laser capture 
microscopy to purify and analyse malignant and pre-malignant cells separately. 
c-MYC copy number analysis indicated that the incidence of cases that contained a 
specific copy number increase of c-MYC  was higher in the radiogenic breast cancer 
cohort than the sporadic breast cancer cohort. Furthermore, the absolute number of 
copies of c-MYC was higher in radiogenic breast cancer compared to sporadic breast 
cancer indicating a tendency towards the acquisition of higher-copy number gains. 
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These data therefore indicate that c-MYC amplification is more common in radiogenic 
breast cancer than sporadic breast cancer.  
Results from the present study agree with the findings of Miura et al. (2008) which 
investigated c-MYC amplification in breast cancer cases from survivors of the atomic 
bomb at Nagasaki. The study reported that the incidence of breast cancers with c-MYC 
amplification (at least 2 fold greater number of c-MYC copies compared to chromosome 
8 copies) was higher in individuals exposed to ionising radiation compared to an age 
matched control group and that the incidence of c-MYC amplification increased as 
estimated radiation dose increased. We did not observe an association between the 
incidence of c-MYC amplification and radiation dose received by an individual in the 
present study; however the number of cases analysed was small. Also, the doses 
received by the Hodgkin lymphoma patients were relatively high compared to atomic 
bomb survivors. A difference in c-MYC incidence was observed by Miura et al. (2008) 
between groups of individuals who had received < 1.2 Gγ and ≥ 1.2 Gγ. The lowest 
dose received by a Hodgkin lymphoma patient was 1.2 Gγ. It is therefore possible that 
the relationship between c-MYC amplification incidence and dose is lost at the higher 
dose range. 
Miura et al. (2008) also reported an association between c-MYC amplification and 
HER2 amplification in atomic bomb survivors. Amplifications of c-MYC and HER2 are 
closely associated in breast cancer (Park et al., 2005). It has been demonstrated that 
radiation exposure during breast maturation increases the risk of HER2 amplification 
and increased incidence of HER2 positive breast cancer was identified in radiogenic 
breast cancer from Hodgkin lymphoma patients (Castiglioni et al., 2007; Sanna et al., 
2007; Broeks et al., 2010). The increased incidence of c-MYC amplification identified 
in the present study may therefore in part relate to an increase in incidence of HER2 
positive breast cancer.  
Caution must be exercised when comparing results between the atomic bomb study and 
the present study as the breast cancer cohorts and circumstances of radiation exposure 
were very different. For example, the incidence of breast cancer per unit population in 
Japan is lower than in Western populations, mainly due to lifestyle factors such as 
contraceptive methods and alcohol intake (Iwasaki and Tsugane, 2011). Differences in 
genetic background between Asian and European populations may also impact on breast 
cancer risk, radiation sensitivity or risk of oncogene amplification. Also, although both 
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cohorts are from populations which have an established increased risk of breast cancer 
following exposure to ionising radiation, the atomic bomb survivors were exposed to a 
single dose of irradiation compared to fractionated doses in Hodgkin lymphoma patients. 
Despite these differences the incidence of c-MYC amplification appears to be elevated 
in both cohorts compared to spontaneous breast cancer, and the common factor which 
links the cohorts is exposure to ionising radiation significantly above background levels.  
c-MYC amplification has also been implicated in radiation-induced secondary 
angiosarcoma (AS) following radiotherapy for breast cancer and radiation-induced skin 
cancer in rats (Felber et al., 1992; Manner et al., 2010; Guo et al., 2011). c-MYC 
amplification was identified in 100% of radiation-induced secondary AS on the breast 
but was not identified in any radiation-induced atypical vascular lesions (AVL’s), which 
are reported to be pre-malignant precursors to secondary AS (Guo et al., 2011), 
suggesting that c-MYC amplification is not an initiating event, but develops later  
during tumour formation. However, the role of AVL’s as precursors to AS is not 
established and AVL’s are considered benign entities (Mandrell et al., 2010). The 
absence of c-MYC amplification in AVL’s may not therefore rule out c-MYC 
amplification as being an early event in secondary AS.  
It is possible that c-MYC amplification is a common late stage event in radiogenic breast 
cancer; however the mechanism by which c-MYC could be amplified due to ionising 
radiation many years after the initial exposure is unclear. The identification of radiation-
induced c-MYC amplification in MCF-10A cells prior to cell transformation, and 
increased incidence of amplification in two different cohorts of radiogenic breast cancer 
implicate c-MYC amplification as a common early genetic event. Based on the field 
cancerization theory discussed previously, the identification of c-MYC copy number 
increases in radiation exposed pre-malignant breast tissue would suggest an early role 
for c-MYC amplification during transformation and would be an interesting line of 
investigation in future studies. 
8.6.4 c-MYC protein expression 
Protein expression analysis showed that mean c-MYC expression was higher in the 
radiogenic breast cancer cohort compared to the sporadic cohort and identified a 
borderline significant correlation between radiation dose and expression. There was no 
difference between the cohorts in the proportion of cases which showed no c-MYC 
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expression; however there was an increase in the proportion of samples with high c-
MYC expression. Expression of c-MYC has not previously been analysed in radiogenic 
cancer. 
It has been demonstrated in vitro that increased c-MYC copy number increases c-MYC 
expression; however there was no correlation between c-MYC copy number and 
expression in primary breast cancer tissue in the present study. The lack of correlation 
will in part be due to the low number of cases for which both copy number and 
expression data was available, however inconsistency between c-MYC amplification and 
protein expression are not uncommon and has been described in breast, pancreatic, 
bladder and colon cancer studies (Erisman et al., 1985; Sauter et al., 1995; Chrzan et al., 
2001b; Schleger et al., 2002). Cases in which protein expression appears inconsistent to 
gene copy number are likely to be due to gene regulatory mechanisms such as 
transcriptional activation/repression and mRNA/protein stability affecting expression of 
the protein (Xu et al., 2010).  
Despite this, a non-significant 3 fold increase in mean c-MYC expression in cases with 
a mean c-MYC copy number score > 3 was identified. Likewise, (Blancato et al., 2004) 
reported a correlation between c-MYC amplification and expression in breast cancer. 
The increased incidence of c-MYC amplification and increased tendency of higher copy 
number gains in radiogenic breast cancer may therefore partly explain increased c-MYC 
expression in radiogenic breast cancer; however the limited number of radiogenic 
samples for which there is copy number data makes confirmation of this hypothesis 
difficult at the present time. 
The observed dose dependant increase in c-MYC expression in primary tissue samples 
may be caused via positive selection of cells which express high levels of c-MYC. 
Fractionated dose exposure causes multiple cycles of cell death and re-population in the 
irradiated area (Phillips et al., 2006; Vlashi et al., 2009). If c-MYC expression confers a 
growth advantage during cycles of cell death and re-population then fractionated dose 
exposure may select for cells with increasing expression of c-MYC. Over-expression of 
c-MYC increases cell proliferation which would provide an obvious growth advantage 
during repopulation of an irradiated area (Dang et al., 2006; Meyer and Penn, 2008; Xu 
et al., 2010). c-MYC has also been implicated in increasing radiation resistance, which 
would reduce cell death during repeated exposure to ionising radiation, also leading to 
an increase of c-MYC expressing cells (Chiang et al., 1998; Davey et al., 2004; Kim et 
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al., 2011a). The present study has demonstrated that c-MYC amplified cells have an 
expression profile with features similar to the cancer stem cell, which is known to be a 
radiation-resistant cell population and is a favoured candidate for causing radiation-
resistance in breast cancer (Vlashi et al., 2009). Over-expression of transcriptional 
activators of c-MYC such as JAGGED-1, NOTCH-1 and the WNT/β-CATENIN 
pathway have been reported in radiation-resistant cancer stem cell populations, 
providing further evidence for a putative role for c-MYC in radiation-resistance 
(Phillips et al., 2006; Woodward et al., 2007). Selection of cell populations with 
increasing expression of c-MYC during fractionated radiation exposure may therefore 
explain the apparent dose dependant relationship in the Hodgkin lymphoma cohort. 
Selection of cell populations with high levels of c-MYC would also explain the 
presence of cell populations which over-express c-MYC but do not have c-MYC 
amplification.  
It is possible that the radiation induced c-MYC amplification model and c-MYC 
selection model work synergistically in circumstances of repeat exposure to ionising 
radiation. Ionising radiation may induce amplification of c-MYC in a sub-population of 
cells which is subsequently selected for during cycles of cell death and re-population 
during repeat radiation exposure.  
8.6.5 c-MYC and oestrogen in radiogenic breast cancer 
The relationship between oestrogen and c-MYC amplification in radiogenic breast 
carcinogenesis must also be considered, as loss of circulating oestrogen can attenuate 
the risk of radiogenic breast cancer (Travis et al., 2003; van Leeuwen et al., 2003).  
Over-expression of c-MYC is insufficient on its own to induce cell transformation 
(Land et al., 1983; Xu et al., 2010). Further genetic mutations are therefore needed. 
Exposure to oestrogen and its metabolites may promote the accumulation of mutations 
needed for the development of breast cancer. Loss of circulating oestrogen may reduce 
the probability of accumulating these alterations and therefore attenuate breast cancer 
risk.  
c-MYC is a downstream transcriptional target of ERα and is up-regulated in ERα 
positive breast cancer. Following c-MYC amplification, high circulating oestrogen 
concentrations may further enhance c-MYC expression and therefore increase genetic 
instability. Oestrogen has also been reported to stabilise c-MYC protein (Rodrik et al., 
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2006). It is postulated that stabilisation is mediated by ERα but this yet to be 
conclusively demonstrated. Loss of oestrogen exposure may therefore lead to c-MYC 
degradation and attenuation of c-MYC oncogenic activity.  
Conversely, previous studies have reported an increased incidence of basal-like breast 
cancers (which are ERα negative) in radiogenic cohorts compared to age matched 
sporadic cohorts (Sanna et al., 2007; Broeks et al., 2010). Over-expression of c-MYC is 
common in the basal-like breast cancer subtype and is believed to mimic a large part of 
ER transcriptional regulation; suggesting a mechanism via which these cancers attain 
oestrogen independence (Alles et al., 2009). Epithelial to mesenchymal transition is 
implicated in the development of basal-like breast cancers and c-MYC over-expression 
has been shown to induce EMT (Cowling and Cole, 2007; Trimboli et al., 2008; Liu et 
al., 2009; Smith et al., 2009; Cho et al., 2010). The present study has demonstrated that 
c-MYC amplification induced phenotypic and gene expression changes related to EMT 
in MCF-10A cells. c-MYC over-expression may therefore be an early event in the 
induction of basal–like breast cancer. It should be noted however, that although c-MYC 
over-expression has been associated with basal-like sporadic breast cancer, c-MYC 
amplification was reported to be rare (Rodriguez-Pinilla et al., 2007). The higher 
incidence of c-MYC amplification in radiogenic breast cancer may therefore suggest a 
novel mechanism for the induction of basal-like breast cancer not observed in sporadic 
cancer. Investigation of c-MYC copy number status in radiogenic basal-like breast 
cancers would allow this hypothesis to be tested. 
In summary, evidence has been provided that the incidence of c-MYC amplification and 
expression of c-MYC is higher in radiogenic breast cancer compared to sporadic breast 
cancer and may therefore be a molecular marker of radiogenic breast cancer. Whether c-
MYC amplification occurs early or late during transformation remains unclear; however 
it is hypothesised that ionising radiation induces c-MYC amplification at the time of 
exposure which contributes to the accumulation of mutations ultimately leading to 
cancer. Whether c-MYC amplification is a common radiation-induced event in all cancer 
types is also unknown and investigation of other radiogenic cancer types is warranted. 
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Chapter 9: Final Discussion 
The aim of the present study was to develop an in vitro model of radiation-induced 
breast epithelial cell transformation in order to identify copy number alterations induced 
by ionising radiation exposure, which in turn could be investigated in a cohort of 
primary human radiogenic breast cancer samples. The overall aim was to identify 
alterations that could be used as genetic markers to identify radiogenic breast cancer and 
to gain further understanding of the molecular genetic mechanisms underlying 
radiogenic breast cancer development. Two in vitro models were investigated in detail, 
where cells were exposed to 5 Gγ fractionated doses of X-rays either with our without 
the addition of exogenous oestrogen. Cell populations from both models contained 
radiation-induced copy number alterations and demonstrated phenotypic changes 
associated with cell transformation. However cell transformation was not fully 
confirmed in either cell model.  
Copy number alterations were identified in cell populations from both models that were 
putatively related to radiogenic cancer. For example, a region of mono-allelic deletion 
was observed on chromosome 11q containing ATM and putative tumour suppressor 
genes CADM1 and CUL5 that had previously been reported as an area of LOH 
following radiation-induced breast epithelial cell transformation (Roy et al., 2006; Du et 
al., 2010b). Copy number loss of this region was not investigated further in primary 
human radiogenic breast cancers in the present study but may be a region of interest in 
future work.  
Focal copy number alterations which affected the POU2F1 locus (deletion) and c-MYC 
locus (copy number gain) were selected for further investigation in primary human 
radiogenic breast samples. POU2F1 was chosen for further study due to its known 
function in mediating the response to DNA damage and maintaining genetic stability 
(Meighan-Mantha et al., 1999; Zhao et al., 2000; Jin et al., 2001; Fan et al., 2002; 
Schild-Poulter et al., 2003; Tantin et al., 2005; Maekawa et al., 2008; Nenoi et al., 2009; 
Saha et al., 2010). The latent development of breast cancer following radiation exposure 
has been hypothesised to be due to initiating alterations that increase genetic instability 
and allow the gradual accumulation of transforming mutations. Loss of POU2F1 
function is predicted to cause an increase in genetic instability, identifying deletion of 
the POU2F1 locus as an interesting novel target for further investigation. Furthermore, 
POU2F1 is involved in BRCA1 mediated transcriptional activation of ERα (Hosey et al., 
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2007). Specifically, POU2F1 was shown to simultaneously occupy the ESR1 (ERα 
gene) promoter with BRCA1, suggesting that POU2F1 and BRCA1 heterodimerise to 
regulate ESR1. Consistent with this model, siRNA-mediated depletion of endogenous 
POU2F1 abrogates BRCA1 binding to the ESR1 promoter and reduces expression of 
ERα (Hosey et al., 2007). BRCA1 mutant breast cancers are more likely to be ERα 
negative (Lakhani et al., 2005). Likewise, radiogenic breast cancer is also more likely to 
be ERα negative compared to sporadic breast cancer (Foulkes et al., 2004; Broeks et al., 
2010; Dores et al., 2010), with loss of POU2F1 via gene deletion as one possible 
mechanism.  
POU2F1 expression was not lost in any sporadic breast cancer tissue samples analysed 
(n=33) and in only one radiogenic breast cancer tissue sample (n=18) which indicates 
that POU2F1 expression loss would not be a good marker for identifying radiation-
induced breast cancer. Copy number state of the POU2F1 locus was not analysed in the 
available primary human breast cancer tissues, although this would be an interesting 
line of further investigation especially given the observed deletion in vitro. However, 
the low frequency of protein expression loss in the primary human tissue samples makes 
it unlikely that POU2F1 deletion is a common event in radiogenic breast cancer. 
c-MYC was focally amplified (> 1 copy number increase) in MCF-10A and further 
chromosomal alterations of chromosome 8q which affected the c-MYC locus were also 
identified. Re-arrangement of chromosome 8q was previously identified in a radiation 
transformed breast epithelial cell population (Unger et al., 2010) and the incidence of c-
MYC amplification (2 fold increase in c-MYC copy number over chromosome 8 copy 
number) was reported to be higher in breast cancers from radiation exposed atomic 
bomb survivors compared to individuals not exposed to irradiation (Miura et al., 2008). 
The incidence of specific copy number increases of c-MYC and the mean number of c-
MYC copies was higher in the radiogenic breast cancer tissue samples than the sporadic 
breast cancer tissues analysed in the present study. Evidence therefore suggests that 
chromosomal rearrangements involving chromosome 8q and the c-MYC locus may be 
induced by ionising radiation exposure, potentially due to the presence of fragile sites 
that span the c-MYC locus, and that copy number gain may be a frequent outcome of 
these rearrangements (Ferber et al., 2004; Arlt et al., 2006).  
A recent study by Best et al. (2011) reported that two genetic variants which form a 
haplotype that reduces basal expression and abrogates radiation-induced expression of 
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the transcriptional repressor PRDM1, was significantly associated with development of 
breast cancer following radiotherapy for Hodgkin lymphoma. PRDM1 is a tumour 
suppressor in activated diffuse large B cell lymphoma (Calado et al., 2010; 
Mandelbaum et al., 2010) and is frequently lost in many cancers including solid 
tumours (Beroukhim et al., 2010). PRDM1 is located on chromosome 6q; LOH of 
which was shown to be more common in radiogenic breast cancer than sporadic breast 
cancer, although markers at the PRDM1 locus were not specifically investigated 
(Behrens et al., 2000). PRDM1 is involved in a variety of cellular processes such as 
proliferation, differentiation and apoptosis and is known to negatively regulate c-MYC 
(Lin et al., 1997; Calame, 2010). Best et al. (2011) showed that cells homozygous for 
the haplotype that reduces PRDM1 expression abrogated c-MYC repression following 
ionising radiation and therefore suggested a role for PRDM1 as a radiation-responsive 
tumour suppressor. Overall, evidence suggests that dysregulation of c-MYC expression 
is an important event in the aetiology of radiogenic breast cancer. Loss of PRDM1 
expression and amplification of c-MYC is predicted to result in the same phenotype.   
Evidence that c-MYC copy number increase is induced by ionising radiation suggests 
that c-MYC amplification may be an important initiator of c-MYC dysregulation in 
some cases of radiogenic breast cancer. 
The value of c-MYC amplification as a marker of radiogenic breast cancer is 
questionable, as c-MYC amplification is an established event in sporadic breast cancer 
and has been reported to be present in approximately 15% of all breast cancer cases 
(Deming et al., 2000). However, it is possible that a fraction of sporadic breast cancer 
cases might have a radiation aetiology and that c-MYC amplification or c-MYC over-
expression in such “sporadic” cases may reflect this. Exposure to ionising radiation is 
ubiquitous, and is derived from both artificial and natural sources, and although the dose 
of irradiation for most people is very low, exposure to radiation may still cause DNA 
damage and could contribute to cancer risk. If the c-MYC locus is susceptible to 
radiation-induced amplification or rearrangement, as evidence suggests, it is possible 
that a proportion of sporadic cancers that display these genetic events do in fact have a 
radiation aetiology. Exploring the incidence of c-MYC amplification and c-MYC over-
expression in other radiogenic solid tumours would be an interesting line of future 
investigation, and could provide further evidence that c-MYC dysregulation is a 
common radiation-induced event.  
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If c-MYC amplification is an early event in radiogenic breast cancer, it is theoretically 
possible that following relatively high doses of radiation exposure monitoring 
individuals for c-MYC amplification or c-MYC expression increase in areas of the 
breast exposed to radiation may be an early indicator of risk of developing breast cancer 
later in life; however current technology would make this an invasive and unrealistic 
procedure to undertake. The development and application of targeted therapy against 
cells with c-MYC dysregulation could prove efficacious in the treatment of radiogenic 
breast cancer and might also be of value as prophylaxis to inhibit the outgrowth of c-
MYC-deregulated cells following radiation exposure.  
Evidence suggests that oestrogen and radiation interact to drive transformation in the 
breast (Travis et al., 2003; van Leeuwen et al., 2003), although the mechanisms 
responsible remain to be elucidated. The contribution of the pro-proliferative and 
genotoxic effects of oestrogen on the accumulation of transforming mutations following 
a radiation-induced initiating event, such as c-MYC dysregulation, remains a robust 
hypothesis. Interestingly, the PRDM1 repressive haplotype discovered by Best et al. 
(2011) only associated with breast cancer development in young Hodgkin lymphoma 
patients that received radiotherapy (median age = 15.6) and not with older Hodgkin 
lymphoma patients (median age = 24) (although the number of adult cases was smaller). 
If the repressive effect of PRDM1 mediates radiogenic breast cancer development via c-
MYC dysregulation then this result suggests that an interaction between c-MYC over-
expression and oestrogen exposure may exist. It should be noted however that 
repression of PRDM1 will have effects other than dysregulation of c-MYC which might 
also contribute to radiogenic breast transformation.  
In summary, the present study has identified radiation-induced genetic alterations in an 
in vitro model system that was also observed in primary human radiogenic breast tissue 
samples. Specifically, this study is the first to identify a radiation-induced focal copy 
number increase of the c-MYC locus in breast epithelial cells in vitro and the first to 
implicate increased incidence of c-MYC amplification, increased absolute copy number 
of c-MYC and increased c-MYC expression in radiogenic breast cancer samples from 
Hodgkin lymphoma patients compared to sporadic breast cancer.     
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9.1 Future directions 
A number of further investigations would be desirable following the findings of the 
present study. 
9.1.1 SNP array analysis 
A repeat of the irradiation series may be useful to attempt to recreate copy number 
alterations identified in the present study. Recreation of copy number changes would 
provide strong evidence that an alteration is preferentially induced by ionising radiation.    
9.1.2 POU2F1 function 
Evidence suggests that loss of POU2F1 renders cells sensitive to DNA damaging agents. 
Ectopic expression of POU2F1 following transfection of an expression vector could be 
used to test whether this phenotype can be rescued in POU2F1-deleted MCF-10A cells. 
Likewise, POU2F1 RNAi experiments in un-irradiated MCF-10A cells could elucidate 
whether loss of POU2F1 expression sensitised cells to DNA damaging agents, including 
ionising radiation, in a fully controlled isogenic system. Chromatin 
immunoprecipitation experiments could also determine if POU2F1 interacts with 
putative POU2F1 binding sites in DNA repair genes which show altered expression. 
These experiments would further elucidate the role of POU2F1 in cellular response to 
ionising radiation. 
9.1.3 Phenotypic characterisation of c-MYC amplified cells 
Further phenotypic characterisation of the Second 5 Gγ series, particularly in 
populations with increased c-MYC copy number and expression could provide further 
evidence that c-MYC induces EMT. For example, cell migration and invasion assays 
could potentially reveal further EMT related phenotypes.  
9.1.4 Mutation analysis in primary tissue samples 
Copy number analysis of the POU2F1 locus in radiogenic and sporadic breast cancer 
samples could identify whether deletion of POU2F1 is common in radiogenic breast 
cancer.  
Re-analysis of c-MYC copy number status in tissue sections in situ rather than isolated 
nuclei could also provide more conclusive information on the incidence of c-MYC 
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amplification in breast tumour cells, and allow a more informative correlation with 
expression of c-MYC using the IHC data. Analysis of c-MYC copy number status in 
primary human pre-malignant cells could identify whether c-MYC amplification was an 
early event in radiogenic breast transformation. 
Analysis of c-MYC amplification and c-MYC expression in other human tissues 
susceptible to radiation transformation, such as the pancreas and stomach, by FISH and 
IHC could provide further information on whether radiation-induced c-MYC 
amplification is common to all tissue types or is a tissue specific phenomenon. 
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Appendices 
1.1 List of genes discussed in text and genes that encode proteins discussed in text. 
ABL Abelson murine leukemia viral oncogene homolog1  
APC Adenomatous polyposis coli 
APEX1/2 Apurinic/apyrimidinic endonuclease 
ARF ADP-ribosylation factor 
ARLF Aprataxin- and PNK-Like Factor 
ASAP3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 
ATM Ataxia-telangiectasia mutated 
BCL6 B-cell CLL/lymphoma 6 
BCR Breakpoint Cluster Region 
BMP Bone morphogenetic protein  
BMPR1A  Bone morphogenetic protein receptor, type IA 
BPIR1 BRCA1 interacting protein C-terminal helicase 1 
BRCA1/2 Breast cancer. early onset 
CADM1 Cell adhesion molecule 1 
CCL20 Chemokine (C-C motif) ligand 20 
CCND2/E1/E2/A2 Cyclin  
CCR6 chemokine receptor 6 
CD24/44/247 Cluster of differentiation  
CDC25A/B Cell division cycle 25 homolog  
CDH1 E-cadherin (epithelial)  
CDH2 N-cadherin (neuronal) 
CDK4 Cyclin dependant kinase 4 
CDNK2A/B Cyclin-dependent kinase inhibitor 2 
CHEK1/2 Checkpoint homolog 
CHORDC1 Cysteine and histidine-rich domain containing 1 
c-JUN Mitogen-activated protein kinase 9 
CLIP2 CAP-GLY domain containing linker protein 2 
COMT Catechol O-methyltransferase  
CPM Carboxypeptidase M 
CUL5 Cullin 5 
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 
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DCC Deleted in colorectal cancer 
DCP2 DCP2 decapping enzyme homolog 
DKK1 Dickkopf homolog 1  
DNA-PKcs Protein kinase, DNA-activated, catalytic polypeptide1  
DP-1 Rranscription factor Dp-1  
DUSP27 Dual specificity phosphatase 27 
E2F1/2/4/5 E2F transcription factor  
EB1 Microtubule-associated protein, RP/EB family, member 1 
EGR1 Early growth response 1 
EP300 E1A binding protein p300 
ERBB v-erb-b2 erythroblastic leukemia viral oncogene homolog 
ERK Mitogen-activated protein kinase 1 
EX01 Exonuclease 1 
EYA2 Eyes absent homolog 2  
FAK Focal adhesion kinase 
FAM19A1 Family with sequence similarity 19 (chemokine (C-C motif)-
like), member A1 
FGFBP1 Fibroblast growth factor binding protein 1 
FGFR2 Fibroblast growth factor receptor 2 
FIN Fibronectin 
FOXO1 Forkhead box O1 
FRA-1 Fos-related antigen-1 
FRA8C/D Fragile site 
GADD45 Growth arrest and DNA-damage-inducible 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GCLM Glutamate-cysteine ligase, modifier subunit 
GPA33 Glycoprotein A33  
GRID1 Glutamate receptor, ionotropic, delta 1 
GSK3 Glycogen synthase kinase 3 
GST Glutathione S-transferase  
H19 H19, imprinted maternally expressed transcript (non-protein 
coding) 
H2AFX H2A histone family, member X 
H2B Histone cluster 1, H2be  
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HAS2 Hyaluronan synthase 2 
HER2/ErbB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 
IGF2R Insulin-like growth factor 2 receptor 
IGF-I Insulin-like growth factor-1  
IGFR1 Insulin-like growth factor 1 receptor 
IgH Immunoglobulin heavy locus 
IL24 Interleukin 24 
KRT(14,17P3 etc) Keratin 
Ku70/80 X-ray repair complementing defective repair in Chinese hamster 
cells 6 
LCIS Lobular carcinoma in situ 
LEPREL1 Leprecan-like 1 
LET Linear energy transfer 
LIG(I/II/II etc) Ligase 
LMTK3 Lemur tyrosine kinase 3 
LUCA1 Hyaluronoglucosaminidase 1 
MAD2 Mitotic arrest deficient-like2 
MAEL Maelstrom homolog 
MAPK Mitogen-activated protein kinase  
MAX MYC associated factor X 
MDM4 Mdm4 p53 binding protein homolog 
MGMT O-6-methylguanine-DNA methyltransferase 
MLH3 MutL homolog 3 
MNDA Myeloid cell nuclear differentiation antigen 
MPG N-methylpurine-DNA glycosylase 
MRE11 Meiotic recombination 11 homolog  
MRN MRE11/RAD50/NBN  
MSH4 MutS homolog 4 
MYC Myelocytomatosis viral oncogene homolog 
NBN Nibrin 
NEIL1 /2/3 Nei endonuclease VIII-like 
NF-YA  Nuclear transcription factor Y, alpha 
NTHL1 Nth endonuclease III-like 1 (E. coli)  
OGG1 8-oxoguanine DNA glycosylase 
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p107 Retinoblastoma-like 1 
P48 Pancreas specific transcription factor 
P53 Tumour protein 53 gene 
PALB2 Partner and localiser of BRCA2 
PARP Poly ADP ribose polymerase 
PI3 Peptidase inhibitor 3, skin-derived 
PNK Polynucleotide kinase  
POL Polymerase 
POU2F1 POU class 2 homeobox 1 
PRDM1 PR domain containing 1, with ZNF domain 
PTC Papillary thyroid carcinomas  
PTEN Phosphatase and tensin homolog  
PU.1 Spleen focus forming virus (SFFV) proviral integration oncogene 
spi1 
PUF Poly-U binding splicing factor 
RAD (50, 51 etc) Radiation sensitivity abnormal 
RAF v-raf-1 murine leukemia viral oncogene homolog 
RAS Rat sarcoma 
Rb Retinoblastoma 
REEP5 Receptor accessory protein 5 
RET Ret proto-oncogene 
RPA Replication protein A 
SERPINE1 Serpin peptidase inhibitor, clade E member 1 
SFRP1 Secreted frizzled-related protein 1 
SIDT2 SID1 transmembrane family, member 2 
SIX1 SIX homeobox 1 
SLIT2 Slit homolog 2  
SLUG Snail homolog 2 
SMAD(1,2 etc) Mothers against decapentaplegic homolog 
SNAIL Zinc finger protein snai1 
SNP Single nucleotide polymorphism 
SOD1/2 Superoxide dismutase 
SRP19 Signal recognition particle 19kDa 
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SULT1A3 Sulfotransferase family, cytosolic, 1A, phenol-preferring, 
member 3 
TBX3/5 T-box 
TEL ETS-related protein 
TERT telomerase reverse transcriptase  
TGF Transforming growth factor 
TIE2 Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 
TRF1/2 Telomeric repeat binding factor 
TUBA1A Tubulin, alpha 1a 
TWIST Class A basic helix-loop-helix protein  
VEGF Vascular endothelial growth factor 
VIM Vimentin 
WNT Wingless-type MMTV integration site family 
WRN Werner syndrome, RecQ helicase-like 
XLF XRCC4-Like-Factor 
XPA Xeroderma pigmentosum, complementation group A 
XRCC1 X-ray repair complementing defective repair in Chinese hamster 
cells 1 
XRCC4 X-ray repair complementing defective repair in Chinese hamster 
cells 4 
YES v-yes-1 Yamaguchi sarcoma viral oncogene homolog 
ESR1 Estrogen receptor 1 
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1.2 Online resources  
http://www.doubling-time.com/compute.php - Roth V. 2006 
http://david.abcc.ncifcrf.gov/ - Huang et al 2009a; 2009b 
http://www.ebi.ac.uk/QuickGO/ 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php 
http://www.ensemble.org 
http://www.ncbi.nlm.nih.gov/pubmed/ 
http://www.ukradon.org/ 
http://www.hpa.org.uk/ 
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